
<html lang="en"     class="pb-page"  data-request-id="2b2d19e4-d2bd-44fd-9aae-285175ea29cb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.8b00697;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2018.61.issue-19;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism" /></meta><meta name="dc.Creator" content="Marie-Céline  Frantz" /></meta><meta name="dc.Creator" content="Lucie P.  Pellissier" /></meta><meta name="dc.Creator" content="Elsa  Pflimlin" /></meta><meta name="dc.Creator" content="Stéphanie  Loison" /></meta><meta name="dc.Creator" content="Jorge  Gandía" /></meta><meta name="dc.Creator" content="Claire  Marsol" /></meta><meta name="dc.Creator" content="Thierry  Durroux" /></meta><meta name="dc.Creator" content="Bernard  Mouillac" /></meta><meta name="dc.Creator" content="Jérôme A. J.  Becker" /></meta><meta name="dc.Creator" content="Julie  Le Merrer" /></meta><meta name="dc.Creator" content="Christel  Valencia" /></meta><meta name="dc.Creator" content="Pascal  Villa" /></meta><meta name="dc.Creator" content="Dominique  Bonnet" /></meta><meta name="dc.Creator" content="Marcel  Hibert" /></meta><meta name="dc.Description" content="Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin ag..." /></meta><meta name="Description" content="Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin ag..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 10, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00697" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00697" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00697" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00697" /></link>
        
    
    

<title>LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00697" /></meta><meta property="og:title" content="LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0019.jpeg" /></meta><meta property="og:description" content="Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure–affinity and structure–efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00697"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00697">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00697&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00697&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00697&amp;href=/doi/10.1021/acs.jmedchem.8b00697" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8670-8692</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00655" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00705" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marie-Céline Frantz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie-Céline Frantz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie-C%C3%A9line++Frantz">Marie-Céline Frantz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lucie P. Pellissier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lucie P. Pellissier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, IFCE, Inserm, Université François Rabelais de Tours, F-37380 Nouzilly, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lucie+P.++Pellissier">Lucie P. Pellissier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elsa Pflimlin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elsa Pflimlin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elsa++Pflimlin">Elsa Pflimlin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stéphanie Loison</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stéphanie Loison</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=St%C3%A9phanie++Loison">Stéphanie Loison</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jorge Gandía</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jorge Gandía</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, IFCE, Inserm, Université François Rabelais de Tours, F-37380 Nouzilly, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jorge++Gand%C3%ADa">Jorge Gandía</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claire Marsol</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire Marsol</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div><div class="loa-info-affiliations-info">LabEx MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</div><div class="loa-info-affiliations-info">PCBIS Plateforme de Chimie Biologique Intégrative de Strasbourg, UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Marsol">Claire Marsol</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thierry Durroux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thierry Durroux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Génomique Fonctionnelle, CNRS UMR5203, INSERM U661, Université de Montpellier (IFR3), 141 Rue de la Cardonille, F-34094 Montpellier Cedex 5, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thierry++Durroux">Thierry Durroux</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernard Mouillac</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernard Mouillac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institut de Génomique Fonctionnelle, CNRS UMR5203, INSERM U661, Université de Montpellier (IFR3), 141 Rue de la Cardonille, F-34094 Montpellier Cedex 5, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernard++Mouillac">Bernard Mouillac</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jérôme A. J. Becker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jérôme A. J. Becker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, IFCE, Inserm, Université François Rabelais de Tours, F-37380 Nouzilly, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%A9r%C3%B4me+A.+J.++Becker">Jérôme A. J. Becker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Le Merrer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Le Merrer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, IFCE, Inserm, Université François Rabelais de Tours, F-37380 Nouzilly, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Le+Merrer">Julie Le Merrer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christel Valencia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christel Valencia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">LabEx MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</div><div class="loa-info-affiliations-info">PCBIS Plateforme de Chimie Biologique Intégrative de Strasbourg, UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christel++Valencia">Christel Valencia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pascal Villa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pascal Villa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">LabEx MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</div><div class="loa-info-affiliations-info">PCBIS Plateforme de Chimie Biologique Intégrative de Strasbourg, UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pascal++Villa">Pascal Villa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3466-4852" title="Orcid link">http://orcid.org/0000-0003-3466-4852</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dominique Bonnet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dominique Bonnet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div><div class="loa-info-affiliations-info">LabEx MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dominique++Bonnet">Dominique Bonnet</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8252-9199" title="Orcid link">http://orcid.org/0000-0002-8252-9199</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marcel Hibert</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcel Hibert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</div><div class="loa-info-affiliations-info">LabEx MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +33 (0)3 68 85 42 32. Fax: +33 (0)3 68 85 43 10. E-mail: <a href="/cdn-cgi/l/email-protection#395451505b5c4b4d794c57504a4d4b58175f4b"><span class="__cf_email__" data-cfemail="eb868382898e999fab9e8582989f998ac58d99">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcel++Hibert">Marcel Hibert</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7786-7276" title="Orcid link">http://orcid.org/0000-0001-7786-7276</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00697&amp;href=/doi/10.1021%2Facs.jmedchem.8b00697" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8670–8692</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 10, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 May 2018</li><li><span class="item_label"><b>Published</b> online</span>10 September 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00697" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00697</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8670%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMarie-C%25C3%25A9line%2BFrantz%252C%2BLucie%2BP.%2BPellissier%252C%2BElsa%2BPflimlin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D19%26contentID%3Dacs.jmedchem.8b00697%26title%3DLIT-001%252C%2Bthe%2BFirst%2BNonpeptide%2BOxytocin%2BReceptor%2BAgonist%2Bthat%2BImproves%2BSocial%2BInteraction%2Bin%2Ba%2BMouse%2BModel%2Bof%2BAutism%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8692%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00697"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3237</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00697" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marie-Céline&quot;,&quot;last_name&quot;:&quot;Frantz&quot;},{&quot;first_name&quot;:&quot;Lucie&quot;,&quot;last_name&quot;:&quot;P. Pellissier&quot;},{&quot;first_name&quot;:&quot;Elsa&quot;,&quot;last_name&quot;:&quot;Pflimlin&quot;},{&quot;first_name&quot;:&quot;Stéphanie&quot;,&quot;last_name&quot;:&quot;Loison&quot;},{&quot;first_name&quot;:&quot;Jorge&quot;,&quot;last_name&quot;:&quot;Gandía&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Marsol&quot;},{&quot;first_name&quot;:&quot;Thierry&quot;,&quot;last_name&quot;:&quot;Durroux&quot;},{&quot;first_name&quot;:&quot;Bernard&quot;,&quot;last_name&quot;:&quot;Mouillac&quot;},{&quot;first_name&quot;:&quot;Jérôme&quot;,&quot;last_name&quot;:&quot;A. J. Becker&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Le Merrer&quot;},{&quot;first_name&quot;:&quot;Christel&quot;,&quot;last_name&quot;:&quot;Valencia&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;Villa&quot;},{&quot;first_name&quot;:&quot;Dominique&quot;,&quot;last_name&quot;:&quot;Bonnet&quot;},{&quot;first_name&quot;:&quot;Marcel&quot;,&quot;last_name&quot;:&quot;Hibert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8670-8692&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00697&quot;},&quot;abstract&quot;:&quot;Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure–affinity and structure–efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00697&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00697" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00697&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00697" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00697&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00697" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00697&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00697&amp;href=/doi/10.1021/acs.jmedchem.8b00697" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00697" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00697" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00697%26sid%3Dliteratum%253Aachs%26pmid%3D30199637%26genre%3Darticle%26aulast%3DFrantz%26date%3D2018%26atitle%3DLIT-001%252C%2Bthe%2BFirst%2BNonpeptide%2BOxytocin%2BReceptor%2BAgonist%2Bthat%2BImproves%2BSocial%2BInteraction%2Bin%2Ba%2BMouse%2BModel%2Bof%2BAutism%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D19%26spage%3D8670%26epage%3D8692%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/jmcmar.2018.61.issue-19/20181011/jmcmar.2018.61.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V<sub>1a</sub> and V<sub>2</sub> vasopressin receptor subtypes (V<sub>1a</sub>-R and V<sub>2</sub>-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure–affinity and structure–efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45826" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45826" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Autism spectrum disorders (ASD) are neurodevelopment diseases characterized by impaired social interaction and communication together with repetitive behaviors and restricted social interest (American Psychiatric Association, 2013). These core symptoms must be present in the early developmental period (by 3 years of age) for the diagnosis of ASD to be made. The prevalence of ASD is currently estimated at 1 case for 88 births, however, with a very large diversity of the associated mental disorders.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The etiology of ASD is complex. Hundreds of genetic mutations have been associated with the disease, explaining a number of ASD cases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The identification of vulnerability genes, most of them coding for proteins involved in synaptic function, as well as environmental risk factors during pregnancy and development, has provided important insights into the understanding of the anatomical and molecular underpinnings of ASD, notably by giving access to valuable animal models.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> However, most of the etiopathological mechanisms leading to ASD remain to be identified. The social impact of ASD is huge. U.S. annual direct medical, direct nonmedical, and productivity costs combined will be $268 billion for 2015 and $461 billion for 2025.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Up to now, no drug has been approved to treat core symptoms of ASD. Antipsychotics (aripiprazol, risperidone) or antidepressants (fluoxetine, citalopram) are often administered to treat some of the severe associated symptoms such as irritability and compulsive, repetitive behaviors, respectively, with associated side effects (drowsiness, weight gain, etc.). Novartis has developed up to phase II clinical trial an mGluR5 inhibitor, mavoglurant, showing a very marginal improvement in Fragile X patients diagnosed with ASD. Unfortunately, trial results did not meet the primary end point of showing significant improvement in abnormal behaviors compared to placebo and the development has been stopped.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Similarly, arbaclofen, the R enantiomer of baclofen, showed little effect on irritability subscale and development was stopped after phase IIb studies.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Balovaptan is a promising drug candidate developed by Hoffmann-La Roche and entering a phase III clinical study in ASD adults (<a href="https://clinicaltrials.gov/ct2/show/NCT03504917" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03504917</a>) with a FDA Breakthrough Therapy designation. This compound is claimed to be a specific V<sub>1a</sub> receptor antagonist. Unfortunately, no preclinical pharmacological data have been published yet to support its mechanism of action. The effect of a diuretic, bumetanide, blocking GABA-gated chloride channels, has recently been reported by Ben Ari et al. and looks promising.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Interestingly, there is a clear relationship between this signaling pathway and oxytocin.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Furthermore, many studies in patients demonstrate that OT may significantly improve social abilities related to autism spectrum.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35">(13−35)</a> These studies differ significantly in terms of age and gender of participants, administration route (intravenous or intranasal), doses of OT, single or multiple long-term administration, and outcomes (repetitive behavior, comprehension of affective speech, social ball tossing game, reading the mind in eyes, etc.), making definitive conclusions difficult to draw. However, OT clearly appears as a promising target to alleviate social impairments in patients with ASD.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Surprisingly, these OT clinical trials are running while very little is known about the precise molecular pharmacology, pharmacokinetics, and pathophysiological functions of OT in animals and in man. Understanding the distribution and functions of this neurotransmitter is crucial for the meaningful interpretation of animal and clinical studies and to rationalize the design of better drug candidates. For instance, no OT-R specific brain penetrating positron emission tomography (PET) probe is currently available.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Furthermore, the only way to get central activity with OT is intranasal (i.n.) administration because, as with most peptides, OT is not orally absorbed,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> is rapidly metabolized after iv administration (few minutes),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and poorly crosses blood–brain barrier except very modestly via the intranasal route.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> That is far from ideal in terms of formulation because the actual concentrations of OT being administered and reaching the different brain regions are unknown.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, the pharmacodynamics of this hormone is poorly documented. Thus, OT has very similar affinities for its OT-R and for the vasopressin receptors V<sub>1a</sub>-R and V<sub>1b</sub>-R and it is not fully understood which receptor is indeed associated with the different OT functions.<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43−45)</a> Furthermore, these receptors are able to activate different signaling pathways (different G proteins, arrestin), and the relationship between these pathways and the different physiological functions mediated by OT remains to be better understood.<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43−45)</a></div><div class="NLM_p">Finally, it is very unlikely that OT could ever be marketed to treat ASD because performing full dedicated clinical trials would be very costly while intellectual property cannot be protected.</div><div class="NLM_p">These different elements indicate that there is a clear need to discover novel centrally active, nonpeptide OT agonists both for fundamental research and for drug development.</div><div class="NLM_p">Consequently, our aim was to design and develop a novel nonpeptide OT-R agonist active in animal models of autism after peripheral administration. To our knowledge, no compound with such a profile has yet been disclosed. Few peptide or peptide-like OT-R agonists have been described, but their bioavailability is not much improved over OT and their in vivo efficacy in autism models has not been reported.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Two nonpeptide compounds showing some agonist activity have been discovered by Ferring and Wyeth.<a onclick="showRef(event, 'ref40 ref48'); return false;" href="javascript:void(0);" class="ref ref40 ref48">(40,48)</a> The Ferring compound is in fact more efficient as a V<sub>1a</sub>-R antagonist than as OT-R agonist,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and its clinical development has been stopped. The Wyeth compound, WAY-267464, has been reported as a high-affinity, potent, and selective (vs V<sub>1a</sub>, V<sub>1b,</sub> V<sub>2</sub>) agonist of the OT receptor in a given experimental system.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> It is more and more often used and referenced as a selective full OT-R agonist.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, in a different experimental setup, this compound was found to have an 8-fold higher affinity for the V<sub>1a</sub> receptor with a poor functional selectivity (2× selective for OT-R agonism over V<sub>1a</sub>-R antagonism)<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and partial OT agonism (see below). Our own efforts to discover OT-R agonists by virtual<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and biological high throughput screening of diverse libraries or by rational design of oxytocin mimics failed. Actually, OT-R ligands were found but none of them showed agonist activity (unpublished results and ref <a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a>). We came back to a more classical approach in looking for a common basic pharmacophore among ligands of vasopressin/oxytocin receptors as a starting template to develop a full OT agonist. In our eyes, this makes sense because there is a high sequence similarity between the three vasopressin receptor subtypes and the oxytocin receptor that all belong to the same branch of the GPCR family.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> On the other hand, vasopressin and oxytocin bind with moderate to high affinity to these four receptors. Furthermore, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> shows that compounds with similar structures have already been characterized as high affinity ligands of one or several of these four receptor subtypes.<a onclick="showRef(event, 'ref40 ref48 ref51 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref40 ref48 ref51 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61">(40,48,51,54−61)</a> A simple examination of these representative series of ligands reveals that a benzoyl benzazepine pharmacophore is clearly shared by this set of molecules showing affinity for at least one member of the vasopressin/oxytocin receptor family. Most compounds are antagonists except VNA-932 and WAY-141608 that display V<sub>2</sub> receptor agonism<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> and the Ferring and Wyeth OT partial agonists.<a onclick="showRef(event, 'ref48 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref51">(48,51)</a> Thus, this arylacyl benzazepine pharmacophore seems appropriate to afford improved OT agonists. In addition, compared to OT, it displays the potential advantages of structural simplicity, low molecular weight, and druglikeness.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selection of Literature Vasopressin/Oxytocin Ligands with the Benzoylbenzazepine Pharmacophore</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0010.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Gene reporter assay.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Changes in intracellular Ca<sup>2+</sup>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">cAMP accumulation.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Isolated organ (rat artery for V<sub>1a</sub>-R, rat uterus for OT-R).</p></div></div><div></div></div><div class="NLM_p">We report here the binding and efficacy studies around the pharmacophore of V<sub>1a</sub>, V<sub>1b</sub>, V<sub>2</sub>, and OT receptor ligands using three series of compounds with (i) variations of the side chain on the 4-position of the simplest benzoylbenzazepine pharmacophoric nucleus (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), (ii) variations on the benzazepine fragment keeping the pyrazole side chain selected previously (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), and (iii) variation of the side chain of the pyrazolobenzodiazepine fragment selected on OT agonism potential (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This led to the first identification of a new nonpeptide OT-R agonist, active in a mouse model of autism after peripheral intraperitoneal administration.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Affinity and Potency of Benzazepine Derivatives on V<sub>1a</sub>, V<sub>2</sub>, and OT Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0012.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The inhibition constants (<i>K</i><sub>i</sub> in nM) for human V<sub>1a</sub>, V<sub>2</sub>, and OT receptors were determined on CHO cell membranes by competition binding assays (displacement of radioactive [<sup>3</sup>H]AVP). Results are expressed as mean ± SEM of at least three separate experiments performed in triplicate. When <i>K</i><sub>i</sub> >1000 or >5000 nM, these are results of at least two separate experiments performed in triplicate.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">The activation constants (<i>K</i><sub>act</sub> in nM) were measured in CHO cell lines expressing either vasopressin V<sub>1a</sub> or V<sub>2</sub> or oxytocin receptor by IP-One (V<sub>1a</sub> and OT-R, IP<sub>1</sub> accumulation) or cAMP dynamic 2 (V<sub>2</sub>, cAMP accumulation) assays. These values are the mean ± SEM of at least three separate experiments performed in triplicate. The maximal stimulations (<i>E</i><sub>max</sub>) are expressed as percentages of the endogenous agonist maximal stimulation (<i>n</i> = 3). When there is only a weak stimulation, results are expressed as percentages of the endogenous agonist maximal stimulation at [ligand] = 1 μM (<i>n</i> = 2). Results are not significant (ns) when there is <10% response at [ligand] = 1 μM (<i>n</i> = 2).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">The inactivation constants (<i>K</i><sub>inact</sub> in nM) were measured in CHO cell lines expressing either vasopressin V<sub>1a</sub> or V<sub>2</sub> or oxytocin receptor by IP-One (V<sub>1a</sub> and OT-R, inhibition of agonist-induced IP<sub>1</sub> accumulation) or cAMP dynamic 2 (V<sub>2</sub>, inhibition of agonist-induced cAMP accumulation) assays. These values are the mean ± SEM of at least three separate experiments performed in triplicate. When there is only a weak inhibition, results are expressed as percentages of endogenous agonist-response inhibition at [ligand] = 1 μM (<i>n</i> = 2). Results are not significant (ns) when there is <10% response inhibition at [ligand] = 1 μM (<i>n</i> = 2).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last"><i>n</i> = 4.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last"><i>n</i> = 2.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Affinity and Potency of Pyrazole Derivatives on V<sub>1a</sub>, V<sub>2</sub>, and OT Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0014.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The inhibition constants (<i>K</i><sub>i</sub> in nM) for human V<sub>1a</sub>, V<sub>2</sub>, and OT receptors were determined on CHO cell membranes by competition binding assays (displacement of radioactive [<sup>3</sup>H]AVP). Results are expressed as mean ± SEM of at least three separate experiments performed in triplicate. When <i>K</i><sub>i</sub> >1000 or >5000 nM, these are results of at least two separate experiments performed in triplicate.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">The activation constants (<i>K</i><sub>act</sub> in nM) were measured in CHO cell lines expressing either vasopressin V<sub>1a</sub> or V<sub>2</sub> or oxytocin receptor by IP-One (V<sub>1a</sub> and OT-R, IP<sub>1</sub> accumulation) or cAMP dynamic 2 (V<sub>2</sub>, cAMP accumulation) assays. These values are the mean ± SEM of at least three separate experiments performed in triplicate. The maximal stimulations (<i>E</i><sub>max</sub>) are expressed as percentages of the endogenous agonist maximal stimulation (<i>n</i> = 3). When there is only a weak stimulation, results are expressed as percentages of the endogenous agonist maximal stimulation at [ligand] = 1 μM (<i>n</i> = 2). Results are not significant (ns) when there is <10% response at [ligand] = 1 μM (<i>n</i> = 2).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">The inactivation constants (<i>K</i><sub>inact</sub> in nM) were measured in CHO cell lines expressing either vasopressin V<sub>1a</sub> or V<sub>2</sub> or oxytocin receptor by IP-One (V<sub>1a</sub> and OT-R, inhibition of agonist-induced IP<sub>1</sub> accumulation), or cAMP dynamic 2 (V<sub>2</sub>, inhibition of agonist-induced cAMP accumulation) assays. These values are the mean ± SEM of at least three separate experiments performed in triplicate. When there is only a weak inhibition, results are expressed as percentages of endogenous agonist-response inhibition at [ligand] = 1 μM (<i>n</i> = 2). Results are not significant (ns) when there is <10% response inhibition at [ligand] = 1 μM (<i>n</i> = 2).</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last"><i>n</i> = 5.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">Not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Affinity and Potency of Pyrazolobenzodiazepine Derivatives on V<sub>1a</sub>, V<sub>2</sub>, and OT Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0015.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0016.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>i</sub> values are expressed in nM and are determined by a TR-FRET binding assay on HEK cells expressing SNAP-tagged V<sub>1a</sub>, V<sub>2</sub>, or OT receptors and incubated with a fluorescent ligand (DY647, 20 nM) with an increasing concentration of competitor. Results are expressed as mean ± SEM of one or two independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> values (intracellular calcium flux) are expressed in nM. The maximal effect is given as the percentage of the maximal response induced by OT or AVP and corresponds to mean ± SEM of two independent experiments.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> (calcium flux) are expressed in nM and correspond to mean ± SEM of two independent experiments.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">ns (nonsignificant) below 5–10% of response at 1 μM compared to the maximal response of the endogenous agonist.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">ns (nonsignificant) below 5–10% of inhibition of the response induced by the endogenous agonist at [ligand] = 1 μM.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">nd (not determined).</p></div></div><div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Chemistry</h3><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Benzazepine Derivatives</h4><div class="NLM_p">Benzazepine derivatives were prepared by coupling benzazepine <b>8</b> with a series of substituted aryl acids synthesized as indicated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The acid precursors <b>3a</b>,<b>b</b> were prepared according to the method described by Kondo et al. (2000).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Acid precursors <b>5a</b>,<b>b</b> were prepared by Suzuki coupling according to the method of Gong et al. (2000),<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> optimized for microwave conditions.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of the Acid Precursors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-methylpyrazole, K<sub>2</sub>CO<sub>3</sub>, NMP, 120 °C, 6 h, 21–41%; (ii) HCl/H<sub>2</sub>O, AcOH, reflux, 7 h, 96–98%; (iii) aryl bromide, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, MeCN, MW 140–150 °C, 15–20 min.</p></p></figure><div class="NLM_p">Benzazepine <b>8</b> was prepared from the corresponding oxime <b>7</b> as described (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Coupling was achieved by using commercially available acid chlorides (for compounds <b>9</b>–<b>14</b> and <b>18</b>) or starting from prepared acids <b>3a</b> and <b>5a</b> (for compounds <b>15</b>–<b>17</b>) using thionyl chloride.<a onclick="showRef(event, 'ref59 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref59 ref64 ref65">(59,64,65)</a> The reduction of the nitro group of <b>18</b> was achieved as described by Ogawa et al. (1996).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Double methylation of aniline <b>19</b> was performed as described by Kondo et al. (2000).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Peralkylation of <b>20</b> was achieved with methyl iodide and silver perchlorate following a procedure described by Miller et al. (1989),<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> while acetylation of <b>19</b> led to <b>22</b>. The reference antagonist <b>23</b> was obtained by acylation of <b>19</b> with 2-biphenylcarboxylic acid as previously described by Matsuhisa et al. (1997).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Structures and yields are given in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Unsubstituted Benzazepine <b>8</b> and Acid Coupling<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NH<sub>2</sub>OH·HCl, KOH, H<sub>2</sub>O, EtOH, 100 °C, 30 min, 92%, (ii) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 4 h, 73%, (iii) acyl chloride, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 4–20 h, (iv) <b>18</b>, H<sub>2</sub>, Pd/C, EtOH, AcOEt, 5 h, (v) <b>19</b>, MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 6 h, (vi) <b>20</b>, MeI, AgClO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 2 h, (vii) <b>19</b>, Ac<sub>2</sub>O, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 4 h, (viii) (a) 2-phenylbenzoic acid, (COCl)<sub>2</sub>, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, 2 h; (b) <b>19</b>, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0–10 °C, 2 h.</p></p></figure></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Aryl-1-(3-Me)-pyrazolyl Derivatives</h4><div class="NLM_p">A series of compounds resulting from the coupling of substituted 1-(3-Me)-pyrazolyl-benzoic acids <b>3a</b>,<b>b</b> with cyclic amines have been prepared. The cyclic amines have been synthesized (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) according to existing procedures. Ketone <b>25</b> was prepared as described by Proctor et al. (1961).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> We had already described the synthesis of benzazepinone <b>26</b>.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a><i>N</i>-Dimethylbenzazepine <b>28</b> was prepared from ketone <b>25</b> according to a procedure described by Ogawa et al. (1996).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The pyrrolobenzodiazepine <b>31</b> was obtained following a procedure described by Artico et al. (1969).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The pyrazolobenzodiazepine <b>37</b> was prepared according to the method described by Pitt et al. (2004).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Azepine is commercially available. The different benzazepines were coupled to the aromatic acids as described before via acyl chloride intermediate (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The V<sub>2</sub> receptor agonist VNA-932 (<b>42</b>) was prepared from benzodiazepine <b>31</b>.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The coupling products <b>39a</b> and <b>39b</b>, obtained from ketone <b>26</b>, were further reduced by sodium borohydride to obtain the alcohols <b>40a</b> and <b>40b</b>.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Structures and yields are given in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Cyclic Amines Used<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, pyridine, 0 °C, 1 h, 98%; (ii) (a) NaH, Br(CH<sub>2</sub>)<sub>3</sub>COOEt, DMF, 14 h, rt, then 90 °C, 6 h, (b) NaH, MeOH/toluene 17 h, (c) AcOH, HCl, EtOH, H<sub>2</sub>O, 100 °C, 8 h, 62%; (iii) PPA, 110 °C, 2 h, quant; (iv) (a) MeNH<sub>2</sub>, MeOH, MW 130 °C, 8 min, (b) NaBH<sub>4</sub>, 1 h, 98%; (v) HCHO, NaBH<sub>3</sub>CN, AcOH, MeOH, 2 h, 90%; (vi) PPA, 120 °C, 2 h, quant; (vii) pyrrole-2-carboxaldehyde, NaH, DMF, 4 h, quant; (viii) H<sub>2</sub>, Pd/C, EtOH, 60 psi, 3 h, 70%; (ix) MeNHNH<sub>2</sub>, EtOH, reflux, 17 h, 92%; (x) NaH, 2-fluoronitrobenzene, THF, 48 h, 78%; (xi) H<sub>2</sub>, Pd/C, EtOH, AcOEt, 1 h, 99%; (xii) AcOH/<i>i</i>PrOH 1:9, 160 °C, 48 h, 89%; (xiii) LiAlH<sub>4</sub>, THF, reflux, 44 h, 86%.</p></p></figure><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Coupling of the Different Amines with Acids <b>3a</b> and <b>3b</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Pyrazolobenzodiazepine Derivatives</h4><div class="NLM_p">A series of amines was prepared according to <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> and <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The first series dealt with proline analogues (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). <i>N</i>-Boc-proline <b>45</b> reacted with <i>N</i>,<i>N</i>-dimethylamine to afford the corresponding carboxamide <b>46</b> with a 75% yield. The carboxamide <b>46</b> was transformed into the corresponding thiocarboxamide <b>47</b> with the Lawesson reagent in 52% yield. Finally, Boc protection was removed with TFA/CH<sub>2</sub>Cl<sub>2</sub>:1/1 to afford quantitatively the building blocks <b>48</b> and <b>49</b>. A second series of building blocks was derived from glycine (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). <i>N</i>-Protected glycine was first turned into the <i>N</i>,<i>N</i>-dimethyl carboxamide <b>50</b> and then into the thiocarboxamide <b>51</b> following the same sequence as above for proline derivatives. Deprotection in acidic medium afforded the free amino thiocarboxamide <b>52</b> and carboxamide <b>53</b> with quantitative yields. The methyl ester of glycine, <b>54</b>, was commercially available. The pyrazolobenzodiazepine <b>37</b> reacted with 4-cyano-3-methyl benzoic acid chloride to afford compound <b>55</b> in a 70% yield (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). The cyano group was reduced with sodium borohydride in the presence of cobalt chloride hexahydrate to provide the primary amine <b>56</b> with 81% yield. A urea connection was then created with carbonyldiimidazole (CDI) between the amine <b>56</b> and the previously synthesized amines <b>48</b>, <b>49</b>, and <b>52</b>–<b>54</b>, leading to compounds <b>57</b>–<b>61</b>. Yields ranged from 41% to 67% (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Proline Derivatives <b>45</b>–<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDCI, HOBt, Et<sub>3</sub>N, NMe<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, overnight; (ii) Lawesson reagent, toluene, overnight, 70 °C; (iii) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, v/v), 30 min.</p></p></figure><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Fragments <b>52</b>–<b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDCI, HOBt, Et<sub>3</sub>N, NMe<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, overnight, 46%; (ii) Lawesson reagent, toluene, overnight, 70 °C, 63%; (iii) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, 30 min), quant.</p></p></figure><figure id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>57</b>–<b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(i) (a) (COCl)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, 2 h, (b) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, overnight; (ii) NaBH<sub>4</sub>, CoCl<sub>2</sub>.6H<sub>2</sub>O, MeOH, 1 h; (iii) (a) compounds <b>48</b>, <b>49</b>, or <b>52</b>–<b>54</b>, CDI, DIEA, DMF, overnight, 41–67%.</p></p></figure></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Structure–Activity Relationship Studies</h3><div class="NLM_p">The affinities of the different ligands for the human vasopressin receptor subtypes and the oxytocin receptor were determined as described previously (i) on CHO cell membranes by competition experiments against [<sup>3</sup>H]AVP,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and (ii) on HEK cells using a FRET based assay.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The functional agonist and competitive antagonist properties of each ligand were determined for the human vasopressin and oxytocin receptor subtypes in different experimental conditions. (i) In CHO cells stably expressing receptors, the accumulation of <i>myo</i>-inositol 1-phosphate (V<sub>1a</sub> and OT receptors) and the accumulation of cAMP (V<sub>2</sub> receptor) were determined using immunoassays based on the competition between free IP<sub>1</sub> or cAMP and IP<sub>1</sub>-d2 or cAMP-d2 conjugate, respectively.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (ii) In HEK cells stably expressing V<sub>1a</sub> and OT receptors, the intracellular calcium flux was determined using the fluorescent dye Indo1.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Benzazepine Series</h4><div class="NLM_p last">The binding and efficacy profiles of benzoylbenzazepines <b>9</b>–<b>23</b> for the V<sub>1a</sub>, V<sub>2</sub>, and OT receptors are given in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Simple halogen substitution of the benzoyl fragment in <i>para</i> of the carboxamide link was sufficient to retain a submicromolar affinity (<b>9</b>–<b>11</b>). A two-digit nanomolar affinity was even obtained for the iodo derivative <b>11</b> on the V<sub>1a</sub> receptor (<i>K</i><sub>i</sub> = 48 nM), whereas a 396 nM affinity was obtained for the OT-R. Antagonist activity was clearly observed for the V<sub>1a</sub> and OT receptors, while a mixed agonist/antagonist profile was obtained on the V<sub>2</sub> receptor. The <i>n</i>-alkyl substituents in <b>12</b> and <b>13</b> afforded compounds with an increased potency compared to halogens. Hence the <i>n</i>-butyl analogue <b>13</b> had affinity constants of 28, 52, and 37.4 nM for the V<sub>1a</sub>, V<sub>2</sub>, and OT receptors, respectively. This is quite noticeable considering the simplicity and low molecular weight of this compound. It behaved as a relatively potent antagonist at the V<sub>1a</sub> and OT receptors (<i>K</i><sub>inact</sub> = 421 and 113 nM, respectively) and a quite potent V<sub>2</sub> partial agonist (EC<sub>50</sub> = 18 nM; intrinsic activity, 74% of maximum AVP induced response). The substitution by a phenyl fragment (<b>14</b>) led to a further increase in affinity with <i>K</i><sub>i</sub> of 2.28, 78, and 10.4 nM for the V<sub>1a</sub>, V<sub>2</sub>, and OR receptors, respectively. Compound <b>14</b> is a potent antagonist at the three receptor subtypes (<i>K</i><sub>inact</sub> = 7, 132, and 42 nM, respectively) with a preference for the V<sub>1a</sub> site. The heterocyclic homologues <b>15</b> and <b>16</b> have similar profiles with lower affinity and potency on all sites. Interestingly, the 3-methyl-pyrazolo analogue <b>17</b> recovered a high affinity at both V<sub>1a</sub> (34 nM) and OT (84 nM) receptors and a lower one (282 nM) at the V<sub>2</sub> receptor. It showed high potency at all sites as a V<sub>1a</sub>-R and OT-R antagonist (<i>K</i><sub>inact</sub> = 48 and 112 nM, respectively) and V<sub>2</sub>-R full agonist (EC<sub>50</sub> = 13 nM). Attempts to introduce an amino function on the benzoyl nucleus led to clear-cut changes: whereas the primary amino derivative <b>19</b> and the corresponding quaternary ammonium <b>21</b> mostly lost activity at all receptors, the intermediate dimethyl amino compound <b>20</b> showed an 82 nM affinity for the V<sub>1a</sub> subtype, a 468 nM affinity for the V<sub>2</sub> subtype, and no affinity for the OT receptor. As most other compounds, <b>20</b> is a potent V<sub>1a</sub>-R antagonist and a V<sub>2</sub>-R agonist with potencies of 81 and 80 nM, respectively. Finally, in contrast to the inactive acetyl compound <b>22</b>, the biphenyl compound <b>23</b> was confirmed<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> as a very potent <i>antagonist</i> at the three receptor subtypes with affinities of 2.74, 0.57, and 109 nM for the V<sub>1a</sub>, V<sub>2</sub>, and OT receptors, respectively, and a marked preference for the blockade of the V<sub>2</sub>-R mediated function (<i>K</i><sub>inact</sub> = 0.096 nM compared to 63 nM for V<sub>1a</sub>-R and 171 nM for OT-R).</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Pyrazole Series</h4><div class="NLM_p last">The binding and potency profiles of pyrazole derivatives <b>17</b> and <b>38</b>–<b>44</b> for the V<sub>1a</sub>, V<sub>2</sub>, and OT receptors are given in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. In this series, the substitution of the aryl linker with chlorine (compound <b>38</b>) led to a selectivity reversal compared to the unsubstituted compound <b>17</b>, with a decrease in affinity for the V<sub>1a</sub> and OT receptors and an increase for the V<sub>2</sub> receptor. The potency profile remained unaffected, with agonism for the V<sub>2</sub> (EC<sub>50</sub> = 16 nM) and antagonism for the two other receptor subtypes. Introduction of a keto group on the benzazepine nucleus (compounds <b>39a</b> and <b>39b</b>) resulted in a drastic loss of affinity and potency on all subtypes. This effect was less marked with the corresponding hydroxyl substitution (compound <b>40a</b> and <b>40b</b>), in particular with a chlorine substituent because <b>40b</b> showed moderate affinity (<i>K</i><sub>i</sub> = 100 nM) and a good agonist potency (EC<sub>50</sub> = 28 nM) at the V<sub>2</sub> receptor. No agonist activity was observed for the other receptor subtypes. A similar detrimental effect was observed with an <i>N</i>,<i>N</i>-dimethylamine substitution (compounds <b>41a</b> and <b>41b</b>). Interestingly, this structural modification is the only one that triggered a functional switch of the V<sub>2</sub> receptor from agonism to antagonism (<b>41b</b>; <i>K</i><sub>inact</sub> = 126 nM). Compound WAY-VNA-932 (<b>43</b>) was prepared and tested. Overall, its binding and potency profiles correspond to literature data.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> It behaved in our hands as a moderately potent, nonspecific V<sub>1a</sub> and OT receptor antagonist (<i>K</i><sub>i</sub> = 344 and 199 nM, respectively) and V<sub>2</sub> receptor partial agonist (<i>K</i><sub>i</sub> = 50 nM; EC<sub>50</sub> = 9.5 nM with 75% of maximal response). The introduction of the Ferring and WAY-267464 pyrazolobenzodiazepine nucleus led to the potent, nonspecific ligand <b>43</b> (<i>K</i><sub>i</sub> = 27, 29, and 17 nM for the V<sub>1a</sub>, V<sub>2</sub>, and OT receptors, respectively). Again, <b>43</b> was a potent V<sub>2</sub>-R agonist (EC<sub>50</sub> = 8.4 nM) but remained antagonist at the two other receptor subtypes. Finally, removal of the aromatic component of this fragment of the molecule as in <b>44</b> led to a complete loss of activity at all receptors.</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Pyrazolobenzodiazepine Series</h4><div class="NLM_p last">The combination of the pyrazolobenzodiazepine nucleus with a series of homologous side chains led to compounds <b>57</b>–<b>61</b> whose pharmacological profiles are reported in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. In our experimental conditions, the Ferring compound had a weak affinity for the V<sub>1a</sub> and OT receptors (<i>K</i><sub>i</sub> = 196 and 141 nM, respectively) and no activity at the V<sub>2</sub>-R at micromolar concentration. We confirmed an OT-R agonist behavior with an EC<sub>50</sub> = 28 nM and an 84% maximal response (based on Ca<sup>2+</sup> release) compared to OT. However, this compound behaved as a potent V<sub>1a</sub> receptor antagonist (Ca<sup>2+</sup> release) with an IC<sub>50</sub> = 8 nM. In comparison, WAY 267464 had a better affinity at both V<sub>1a</sub> (<i>K</i><sub>i</sub> = 12.5 nM) and OT (<i>K</i><sub>i</sub> = 30.5 nM) receptors whereas no activity was measured at the V<sub>2</sub> receptor. This compound is an equipotent V<sub>1a</sub>-R antagonist compared to the Ferring compound (EC<sub>50</sub> = 7 nM) and a potent OT-R agonist (EC<sub>50</sub> = 3 nM). However, the maximal response obtained in our experimental conditions is limited to 40% of the maximal response obtained with OT. Hence, the gain in affinity is balanced by a loss in potency due to partial agonism. The compound <b>57</b> had lower affinity on all receptor subtypes with a preference for the OT-R (<i>K</i><sub>i</sub> = 226 nM). Very interestingly, <b>57</b> remains an agonist with a high potency (EC<sub>50</sub> = 55 nM) and an increased intrinsic activity compared to WAY 267464 (52% instead of 40% of the maximal response). The functional selectivity of <b>57</b> versus the V<sub>1a</sub>-R is also reversed compared to the Ferring compound because there was a moderate (2-fold) preference for the OT-R. A very low affinity was detected at the V<sub>2</sub> receptor (<i>K</i><sub>i</sub> = 1666 nM). The carboxamide analogue <b>58</b> of the thiocarboxamide <b>57</b> had a parallel profile but was much less potent. Remarkably, the three open chain analogues <b>59</b>–<b>61</b> retained some activity but switched to low affinity OT-R <i>antagonists</i>. Despite its small size and its relative flexibility, the thiocarboxamide <b>60</b> was actually a rather potent (IC<sub>50</sub> = 9 nM) and specific V<sub>1a</sub> receptor antagonist based on functional assays because it was 60-fold less potent as an OT-R antagonist and showed no affinity for the V<sub>2</sub> subtype up to 1 μM concentration.</div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Signaling Profile of Compound <b>57</b> in Vitro</h3><div class="NLM_p">On the basis of previous screening data and predictive bioavailability characteristics (see below), we focused on our best candidate, compound <b>57</b>, and further studied its pharmacological profile by assessing its effects on calcium release and β-arrestin2 recruitment in HEK293FT cell lines transiently expressing human OT, V<sub>1a</sub>, V<sub>1b</sub>, or V<sub>2</sub> receptors with either aequorin sensor or β-arrestin2 for calcium or BRET1 recruitment assays, respectively. This activity was compared to those of several reference molecules: oxytocin and carbetocin as full and biased peptide agonists, respectively, and WAY-267464 as nonpeptide partial agonist (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0001.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pharmacological profile of OTR agonists, oxytocin, compound <b>57</b>, carbetocin, and WAY-267464, on oxytocin and vasopressin receptors. Representative dose–responses from three to four experiments of oxytocin (red), compound <b>57</b> (orange), carbetocin (purple), and WAY-267464 (black) on OT (A,B), V<sub>1a</sub> (C,D), V<sub>1b</sub> (E,F), and V<sub>2</sub> (G,H) receptors are presented on the two major signaling pathways of these receptors, calcium release (A,C,E,G), and β-arrestin2 recruitment (B,D,F,H). Oxytocin appears as the most potent agonist on OTR to activate calcium release; carbetocin, WAY-267464, and compound <b>57</b> have similar affinities, with compound <b>57</b> showing the best maximal effect. Regarding β-arrestin recruitment, carbetocin acts as a partial agonist and WAY-267464 shows lower affinity compared to that measured for calcium release, suggesting a bias in its signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Affinity and Potency of OTR Agonists Compound <b>57</b>, Carbetocin, and WAY-267464 on Calcium Release and β-Arrestin Recruitment on Oxytocin and Vasopressin Receptors<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center">oxytocin</th><th class="rowsep1 colsep0" align="center">carbetocin</th><th class="rowsep1 colsep0" colspan="2" align="center">compd <b>57</b></th><th class="rowsep1 colsep0" align="center">PF3274167</th><th class="rowsep1 colsep0" align="center">WAY-267464</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">antagonist (AVP 2 nM)</th><th class="colsep0 rowsep0" align="center">antagonist on compd <b>57</b></th><th class="colsep0 rowsep0" align="center">agonist</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">calcium</td><td class="colsep0 rowsep0" align="left">hOTR</td><td class="colsep0 rowsep0" align="center">0.7 ± 0.3 (100)</td><td class="colsep0 rowsep0" align="center">41 ± 17 (83 ± 20)</td><td class="colsep0 rowsep0" align="center">25 ± 7 (96 ± 8)</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">600 ± 300</td><td class="colsep0 rowsep0" align="center">24 ± 12 (70 ± 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mOTR</td><td class="colsep0 rowsep0" align="center">2.0 ± 0.4 (100)</td><td class="colsep0 rowsep0" align="center">62 ± 31 (85 ± 4)</td><td class="colsep0 rowsep0" align="center">18 ± 8 (95 ± 4)</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">78 ± 25 (86 ± 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">V<sub>1a</sub>R</td><td class="colsep0 rowsep0" align="center">260 ± 130 (100)</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">5900 ± 2700</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">ns</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">V<sub>1b</sub>R</td><td class="colsep0 rowsep0" align="center">39 ± 7 (100)</td><td class="colsep0 rowsep0" align="center">27000 ± 17000 (75 ± 8)</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">ns</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">V<sub>2</sub>R</td><td class="colsep0 rowsep0" align="center">210 ± 40 (100)</td><td class="colsep0 rowsep0" align="center">6700 ± 2700 (103 ± 7)</td><td class="colsep0 rowsep0" align="center">41 ± 4 (101 ± 4)</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">1530 ± 550</td><td class="colsep0 rowsep0" align="center">2300 ± 2000 (43 ± 9)</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">agonist</th><th class="colsep0 rowsep0" align="center">antagonist (AVP 100 nM)</th><th class="colsep0 rowsep0" align="center">antagonist on compd <b>57</b></th><th class="colsep0 rowsep0" align="center">agonist</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β-arrestin</td><td class="colsep0 rowsep0" align="center">OTR</td><td class="colsep0 rowsep0" align="center">26 ± 15 (100)</td><td class="colsep0 rowsep0" align="center">10 ± 6 (42 ± 7)</td><td class="colsep0 rowsep0" align="center">62 ± 43 (77 ± 11)</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">63 ± 42</td><td class="colsep0 rowsep0" align="center">150 ± 60 (84 ± 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">V<sub>1a</sub>R</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">2200 ± 200</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">ns</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">V<sub>1b</sub>R</td><td class="colsep0 rowsep0" align="center">29 ± 14 (49 ± 12)</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">ns</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">ns</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">V<sub>2</sub>R</td><td class="colsep0 rowsep0" align="center">810 ± 250 (69 ± 18)</td><td class="colsep0 rowsep0" align="center">1100 ± 600 (8 ± 2)</td><td class="colsep0 rowsep0" align="center">660 ± 220 (97 ± 4)</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">2620 ± 1260</td><td class="colsep0 rowsep0" align="center">ns</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> (“agonist”) or IC<sub>50</sub> (“antagonist”) and <i>E</i><sub>max</sub> values are expressed respectively in nM and as the percentage of the maximal response induced by OT or AVP. The values were measured in HEK293FT cell lines expressing transiently human OT, mouse OT, V<sub>1a</sub>, V<sub>1b</sub>, or V<sub>2</sub> receptors with either aequorin sensor or β-arrestin2 for calcium or BRET1 recruitment assays, respectively. These values are the mean ± SEM of at least three to four separate experiments performed in triplicate per receptor and per compound. ns: nonsignificant (no value measured). nd: not determined.</p></div></div></div><div class="NLM_p last">Regarding calcium release (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), oxytocin was the most potent agonist on OT-R; carbetocin, WAY-267464, and compound <b>57</b> had similar potencies (EC<sub>50</sub> = 25 nM), with compound <b>57</b> showing the best maximal effect (<i>E</i><sub>max</sub> = 96%). We compared these four compounds on mouse OT-R calcium release prior to in vivo testing in mice. Oxytocin was the most potent agonist, and compound <b>57</b> showed better potency (EC<sub>50</sub> = 18 nM) and maximal effect (<i>E</i><sub>max</sub> = 96%) than carbetocin and WAY-267464 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">Figure S1A</a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Now focusing on β-arrestin recruitment (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), carbetocin retained a high potency (EC<sub>50</sub> = 10 nM) however with a partial maximal response (<i>E</i><sub>max</sub> = 42%); WAY-267464 showed a 6-fold lower potency compared to that measured for calcium release, suggesting a potential bias in its signaling. Compound <b>57</b> retained high potency (EC<sub>50</sub> = 62 nM) and maximal response (<i>E</i><sub>max</sub> = 77%). Thus, compound <b>57</b> was the most potent agonist behind oxytocin to recruit β-arrestin. Furthermore, we tested the specificity of previous compounds by measuring their effects on V<sub>1a</sub>, V<sub>1b</sub>, and V<sub>2</sub> vasopressin receptor-mediated activation of calcium release and β-arrestin recruitment (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C–H and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Carbetocin poorly activated V<sub>1b</sub>-R and V<sub>2</sub>-R without effect on V<sub>1a</sub>-R-induced calcium release. It had no effect on β-arrestin recruitment mediated by V<sub>1a</sub>-R and V<sub>1b</sub>-R and a very small effect on V<sub>2</sub>-R mediated arrestin release (<i>E</i><sub>max</sub> = 8% at micromolar concentration). WAY-267464 activated partially V<sub>2</sub>-R mediated calcium release (EC<sub>50</sub> = 2300 nM; <i>E</i><sub>max</sub> = 43%) and had no effect on AVP induced arrestin release on the three receptor subtypes. WAY-267464 is also known to antagonize V<sub>1a</sub> receptors.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> We thus tested whether <b>57</b> would similarly block the effects of vasopressin on V<sub>1a</sub> and V<sub>1b</sub> receptors. We found that compound <b>57</b> poorly antagonized vasopressin induced calcium release on V<sub>1a</sub>-R (IC<sub>50</sub> = 5900 nM) and was devoid of effect on V<sub>1b</sub>-R (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">Figure S1B,C</a>). However, compound <b>57</b> significantly activated V<sub>2</sub> receptors as measured on both pathways. Finally, we tested the effects of the Pfizer OT-R antagonist PF 3274167<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> on the activation of OT and V<sub>2</sub> receptors by compound <b>57</b>. PF3274167 totally suppressed and partially reduced the effects of <b>57</b> on OT-R and V<sub>2</sub>-R, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>; Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">Figure S1D,E</a>). In conclusion, compound <b>57</b> acts as a nonbiased agonist on OT-R with the most potent and specific effects among tested synthetic compounds.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Biological Activity of Compound <b>57</b> in Vivo: Effects in a Mouse Model of ASD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>)</h3><div class="NLM_p">Mice lacking the mu opioid receptor (<i>Oprm1</i><sup><i>–/–</i></sup>) recapitulate all core symptoms of ASD: deficient social interaction and altered communication together with stereotyped behaviors; they also display multiple comorbid symptoms of ASD such as exacerbated anxiety and increased sensitivity to seizures.<a onclick="showRef(event, 'ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref73 ref74 ref75">(73−75)</a> They thus demonstrate remarkable face validity as a mouse model of ASD. Interestingly, these animals also display alterations in the oxytocin/vasopressin system, as evidenced by reduced number of oxytocin transcripts in the nucleus accumbens,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> a key structure for social reward,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> and consistent increase in OT-R binding in this same region as well as in the amygdala.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Here we reasoned that stimulating OT receptors using the promising OT-R agonist compound <b>57</b> should relieve social interaction deficits in <i>Oprm1</i><sup><i>–/–</i></sup> animals. To challenge this hypothesis, we administered an acute intraperitoneal injection of vehicle or <b>57</b> (at 10 or 20 mg/kg) to <i>Oprm1</i><sup><i>+/+</i></sup> or <i>Oprm1</i><sup><i>–/–</i></sup> unfamiliar (non cagemates, same age, same sex, and same treatment) mice before introducing them by pairs in an open-field for 10 min testing. Behavioral parameters were scored on video recordings to assess the quality of social interactions in these animals, namely the number of nose contacts (NCs), the time spent in NC, the mean duration of NCs, the number of following episodes, and the number of grooming episodes occurring after a social contact, an index of social avoidance.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> At the dose of 10 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), <b>57</b> restored the number of NCs (genotype effect, <i>F</i><sub>1,42</sub> = 54.2, <i>p</i> < 0.0001; dose effect, <i>F</i><sub>2,42</sub> = 9.6, <i>p</i> < 0.001; genotype × dose interaction, <i>F</i><sub>2,42</sub> = 16.8, <i>p</i> < 0.0001) and time spent in NC (genotype, <i>F</i><sub>1,42</sub> = 45.6, <i>p</i> < 0.0001; dose, <i>F</i><sub>2,42</sub> = 19.9, <i>p</i> < 0.0001; genotype × dose: <i>F</i><sub>2,42</sub> = 17.4, <i>p</i> < 0.0001), the mean duration of NC (genotype, <i>F</i><sub>1,42</sub> = 15.1, <i>p</i> < 0.001; dose, <i>F</i><sub>2,42</sub> = 19.5, <i>p</i> < 0.0001; genotype × dose, <i>F</i><sub>2,42</sub> = 19.8, <i>p</i> < 0.0001) and the number of following episodes (genotype, <i>F</i><sub>1,42</sub> = 38.9, <i>p</i> < 0.001; dose, <i>F</i><sub>2,42</sub> = 24.4, <i>p</i> < 0.0001; genotype × dose, <i>F</i><sub>2,42</sub> = 4.2, <i>p</i> < 0.05) measured in <i>Oprm1</i><sup><i>–/–</i></sup> mice to similar levels as measured in wild-type controls. Moreover, at this dose, <b>57</b> also suppressed grooming episodes occurring after a social contact in mutants (genotype, <i>F</i><sub>1,42</sub> = 8.5, <i>p</i> < 0.01; dose, <i>F</i><sub>2,42</sub> = 11.3, <i>p</i> < 0.001; genotype × dose, <i>F</i><sub>2,42</sub> = 21.4, <i>p</i> < 0.0001). The OT-R agonist had no effect in <i>Oprm1</i><sup><i>+/+</i></sup> mice at this dose, except that it increased the number of following episodes. At the dose of 20 mg/kg, compound <b>57</b> demonstrated less significant beneficial effects on social parameters measured in mutant animals and started to show some detrimental effects on these parameters in wild-type controls (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A–E). Such effects may have resulted either from excessive OT-R activation or from recruitment/blockade of V<sub>1a</sub> or V<sub>1b</sub> vasopressin receptors at high doses, peripherally or centrally. To our knowledge, our results are the first evidence that a nonpeptidic OT-R compound can alleviate core symptoms in the context of ASD.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0002.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>57</b> restores social interaction in <i>Oprm1</i><sup><i>–/–</i></sup> mice. In the direct social interaction test, an acute administration of compound <b>57</b> (ip; 10 or 20 mg/kg) increases the number of nose contacts (NCs), the time spent in NC, duration of NC, and number of following episodes in <i>Oprm1</i><sup><i>–/–</i></sup> mice while it decreases the number of grooming episodes occurring after a social contact. Compound <b>57</b> at a moderate dose (10 mg/kg) fully restores these social parameters to <i>Oprm1</i><sup><i>+/+</i></sup> levels, whereas at a higher dose (20 mg/kg) this beneficial outcome is less significant and detrimental effects start to be observed in wild-type controls. Data are presented as mean ± SEM (<i>n</i> = 8 per genotype and treatment). Solid stars: comparison to vehicle-treated <i>Oprm1</i><sup><i>+/+</i></sup> mice. Asterisks: comparison to vehicle-treated animals of the same genotype (two-way ANOVA followed by Newman–Keules posthoc test). One symbo,: <i>p</i> < 0.05; two symbols, <i>p</i> < 0.01; three symbols, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The actual presence in the mouse brain of compound <b>57</b> after a 10 mg/kg ip administration has been determined by showing an experimental brain exposure of 399 ± 104 min.ng/g.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our ultimate goal is the design and development of drugs improving life of patients with autism spectrum disorders. As discussed in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, the oxytocin receptor appears as a valid target because OT has already shown beneficial effects in human after i.n. administration.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36">(15−36)</a> However, OT is not metabolically stable, poorly penetrates the brain, even after intranasal administration, and its development as a marketed drug to treat ASD is hampered by intellectual property considerations. Consequently, our aim was to design and develop a novel nonpeptide OT-R agonist active in animal models of autism after peripheral administration. To our knowledge, no compound with such a profile has been disclosed yet.</div><div class="NLM_p">From the first SAR run (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), we concluded that the benzoylbenzazepine pharmacophore is indeed relevant to generate ligands with high affinity at the vasopressin/oxytocin receptors. Very minimal substitution, such as a halogen (<b>11</b>), an alkyl (<b>13</b>), a heterocycle (<b>17</b>), or an amine (<b>20</b>), are sufficient to afford two-digit nanomolar ligands at one or several receptor subtypes. It was encouraging to observe that minor structural changes afforded high affinity V<sub>2</sub>-R ligands with functional profiles ranging from full antagonist (<b>23</b>) to full agonist (<b>17</b>). Hence, as expected, replacement of the bulky and hydrophobic aromatic biphenyl fragment of the potent, nonspecific antagonist <b>23</b> by a smaller, more hydrophilic 3-methyl-pyrazole fragment led to a V<sub>2</sub>-R full agonist (compound <b>17</b>). It was, however, disappointing to observe that such a shift could not be obtained on the V<sub>1a</sub>-R or OT-R where the compound remained an antagonist despite the very high sequence homology and structural similarity of the vasopressin/oxytocin binding sites. This illustrates one more time the subtlety of ligand–receptor interaction and activation in this receptor family.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Because the 3-methyl-pyrazole derivative <b>17</b> of the benzoylbenzazepine pharmacophore was the only compound showing full agonist activity at a vasopressin/oxytocin receptor (V<sub>2</sub> subtype), we decided to pursue our quest for an OT-R agonist around the 3-methyl-1-pyrazoloaryl pharmacophore in replacing the benzazepine fragment by other nuclei derived from reference ligands. The central aryl linker was bare or substituted with chlorine in position 2. The binding and functional profiles of these hybrid molecules are reported in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Taken together, the results confirm that it is indeed possible to modulate the affinity and selectivity profile of vasopressin/oxytocin ligands in playing with the benzazepine component of the ligands. Hybrid molecules with the aryl-1-(3-methyl)pyrazole pharmacophore remained in most cases agonists at the V<sub>2</sub>-R, however, they did not switch to agonists neither at the V<sub>1a</sub> receptor nor at the target OT receptor. It thus appeared from this study and from our previous work<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> that the only entry to OT agonism is the pyrazolobenzodiazepine synthon as in Ferring and Wyeth WAY-267464 compounds.</div><div class="NLM_p">Very limited SAR studies were reported around the Ferring compound. In the initial disclosure,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> its functional potency using a reporter gene assay on OT-R and V<sub>2</sub>-R was reported (EC<sub>50</sub> = 33 and 850 nM, respectively). Affinity data as well as its extended functional profile were published later, together with a troncature study and the profiling of few hybrid molecules.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> To our knowledge, only one SAR study was published around WAY-267464, dealing with flexible analogues that turned from OT-R agonists to V1a-R antagonists, confirming the high sensitivity of the system.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Our own SAR study around the pyrazolobenzodiazepine reported here (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) led to the discovery of a new potent agonist, compound <b>57</b>, that shows lower molecular weight, better selectivity versus the V<sub>1a</sub> receptor, similar EC<sub>50</sub>, and improved efficacy (52%−96%) compared to Ferring compound or WAY-267464. However, we found difficult to conclude to a superiority of <b>57</b> based on in vitro affinity or simple potency and intrinsic activity measurements. Indeed, in our experience, such data are very much dependent on the experimental conditions (cells, expression vectors, stable or transient expression, receptor density, and environment, assay, experimenter, etc.). As an illustration, we report in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> binding and potency data for OT, Ferring compound, WAY-267464, and compound <b>57</b> collected from literature and from our own experiments. As can be observed, affinity data are usually consistent but may vary significantly. For example, <i>K</i><sub>i</sub> varies from 12.5 to 113 nM<a onclick="showRef(event, 'ref40 ref49 ref51'); return false;" href="javascript:void(0);" class="ref ref40 ref49 ref51">(40,49,51)</a> to more than 5800 nM<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> for the reference WAY-267464. As expected, more drastic differences are observed for potency. Hence EC<sub>50</sub> may vary for the same compound from 33 to 667 nM (Ferring compound), from 3 nM to 881 nM (WAY-267464), or from 16 to 55 nM (<b>57</b>) according to differences in systems of expression or in quantification assays. Important variations are also observed in the achievable maximal responses. For instance, for the Ferring compound, maximal efficacy varies from 58% to 84% and ultimately 100% in moving from an IP1, to a Ca<sup>2+</sup> and to a gene reporter assay in CHO cells, respectively, which might be understood because different levels of amplification are involved. However, in looking at the Ca<sup>2+</sup> signal in HEK cells, the Ferring compound behaved mainly as a full agonist (EC<sub>50</sub> = 111–149 nM; 88–100% maximal response). The reverse trend is observed for the widely used OT-R “agonist” WAY-267464 compound which displayed maximal responses varying from 87% (CHO/Ca<sup>2+</sup>) to 27% (HEK/Ca<sup>2+</sup>). As can be seen from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, compound <b>57</b> behaved as a partial agonist in one series of experiment (52%; HEK/Ca<sup>2+</sup>) and a full agonist in another series (96%; transient HEK/Ca<sup>2+</sup>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Binding Profiles and Potency Evaluation at OT-R of Reference Compounds and Compound <b>57</b> in Different Experimental Conditions</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">affinity (<i>K</i><sub>i</sub>; nM ± SD)</th><th class="rowsep1 colsep0" colspan="2" align="center">efficacy at OT-R</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">experimental conditions</th><th class="colsep0 rowsep0" align="center">V<sub>1a</sub>-R</th><th class="colsep0 rowsep0" align="center">V<sub>2</sub>-R</th><th class="colsep0 rowsep0" align="center">OT-R</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM ± SD)</th><th class="colsep0 rowsep0" align="center">maximal response (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OT</td><td class="colsep0 rowsep0" align="center">IP1 (CHO; stable)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">10.6 ± 0.3</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">gene reporter (CHO; transient)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">0.18 ± 0.07 (<i>n</i> = 20)</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ferring</td><td class="colsep0 rowsep0" align="center">radioligand binding (CHO)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td><td class="colsep0 rowsep0" align="center">330 ± 38</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">147 ± 11</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">FRET binding (HEK)</td><td class="colsep0 rowsep0" align="center">196 ± 67</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">28 ± 11</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">IP1 (CHO; stable)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">667 ± 68 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="center">58 ± 2 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">gene reporter<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (CHO; transient)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">33 ± 15 (<i>n</i> ≥ 3)</td><td class="colsep0 rowsep0" align="center">100 (<i>n</i> ≥ 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WAY-267464</td><td class="colsep0 rowsep0" align="center">radioligand binding<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (CHO; stable)</td><td class="colsep0 rowsep0" align="center">>5800</td><td class="colsep0 rowsep0" align="center">>5800</td><td class="colsep0 rowsep0" align="center">58.4 ± 11.3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">radioligand binding<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> (HEK; membranes)</td><td class="colsep0 rowsep0" align="center">27 ± 3</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">230 ± 31</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">radioligand binding<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (HEK; membranes)</td><td class="colsep0 rowsep0" align="center">113 ± 32</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">978 ± 71</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">FRET binding (HEK; stable)</td><td class="colsep0 rowsep0" align="center">12.5 ± 1.5</td><td class="colsep0 rowsep0" align="center">>1000</td><td class="colsep0 rowsep0" align="center">30.5 ± 6.5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">calcium<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (CHO; stable)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">61.3 ± 4.5</td><td class="colsep0 rowsep0" align="center">87.1 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">IP1<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> (HEK; stable)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">420 ± 59</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">calcium<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (HEK; stable)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">881 ± 383</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">calcium (HEK; stable)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">3 ± 0</td><td class="colsep0 rowsep0" align="center">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="center">calcium (HEK; stable)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">55 ± 7</td><td class="colsep0 rowsep0" align="center">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">calcium (HEK; transient)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">25 ± 7</td><td class="colsep0 rowsep0" align="center">96 ± 8</td></tr></tbody></table></div></div><div class="NLM_p">As reported above, variations in measurements of in vitro affinity, potency, and intrinsic activity profiles of pharmacological probes may lead to misinterpretation of in vivo data. In particular, WAY-267464 was used as a specific nonpeptide OT agonist in several studies,<a onclick="showRef(event, 'ref40 ref50'); return false;" href="javascript:void(0);" class="ref ref40 ref50">(40,50)</a> while it has clearly been demonstrated more recently that some of its in vivo pharmacological functions are mainly driven by its V<sub>1a</sub> antagonist activity.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The correspondence between diverse in vitro and in vivo data is not straightforward, and this led us to evaluate the signaling profile and the efficacy of one of our new compounds in animal models of the target disease. The selection criteria of the molecule to be further tested in vitro and in vivo were a combination of its in vitro activity and its putative ability to penetrate the brain. Some appropriate physicochemical parameters of the best candidates were calculated<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Compound <b>57</b> has a molecular weight slightly lower than the reference WAY-267464, which may favor passive absorption. Its thermodynamic solubility in buffer at pH 7.4 is fair: 0.68 ± 0.07 mM (WAY-267464, 5 mM). Its calculated log <i>D</i> is in the perfect range for brain penetration (log <i>D</i> = 2.84; experimental log <i>D</i> = 2.0 ± 0.3 at pH = 7.4). The polar surface area is also more favorable, which leads to a logBB value (log BB = 0.133 – 0.0153PSA + 0.1522log <i>P</i>) above the target threshold (log BB = −1) to optimize brain penetration.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> On this basis, compound <b>57</b> (named <b>LIT-001</b>) was selected for a more detailed signaling study (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">Figure S1</a>) and for in vivo studies (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Calculated Physicochemical Characteristics of Reference and Compound <b>57</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0017.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0018.gif" alt="" id="GRAPHIC-d7e3585-autogenerated" /></img><div></div></div><div class="NLM_p">In vitro signaling experiments allowed us to identify compound <b>57</b> as a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V<sub>1a</sub> and agonist effect on V<sub>1b</sub> receptors, observed at high concentrations only (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Compound <b>57</b>, however, activated V<sub>2</sub>-R, which is not likely to impact social behavior as V<sub>2</sub>-R are not expressed in the central nervous system<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> but may cause fluid retention.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> This agonist effect was similar to the effect of oxytocin, which was shown to be safe for chronic use in patients.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> In comparison, the reference molecule WAY-267464, in our experimental setup, had only partial effects or lower affinity to stimulate OT-R-mediated signaling. WAY-267464, as compound <b>57</b>, antagonizes V<sub>1a</sub>-R, an effect that may contribute to facilitate social interaction.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> We could not evidence G protein-biased agonism of carbetocin on OT-R, as previously shown,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> but such bias was very clear on V<sub>1b</sub> and V<sub>2</sub> receptors. Finally, oxytocin bound and activated OT-R as well as V<sub>1a</sub>, V<sub>1b</sub>, and V<sub>2</sub> receptors, as previously demonstrated.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Thus, compound <b>57</b> clearly appeared as the most promising alternative to oxytocin for therapeutic development as a potent nonpeptidic OT-R agonist, with potential selectivity in the CNS after peripheral administration.</div><div class="NLM_p last">Consistent with this, <b>57</b> efficiently relieved social interaction deficits in <i>Oprm1</i><sup><i>–/–</i></sup> mice, a mouse model of autism,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> by normalizing the number and duration of nose contacts, the frequency of following episodes and the occurrence of grooming episodes after a social contact to wild-type levels at the dose of 10 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). These effects were observed following systemic (intraperitoneal) administration that led to a measured brain concentration of compound <b>57</b> in the range of its <i>K</i><sub>i</sub> (399 min·ng/g at 10 mg/kg ip). A full pharmacokinetic study remains to be done but these preliminary results suggest brain penetrance and bioavailability for this OT-R agonist, while oxytocin is known as poorly brain penetrant (except through i.n. route) and highly sensitive to peripheral degradation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68833" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68833" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">An extended structure–activity relationship study around vasopressin/oxytocin nonpeptide pharmacophores further illustrated<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> the subtlety of the activation mechanisms of the V<sub>1a</sub>, V<sub>1b</sub>, V<sub>2</sub>, and OT receptors. Minor structural changes affect significantly the affinity and selectivity profiles of ligands in spite of the high structural similarity of the binding clefts of the members of this GPCR subgroup. In this context, finding OT-R nonpeptide agonists represented a challenge. Our study led to the discovery of <b>LIT-001</b> (compound <b>57</b>) that represents the first nonpeptide OT receptor agonist active in an animal model of ASD after peripheral ip administration. As a proof of concept, <b>LIT-001</b> is a useful pharmacological tool to explore the implication of oxytocin in social attachment behaviors and it may pave the way to the development of optimized preclinical candidates to treat some components of autism.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Methods</h4><div class="NLM_p">General methods are as described in ref <a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a>. Purity (≥95% for all compounds) was determined by analytical HPLC in the same conditions as previously reported.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Elementary analysis of the final compounds have been determined by the Service Central d’Analyse of the Centre National de la Recherche Scientifique (CNRS; Vernaison) or by the core service of microanalysis of the Institute of Chemistry, Strasbourg University.</div><div class="NLM_p last">The synthesis of precursor compounds <b>1</b>–<b>8</b>, <b>28</b>, <b>31</b>, and <b>37</b> is reported and available in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Method A for the Coupling of Amines and Benzoic Acids</h4><div class="NLM_p">To a solution of benzoic acids (1.1 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> under argon were added 2–3 drops of NMP and 1.2 equiv of SOCl<sub>2</sub>. The mixture was stirred overnight at rt and evaporated. The residue was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> and added dropwise at 0 °C under argon to a mixture of the amine (1.0 equiv) and anhydrous pyridine (5.0 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred 30 min at 0 °C and then at rt for 4–20 h. The mixture was then poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The aqueous phase was washed with 1 N HCl and saturated aqueous K<sub>2</sub>CO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The residue was purified by chromatography on a silica gel column (heptane → AcOEt excepted AcOEt → AcOEt/MeOH 9:1 for <b>41a</b>,<b>b</b>).</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-(4-Chlorobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>9</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-chlorobenzoic acid according to general method A to give <b>9</b> as a white solid (yield 78%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 7/3). MP = 84 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.40–1.60 (m, 1H), 1.90–2.18 (m, 3H), 2.70–3.10 (m, 3H), 5.00 (dl app, 1H, <i>J</i> = 13.4 Hz), 6.62 (d, 1H, <i>J</i> = 7.8 Hz), 6.93 (t, 1H, <i>J</i> = 7.2 Hz), 7.03–7.18 (m, 5H), 7.23 (d, 1H, <i>J</i> = 6.8 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.2, 29.6, 35.0, 47.7, 127.1, 127.3, 127.9, 128.2, 129.6, 130.1, 134.6, 135.5, 139.2, 143.7, 167.9. IR (ATR): λ (cm<sup>–1</sup>) 2940, 2918, 1644, 1592, 1576, 1488, 1434, 1398, 1376, 1359, 1306, 1273, 1258, 1174, 1137, 1092, 1071, 1012, 960, 917, 852, 841, 823, 766, 751, 745, 724, 692, 574, 555, 540. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>16</sub>ClNO [M + Na]<sup>+</sup> 308.0813, found 308.0819. HPLC <i>t</i><sub><i>R</i></sub> = 20.7 min, purity 98.8% (254 nm).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(4-Bromobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>10</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-bromobenzoic acid according to general method A to give <b>10</b> as a white solid (yield 79%). <i>R</i><sub><i>f</i></sub> = 0.5 (hept/AcOEt 7/3). MP = 102 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.40–1.60 (m, 1H), 1.87–2.20 (m, 3H), 2.70–3.10 (m, 3H), 5.00 (dl app, 1H, <i>J</i> = 13.1 Hz), 6.62 (d, 1H, <i>J</i> = 7.8 Hz), 6.93 (t, 1H, <i>J</i> = 7.6 Hz), 7.05 (d, 2H, <i>J</i> = 8.4 Hz), 7.10 (t, 1H, <i>J</i> = 6.8 Hz), 7.23 (d, 1H, <i>J</i> = 7.8 Hz), 7.28 (d, 2H, <i>J</i> = 8.4 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.2, 29.6, 34.9, 47.7, 123.9, 127.1, 127.4, 128.2, 129.8, 130.1 130.8, 135.1, 139.2, 143.7, 168.0. IR (ATR): λ (cm<sup>–1</sup>) 2935, 2911, 1650, 1637, 1577, 1567, 1488, 1448, 1434, 1393, 1377, 1357, 1310, 1274, 1256, 1182, 1139, 1072, 1063, 1030, 1006, 954, 853, 841, 827, 760, 739, 625, 575, 550, 535. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>16</sub>BrNO [M + Na]<sup>+</sup> 352.0307, found 352.0324. HPLC <i>t</i><sub><i>R</i></sub> = 21.1 min, purity 98.9% (254 nm).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 1-(4-Iodobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>11</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-iodobenzoic acid according to general method A to give <b>11</b> as a white solid (yield 38%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 7/3). MP = 137 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.40–1.60 (m, 1H), 1.87–2.18 (m, 3H), 2.70–3.10 (m, 3H), 5.00 (d, 1H, <i>J</i> = 13.1 Hz), 6.62 (d, 1H, <i>J</i> = 7.5 Hz), 6.91 (d, 2H, <i>J</i> = 8.4 Hz), 6.93 (m, 1H), 7.10 (t, 1H, <i>J</i> = 7.5 Hz), 7.23 (d, 1H, <i>J</i> = 7.5 Hz), 7.48 (d, 2H, <i>J</i> = 8.4 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.2, 29.5, 34.9, 47.7, 96.0, 127.1, 127.4, 128.2, 129.8, 130.1, 135.7, 136.8, 139.2, 143.7, 168.1. IR (ATR): λ (cm<sup>–1</sup>) 2931, 2906, 2850, 2837, 1635, 1602, 1582, 1491, 1438, 1392, 1381, 1356, 1309, 1274, 1257, 1180, 1140, 1007, 950, 823, 765, 743, 660, 574, 552. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>16</sub>INO [M + H]<sup>+</sup> 378.0349, found 378.0334. HPLC <i>t</i><sub><i>R</i></sub> = 21.7 min, purity 98.1% (254 nm).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 1-(4-Propylbenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>12</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-<i>n</i>-propylbenzoic acid according to general method A to give <b>12</b> as a beige glass (yield 86%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 8/2). MP = 36 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.85 (t, 3H, <i>J</i> = 7.4 Hz), 1.43–1.64 (m, 3H), 1.87–2.16 (m, 3H), 2.48 (t, 2H, <i>J</i> = 7.5 Hz), 2.76 (t, 1H, <i>J</i> = 11.6 Hz), 2.82–2.93 (m, 1H), 3.05 (t, 1H, <i>J</i> = 13.5 Hz), 5.04 (dl app, 1H, <i>J</i> = 14.1 Hz), 6.64 (d, 1H, <i>J</i> = 7.8 Hz), 6.84–6.92 (m, 1H), 6.94 (d, 2H, <i>J</i> = 8.1 Hz), 7.02–7.17 (m, 3H), 7.22 (d, 1H, <i>J</i> = 7.2 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 13.6, 24.1, 26.3, 29.7, 35.0, 37.7, 47.6, 126.8, 126.9, 127.7, 128.2, 128.3, 129.9, 133.5, 139.2, 144.3, 169.1. IR (ATR): λ (cm<sup>–1</sup>) 2927, 2854, 1634, 1580, 1491, 1438, 1382, 1354, 1307, 1275, 1260, 1179, 1139, 955, 852, 808, 755, 740, 720, 578, 547, 485, 466, 438. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>NO [M + H]<sup>+</sup> 294.1852, found 294.1845. HPLC <i>t</i><sub><i>R</i></sub> = 20.3 min, purity 98.8% (254 nm).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 1-(4-Butylbenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>13</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-<i>n</i>-butylbenzoic acid according to general method A to give <b>13</b> as a beige solid (yield 83%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 8/2). MP = 42 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.87 (t, 3H, <i>J</i> = 7.1 Hz), 1.26 (sext, 2H, <i>J</i> = 7.3 Hz), 1.50 (quint, 2H, <i>J</i> = 7.4 Hz), 1.40–1.63 (m, 1H), 1.85–2.19 (m, 3H), 2.50 (t, 2H, <i>J</i> = 7.7 Hz), 2.66–2.95 (m, 2H), 3.05 (t, 1H, <i>J</i> = 13.3 Hz), 5.04 (d, 1H, <i>J</i> = 13.4 Hz), 6.64 (d, 1H, <i>J</i> = 7.6 Hz), 6.82–6.95 (m, 1H), 6.94 (d, 2H, <i>J</i> = 8.2 Hz), 7.00–7.12 (m, 1H), 7.10 (d, 2H, <i>J</i> = 7.8 Hz), 7.23 (dd, 1H, <i>J</i> = 7.4, 1.2 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 13.8, 22.2, 26.3, 29.7, 33.2, 35.0, 35.3, 47.6, 126.9, 126.9, 127.6, 128.2, 128.3, 129.9, 133.4, 139.2, 144.3, 144.5, 169.1. IR (ATR): λ (cm<sup>–1</sup>) 2956, 2925, 2854, 1632, 1611, 1580, 1491, 1452, 1435, 1383, 1355, 1307, 1275, 1261, 1179, 1139, 954, 851, 837, 767, 748, 713, 579, 549. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>25</sub>NO [M + H]<sup>+</sup> 308.2009, found 308.1994. HPLC <i>t</i><sub><i>R</i></sub> = 21.8 min, purity 98.9% (254 nm).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 1-(1,1′-Biphenyl-4-ylcarbonyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>14</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with 4-phenylbenzoic acid according to general method A to give <b>14</b> as a white solid (yield 87%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 7/3). MP = 162 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.36–1.63 (m, 1H), 1.77–2.20 (m, 3H), 2.60–3.20 (m, 3H), 5.06 (d, 1H, <i>J</i> = 13.9 Hz), 6.69 (d, 1H, <i>J</i> = 7.6 Hz), 6.92 (t, 1H, <i>J</i> = 7.1 Hz), 7.00–7.58 (m, 11H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.3, 29.7, 35.0, 47.7, 126.2, 127.0, 127.1, 127.6, 128.3, 128.7, 130.0, 135.0, 139.2, 140.1, 142.1, 144.1, 168.8. IR (ATR): λ (cm<sup>–1</sup>) 3061, 2939, 2924, 2914, 2881, 2852, 2837, 1626, 1615, 1575, 1557, 1488, 1454, 1441, 1434, 1402, 1385, 1355, 1310, 1274, 1258, 1139, 1110, 948, 854, 840, 775, 767, 756, 747, 735, 700, 676, 579. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>21</sub>NO [M + Na]<sup>+</sup> 350.1515, found 350.1534. HPLC <i>t</i><sub><i>R</i></sub> = 22.6 min, purity 99.4% (254 nm).</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 1-(4-Pyridin-3-ylbenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>15</b>)</h5><div class="NLM_p last">To a suspension of <b>5a</b> (232 mg, 0.987 mmol) in 6 mL of anhydrous THF under argon atmosphere were added SOCl<sub>2</sub> (0.36 mL, 4.935 mmol) and 3 drops of DMF. The mixture was stirred overnight at rt. The liquid was evaporated, and the residue was dissolved in 2 mL of anhydrous THF, evaporated again, and dried in vacuo. A solid was obtained. It was suspended with DMAP (3.0 mg, 0.024 mmol) in 6 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub>. A solution of <b>8</b> (120 mg, 0.815 mmol) and anhydrous pyridine (0.20 mL, 2.445 mmol) in 1 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was added dropwise at 0 °C under argon atmosphere. Stirring was maintained 4 h at rt. The mixture was then diluted in 30 mL of CH<sub>2</sub>Cl<sub>2</sub> and washed with 10 mL of 1 N HCl and 10 mL of a saturated aqueous NaHCO<sub>3</sub>. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by chromatography on a silica gel column (hept → hept/AcOEt 4/6). Recrystallization from EtOH afforded white crystals (130 mg; yield 49%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 25/75). MP = 128 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.44–1.63 (m, 1H), 1.88–2.20 (m, 3H), 2.72–2.98 (m, 2H), 3.08 (t, 1H, <i>J</i> = 13.0 Hz), 5.05 (d, 1H, <i>J</i> = 13.2 Hz), 6.68 (d, 1H, <i>J</i> = 7.8 Hz), 6.93 (t, 1H, <i>J</i> = 7.4 Hz), 7.10 (t, 1H, <i>J</i> = 7.4 Hz), 7.20–7.40 (m, 2H), 7.30 (d, 2H, <i>J</i> = 8.1 Hz), 7.38 (d, 2H, <i>J</i> = 8.4 Hz), 7.79 (d, 1H, <i>J</i> = 7.8 Hz), 8.57 (d, 1H, <i>J</i> = 3.3 Hz), 8.76 (s, 1H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 26.3, 29.6, 35.0, 47.7, 123.5, 126.3, 127.1, 127.3, 128.3, 129.0, 130.1, 134.2, 135.6, 136.0, 138.7, 139.3, 143.9, 148.2, 148.8, 168.4. IR (ATR): λ (cm<sup>–1</sup>) 3052, 3033, 3004, 2930, 2855, 1632, 1576, 1495, 1435, 1393, 1358, 1315, 1278, 1259, 1143, 1003, 951, 854, 810, 761, 741, 715, 600, 583, 549, 409. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 329.1648, found 329.1651. HPLC <i>t</i><sub><i>R</i></sub> = 14.4 min, purity 99.3% (254 nm).</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 1-(4-Pyrimidin-2-ylbenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>16</b>)</h5><div class="NLM_p last">To a suspension of <b>5b</b> (164 mg, 0.821 mmol) in 8 mL of an anhydrous mixture of CH<sub>2</sub>Cl<sub>2</sub>/THF 1/1 under argon atmosphere were added SOCl<sub>2</sub> (0.18 mL, 2.463 mmol) and 3 drops of DMF. The mixture was stirred overnight at rt. Solvents were evaporated, and the residue was disolved in 2 mL of anhydrous THF, evaporated, and then dried in vacuo. The solid that was obtained was mixed with DMAP (2.5 mg, 0.020 mmol) in 5 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub>. A solution of benzazepine <b>8</b> (100 mg, 0.679 mmol) and anhydrous pyridine (0.16 mL, 2.040 mmol) in 1 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was added dropwise to this suspension, at 0 °C under argon atmosphere. The mixture was stirred overnight at rt. It was then diluted with 20 mL of CH<sub>2</sub>Cl<sub>2</sub> and washed with 10 mL of 1 N HCl and 10 mL of a saturated aqueous solution of NaHCO<sub>3</sub>. The organic phase was then collected, dried on Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The residue was purified on a chromatography on a silica gel column (hept → hept/AcOEt 6/4). Recrystallization from EtOH affords transparent crystals (158 mg; yield 70%). <i>R</i><sub><i>f</i></sub> = 0.6 (hept/AcOEt 25/75). MP = 173 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.40–1.72 (m, 1H), 1.87–2.20 (m, 3H), 2.68–2.98 (m, 2H), 3.09 (t, 1H, <i>J</i> = 12.9 Hz), 5.05 (d app, 1H, <i>J</i> = 13.4 Hz), 6.66 (d, 1H, <i>J</i> = 7.6 Hz), 6.87 (t, 1H, <i>J</i> = 7.5 Hz), 7.05 (t, 1H, <i>J</i> = 7.4 Hz), 7.11–7.36 (m, 2H), 7.31 (d, 2H, <i>J</i> = 8.2 Hz), 8.23 (d, 2H, <i>J</i> = 8.4 Hz), 8.76 (d, 2H, <i>J</i> = 4.6 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 26.4 29.6, 35.0, 47.7, 119.3, 127.0, 127.3, 127.4, 128.3, 130.0, 138.3, 138.4, 139.3, 143.8, 157.2, 164.0, 168.8. IR (ATR): λ (cm<sup>–1</sup>) 3066, 3050, 2922, 2882, 2853, 1628, 1575, 1566, 1556, 1494, 1417, 1404, 1385, 1356, 1313, 1279, 1260, 1142, 1018, 953, 866, 815, 804, 778, 761, 752, 744, 656, 641, 627, 582, 550, 476. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 330.1601, found 330.1596. HPLC <i>t</i><sub><i>R</i></sub> = 20.2 min, purity 99.9% (254 nm).</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 1-[4-(3-Methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>17</b>)</h5><div class="NLM_p last">Benzazepine <b>8</b> reacted with the acid <b>3a</b> according to general method A to give <b>17</b> as transparent crystals after recrystallization from AcOEt (yield 88%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 5/5). MP = 124 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.40–1.65 (m, 1H), 1.80–2.20 (m, 3H), 2.32 (s, 3H), 2.65–3.20 (m, 3H), 5.03 (d, 1H, <i>J</i> = 13.2 Hz), 6.20 (d, 1H, <i>J</i> = 2.2 Hz), 6.64 (d, 1H, <i>J</i> = 7.8 Hz), 6.89 (t, 1H, <i>J</i> = 7.6 Hz), 7.06 (td, 1H, <i>J</i> = 7.6, 1.0 Hz), 7.15–7.35 (m, 3H), 7.43 (d, 2H, <i>J</i> = 8.6 Hz), 7.74 (d, 1H, <i>J</i> = 2.4 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 13.6, 26.2, 29.5, 34.9, 47.6, 107.9, 117.3, 127.0, 127.2, 127.2, 128.2, 129.5, 129.9, 133.4, 139.1, 140.4, 143.9, 150.9, 168.1. IR (KBr): λ (cm<sup>–1</sup>) 3054, 2933, 2854, 1638, 1611, 1579, 1542, 1491, 1452, 1439, 1426, 1398, 1384, 1360, 1309, 1275, 1258, 1226, 1177, 1140, 1047, 958, 945, 837, 772, 758, 577. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 332.1757, found 332.1746. HPLC <i>t</i><sub><i>R</i></sub> = 18.9 min, purity 99.2% (254 nm). Elemental analysis calculated (%) for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O: C 76.11, H 6.39, N 12.68. Found: C 75.92, H 6.66, N 12.68.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 1-(4-Nitrobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>18</b>)</h5><div class="NLM_p last">A mixture of benzazepine <b>8</b> (258 mg, 1.75 mmol) and anhydrous pyridine (0.70 mL, 8.76 mmol) in 3 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was added dropwise to a solution of 4-nitrobenzoyl chloride (390 mg, 2.10 mmol) in 10 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> under argon atmosphere at 0 °C. The mixture was stirred for 45 min at 0 °C and one night at rt. The products were poured into 10 mL of water and extracted twice with 30 mL of CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed with 20 mL of 0.5 N HCl and 20 mL of water, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The residue was purified by chromatography on a silica gel column (hept/AcOEt 7/3 → 6/4) affording white crystals (360 mg; yield 69%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 7/3). MP = 141 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.40–1.70 (m, 1H), 1.85–2.25 (m, 3H), 2.70–3.15 (m, 3H), 4.99 (d, 1H, <i>J</i> = 13.4 Hz), 6.60 (d, 1H, <i>J</i> = 7.6 Hz), 6.91 (td, 1H, <i>J</i> = 7.7, 1.7 Hz), 7.11 (td, 1H, <i>J</i> = 7.5, 1.2 Hz), 7.25 (d, 1H), 7.35 (d, 2H, <i>J</i> = 9.0 Hz), 8.01 (d, 2H, <i>J</i> = 9.0 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.3, 29.5, 35.0, 47.8, 123.0, 127.2, 127.9, 128.2, 128.8, 130.4, 139.4, 142.5, 142.9, 147.9, 168.4. IR (KBr): λ (cm<sup>–1</sup>) 3102, 3074, 2939, 2916, 2849, 1642, 1598, 1513, 1491, 1440, 1412, 1344, 1316, 1271, 861, 765, 735.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>19</b>)</h5><div class="NLM_p last">A few mg of 10% Pd/C were added to compound <b>18</b> (356 mg, 1.20 mmol) in 10 mL of EtOH and 10 mL of AcOEt and the suspension was stirred under H<sub>2</sub> (20 psi) at rt for 5 h. The mixture was then filtered on Celite, and the filtrate was evaporated. The residue was taken up in 50 mL of CH<sub>2</sub>Cl<sub>2</sub> and washed with 40 mL of water. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Compound <b>19</b> was obtained as a white powder (326 mg; quantitative yield). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 5/5). MP = 162 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.49 (m, 1H), 1.70–2.20 (m, 3H), 2.50–3.10 (m, 3H), 3.15–4.00 (bs, 1H), 5.02 (m, 1H), 6.38 (d, 2H, <i>J</i> = 8.1 Hz), 6.67 (d, 1H, <i>J</i> = 7.8 Hz), 6.93 (t, 1H, <i>J</i> = 7.6 Hz), 7.02 (d, 2H, <i>J</i> = 8.1 Hz), 7.07 (t, 1H, <i>J</i> = 7.5 Hz), 7.22 (d, 1H, <i>J</i> = 7.5 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.2, 29.7, 34.9, 47.6, 113.7, 125.8, 126.7, 126.9, 128.2, 129.9, 130.4, 139.0, 144.8, 147.5, 168.9. IR (KBr): λ (cm<sup>–1</sup>) 3447, 3351, 2931, 2838, 1617, 1383, 1308, 1273, 1170, 764, 503. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>NO [M + H]<sup>+</sup> 267.1492, found 267.1477. HPLC <i>t</i><sub><i>R</i></sub> = 17.8 min, purity 99.2% (254 nm). Elemental analysis calculated (%) for C<sub>18</sub>H<sub>20</sub>NO: C 76.66, H 6.81, N 10.52. Found: C 76.50, H 6.98, N 10.29.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>,<i>N</i>,<i>N</i>-Trimethyl-4-(2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-1-ylcarbonyl)benzenaminium (<b>20</b>)</h5><div class="NLM_p last">A solution of <b>19</b> (400 mg, 1.50 mmol), MeI (0.20 mL, 3.00 mmol), and K<sub>2</sub>CO<sub>3</sub> (311 mg, 2.25 mmol) in 8 mL of CH<sub>2</sub>Cl<sub>2</sub> was warmed at 70 °C under argon atmosphere during 6 h. After return to rt, the mixture was poured into 50 mL of water and extracted with 80 mL of AcOEt/toluene. The organic phase was washed with 25 mL of water, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. Recrystallization from MeOH afforded white crystals (293 mg, yield 66%). <i>R</i><sub><i>f</i></sub> = 0.6 (hept/AcOEt 5/5). MP = 152 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.45 (m, 1H), 1.75–2.20 (m, 3H), 2.50–3.20 (m, 9H), 4.90–5.30 (m, 1H), 6.34 (d, 2H, <i>J</i> = 7.9 Hz), 6.66 (m, 1H), 6.89 (m, 1H), 7.00–7.40 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 25.9, 29.5, 34.6, 39.6, 47.3, 110.0, 122.3, 126.3, 126.6, 127.8, 129.6, 130.1, 138.6, 144.8, 150.7, 168.6. IR (KBr): λ (cm<sup>–1</sup>) 3094, 3007, 2933, 2845, 1612, 1524, 1484, 1437, 1369, 1302, 1194, 1169, 762, 500. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 295.1805, found 295.1798. HPLC <i>t</i><sub><i>R</i></sub> = 21.1 min, purity 98.8% (254 nm). Elemental analysis calculated (%) for C<sub>19</sub>H<sub>22</sub>N<sub>2</sub>O: C 77.52, H 7.53, N 9.52. Found: C 77.69, H 7.75, N 9.62.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>,<i>N</i>,<i>N</i>-Trimethyl-4-(2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-1-ylcarbonyl)benzenaminium, Trifluoroacetate (<b>21</b>)</h5><div class="NLM_p last">To a solution of <b>20</b> (80 mg, 0.273 mmol) in 10 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> under argon atmosphere were added AgClO<sub>4</sub> (62 mg, 0.300 mmol) then MeI (19 μL, 0.300 mmol). The mixture was stirred for 2 h at rt in the dark, then filtered, and the solvent was evaporated. The residue was purified by semipreparative HPLC (H<sub>2</sub>O/0.1% TFA) for 5 min, then from 0 to 100% of MeCN/0.1% TFA in H<sub>2</sub>O/0.1% TFA from 5 to 30 min, at a flow rate of 10 mL/min. After lyophilization, compound <b>21</b> was obtained as a hygroscopic white powder (49 mg; yield 42%). <i>R</i><sub><i>f</i></sub> = 0.2 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 8/2). MP = 60 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.53 (m, 1H), 1.90–2.20 (m, 3H), 2.35 (bs, 2H), 2.72–2.92 (m, 2H), 3.03 (t, 1H, <i>J</i> = 12.9 Hz), 3.75 (s, 9H), 4.95 (d, 1H, <i>J</i> = 12.9 Hz), 6.60 (d, 1H, <i>J</i> = 7.5 Hz), 6.92 (t, 1H, <i>J</i> = 7.6 Hz), 7.11 (t, 1H, <i>J</i> = 7.4 Hz, <i>H</i><sub>9</sub>), 7.24 (d, 1H, <i>J</i> = 7.2 Hz, <i>H</i><sub>8</sub>), 7.37 (d, 2H, <i>J</i> = 8.7 Hz, <i>H</i><sub>15a,b</sub>), 7.70 (d, 2H, <i>J</i> = 9.0 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.2, 29.5, 34.8, 47.9, 57.0, 119.4, 127.2, 128.0, 128.1, 130.2, 130.4, 138.8, 139.3, 142.8, 147.3, 160.9, 161.2, 166.5. IR (ATR): λ (cm<sup>–1</sup>) 3417, 3042, 2930, 2854, 1683, 1633, 1579, 1492, 1455, 1442, 1414, 1396, 1358, 1314, 1277, 1198, 1168, 1146, 1118, 1071, 1016, 956, 940, 847, 824, 800, 761, 749, 717, 598. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O·C<sub>2</sub>F<sub>3</sub>O<sub>2</sub>·H<sub>2</sub>O [M]<sup>+</sup> 309.1961, found 309.1961. Elemental analysis calculated (%) for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O·C<sub>2</sub>F<sub>3</sub>O<sub>2</sub>·H<sub>2</sub>O: C 59.99, H 6.18, N 6.36. Found: C 59.21, H 6.56, N 6.18.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-[4-(2,3,4,5-Tetrahydro-1<i>H</i>-1-benzazepin-1-ylcarbonyl)phenyl]acetamide (<b>22</b>)</h5><div class="NLM_p last">A solution of <b>19</b> (60 mg, 0.225 mmol), Ac<sub>2</sub>O (25 μL, 0.248 mmol), and DIEA (60 μL, 0.338 mmol) in 1.5 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> was stirred for 4 h at rt. The mixture was then diluted with 10 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed with 5 mL of water, 5 mL of 10% citric acid, and 5 mL of saturated aqueous Na<sub>2</sub>CO<sub>3</sub>. The aqueous phases were extracted again with 40 mL of CH<sub>2</sub>Cl<sub>2</sub>. The organic phases were gathered, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The residue was purified by chromatography on silica gel column (hept/AcOEt 5/5 → 1/9). Compound <b>22</b> was obtained as a white powder (68 mg; yield 98%). <i>R</i><sub><i>f</i></sub> = 0.5 (hept/AcOEt 1/9). MP = 168 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.51 (m, 1H, 1.75–2.00 (m, 3H), 2.09 (s, 3H), 2.65–3.10 (m, 3H), 5.00 (d, 1H, <i>J</i> = 13.5 Hz), 6.61 (d, 1H, <i>J</i> = 7.5 Hz), 6.89 (t, 1H, <i>J</i> = 7.2 Hz), 7.00–7.15 (m, 3H), 7.21 (d, 1H, <i>J</i> = 7.2 Hz), 7.20–7.40 (m, 2H), 7.72 (bs, 1H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 24.6, 26.2, 29.6, 34.9, 47.7, 118.3, 127.0, 127.2, 128.2, 129.2, 130.0, 131.4, 139.1, 139.3, 144.0, 168.5, 168.6. IR (KBr): λ (cm<sup>–1</sup>) 3289, 3036, 2925, 2861, 1691, 1620, 1529, 1406, 1308, 1262, 503. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 309.1598, found 309.1587. HPLC <i>t</i><sub><i>R</i></sub> = 14.2 min, purity 99.0% (254 nm). Elemental analysis calculated (%) for C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub>: C 74.00, H 6.54, N 9.08. Found: C 74.04, H 6.75, N 9.15.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 1-[4-[(1,1′-Biphenyl-2-ylcarbonyl)amino]benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>23</b>)</h5><div class="NLM_p last">To a solution of 2-biphenylcarboxylic acid (113 mg, 0.56 mmol) in 1.5 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub> at 0 °C under argon atmosphere were added 3–4 drops of DMF and (COCl)<sub>2</sub> (70 μL, 0.76 mmol). The mixture was stirred for 2 h at 0 °C. The CH<sub>2</sub>Cl<sub>2</sub> was evaported and the residue dissolved in 1.5 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub>. This solution was added dropwise, at 0 °C under argon to a mixture of <b>19</b> (30 mg, 0.11 mmol) and NEt<sub>3</sub> (80 μL, 0.56 mmol) in 1.5 mL of anhydrous CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred 2 h between 0 and 10 °C before being washed with 3 mL of H<sub>2</sub>O, 3 mL of 10% acetic acid, and 3 mL of saturated aqueous NaHCO<sub>3</sub>. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by chromatography on a silica gel column (CH<sub>2</sub>Cl<sub>2</sub>→ CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98/2). Compound <b>23</b> was obtained as a white powder (37 mg; yield 75%). <i>R</i><sub><i>f</i></sub> = 0.6 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9/1). MP = 201 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.40–1.60 (m, 1H), 1.80–2.20 (m, 3H), 2.60–3.20 (m, 3H), 4.99 (d, 1H, <i>J</i> = 12.8 Hz), 6.60 (d, 1H, <i>J</i> = 7.5 Hz), 6.80–7.20 (m, 7H), 7.21 (d, 1H, <i>J</i> = 7.5 Hz), 7.30–7.70 (m, 8H), 7.82 (d, 1H, <i>J</i> = 7.5 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 26.6, 30.0, 35.3, 48.1, 118.6, 127.5, 128.3, 128.5, 128.6, 129.1, 129.3, 129.6, 123.0, 130.4, 130.7, 131.2, 132.2, 135.3, 139.1, 139.5, 140.1, 144.5, 167.4, 168.7. IR (KBr): λ (cm<sup>–1</sup>) 3250, 3178, 3094, 3036, 2945, 2931, 1691, 1607, 1529, 1445, 1406, 1315, 1250, 743, 503. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 447.2067, found 447.2043. HPLC <i>t</i><sub><i>R</i></sub> = 21.5 min, purity 98.2% (254 nm). Elemental analysis calculated (%) for C<sub>30</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>: C 80.69, H 5.87, N 6.27. Found: C 79.98, H 6.12, N 6.20.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 1-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepine (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was prepared according to general method A, affording a creamy powder (yield 61%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 5/5). MP = 112–114 °C (lit:<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> 117–120 °C). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.40–1.80 (m, 1H), 1.85–2.20 (m, 3H), 2.32 (s, 2.59H), 2.39 (s, 0.41H), 2.70–2.95 (m, 2H), 3.05 (t, 1H, <i>J</i> = 13.0 Hz), 4.95 (d, 1H, <i>J</i> = 13.4 Hz), 6.21 (d, 0.87H, <i>J</i> = 2.4 Hz), 6.30 (d, 0.13H, <i>J</i> = 2.4 Hz), 6.83–7.17 (m, 5.10H), 7.31 (d, 0.56H, <i>J</i> = 2.0 Hz), 7.38–7.58 (m, 0.43H), 7.62 (d, 0.81H, <i>J</i> = 2.0 Hz), 7.70 (d, 0.93H, <i>J</i> = 2.4 Hz), 7.84 (t, 0.18H, <i>J</i> = 2.1 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 13.6, 26.4, 29.3, 35.0, 47.5, 108.3, 115.8, 119.3, 127.0, 127.3, 127.4, 127.6, 128.4, 130.0, 132.2, 133.9, 139.4, 140.5, 142.4, 151.3, 166.3. IR (KBr): λ (cm<sup>–1</sup>) 3147, 3024, 2929, 2853, 1650, 1602, 1396, 1314, 759. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>ClN<sub>3</sub>O [M + H]<sup>+</sup> 366.1368, found 366.1360. HPLC <i>t</i><sub><i>R</i></sub> = 20.5 min, purity 98.5% (254 nm). Elemental analysis (%) calculated for C<sub>21</sub>H<sub>20</sub>ClN<sub>3</sub>O: C 68.94, H 5.51, N 11.49. Found: C 68.93, H 5.96, N 10.83.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 1-[4-(3-Methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-1,2,3,4-tetrahydro-5<i>H</i>-1-benzazepin-5-one (<b>39a</b>)</h5><div class="NLM_p last">Compound <b>39a</b> was prepared from the amine <b>26</b> and the acid <b>3a</b> according to general method A, affording yellow crystals after recrystallization from EtOH (yield 32%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 5/5). MP = 140 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.18 (m, 2H), 2.34 (s, 3H), 2.92 (t, 2H, <i>J</i> = 6.2 Hz), 6.24 (d, 1H, <i>J</i> = 2.2 Hz), 6.74 (d, 1H, <i>J</i> = 7.8 Hz), 7.23 (m, 2H), 7.31 (d, 2H, <i>J</i> = 8.7 Hz), 7.49 (d, 2H, <i>J</i> = 8.7 Hz), 7.76 (d, 1H, <i>J</i> = 2.2 Hz), 7.87 (dd, 1H, <i>J</i> = 7.8, 1.6 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 14.1, 23.0, 40.6, 47.9, 108.7, 118.0, 127.7, 127.8, 129.4, 129.9, 130.6, 132.8, 133.5, 134.5, 141.5, 143.2, 151.7, 169.8, 202.4. IR (KBr): λ (cm<sup>–1</sup>) 3600–3200, 3130, 3061, 2929, 2901, 2873, 1680, 1639, 1604, 1535, 1354, 1264, 772. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 346.1550, found 346.1537. HPLC <i>t</i><sub><i>R</i></sub> = 23.1 min, purity 99.1% (254 nm). Elemental analysis (%) calculated for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>: C 73.03, H 5.54, N 12.17. Found: C 72.67, H 5.61, N 12.01.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 1-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-1,2,3,4-tetrahydro-5<i>H</i>-1-benzazepin-5-one (<b>39b</b>)</h5><div class="NLM_p last">Compound <b>39b</b> was prepared from the amine <b>26</b> and the acid <b>3b</b> according to general method A, affording a beige powder (yield 30%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 5/5). MP = 147 °C. <sup>1</sup>H (200 MHz, CDCl<sub>3</sub>): δ 2.14 (m, 2H), 2.33 (s, 3H), 2.90 (t, 2H, <i>J</i> = 6.0 Hz), 6.23 (d, 1H, <i>J</i> = 2.2 Hz), 6.96 (dd, 1H, <i>J</i> = 5.6, 3.4 Hz), 7.02–7.17 (m, 1H), 7.20–7.30 (m, 2H), 7.35 (d, 1H, <i>J</i> = 8.1 Hz), 7.58 (s, 1H), 7.71 (d, 1H, <i>J</i> = 2.4 Hz), 7.76 (dd, 1H, <i>J</i> = 5.9, 3.4 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 14.0, 22.2, 40.4, 46.6, 109.0, 116.3, 119.7, 127.7, 128.6, 128.8, 129.9, 133.4, 133.5, 135.7, 140.4, 141.3, 152.0, 168.3, 202.7. IR (KBr): λ (cm<sup>–1</sup>) 3600–3200, 3123, 3068, 3040, 2929, 2874, 1681, 1639, 1604, 1382, 758. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 380.1160, found 380.1161. HPLC <i>t</i><sub><i>R</i></sub> = 23.5 min, purity 95.8% (254 nm). Elemental analysis (%) calculated for C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2:</sub> C 66.40, H 4.78, N 11.06. Found: C 67.41, H 5.51, N 10.22.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 1-[4-(3-Methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-5-ol (<b>40a</b>)</h5><div class="NLM_p last">Compound <b>39a</b> (1.0 eq, 0.015M) and NaBH<sub>4</sub> (1.5 equiv) were stirred in MeOH for 2 h at rt. After evaporation of the solvent, the residue was dissolved in AcOEt and washed with H<sub>2</sub>O. The organic phase was dried on Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. Column chromatography (gradient hept/AcOEt) afforded a beige powder (yield 95%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 2/8). MP = 178 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.60–2.30 (m, 4H), 2.34 (s, 3H), 2.83 (t, <i>J</i> = 12.0 Hz, 1H), 4.70–5.30 (m, 2H,), 6.21 (d, 1H, <i>J</i> = 2.2 Hz), 6.63 (d, 1H, <i>J</i> = 7.6 Hz), 6.96 (t app, 1H, <i>J</i> = 7.3 Hz), 7.15–7.35 (m, 2H), 7.43 (d, 2H, <i>J</i> = 8.3 Hz), 7.54 (m, 1H), 7.66 (d, 1H, <i>J</i> = 7.6 Hz), 7.74 (d, 1H, <i>J</i> = 2.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 13.6, 23.1, 25.9, 29.7, 32.9, 35.7, 46.8, 48.0, 71.0, 74.9, 108.0, 117.5, 124.7, 127.3, 127.5, 128.1, 129.7, 130.3, 132.9, 140.2, 140.7, 141.1, 151.1, 168.3. IR (KBr): λ (cm<sup>–1</sup>) 3434, 3372, 3268, 3117, 2925, 2856, 1631, 1604, 1535, 1432, 1383, 1356, 1307, 1260, 1053, 757, 503. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 348.1707, found 348.1691. HPLC <i>t</i><sub><i>R</i></sub> = 20.9 min, purity 99.9% (254 nm). Elemental analysis (%) calculated for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>: C 72.60, H 6.09, N 12.09. Found: C 72.14, H 6.01, N 11.70.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 1-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-5-ol (<b>40b</b>)</h5><div class="NLM_p last">Compound <b>39b</b> (1.0 eq, 0.015M) and NaBH<sub>4</sub> (1.5 equiv) were stirred in MeOH for 2 h at rt. After evaporation of the solvent, the residue was dissolved in AcOEt and washed with H<sub>2</sub>O. The organic phase was dried on Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. Column chromatography (gradient hept/AcOEt) afforded a beige powder (yield 73%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 2/8). MP = 68 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.60–2.30 (m, 4 H), 2.33 (s, 2 H), 2.39 (s, 1 H), 2.88 (t, 1 H, <i>J</i> = 12.2 Hz), 4.70–5.20 (m, 2 H), 6.22 (d, 0.78 H, <i>J</i> = 2.5 Hz), 6.31 (d, 0.22 H, <i>J</i> = 2.5 Hz), 6.85–7.10 (m, 3 H), 7.18 (t, 1 H, <i>J</i> = 7.6 Hz), 7.25–7.50 (m, 1 H), 7.57 (d, 0.72 H, <i>J</i> = 7.8 Hz), 7.62 (d, 0.86 H, <i>J</i> = 1.9 Hz), 7.70 (d, 1 H, <i>J</i> = 2.2 Hz), 7.84 (m, 1 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 13.6, 22.6, 25.7, 33.1, 35.9, 46.5, 47.7, 71.1, 74.9, 108.2, 108.4, 115.7, 115.8, 116.9, 119.2, 119.3, 124.4, 127.3, 127.5, 127.8, 128.4, 128.8, 129.8, 130.1, 132.2, 133.5, 138.3, 138.7, 140.6, 141.2, 142.0, 151.2, 151.4,166.5. IR (KBr): λ (cm<sup>–1</sup>) 3392, 3124, 2925, 2856, 1638, 1604, 1535, 1445, 1411, 1362, 1315, 1053, 757. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 382.1317, found 382.1316. HPLC <i>t</i><sub><i>R</i></sub> = 23.2 min, purity 99.6% (254 nm). Elemental analysis (%) calculated for C<sub>21</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>2</sub>·H<sub>2</sub>O: C 63.08, H 5.55, N 10.51. Found: C 63.69, H 5.34, N 10.31.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>N</i>,<i>N</i>-Dimethyl-1-[4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-5-amine (<b>41a</b>)</h5><div class="NLM_p last">Compound <b>41a</b> was prepared from the amine <b>28</b> and the acid <b>3a</b> according to general method A, affording white crystals after recrystallization from MeOH (yield 70%). <i>R</i><sub><i>f</i></sub> = 0.5 (AcOEt/MeOH 9/1). MP = 156 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.10–2.00 (m, 4H, 2.19 (s, 3H), 2.34 (s, 3H), 2.45 (s, 3H), 2.60–5.20 (m, 3H), 6.22 (d, 1H, <i>J</i> = 1.9 Hz), 6.60 (d, 1H, <i>J</i> = 8.1 Hz), 6.95 (t, 1H), 7.10–7.35 (m, 3H), 7.46 (d, 2H, <i>J</i> = 8.3 Hz), 7.60 (d, 1H, <i>J</i> = 8.1 Hz), 7.76 (d, 1H, <i>J</i> = 2.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 13.7, 23.1, 24.3, 28.8, 29.6, 43.9, 44.9, 46.5, 48.0, 65.4, 107.8, 108.0, 117.4, 126.3, 127.3, 127.6, 128.7, 129.9, 131.4, 132.4, 133.1, 140.7, 151.0, 168.9. IR (KBr): λ (cm<sup>–1</sup>) 3097, 2952, 2923, 2882, 2824, 2788, 1638, 1608, 1539, 1481, 1451, 1353, 759, 504. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 375.2179, found 375.2166. HPLC mixture of diastereoisomers: <i>t</i><sub><i>R</i></sub> = 15.6 min (46.3%), <i>t</i><sub><i>R</i></sub> = 15.9 min (52.7%), purity 99.0% (254 nm). Elemental analysis (%) calculated for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O: C 73.77, H 7.00, N 14.96. Found: C 73.17, H 6.97, N 14.91.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 1-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-<i>N</i>,<i>N</i>-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-1-benzazepin-5-amine (<b>41b</b>)</h5><div class="NLM_p last">Compound <b>41b</b> was prepared from the amine <b>28</b> and the acid <b>3b</b> according to general method A, affording white crystals after recrystallization from MeOH (yield 17%). <i>R</i><sub><i>f</i></sub> = 0.5 (AcOEt/MeOH 9/1). MP = 182 °C. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 1.10–2.00 (m, 4H), 2.19 (s, 3H), 2.33 (s, 3H), 2.39 (s, 3H), 2.60–5.20 (m, 3H), 6.23 (s, 0.77 H), 6.30 (d, 0.23H, <i>J</i> = 2.4 Hz), 6.80–7.17 (m, 3H), 7.17–7.45 (m, 2.74H), 7.17–7.68 (m, 1.81 Hz), 7.72 (d, 0.88H, <i>J</i> = 2.2 Hz), 7.79 (bs, 0.33H), 7.84 (d, 0.24H, <i>J</i> = 2.4 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ 13.6, 23.0, 24.1, 29.0, 29.9, 43.9, 44.7, 45.3, 46.1, 47.6, 64.9, 72.5, 108.2, 108.4, 115.7, 115.8, 116.9, 119.0, 119.2, 126.2, 126.8, 127.1, 127.3, 127.8, 127.9, 128.2, 128.7, 129.1, 129.9, 132.3, 134.5, 137.9, 138.4, 140.3, 140.6, 140.9, 142.3, 151.2, 151.4, 166.4, 167.0. IR (KBr): λ (cm<sup>–1</sup>) 3087, 2980, 2944, 2867, 2820, 2773, 1645, 1604, 1450, 1360, 1050, 759, 504. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>25</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 409.1790, found 409.1785. HPLC, mixture of diastereoisomers: <i>t</i><sub><i>R</i></sub> = 16.1 min (30.7%), <i>t</i><sub><i>R</i></sub> = 16.5 min (67.0%); purity 97.7% (254 nm). Elemental analysis (%) calculated for C<sub>23</sub>H<sub>25</sub>ClN<sub>4</sub>O: C 67.56, H 6.16, N 13.70. Found: C 67.54, H 6.28, N 13.63.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 10-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-10,11-dihydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine (<b>42</b>; WAY-VNA-932).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></h5><div class="NLM_p last">Compound <b>42</b> was prepared from the amine <b>31</b> and the acid <b>3b</b> according to general method A, affording a white powder (yield 43%). <i>R</i><sub><i>f</i></sub> = 0.4 (hept/AcOEt 5/5). MP = 105–108 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.33 (s, 2.31H), 2.37 (s, 0.69H), 4.60–5.40 (m, 4H), 6.07 (m, 2H), 6.23 (d, 0.79H, <i>J</i> = 2.2 Hz), 6.30 (m, 0.21H), 6.68 (bs, 1H), 6.95–7.56 (m, 6H), 7.61 (d, 0.80H, <i>J</i> = 1.7 Hz), 7.72 (d, 0.80H, <i>J</i> = 2.2 Hz), 7.84 (m, 0.40H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 13.7, 45.7, 51.1, 107.6, 108.6, 109.0, 115.9, 119.3, 121.7, 125.7, 127.3, 127.9, 128.5, 128.6, 129.1, 129.8, 132.3, 133.1, 134.6, 140.3, 140.8, 151.5, 167.3. IR (KBr): λ (cm<sup>–1</sup>) 3122, 2953, 2953, 2861, 1648, 1606, 1529, 1500, 1366, 1049, 759, 710, 505. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup> 403.1320, found 403.1316. HPLC <i>t</i><sub><i>R</i></sub> = 21.2 min, purity 97.5% (254 nm). Elemental analysis (%) calculated for C<sub>23</sub>H<sub>19</sub>ClN<sub>4</sub>O: C 68.57, H 4.75, N 13.91. Found: C 68.58, H 5.26, N 13.04.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 5-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]-1-methyl-1,4,5,10-tetrahydro pyrazolo[3,4-<i>b</i>][1,5]benzodiazepine (<b>43</b>)</h5><div class="NLM_p last">Compound <b>43</b> was prepared from the amine <b>37</b> (182 mg, 0.907 mmol) and the acid <b>3b</b> (280 mg, 1.18 mmol) according to general method A, as was previously described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 1-[2-Chloro-4-(3-methyl-1<i>H</i>-pyrazol-1-yl)benzoyl]azepane (<b>44</b>)</h5><div class="NLM_p last">Compound <b>44</b> was prepared from the azepine and the acid <b>3b</b> according to general method A, affording a white powder (22 mg; yield 35%). <i>R</i><sub><i>f</i></sub> = 0.3 (hept/AcOEt 5/5). MP = 100 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.40–2.00 (m, 8H), 2.35 (s, 3H), 3.20–3.40 (m, 2H), 3.55–3.90 (dt, 2H, <i>J</i> = 18.6, 5.6 Hz), 6.25 (d, 1H, <i>J</i> = 2.2 Hz), 7.30 (d, 1H, <i>J</i> = 8.3 Hz), 7.56 (dd, 1H, <i>J</i> = 8.3, 1.9 Hz), 7.74 (d, 1H, <i>J</i> = 1.9 Hz), 7.79 (d, 1H, <i>J</i> = 2.2 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 13.7, 26.5, 27.3, 27.7, 28.9, 45.6, 49.0, 108.7, 116.8, 119.6, 127.4, 128.4, 131.3, 134.0, 140.8, 151.4, 167.7. IR (KBr): λ (cm<sup>–1</sup>) 3118, 2926, 2856, 1622, 1603, 1539, 1482, 1437, 1378, 1359, 1306, 1057, 882, 757. HRMS (ES) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>20</sub>ClN<sub>3</sub>O [M + H]<sup>+</sup> 318.1368, found 318.1356. HPLC <i>t</i><sub><i>R</i></sub> = 24.9 min, purity 99.2% (254 nm).</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>S</i>)-<i>tert</i>-Butyl 2-(Dimethylcarbamoyl)pyrrolidine-1-carbamate (<b>46</b>)</h5><div class="NLM_p last">A solution of (<i>S</i>) Boc-proline (1 equiv), trimethylamine (2 equiv), and HOBt (1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> was stirred for 20 min at rt. Dimethylamine hydrochloride (1 equiv) was then added. The mixture was stirred for 20 h at rt. CH<sub>2</sub>Cl<sub>2</sub> was then added, and the mixture was washed with 0.3 M aqueous potassium sulfate, saturated aqueous sodium bicarbonate, and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated in vacuo. The expected compound was obtained after purification by chromatography on silica gel column (AcOEt, 1% Et<sub>3</sub>N) to afford a colorless oil (yield 75%). <i>R</i><sub><i>f</i></sub> = 0.55 (Hept/AcOEt, 1/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.68–4.47 (m, 1H), 3.63–3.34 (m, 2H), 3.14–2.86 (m, 6H), 2.19–1.94 (m, 2H), 1.89–1.74 (m, 2H), 1.44–1.35 (m, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.0, 172.5, 154.7, 154.0, 79.6, 79.5, 56.6, 56.5, 47.0, 46.8, 37.1, 36.1, 30.5, 29.7, 28.7, 28.5, 24.3, 23.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>S</i>)-<i>tert</i>-Butyl 2-(Dimethylcarbamothioyl)pyrrolidine-1-carbamate (<b>47</b>)</h5><div class="NLM_p last">To a solution of <b>46</b> (1 equiv) in anhydrous toluene under argon atmosphere was added Lawesson reagent (1.2 equiv). The reaction mixture was warmed at reflux for one night and then evaporated under reduced pressure. Purification by chromatography on silica gel column (AcOEt/hept, 3/7, v/v then 5/5, v/v +1% Et<sub>3</sub>N) afforded <b>47</b> as a colorless oil (yield 52%). <i>R</i><sub><i>f</i></sub> = 0.63 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 95/5). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.89–4.72 (m, 1 H), 3.72–3.46 (m, 2H), 3.46–3.26 (m, 6H), 2.24–2.08 (m, 2H), 1.86–1.70 (m, 2H), 1.43–1.27 (m, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 206.4, 205.1, 154.7, 153.7, 79.8, 79.7, 62.8, 62.6, 47.2, 47.0, 45.4, 45.2, 41.4, 41.3, 32.7 31.7, 28.8, 28.6, 24.0, 23.5.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>S</i>)-<i>N</i>,<i>N</i>-Dimethylpyrrolidine-2-carbothioamide, Trifluoroacetate (<b>48</b>)</h5><div class="NLM_p last">Compound <b>47</b> in TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, v/v) was stirred 30 min at rt and then evaporated and lyophilized to obtain the expected <b>48</b> as an oil (quantitative yield). <i>R</i><sub><i>f</i></sub> = 0.15 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 9/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.09 (s, 1H), 3.62–3.43 (m, 2H), 3.50 (s, 3H), 3.39 (m, 3H), 2.63–2.49 (m, 1H), 2.21–2.04 (m, 2H), 1.85–1.73 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 197.1, 61.7, 46.9, 46.0, 41.8, 31.9, 25.5.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>S</i>)-<i>N</i>,<i>N</i>-Dimethylpyrrolidine-2-carboxamide, Trifluoroacetate (<b>49</b>)</h5><div class="NLM_p last">Compound <b>46</b> in TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, v/v) was stirred 30 min at rt and then evaporated and lyophilized to obtain the expected <b>49</b> as an oil (quantitative yield). <i>R</i><sub><i>f</i></sub> = 0.15 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 9/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.82 (s, 1H), 3.36–3.52 (m, 2H), 3.02 (s, 3H), 2.98 (s, 3H), 2.41–2.55 (m, 1H), 2.06–2.16 (m, 1H), 1.94–2.04 (m, 1H), 1.82–1.93 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 162.3, 58.1, 46.7, 36.9, 37.4, 29.6, 25.0.</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (2-(Dimethylamino)-2-oxoethyl)carbamate (<b>50</b>)</h5><div class="NLM_p last">A solution of Boc-glycine (1 equiv), trimethylamine (2 equiv), and HOBt (1.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> was stirred for 20 min at rt. Dimethylamine hydrochloride (1 equiv) was then added. The mixture was stirred for 20 h at rt. CH<sub>2</sub>Cl<sub>2</sub> was then added, and the mixture was washed with 0.3 M aqueous potassium sulfate, saturated aqueous sodium bicarbonate, and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated in vacuo. The expected compound was obtained after purification by chromatography on silica gel column (AcOEt/hept, 1/1, v/v + 1% Et<sub>3</sub>N) to afford a colorless oil (yield 46%). <i>R</i><sub><i>f</i></sub> = 0.12 (AcOEt/Hept, 1/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.91 (s, 2H), 2.94 (d, 6H, <i>J</i> = 7.9 Hz), 1.41 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.5, 156.0, 79.7, 42.5, 36.0, 35.8, 28.6.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>tert</i>-Butyl (2-(Dimethylamino)-2-thioxoethyl)carbamate (<b>51</b>)</h5><div class="NLM_p last">To a solution of <b>50</b> (1 equiv) in anhydrous toluene under argon atmosphere was added Lawesson reagent (1.2 equiv). The reaction mixture was warmed at reflux for one night and then evaporated under reduced pressure. Purification by chromatography on silica gel column (AcOEt/Hept, 5/95, v/v until 60/40, v/v) afforded a colorless oil (yield 63%). <i>R</i><sub><i>f</i></sub> = 0.34 (AcOEt/Hept, 1/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.03 (s, 2H), 3.48 (s, 3H), 3.27 (s, 3H), 1.43 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 198.2, 155.7, 79.9, 48.2, 45.0, 40.6, 28.6.</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 2-Amino-<i>N</i>,<i>N</i>-dimethylethanethioamide, Trifluoroacetate (<b>52</b>)</h5><div class="NLM_p last">Compound <b>51</b> in TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, <i>v/v</i>) was stirred 30 min at rt and then evaporated and lyophilized to obtain the expected <b>60</b> as a white solid (quantitative yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 3.99 (s, 2H), 3.49 (s, 3H), 3.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 194.1, 45.7, 45.1, 41.0.</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 2-Amino-<i>N</i>,<i>N</i>-dimethylacetamide, Trifluoroacetate (<b>53</b>)</h5><div class="NLM_p last">Compound <b>50</b> in TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, <i>v/v</i>) was stirred 30 min at rt and then evaporated and lyophilized to obtain the expected <b>53</b> as a white solid (quantitative yield). MP = 117 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 3.85 (s, 2H), 2.99 (d, 6H, <i>J</i> = 2.2 Hz). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 166.8, 40.9, 36.4, 36.0.</div></div><div id="sec5_2_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 2-Methyl-4-(1-methyl-1,3<i>a</i>,4,5,10,10<i>a</i>-hexahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzonitrile (<b>55</b>)</h5><div class="NLM_p last">(COCl)<sub>2</sub> (316 μL, 3.67 mmol, 4 equiv) was added dropwise in a solution of 4-cyano-3-methylbenzoic acid (296 mg, 1.84 mmol, 2 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (2.5 mL) and few drops of DMF. The mixture was stirred 15 min at 0 °C, 2 h at rt, concentrated, and dried in vacuo. The residue was taken up in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (1.8 mL) and added dropwise at 0 °C to a solution of 1-methyl-3<i>a</i>,5,10,10<i>a</i>-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepin-4(1<i>H</i>)-one <b>37</b> (184 mg, 0.92 mmol, 1 equiv) and triethylamine (256 μL, 1.84 mmol, 2 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (3.6 mL). The mixture was stirred 30 min at 0 °C and one night at rt. The crude product was taken up in CH<sub>2</sub>Cl<sub>2</sub>, and the organic phase was washed with saturated aqueous KHSO<sub>4</sub>. The aqueous phase was extracted with CHCl<sub>3</sub>/<i>i</i>PrOH (8/2, v/v). The organic phases were gathered, washed with saturated aqueous NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. Purification by chromatography on silica gel column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 95/5, v/v) afforded a beige solid (223 mg; yield 70%). <i>R</i><sub><i>f</i></sub> = 0.3 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 95/5). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.31–7.25 (m, 3H), 7.11 (t, 1H, <i>J</i> = 7.6 Hz), 7.01 (dd, 2H, <i>J</i> = 12.3, 7.6 Hz), 6.68 (dt, 2H, <i>J</i> = 13.8, 6.8 Hz), 5.86 (d, 1H, <i>J</i> = 14.4 Hz), 3.99 (d, 1H, <i>J</i> = 14.4 Hz), 3.85 (s, 3H), 2.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.0, 142.4, 140.4, 139.8, 138.3, 136.1, 132.0, 130.9, 129.9, 129.3, 125.5, 123.0, 119.5, 114.0, 101.6, 43.5, 35.2, 20.5.</div></div><div id="sec5_2_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (4-(Aminomethyl)-3-methylphenyl)(1-methyl-3<i>a</i>,4,10,10<i>a</i>-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepin-5(1<i>H</i>)-yl)methanone (<b>56</b>)</h5><div class="NLM_p last">To a solution of 2-methyl-4-(1-methyl-1,3<i>a</i>,4,5,10,10<i>a</i>-hexahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzonitrile <b>55</b> (223 mg, 0.64 mmol, 1 equiv) in anhydrous methanol at 0 °C were added cobalt chloride hexahydrate (303 mg, 1.28 mmol, 2 equiv) and sodium borohydride (2.41 g, 6.38 mmol, 10 equiv). The black mixture was stirred for 10 min at 0 °C then 1 h at rt. The mixture was neutralized to pH = 7/8 with a solution of 1 M KHSO<sub>4</sub>. The methanol was evaporated, and the residue was diluted in a solution of 1 M KHSO<sub>4</sub> (15 mL). A precipitate was filtered off and washed with Et<sub>2</sub>O. The aqueous phase was extracted with Et<sub>2</sub>O and basified up to pH > 10 with a solution of 10 N NaOH. The color switched from pink to blue. The aqueous phase was then extracted with CHCl<sub>3</sub>. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated in vacuo to afford the expected product as a green powder (180 mg, yield 81%). <i>t</i><sub>R</sub> = 2.41 min. MP = 249 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.28 (d, 1H, <i>J</i> = 8.0 Hz), 7.17 (s, 1H), 7.15–7.06 (m, 2H), 7.01 (s, 1H), 6.86 (d, 1H, <i>J</i> = 8.0 Hz), 6.75–6.60 (m, 2H), 5.68 (d, 1H, <i>J</i> = 14.7 Hz), 3.88 (d, 1H, <i>J</i> = 14.7 Hz), 3.78 (s, 3H), 3.57 (s, 2H), 2.10 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 143.4, 139.8, 138.9, 135.6, 134.6, 130.2, 129.0, 128.1, 125.5, 124.8, 121.2, 119.2, 100.3, 43.1, 42.0, 35.3, 18.3.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> General Method for the Synthesis of Compounds <b>57</b>–<b>61</b></h4><div class="NLM_p">A solution of <b>56</b> (1 equiv), carbonyldiimidazole (1.2 equiv), and DIEA (1.5 equiv) in DMF was stirred for 3 h at rt. To this mixture were added one of the amines <b>48</b>, <b>49</b>, and <b>52</b>–<b>54</b> (1.3 equiv) and DIEA (2.5 equiv) in DMF. The mixture was stirred overnight at rt and evaporated. Semipreparative HPLC yielded expected compounds <b>57</b>–<b>61</b>.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>S</i>)-2-(Dimethylcarbamothioyl)-<i>N</i>-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzyl)pyrrolidine-1-carboxamide, Trifluoroacetate (<b>57</b>; <b>LIT-001</b>)</h5><div class="NLM_p last">Prepared from compounds <b>56</b> and <b>48</b>. White solid (46.7 mg, yield 41%). <i>t</i><sub>R</sub> = 3.32 min. MP = 204 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.65 (s, 1H), 7.30 (d, 1H, <i>J</i> = 8 Hz), 7.23–7.14 (m, 2H), 7.06–6.93 (m, 2H), 6.82–6.72 (m, 2H), 5.84 (d, 1H, <i>J</i> = 14.8 Hz), 5.05 (s, 1H), 4.32–4.15 (m, 2H), 3.98 (d, 1H, <i>J</i> = 14.8 Hz), 3.91 (s, 3H), 3.71–3.63 (m, 1H), 3.36 (s, 3H), 3.25 (s, 3H), 2.27–2.16 (m, 1H), 2.09 (s, 3H), 1.97–1.86 (m, 1H), 1.84–1.72 (m, 1H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 206.1, 171.8, 158.7, 144.6, 141.7, 138.7, 136.4, 135.0, 124.8, 131.5, 130.4, 130.1, 127.4, 127.2, 126.5, 124.4, 121.5, 104.4, 64.4, 47.6, 45.4, 44.3, 42.6, 41.7, 35.1, 32.4, 24.7, 19.0. HPLC <i>t</i><sub><i>R</i></sub> = 2.848 min, purity 100% (254 nm). HRMS (EI) calcd for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 532.2489, found 532.2473.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>S</i>)-<i>N</i><sub>2</sub><i>,N</i><sub>2</sub>-Dimethyl-<i>N</i><sub>1</sub>-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzyl)pyrrolidine-1,2-dicarboxamide, Trifluoroacetate (<b>58</b>)</h5><div class="NLM_p last">Prepared from compounds <b>56</b> and <b>49</b>. White solid (24.1 mg, yield 66%). <i>t</i><sub>R</sub> = 2.99 min. MP = 108.7 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.68 (s, 1H), 7.29 (d, H, <i>J</i> = 7.9 Hz), 7.17 (t, 1 H, <i>J</i> = 7.9 Hz), 7.11 (d, 1H, <i>J</i> = 7.9 Hz), 7.06–6.96 (m, 2H), 6.84–6.72 (m, 2H), 5.84 (d, 1H, <i>J</i> = 14.8 Hz), 4.78 (dd, 1H, <i>J</i> = 8.7, 3.8 Hz), 4.32–4.19 (m, 2H), 3.98 (d, 1H, <i>J</i> = 14.8 Hz), 3.58–3.49 (m, 1H), 3.44–3.37 (m, 1H), 3.10 (s, 3H), 2.91 (d, 3H, <i>J</i> = 2.2 Hz), 2.30–2.15 (m, 1H), 2.15 (s, 3H), 2.09–1.93 (m, 2H), 1.79–1.89 (m, 1H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 175.1, 171.8, 158.9, 144.9, 141.8, 138.8, 136.6, 135.2, 134.8, 134.7, 131.6, 130.6, 130.2, 127.3, 126.6, 124.5, 121.7, 104.8, 58.5, 47.5, 44.3, 42.7, 37.5, 36.4, 35.1, 30.5, 25.5, 19.0. HPLC <i>t</i><sub><i>R</i></sub> = 2.549 min, purity 100% (254 nm). HRMS (EI) calcd for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 516.2717, found 516.2704.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzyl)ureido)acetamide Trifluoroacetate (<b>59</b>)</h5><div class="NLM_p last">Prepared from compounds <b>56</b> and <b>53</b>. White solid (20.1 mg, yield 65%). <i>t</i><sub>R</sub> = 2.88 min. MP = 112.7 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.72 (s, 1H), 7.30 (d, 1H, <i>J</i> = 8.1 Hz), 7.18 (t, 1H, <i>J</i> = 7.6 Hz), 7.07 (d, 1H, <i>J</i> = 7.9 Hz), 7.05 (s, 1H), 6.99 (d, 1H, <i>J</i> = 7.6 Hz), 6.82–6.74 (m, 2H), 5.05 (d, 1H, <i>J</i> = 14.7 Hz), 4.21 (s, 2H), 4.00 (s, 1H), 3.97 (s, 2H), 3.93 (s, 3H), 3.00 (s, 3H), 2.93 (s, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 171.7, 171.6, 160.9, 141.4, 138.6, 137.0, 135.5, 134.8, 134.5, 131.6, 130.7, 130.2, 127.8, 126.7, 124.6, 121.7, 104.9, 44.3, 42.8, 42.5, 36.5, 36.1, 35.1, 19.0. HPLC <i>t</i><sub><i>R</i></sub> = 2.501 min, purity 100% (254 nm). HRMS (EI) calcd for C<sub>25</sub>H<sub>29</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup> 476.2404, found 476.2406.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> <i>N</i>,<i>N</i>-Dimethyl-2-(3-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzyl)ureido)ethanethioamide, Trifluoroacetate (<b>60</b>)</h5><div class="NLM_p last">Prepared from compounds <b>56</b> and <b>52</b>. White solid (20.6 mg, yield 67%). <i>t</i><sub>R</sub> = 3.12 min. MP = 139 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.45 (s, 1H), 7.27 (d, 1H, <i>J</i> = 8 Hz), 7.15 (t, 1H, <i>J</i> = 8 Hz), 7.11 (d, 1H, <i>J</i> = 7.8 Hz), 7.05 (s, 1H), 6.98 (d, 1H, <i>J</i> = 8 Hz), 6.80–6.69 (m, 2H), 5.82 (d, 1H, <i>J</i> = 14.8 Hz), 4.22 (s, 2H), 4.09 (s, 2H), 3.98 (d, 1H, <i>J</i> = 14.8 Hz), 3.89 (s, 3H), 3.47 (s, 3H), 3.13 (t, 1H, <i>J</i> = 5.7 Hz), 2.16 (s, 3H), 1.83–1.65 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 200.8, 171.8, 160.7, 143.9, 141.3, 139.2, 137.0, 125.7, 134.6, 131.6, 130.7, 130.1, 127.8, 126.6, 124.4, 121.4, 103.9, 45.8, 45.2, 44.5, 42.5, 40.8, 35.3, 23.9, 23.2, 19.0. HPLC <i>t</i><sub><i>R</i></sub> = 2.755 min, purity 100% (254 nm). HRMS (EI) calcd for C<sub>25</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 492.2176, found 492.2163.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 2-(3-(2-Methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo[<i>b</i>]pyrazolo[3,4-<i>e</i>][1,4]diazepine-5-carbonyl)benzyl)ureido)methyl acetate, Trifluoroacetate (<b>61</b>)</h5><div class="NLM_p last">Prepared from compounds <b>56</b> and <b>54</b>. White solid (20.5 mg, yield 66%). <i>t</i><sub>R</sub> = 2.99 min. MP = 126.8 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.68 (s, 1H), 7.33–6.96 (m, 6H), 6.84–6.73 (m, 1H), 5.85 (d, 1H, <i>J</i> = 14.9 Hz), 4.21 (s, 2H), 3.99 (d, 1H, <i>J</i> = 14.9 Hz), 3.92 (s, 3H), 3.86 (s, 2H), 3.72–3.67 (m, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 173.3, 171.7, 160.9, 141.3, 138.8, 137.0, 135.6, 134.9, 131.6, 130.7, 130.2, 127.8, 126.7, 124.5, 121.6, 104.5, 52.6, 44.4, 42.8, 42.5, 35.1, 18.9. HPLC <i>t</i><sub><i>R</i></sub> = 2.601 min, purity 75.88% (254 nm). HRMS (EI) calcd for C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>4</sub> [M + H]<sup>+</sup> 463.2088, found 463.2078.</div></div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Biology: Material and Methods</h3><div class="NLM_p">AVP and OT were purchased from Bachem or Novabiochem, [<sup>3</sup>H]AVP from Amersham or PerkinElmer Life and Analytical Sciences, BSA from Sigma, and Ro-20-1724 (4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone) from Calbiochem. Synthesized compounds were initially dissolved in DMSO at 10 or 1 μM and then diluted to the desired concentration with the assay buffer.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Cell Culture</h4><div class="NLM_p last">Culture of CHO cell lines stably expressing the human vasopressin V<sub>1a</sub>, V<sub>2</sub>, or oxytocin receptors was performed as previously described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Culture of HEK293 cell lines stably expressing V<sub>1a</sub>, V<sub>2</sub>, or OT receptors cell culture was performed as previously described.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Membrane Preparations</h4><div class="NLM_p last">To increase the level of expression of some receptors (OT-R, V<sub>1a</sub>-R), the CHO cells were treated overnight with 5 mM sodium butyrate. As already published, this treatment does not modify the pharmacological properties of the receptors.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The membranes were prepared as already described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Radioligand Binding Assays</h4><div class="NLM_p last">Binding assays were performed at 30 °C using [<sup>3</sup>H]AVP as the radioligand and CHO cells-membrane proteins (10–15 μg for V<sub>1a</sub> and OT receptors, 5 μg for V<sub>2</sub> receptor), as previously described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> TR-FRET Binding Assay</h4><div class="NLM_p last">These assays were performed as described in Zwier et al.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Briefly, HEK293 cells stably expressing V<sub>1a</sub>, V<sub>2</sub>, or OT receptors fused to the SNAP-tag suicide enzyme were labeled with the fluorescent donor substrate SNAP-Lumi4-Tb at 100 nM in Tag-lite labeling medium for 1 h at 37 °C. Cells were then washed three times in Tag-lite medium and then incubated with the fluorescent ligands. For competition assays, increasing concentrations of cold competitor ligand in Tag-lite medium were first added to the cells, then a fixed concentration of fluorescent ligand (30 to 50 nM) was added. After 3 h incubation at room temperature, plates were read in an HTRF-compatible multiwell plate reader with a classic HTRF protocol (excitation at 340 nm, donor emission measured at 615 nm and acceptor emission at 665 nm, 50 μs delay, 500 μs integration).</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Functional Assays</h4><div id="sec5_4_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81">I.  CHO Cells</h5><div class="NLM_p last">The functional agonist and competitive antagonist properties of each ligand were determined for the human vasopressin and oxytocin receptors subtypes stably expressed in CHO cells as previously described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The accumulation of <i>myo</i>-inositol 1-phosphate (V<sub>1a</sub> and OT receptors) was determined by the IP-One assay, and the accumulation of cAMP (V<sub>2</sub> receptor) was determined by the cAMP <i>dynamic 2</i> assay, both kindly provided by Cisbio International.</div></div><div id="sec5_4_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82">ii.  HEK Cells</h5><div class="NLM_p">Agonist and antagonist properties of each ligand were determined by measuring intracellular calcium flux. For that, HEK293 cells stably expressing the human vasopressin V<sub>1a</sub> or oxytocin OT receptors were cultured in flasks up to 80–90% confluence. Then the cells were incubated for 45 min at 37 °C with 5 μM of the fluorescent dye Indo1-AM in Hepes buffer supplemented with 0.1% BSA. After a washing step with PBS buffer, the cells were detached using accutase (PAA), and suspended in Hepes-BSA buffer. Then 200 μL of a 0.5 × 10<sup>6</sup> cells/mL suspension were distributed in each well of a 96-well plate. Fluorescence of Indo1 was recorded at 401 and 475 nm (excitation wavelength at 338 nm) for 3 min following addition of ligand using FlexStation<sup>III</sup> reader (Molecular Devices).</div><div class="NLM_p last">To test the antagonist effect, fluorescence was recorded in the same way after addition of a mix made with ligand and the endogenous agonist (10 nM OT for OT receptor or 1 nM AVP for V<sub>1a</sub> receptor). A dose–response curve was generated by plotting normalized fluorescence ratio of Indo1 and ligand concentrations tested. EC<sub>50</sub> values (for agonist properties) and IC<sub>50</sub> values (for antagonist properties) were calculated from the dose–response curves, and the maximal responses induced by ligands were expressed as percentages of maximal stimulation by the endogenous agonist.</div></div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Signaling Assays</h4><div class="NLM_p">HEK293FT cells (Life Technologies, USA) were grown in complete medium (Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1 mM glutamine) (Eurobio, France) at 37 °C in 5% CO<sub>2</sub>. For calcium release and BRET1 assays, transient transfections were performed in 6-well and 96-well plates, respectively (Greiner Bio-One, France), using Metafectene PRO (Biontex, München, Germany) and following the manufacturer’s protocol.</div><div class="NLM_p">Regarding the assessment of β-arrestin2 recruitment, BRET1 assays, pcDNA3.1 plasmids encoding the human OT-R, V<sub>1a</sub>-R, V<sub>1b</sub>-R, or V<sub>2</sub>-R cDNAs tagged at their C-terminus with the luciferase Rluc8 (12.5, 12.5, 25, and 25 ng/well, respectively) and pcDNA3 plasmid encoding <i>β-Arrestin2</i>-Venus (75 ng/well) were diluted in 25 μL of nonsupplemented DMEM, mixed with 25 μL of a nonsupplemented DMEM-Metafectene PRO (0.5 μL) mixture, incubated for 15–20 min at room temperature and added to the well. Cells (10<sup>5</sup> in 200 μL) in complete medium were then added and incubated for 48 h. After overnight serum depletion, cells were stimulated with dose–responses of the drugs diluted in PBS (1×) containing 5 mM HEPES and 5 μM coelenterazine h (Interchim) and BRET was immediately measured upon drug stimulation for 30 min using the Mithras LB 943 plate reader (Berthold, France).</div><div class="NLM_p">For calcium assays, cells were plated 1 day prior to transfection with 250 ng/well of Aequorin (luciferase calcium sensor) plasmid and 150 ng/well pcDNA3.1 plasmids encoding the human OT-R, V<sub>1a</sub>-R, V<sub>1b</sub>-R, or V<sub>2</sub>-R cDNAs (Missouri S&T cDNA Resource Center) diluted in 200 μL of nonsupplemented DMEM-Metafectene PRO (5 μL/well) mixture. After 48 h, cells were incubated 3 h in HBSS without calcium followed by 1 h in HBSS with 1.3 mM calcium, both containing 5 μM of coelenterazine h. Then 40 μL of incubated cells were injected on 10 μL of dose–responses of drugs diluted in HBSS-1.3 mM calcium and calcium release was measured for 20 s using Mithras LB 943 plate reader and, for calcium release normalization, by the addition of ionomycin for 30 s.</div><div class="NLM_p last">For the two assays, cells were stimulated with dose responses of OT, carbetocin, compound <b>57</b> and WAY-267464 (from 10<sup>–5</sup> to 10<sup>–12</sup> M) and vasopressin at 10<sup>–5</sup> M, or dose–responses of compound <b>57</b> in the presence of AVP (at EC<sub>80</sub>) or Pfizer’s OT antagonist PF 3274167<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> in the presence of compound <b>57</b> (at EC<sub>80</sub>). All reference compounds were purchased at Tocris Bioscience and diluted at 10<sup>–2</sup> M stock solution in DMSO. The area under the curves for the two assays (480 nm/540 nm BRET ratio for β-arrestin recruitment and luciferase arbitrary units for calcium assay) were plotted and analyzed using GraphPad Prism 7 software. A representative graph was presented from at least three independent experiments.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> In Vivo Assays</h4><div class="NLM_p last">(i) <i>Animals</i>: Male and female <i>Oprm1</i><sup><i>+/+</i></sup> and <i>Oprm1</i><sup><i>–/–</i></sup> were bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background, group-housed, and maintained on a 12 h light/dark cycle at controlled temperature (21 ± 1 °C) with food and water ad libitum. <i>Oprm1</i><sup><i>+/+</i></sup> and <i>Oprm1</i><sup><i>–/–</i></sup> pups were bred from homozygous parents, as we previously showed that parental care has no influence on behavioral phenotype in these animals (cross-fostering experiments<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a>). All experimental procedures were conducted in accordance with the European Communities Council Directive 2010/63/EU and approved by the Comité d’Ethique en Expérimentation Animale Val de Loire (C2EA-19, APAFIS no. 3086-20l5120813572006 v5). (ii) <i>Drugs</i>: Compound <b>57</b> was dissolved in carboxymethyl cellulose (CMC, 1%)–NaCl (0.9%) as a vehicle solution and administered at the dose of 10 or 20 mg/kg. Compound <b>57</b> or vehicle were injected intraperitoneally to the animals 30 min before testing in a volume of 10 mL/kg. (iii) <i>Behavioral testing</i>: Naı̈ve male and female animals aged 8–10 weeks were used in each experimental group (<i>n</i> = 4 per sex and genotype). The direct social interaction test was performed in four equal square areas (50 cm × 50 cm) separated by 35 cm high opaque white plastic walls over a white Plexiglas platform (infrared floor, View Point, France) covered with a black plastic floor (transparent to infrared). An assay begun when a pair of unfamiliar (not cage mates) age-, sex-, genotype-, and treatment-matched mice was introduced in each arena for 10 min (15 lx). The amount of time spent in nose contacts (NCs), the number and duration of these contacts, the number of following episodes, and the number of grooming episodes occurring immediately (<5 s) after a social contact (nose or paw contact) were scored a posteriori on video recordings (infrared light-sensitive video camera) using an ethological keyboard (Labwatcher, View Point, France) by a trained experimenter and blind to experimental conditions.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Brain Penetration</h4><div class="NLM_p last">Brain penetration of compound <b>57</b> was studied in CD-1 mice. A 1 mg/mL solution of compound <b>57</b> in 0.5% carboxymethylcellulose/0.9% NaCl solution was prepared. Volumes of 10 mL/kg (10 mg/kg) were administered intraperitonally to 12 mice. Three mice were sacrified at the end of each time period after 15, 45, 90, or 240 min. Blood was collected and plasma was separated by centrifugation. Brains were collected after perfusion of animals with a 3 mM EDTA/0.9% NaCl solution. Samples were frozen and stored at −80 °C before treatment. Plasma samples (400 μL) were mixed with acetonitrile to precipitate and discard proteins (15000g centrifugation for 5 min at 16 °C). The supernatants were analyzed by UHPLC-MS/MS (Shimadzu LC-MS 8030). Brains were homogenized in 400 μL of water, then treated with 800 μL of acetonitrile and analyzed in the same way as plasma samples. Two samples from nontreated mice were analyzed in parallel as controls.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00697" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00697" class="ext-link">10.1021/acs.jmedchem.8b00697</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of precursor compounds <b>1</b>–<b>8</b>, <b>28</b>, <b>31</b>, <b>37</b>; signaling data for compound <b>57</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf">jm8b00697_si_001.pdf (452.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_002.csv">jm8b00697_si_002.csv (2.53 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00697" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcel Hibert</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span>; 
    <span class="hlFld-Affiliation affiliation">LabEx
MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7786-7276" title="Orcid link">http://orcid.org/0000-0001-7786-7276</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e2326272c2b3c3a0e3b20273d3a3c2f60283c"><span class="__cf_email__" data-cfemail="395451505b5c4b4d794c57504a4d4b58175f4b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie-Céline Frantz</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucie P. Pellissier</span> - <span class="hlFld-Affiliation affiliation">Physiologie
de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247,
IFCE, Inserm, Université François
Rabelais de Tours, F-37380 Nouzilly, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elsa Pflimlin</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stéphanie Loison</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jorge Gandía</span> - <span class="hlFld-Affiliation affiliation">Physiologie
de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247,
IFCE, Inserm, Université François
Rabelais de Tours, F-37380 Nouzilly, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Marsol</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span>; 
    <span class="hlFld-Affiliation affiliation">LabEx
MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="hlFld-Affiliation affiliation">PCBIS
Plateforme de Chimie Biologique Intégrative de Strasbourg,
UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thierry Durroux</span> - <span class="hlFld-Affiliation affiliation">Institut
de Génomique Fonctionnelle, CNRS UMR5203, INSERM U661, Université de Montpellier (IFR3), 141 Rue de la Cardonille, F-34094 Montpellier Cedex 5, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernard Mouillac</span> - <span class="hlFld-Affiliation affiliation">Institut
de Génomique Fonctionnelle, CNRS UMR5203, INSERM U661, Université de Montpellier (IFR3), 141 Rue de la Cardonille, F-34094 Montpellier Cedex 5, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jérôme A. J. Becker</span> - <span class="hlFld-Affiliation affiliation">Physiologie
de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247,
IFCE, Inserm, Université François
Rabelais de Tours, F-37380 Nouzilly, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Le Merrer</span> - <span class="hlFld-Affiliation affiliation">Physiologie
de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247,
IFCE, Inserm, Université François
Rabelais de Tours, F-37380 Nouzilly, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christel Valencia</span> - <span class="hlFld-Affiliation affiliation">LabEx
MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="hlFld-Affiliation affiliation">PCBIS
Plateforme de Chimie Biologique Intégrative de Strasbourg,
UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal Villa</span> - <span class="hlFld-Affiliation affiliation">LabEx
MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="hlFld-Affiliation affiliation">PCBIS
Plateforme de Chimie Biologique Intégrative de Strasbourg,
UMS3286, CNRS/Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3466-4852" title="Orcid link">http://orcid.org/0000-0003-3466-4852</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominique Bonnet</span> - <span class="hlFld-Affiliation affiliation">Laboratoire
d’Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 Route du Rhin, F-67412 Illkirch, France</span>; 
    <span class="hlFld-Affiliation affiliation">LabEx
MEDALIS, Université de Strasbourg, F-67000 Strasbourg, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8252-9199" title="Orcid link">http://orcid.org/0000-0002-8252-9199</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.-C.F., L.P.P., E.P., and S.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7704-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by research grants from the Centre National de la Recherche Scientifique (CNRS–Mission Interdisciplinaire, programme ITMM), the Université de Strasbourg, the LabEx Medalis (Programme Investissement d’Avenir: grant ANR-10-LABX-0034), the French government under the specific ANR-14-CE16-0005-01 project (OT-ism), Région Centre (ARD2020 Biomédicament–GPCRAb), and the LabEx MabImprove (Tours—Montpellier). This work was performed thanks to the Plateforme Arpeg̀e of Montpellier. HTRF and Tag-lite are registered trademarks of Cisbio Bioassays. Lumi4 is a registered trademark of Lumiphore, Inc. SNAP-tag is a trademark of New England Biolabs, Inc. We thank Cyril Antheaume, Barbara Schaeffer, and Justine Vieville for NMR experiments and experiments and Pascale Buisine and Patrick Wehrung for mass spectrometry (PACSI platform, GDS3670). We are also grateful to Sophie Gioria for some in vitro pharmacological studies (PCBIS, UMS3286). We thank the Experimental Unit PAO-1297 (EU0028) from the INRA–Val de Loire Centre for animal breeding and care. L.P. Pellissier acknowledges postdoctoral support from the Marie-Curie/AgreenSkills Program.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviation Used</td></tr><tr><td class="NLM_term">ASD</td><td class="NLM_def"><p class="first last">autism spectrum disorder</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">attenuated total reflection</p></td></tr><tr><td class="NLM_term">AVP</td><td class="NLM_def"><p class="first last">arginine-vasopressin</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term"><sup>13</sup>C NMR</td><td class="NLM_def"><p class="first last">carbon 13 nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine 5′-monophosphate</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethyl-4-aminopyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">ESI-TOF</td><td class="NLM_def"><p class="first last">electron spray ionization-time-of-flight</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">hept</td><td class="NLM_def"><p class="first last">heptane</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptors</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last"><i>N</i>-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">i.n.</td><td class="NLM_def"><p class="first last">intranasal</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">inositol phosphate</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term"><i>J</i></td><td class="NLM_def"><p class="first last">coupling constant</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">OT</td><td class="NLM_def"><p class="first last">oxytocin</p></td></tr><tr><td class="NLM_term">OT-R</td><td class="NLM_def"><p class="first last">oxytocin receptor</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term"><i>R</i><sub><i>f</i></sub></td><td class="NLM_def"><p class="first last">retention factor</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reverse-phase high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relashionships</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuranne</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">Tris</td><td class="NLM_def"><p class="first last">2-amino-2-hydroxymethyl-1,3-propanediol</p></td></tr><tr><td class="NLM_term">V<sub>1a</sub>-R</td><td class="NLM_def"><p class="first last">vasopressin V<sub>1a</sub> receptor</p></td></tr><tr><td class="NLM_term">V<sub>1b</sub>-R</td><td class="NLM_def"><p class="first last">vasopressin V<sub>1b</sub> receptor</p></td></tr><tr><td class="NLM_term">V<sub>2</sub>-R</td><td class="NLM_def"><p class="first last">vasopressin V<sub>2</sub> receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 92 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doernberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span> <span> </span><span class="NLM_article-title">Neurodevelopmental disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11</span>. <i>CNS Spectrums</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1017%2FS1092852916000262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=295-299&author=E.+Doernbergauthor=E.+Hollander&title=Neurodevelopmental+disorders+%28ASD+and+ADHD%29%3A+DSM-5%2C+ICD-10%2C+and+ICD-11&doi=10.1017%2FS1092852916000262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000262%26sid%3Dliteratum%253Aachs%26aulast%3DDoernberg%26aufirst%3DE.%26aulast%3DHollander%26aufirst%3DE.%26atitle%3DNeurodevelopmental%2520disorders%2520%2528ASD%2520and%2520ADHD%2529%253A%2520DSM-5%252C%2520ICD-10%252C%2520and%2520ICD-11%26jtitle%3DCNS%2520Spectrums%26date%3D2016%26volume%3D21%26spage%3D295%26epage%3D299%26doi%3D10.1017%2FS1092852916000262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Centers
for Disease Control and Prevention</span> <span> </span><span class="NLM_article-title">Prevalence of autism spectrum disorders—Autism
and developmental disabilities monitoring network, 14 sites, United
States, 2008</span>. <i>MMWR Surveill. Summ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1-19&author=Centers%0Afor+Disease+Control+and+Prevention&title=Prevalence+of+autism+spectrum+disorders%E2%80%94Autism%0Aand+developmental+disabilities+monitoring+network%2C+14+sites%2C+United%0AStates%2C+2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPrevalence%2520of%2520autism%2520spectrum%2520disorders%25E2%2580%2594Autism%250Aand%2520developmental%2520disabilities%2520monitoring%2520network%252C%252014%2520sites%252C%2520United%250AStates%252C%25202008%26jtitle%3DMMWR%2520Surveill.%2520Summ.%26date%3D2012%26volume%3D61%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vorstman, J. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-De-Luca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anney, R. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurnberger, J. I.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallmayer, J. F.</span></span> <span> </span><span class="NLM_article-title">Autism genetics: opportunities and challenges for clinical translation</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1038/nrg.2017.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnrg.2017.4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28260791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=362-376&author=J.+A.+S.+Vorstmanauthor=J.+R.+Parrauthor=D.+Moreno-De-Lucaauthor=R.+J.+L.+Anneyauthor=J.+I.+Nurnbergerauthor=J.+F.+Hallmayer&title=Autism+genetics%3A+opportunities+and+challenges+for+clinical+translation&doi=10.1038%2Fnrg.2017.4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Autism genetics: opportunities and challenges for clinical translation</span></div><div class="casAuthors">Vorstman, Jacob A. S.; Parr, Jeremy R.; Moreno-De-Luca, Daniel; Anney, Richard J. L.; Nurnberger, John I., Jr.; Hallmayer, Joachim F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">362-376</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetic studies have revealed the involvement of hundreds of gene variants in autism.  Their risk effects are highly variable, and they are frequently related to other conditions besides autism.  However, many different variants converge on common biol. pathways.  These findings indicate that etiol. heterogeneity, variable penetrance and genetic pleiotropy are pervasive characteristics of autism genetics.  Although this advancing insight should improve clin. care, at present there is a substantial discrepancy between research knowledge and its clin. application.  In this Review, we discuss the current challenges and opportunities for the translation of autism genetics knowledge into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEPKQYBSCnWbVg90H21EOLACvtfcHk0liOP9n1IqeH5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlKns7o%253D&md5=f0ad0bb3fb96e5e9254115023806fe75</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2017.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2017.4%26sid%3Dliteratum%253Aachs%26aulast%3DVorstman%26aufirst%3DJ.%2BA.%2BS.%26aulast%3DParr%26aufirst%3DJ.%2BR.%26aulast%3DMoreno-De-Luca%26aufirst%3DD.%26aulast%3DAnney%26aufirst%3DR.%2BJ.%2BL.%26aulast%3DNurnberger%26aufirst%3DJ.%2BI.%26aulast%3DHallmayer%26aufirst%3DJ.%2BF.%26atitle%3DAutism%2520genetics%253A%2520opportunities%2520and%2520challenges%2520for%2520clinical%2520translation%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2017%26volume%3D18%26spage%3D362%26epage%3D376%26doi%3D10.1038%2Fnrg.2017.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre-Ubieta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geschwind, D. H.</span></span> <span> </span><span class="NLM_article-title">Advancing the understanding of autism disease mechanisms through genetics</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nm.4071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnm.4071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27050589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1GjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=345-361&author=L.+de%0Ala+Torre-Ubietaauthor=H.+Wonauthor=J.+L.+Steinauthor=D.+H.+Geschwind&title=Advancing+the+understanding+of+autism+disease+mechanisms+through+genetics&doi=10.1038%2Fnm.4071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing the understanding of autism disease mechanisms through genetics</span></div><div class="casAuthors">de la Torre-Ubieta, Luis; Won, Hyejung; Stein, Jason L.; Geschwind, Daniel H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-361</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Progress in understanding the genetic etiol. of autism spectrum disorders (ASD) has fueled remarkable advances in our understanding of its potential neurobiol. mechanisms.  Yet, at the same time, these findings highlight extraordinary causal diversity and complexity at many levels ranging from mols. to circuits and emphasize the gaps in our current knowledge.  Here we review current understanding of the genetic architecture of ASD and integrate genetic evidence, neuropathol. and studies in model systems with how they inform mechanistic models of ASD pathophysiol.  Despite the challenges, these advances provide a solid foundation for the development of rational, targeted mol. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5JQSQA5DjbVg90H21EOLACvtfcHk0lhJAu4OoYfg6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1GjsLY%253D&md5=6067f01b5e065abb392cf0538d489390</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.4071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4071%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre-Ubieta%26aufirst%3DL.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DStein%26aufirst%3DJ.%2BL.%26aulast%3DGeschwind%26aufirst%3DD.%2BH.%26atitle%3DAdvancing%2520the%2520understanding%2520of%2520autism%2520disease%2520mechanisms%2520through%2520genetics%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D345%26epage%3D361%26doi%3D10.1038%2Fnm.4071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theesfeld, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadych, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfovsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyanskaya, O. G.</span></span> <span> </span><span class="NLM_article-title">Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1462</span>, <span class="refDoi"> DOI: 10.1038/nn.4353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnn.4353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27479844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=1454-1462&author=A.+Krishnanauthor=R.+Zhangauthor=V.+Yaoauthor=C.+L.+Theesfeldauthor=A.+K.+Wongauthor=A.+Tadychauthor=N.+Volfovskyauthor=A.+Packerauthor=A.+Lashauthor=O.+G.+Troyanskaya&title=Genome-wide+prediction+and+functional+characterization+of+the+genetic+basis+of+autism+spectrum+disorder&doi=10.1038%2Fnn.4353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder</span></div><div class="casAuthors">Krishnan, Arjun; Zhang, Ran; Yao, Victoria; Theesfeld, Chandra L.; Wong, Aaron K.; Tadych, Alicja; Volfovsky, Natalia; Packer, Alan; Lash, Alex; Troyanskaya, Olga G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1462</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic basis.  Yet, only a small fraction of potentially causal genes-about 65 genes out of an estd. several hundred-are known with strong genetic evidence from sequencing studies.  We developed a complementary machine-learning approach based on a human brain-specific gene network to present a genome-wide prediction of autism risk genes, including hundreds of candidates for which there is minimal or no prior genetic evidence.  Our approach was validated in a large independent case-control sequencing study.  Leveraging these genome-wide predictions and the brain-specific network, we demonstrated that the large set of ASD genes converges on a smaller no. of key pathways and developmental stages of the brain.  Finally, we identified likely pathogenic genes within frequent autism-assocd. copy-no. variants and proposed genes and pathways that are likely mediators of ASD across multiple copy-no. variants.  All predictions and functional insights are available at http://asd.princeton.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Vs0FEdOWrrVg90H21EOLACvtfcHk0lhJAu4OoYfg6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73N&md5=3eb90af28009147f808ec3a14b270579</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnn.4353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4353%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DV.%26aulast%3DTheesfeld%26aufirst%3DC.%2BL.%26aulast%3DWong%26aufirst%3DA.%2BK.%26aulast%3DTadych%26aufirst%3DA.%26aulast%3DVolfovsky%26aufirst%3DN.%26aulast%3DPacker%26aufirst%3DA.%26aulast%3DLash%26aufirst%3DA.%26aulast%3DTroyanskaya%26aufirst%3DO.%2BG.%26atitle%3DGenome-wide%2520prediction%2520and%2520functional%2520characterization%2520of%2520the%2520genetic%2520basis%2520of%2520autism%2520spectrum%2520disorder%26jtitle%3DNat.%2520Neurosci.%26date%3D2016%26volume%3D19%26spage%3D1454%26epage%3D1462%26doi%3D10.1038%2Fnn.4353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazdoba, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawley, J. N.</span></span> <span> </span><span class="NLM_article-title">Translational mouse models of autism: advancing toward pharmacological therapeutics</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/7854_2015_5003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2F7854_2015_5003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=1-52&author=T.+M.+Kazdobaauthor=P.+T.+Leachauthor=M.+Yangauthor=J.+L.+Silvermanauthor=M.+Solomonauthor=J.+N.+Crawley&title=Translational+mouse+models+of+autism%3A+advancing+toward+pharmacological+therapeutics&doi=10.1007%2F7854_2015_5003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2F7854_2015_5003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2015_5003%26sid%3Dliteratum%253Aachs%26aulast%3DKazdoba%26aufirst%3DT.%2BM.%26aulast%3DLeach%26aufirst%3DP.%2BT.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSilverman%26aufirst%3DJ.%2BL.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DCrawley%26aufirst%3DJ.%2BN.%26atitle%3DTranslational%2520mouse%2520models%2520of%2520autism%253A%2520advancing%2520toward%2520pharmacological%2520therapeutics%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2015%26volume%3D28%26spage%3D1%26epage%3D52%26doi%3D10.1007%2F7854_2015_5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilby, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill-Yardin, E. L.</span></span> <span> </span><span class="NLM_article-title">Studying autism in rodent models: reconciling endophenotypes with comorbidities</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2013.00417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffnhum.2013.00417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23898259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sfltFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=417&author=A.+Argyropoulosauthor=K.+L.+Gilbyauthor=E.+L.+Hill-Yardin&title=Studying+autism+in+rodent+models%3A+reconciling+endophenotypes+with+comorbidities&doi=10.3389%2Ffnhum.2013.00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Studying autism in rodent models: reconciling endophenotypes with comorbidities</span></div><div class="casAuthors">Argyropoulos Andrew; Gilby Krista L; Hill-Yardin Elisa L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in human neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    </div><div class="casAbstract">Autism spectrum disorder (ASD) patients commonly exhibit a variety of comorbid traits including seizures, anxiety, aggressive behavior, gastrointestinal problems, motor deficits, abnormal sensory processing, and sleep disturbances for which the cause is unknown.  These features impact negatively on daily life and can exaggerate the effects of the core diagnostic traits (social communication deficits and repetitive behaviors).  Studying endophenotypes relevant to both core and comorbid features of ASD in rodent models can provide insight into biological mechanisms underlying these disorders.  Here we review the characterization of endophenotypes in a selection of environmental, genetic, and behavioral rodent models of ASD.  In addition to exhibiting core ASD-like behaviors, each of these animal models display one or more endophenotypes relevant to comorbid features including altered sensory processing, seizure susceptibility, anxiety-like behavior, and disturbed motor functions, suggesting that these traits are indicators of altered biological pathways in ASD.  However, the study of behaviors paralleling comorbid traits in animal models of ASD is an emerging field and further research is needed to assess altered gastrointestinal function, aggression, and disorders of sleep onset across models.  Future studies should include investigation of these endophenotypes in order to advance our understanding of the etiology of this complex disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpzURl5Nx3ae3MPKNEWB5RfW6udTcc2eZKIMtdR6RfSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfltFegtQ%253D%253D&md5=1d799c78d39ad524b9064584a79af0da</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2013.00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2013.00417%26sid%3Dliteratum%253Aachs%26aulast%3DArgyropoulos%26aufirst%3DA.%26aulast%3DGilby%26aufirst%3DK.%2BL.%26aulast%3DHill-Yardin%26aufirst%3DE.%2BL.%26atitle%3DStudying%2520autism%2520in%2520rodent%2520models%253A%2520reconciling%2520endophenotypes%2520with%2520comorbidities%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D417%26doi%3D10.3389%2Ffnhum.2013.00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leigh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States</span>. <i>J. Autism Dev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4139</span>, <span class="refDoi"> DOI: 10.1007/s10803-015-2521-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2Fs10803-015-2521-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26183723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjvVartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=4135-4139&author=J.+P.+Leighauthor=J.+Du&title=Brief+report%3A+forecasting+the+economic+burden+of+autism+in+2015+and+2025+in+the+United+States&doi=10.1007%2Fs10803-015-2521-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Brief Report: Forecasting the Economic Burden of Autism in 2015 and 2025 in the United States</span></div><div class="casAuthors">Leigh J Paul; Du Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autism and developmental disorders</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4135-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Few US estimates of the economic burden of autism spectrum disorders (ASD) are available and none provide estimates for 2015 and 2025.  We forecast annual direct medical, direct non-medical, and productivity costs combined will be $268 billion (range $162-$367 billion; 0.884-2.009 % of GDP) for 2015 and $461 billion (range $276-$1011 billion; 0.982-3.600 % of GDP) for 2025.  These 2015 figures are on a par with recent estimates for diabetes and attention deficit and hyperactivity disorder (ADHD) and exceed the costs of stroke and hypertension.  If the prevalence of ASD continues to grow as it has in recent years, ASD costs will likely far exceed those of diabetes and ADHD by 2025.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGTB-qgTKfBfEeosoOnpOLfW6udTcc2eY7J-7E1M7GE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjvVartQ%253D%253D&md5=947e6ac2f8d4203b58031f258216cf4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs10803-015-2521-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10803-015-2521-7%26sid%3Dliteratum%253Aachs%26aulast%3DLeigh%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DBrief%2520report%253A%2520forecasting%2520the%2520economic%2520burden%2520of%2520autism%2520in%25202015%2520and%25202025%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Autism%2520Dev.%2520Disord.%26date%3D2015%26volume%3D45%26spage%3D4135%26epage%3D4139%26doi%3D10.1007%2Fs10803-015-2521-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">des Portes, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrioli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry-Kravis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjikhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delange, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floesser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Mancilla, B.</span></span> <span> </span><span class="NLM_article-title">Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">64ra1</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3001708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscitranslmed.3001708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=21209411" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=64ra1&author=S.+Jacquemontauthor=A.+Curieauthor=V.+des+Portesauthor=M.+G.+Torrioliauthor=E.+Berry-Kravisauthor=R.+J.+Hagermanauthor=F.+J.+Ramosauthor=K.+Cornishauthor=Y.+Heauthor=C.+Pauldingauthor=G.+Neriauthor=F.+Chenauthor=N.+Hadjikhaniauthor=D.+Martinetauthor=J.+Meyerauthor=J.+S.+Beckmannauthor=K.+Delangeauthor=A.+Brunauthor=G.+Bussyauthor=F.+Gaspariniauthor=T.+Hilseauthor=A.+Floesserauthor=J.+Bransonauthor=G.+Bilbeauthor=D.+Johnsauthor=B.+Gomez-Mancilla&title=Epigenetic+modification+of+the+FMR1+gene+in+fragile+X+syndrome+is+associated+with+differential+response+to+the+mGluR5+antagonist+AFQ056&doi=10.1126%2Fscitranslmed.3001708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001708%26sid%3Dliteratum%253Aachs%26aulast%3DJacquemont%26aufirst%3DS.%26aulast%3DCurie%26aufirst%3DA.%26aulast%3Ddes%2BPortes%26aufirst%3DV.%26aulast%3DTorrioli%26aufirst%3DM.%2BG.%26aulast%3DBerry-Kravis%26aufirst%3DE.%26aulast%3DHagerman%26aufirst%3DR.%2BJ.%26aulast%3DRamos%26aufirst%3DF.%2BJ.%26aulast%3DCornish%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPaulding%26aufirst%3DC.%26aulast%3DNeri%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHadjikhani%26aufirst%3DN.%26aulast%3DMartinet%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DJ.%2BS.%26aulast%3DDelange%26aufirst%3DK.%26aulast%3DBrun%26aufirst%3DA.%26aulast%3DBussy%26aufirst%3DG.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DHilse%26aufirst%3DT.%26aulast%3DFloesser%26aufirst%3DA.%26aulast%3DBranson%26aufirst%3DJ.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DJohns%26aufirst%3DD.%26aulast%3DGomez-Mancilla%26aufirst%3DB.%26atitle%3DEpigenetic%2520modification%2520of%2520the%2520FMR1%2520gene%2520in%2520fragile%2520X%2520syndrome%2520is%2520associated%2520with%2520differential%2520response%2520to%2520the%2520mGluR5%2520antagonist%2520AFQ056%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D64ra1%26doi%3D10.1126%2Fscitranslmed.3001708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder</span>. <i>Drug, Healthcare Patient Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.2147/DHPS.S39595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.2147%2FDHPS.S39595" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=69-76&author=R.+E.+Frye&title=Clinical+potential%2C+safety%2C+and+tolerability+of+arbaclofen+in+the+treatment+of+autism+spectrum+disorder&doi=10.2147%2FDHPS.S39595"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FDHPS.S39595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDHPS.S39595%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520potential%252C%2520safety%252C%2520and%2520tolerability%2520of%2520arbaclofen%2520in%2520the%2520treatment%2520of%2520autism%2520spectrum%2520disorder%26jtitle%3DDrug%252C%2520Healthcare%2520Patient%2520Saf.%26date%3D2014%26volume%3D10%26spage%3D69%26epage%3D76%26doi%3D10.2147%2FDHPS.S39595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemonnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeneuve, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosset, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viellard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Y.</span></span> <span> </span><span class="NLM_article-title">Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1056</span>, <span class="refDoi"> DOI: 10.1038/tp.2017.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2017.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28291262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e1056&author=E.+Lemonnierauthor=N.+Villeneuveauthor=S.+Sonieauthor=S.+Serretauthor=A.+Rosierauthor=M.+Roueauthor=P.+Brossetauthor=M.+Viellardauthor=D.+Bernouxauthor=S.+Rondeauauthor=S.+Thummlerauthor=D.+Ravelauthor=Y.+Ben-Ari&title=Effects+of+bumetanide+on+neurobehavioral+function+in+children+and+adolescents+with+autism+spectrum+disorders&doi=10.1038%2Ftp.2017.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders</span></div><div class="casAuthors">Lemonnier, E.; Villeneuve, N.; Sonie, S.; Serret, S.; Rosier, A.; Roue, M.; Brosset, P.; Viellard, M.; Bernoux, D.; Rondeau, S.; Thummler, S.; Ravel, D.; Ben-Ari, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1056</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In animal models of autism spectrum disorder (ASD), the NKCC1 chloride-importer inhibitor bumetanide restores physiol. (Cl-)i levels, enhances GABAergic inhibition and attenuates elec. and behavioral symptoms of ASD.  In an earlier phase 2 trial; bumetanide reduced the severity of ASD in children and adolescents (3-11 years old).  Here we report the results of a multicenter phase 2B study primarily to assess dose/response and safety effects of bumetanide.  Efficacy outcome measures included the Childhood Autism Rating Scale (CARS), the Social Responsive Scale (SRS) and the Clin. Global Impressions (CGI) Improvement scale (CGI-I).  Eighty-eight patients with ASD spanning across the entire pediatric population (2-18 years old) were subdivided in four age groups and randomized to receive bumetanide (0.5, 1.0 or 2.0 mg twice daily) or placebo for 3 mo.  The mean CARS value was significantly improved in the completers group (P: 0.015).  Also, 23 treated children had more than a six-point improvement in the CARS compared with only one placebo-treated individual.  Bumetanide significantly improved CGI (P: 0.0043) and the SRS score by more than 10 points (P: 0.02).  The most frequent adverse events were hypokalemia, increased urine elimination, loss of appetite, dehydration and asthenia.  Hypokalemia occurred mainly at the beginning of the treatment at 1.0 and 2.0 mg twice-daily doses and improved gradually with oral potassium supplements.  The frequency and incidence of adverse event were directly correlated with the dose of bumetanide.  Therefore, bumetanide improves the core symptoms of ASD and presents a favorable benefit/risk ratio particularly at 1.0 mg twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2IjlM6ANm4bVg90H21EOLACvtfcHk0ljB2Tkg00tqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSnsL0%253D&md5=4745991a7af97307e2562b916afa90bf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Ftp.2017.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2017.10%26sid%3Dliteratum%253Aachs%26aulast%3DLemonnier%26aufirst%3DE.%26aulast%3DVilleneuve%26aufirst%3DN.%26aulast%3DSonie%26aufirst%3DS.%26aulast%3DSerret%26aufirst%3DS.%26aulast%3DRosier%26aufirst%3DA.%26aulast%3DRoue%26aufirst%3DM.%26aulast%3DBrosset%26aufirst%3DP.%26aulast%3DViellard%26aufirst%3DM.%26aulast%3DBernoux%26aufirst%3DD.%26aulast%3DRondeau%26aufirst%3DS.%26aulast%3DThummler%26aufirst%3DS.%26aulast%3DRavel%26aufirst%3DD.%26aulast%3DBen-Ari%26aufirst%3DY.%26atitle%3DEffects%2520of%2520bumetanide%2520on%2520neurobehavioral%2520function%2520in%2520children%2520and%2520adolescents%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DTransl.%2520Psychiatry%26date%3D2017%26volume%3D7%26spage%3De1056%26doi%3D10.1038%2Ftp.2017.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyzio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsintsadze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahrokhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalilov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsintsadze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouchoud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemonnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozovaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Y.</span></span> <span> </span><span class="NLM_article-title">Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1126/science.1247190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1247190" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=675-679&author=R.+Tyzioauthor=R.+Nardouauthor=D.+C.+Ferrariauthor=T.+Tsintsadzeauthor=A.+Shahrokhiauthor=S.+Eftekhariauthor=I.+Khalilovauthor=V.+Tsintsadzeauthor=C.+Brouchoudauthor=G.+Chazalauthor=E.+Lemonnierauthor=N.+Lozovayaauthor=N.+Burnashevauthor=Y.+Ben-Ari&title=Oxytocin-mediated+GABA+inhibition+during+delivery+attenuates+autism+pathogenesis+in+rodent+offspring&doi=10.1126%2Fscience.1247190"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.1247190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1247190%26sid%3Dliteratum%253Aachs%26aulast%3DTyzio%26aufirst%3DR.%26aulast%3DNardou%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DD.%2BC.%26aulast%3DTsintsadze%26aufirst%3DT.%26aulast%3DShahrokhi%26aufirst%3DA.%26aulast%3DEftekhari%26aufirst%3DS.%26aulast%3DKhalilov%26aufirst%3DI.%26aulast%3DTsintsadze%26aufirst%3DV.%26aulast%3DBrouchoud%26aufirst%3DC.%26aulast%3DChazal%26aufirst%3DG.%26aulast%3DLemonnier%26aufirst%3DE.%26aulast%3DLozovaya%26aufirst%3DN.%26aulast%3DBurnashev%26aufirst%3DN.%26aulast%3DBen-Ari%26aufirst%3DY.%26atitle%3DOxytocin-mediated%2520GABA%2520inhibition%2520during%2520delivery%2520attenuates%2520autism%2520pathogenesis%2520in%2520rodent%2520offspring%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D675%26epage%3D679%26doi%3D10.1126%2Fscience.1247190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanratty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCaria, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosovich, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.npp.1300021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=193-198&author=E.+Hollanderauthor=S.+Novotnyauthor=M.+Hanrattyauthor=R.+Yaffeauthor=C.+M.+DeCariaauthor=B.+R.+Aronowitzauthor=S.+Mosovich&title=Oxytocin+infusion+reduces+repetitive+behaviors+in+adults+with+autistic+and+Asperger%E2%80%99s+disorders&doi=10.1038%2Fsj.npp.1300021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300021%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DNovotny%26aufirst%3DS.%26aulast%3DHanratty%26aufirst%3DM.%26aulast%3DYaffe%26aufirst%3DR.%26aulast%3DDeCaria%26aufirst%3DC.%2BM.%26aulast%3DAronowitz%26aufirst%3DB.%2BR.%26aulast%3DMosovich%26aufirst%3DS.%26atitle%3DOxytocin%2520infusion%2520reduces%2520repetitive%2520behaviors%2520in%2520adults%2520with%2520autistic%2520and%2520Asperger%25E2%2580%2599s%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D193%26epage%3D198%26doi%3D10.1038%2Fsj.npp.1300021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soorya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin increases retention of social cognition in autism</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2006.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16904652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=498-550&author=E.+Hollanderauthor=J.+Bartzauthor=W.+Chaplinauthor=A.+Phillipsauthor=J.+Sumnerauthor=L.+Sooryaauthor=E.+Anagnostouauthor=S.+Wasserman&title=Oxytocin+increases+retention+of+social+cognition+in+autism&doi=10.1016%2Fj.biopsych.2006.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin Increases Retention of Social Cognition in Autism</span></div><div class="casAuthors">Hollander, Eric; Bartz, Jennifer; Chaplin, William; Phillips, Ann; Sumner, Jennifer; Soorya, Latha; Anagnostou, Evdokia; Wasserman, Stacey</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-503</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Oxytocin dysfunction might contribute to the development of social deficits in autism, a core symptom domain and potential target for intervention.  This study explored the effect of i.v. oxytocin administration on the retention of social information in autism.  Methods: Oxytocin and placebo challenges were administered to 15 adult subjects diagnosed with autism or Asperger's disorder, and comprehension of affective speech (happy, indifferent, angry, and sad) in neutral content sentences was tested.  Results: All subjects showed improvements in affective speech comprehension from pre- to post-infusion; however, whereas those who received placebo first tended to revert to baseline after a delay, those who received oxytocin first retained the ability to accurately assign emotional significance to speech intonation on the speech comprehension task.  Conclusions: These results are consistent with studies linking oxytocin to social recognition in rodents as well as studies linking oxytocin to prosocial behavior in humans and suggest that oxytocin might facilitate social information processing in those with autism.  These findings also provide preliminary support for the use of oxytocin in the treatment of autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreES3yFX-HhbVg90H21EOLACvtfcHk0ljoDwend_NrWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjurk%253D&md5=e6276eeae44187f43175e253393f141a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DBartz%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DW.%26aulast%3DPhillips%26aufirst%3DA.%26aulast%3DSumner%26aufirst%3DJ.%26aulast%3DSoorya%26aufirst%3DL.%26aulast%3DAnagnostou%26aufirst%3DE.%26aulast%3DWasserman%26aufirst%3DS.%26atitle%3DOxytocin%2520increases%2520retention%2520of%2520social%2520cognition%2520in%2520autism%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D498%26epage%3D550%26doi%3D10.1016%2Fj.biopsych.2006.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhamel, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrecht, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirigu, A.</span></span> <span> </span><span class="NLM_article-title">Promoting social behavior with oxytocin in high-functioning autism spectrum disorders</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4389</span>– <span class="NLM_lpage">4394</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910249107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1073%2Fpnas.0910249107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4389-4394&author=E.+Andariauthor=J.+R.+Duhamelauthor=T.+Zallaauthor=E.+Herbrechtauthor=M.+Leboyerauthor=A.+Sirigu&title=Promoting+social+behavior+with+oxytocin+in+high-functioning+autism+spectrum+disorders&doi=10.1073%2Fpnas.0910249107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910249107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910249107%26sid%3Dliteratum%253Aachs%26aulast%3DAndari%26aufirst%3DE.%26aulast%3DDuhamel%26aufirst%3DJ.%2BR.%26aulast%3DZalla%26aufirst%3DT.%26aulast%3DHerbrecht%26aufirst%3DE.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DSirigu%26aufirst%3DA.%26atitle%3DPromoting%2520social%2520behavior%2520with%2520oxytocin%2520in%2520high-functioning%2520autism%2520spectrum%2520disorders%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0910249107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einfeld, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span> <span> </span><span class="NLM_article-title">Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2009.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=19897177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1akur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=692-694&author=A.+J.+Guastellaauthor=S.+L.+Einfeldauthor=K.+M.+Grayauthor=N.+J.+Rinehartauthor=B.+J.+Tongeauthor=T.+J.+Lambertauthor=I.+B.+Hickie&title=Intranasal+oxytocin+improves+emotion+recognition+for+youth+with+autism+spectrum+disorders&doi=10.1016%2Fj.biopsych.2009.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders</span></div><div class="casAuthors">Guastella, Adam J.; Einfeld, Stewart L.; Gray, Kylie M.; Rinehart, Nicole J.; Tonge, Bruce J.; Lambert, Timothy J.; Hickie, Ian B.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">692-694</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: A diagnostic hallmark of autism spectrum disorders is a qual. impairment in social communication and interaction.  Deficits in the ability to recognize the emotions of others are believed to contribute to this.  There is currently no effective treatment for these problems.  Methods: In a double-blind, randomized, placebo-controlled, crossover design, we administered oxytocin nasal spray (18 or 24 IU) or a placebo to 16 male youth aged 12 to 19 who were diagnosed with Autistic or Asperger's Disorder.  Participants then completed the Reading the Mind in the Eyes Task, a widely used and reliable test of emotion recognition.  Results: In comparison with placebo, oxytocin administration improved performance on the Reading the Mind in the Eyes Task.  This effect was also shown when anal. was restricted to the younger participants aged 12 to 15 who received the lower dose.  Conclusions: This study provides the first evidence that oxytocin nasal spray improves emotion recognition in young people diagnosed with autism spectrum disorders.  Findings suggest the potential of earlier intervention and further evaluation of oxytocin nasal spray as a treatment to improve social communication and interaction in young people with autism spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoMPTv7Z_o7Vg90H21EOLACvtfcHk0ljoDwend_NrWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1akur0%253D&md5=450f9d9fb6fffb0b4716e777828bc306</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26aulast%3DEinfeld%26aufirst%3DS.%2BL.%26aulast%3DGray%26aufirst%3DK.%2BM.%26aulast%3DRinehart%26aufirst%3DN.%2BJ.%26aulast%3DTonge%26aufirst%3DB.%2BJ.%26aulast%3DLambert%26aufirst%3DT.%2BJ.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26atitle%3DIntranasal%2520oxytocin%2520improves%2520emotion%2520recognition%2520for%2520youth%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2010%26volume%3D67%26spage%3D692%26epage%3D694%26doi%3D10.1016%2Fj.biopsych.2009.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munesue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishitobi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span> <span> </span><span class="NLM_article-title">Long-term oxytocin administration improves social behaviors in a girl with autistic disorder</span>. <i>BMC Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">110</span>, <span class="refDoi"> DOI: 10.1186/1471-244X-12-110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1186%2F1471-244X-12-110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=110&author=H.+Kosakaauthor=T.+Munesueauthor=M.+Ishitobiauthor=M.+Asanoauthor=M.+Omoriauthor=M.+Satoauthor=A.+Tomodaauthor=Y.+Wada&title=Long-term+oxytocin+administration+improves+social+behaviors+in+a+girl+with+autistic+disorder&doi=10.1186%2F1471-244X-12-110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1471-244X-12-110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-244X-12-110%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DH.%26aulast%3DMunesue%26aufirst%3DT.%26aulast%3DIshitobi%26aufirst%3DM.%26aulast%3DAsano%26aufirst%3DM.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DTomoda%26aufirst%3DA.%26aulast%3DWada%26aufirst%3DY.%26atitle%3DLong-term%2520oxytocin%2520administration%2520improves%2520social%2520behaviors%2520in%2520a%2520girl%2520with%2520autistic%2520disorder%26jtitle%3DBMC%2520Psychiatry%26date%3D2012%26volume%3D12%26spage%3D110%26doi%3D10.1186%2F1471-244X-12-110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soorya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span> <span> </span><span class="NLM_article-title">Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1580</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2014.01.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.brainres.2014.01.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=24508578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFCkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1580&publication_year=2014&pages=188-198&author=E.+Anagnostouauthor=L.+Sooryaauthor=J.+Brianauthor=A.+Dupuisauthor=D.+Mankadauthor=S.+Smileauthor=S.+Jacob&title=Intranasal+oxytocin+in+the+treatment+of+autism+spectrum+disorders%3A+a+review+of+literature+and+early+safety+and+efficacy+data+in+youth&doi=10.1016%2Fj.brainres.2014.01.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal oxytocin in the treatment of autism spectrum disorders: A review of literature and early safety and efficacy data in youth</span></div><div class="casAuthors">Anagnostou, Evdokia; Soorya, Latha; Brian, Jessica; Dupuis, Annie; Mankad, Deepali; Smile, Sharon; Jacob, Suma</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1580</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188-198</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  There is a paucity of treatments targeting core symptom domains in Autism Spectrum Disorder (ASD).  Several animal models and research in typically developing volunteers suggests that manipulation of the oxytocin system may have therapeutic potential for the treatment of social deficits.  We review the literature for oxytocin and ASD and report on early dosing, safety and efficacy data of multi-dose oxytocin on aspects of social cognition/function, as well as repetitive behaviors and co-occurring anxiety within ASD.  Methods: Fifteen children and adolescents with verbal IQs≥70 were diagnosed with ASD using the ADOS and the ADI-R.  They participated in a modified max. tolerated dose study of intranasal oxytocin (Syntocinon).  Data were modeled using repeated measures regression anal. controlling for week, dose, age, and sex.  Results: Among 4 doses tested, the highest dose evaluated, 0.4 IU/kg/dose, was found to be well tolerated.  No serious or severe adverse events were reported and adverse events reported/obsd. were mild to moderate.  Over 12 wk of treatment, several measures of social cognition/function, repetitive behaviors and anxiety showed sensitivity to change with some measures suggesting maintenance of effect 3 mo past discontinuation of intranasal oxytocin.  Conclusions: This pilot study suggests that daily administration of intranasal oxytocin at 0.4 IU/kg/dose in children and adolescents with ASD is safe and has therapeutic potential.  Larger studies are warranted.This article is part of a Special Issue entitled Oxytocin and Social Behav.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpknvrr6ILrZbVg90H21EOLACvtfcHk0lhZRy6dohVpnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFCkur4%253D&md5=cc7fbed811b4f4b58bae6fca09475ad9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2014.01.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2014.01.049%26sid%3Dliteratum%253Aachs%26aulast%3DAnagnostou%26aufirst%3DE.%26aulast%3DSoorya%26aufirst%3DL.%26aulast%3DBrian%26aufirst%3DJ.%26aulast%3DDupuis%26aufirst%3DA.%26aulast%3DMankad%26aufirst%3DD.%26aulast%3DSmile%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DS.%26atitle%3DIntranasal%2520oxytocin%2520in%2520the%2520treatment%2520of%2520autism%2520spectrum%2520disorders%253A%2520a%2520review%2520of%2520literature%2520and%2520early%2520safety%2520and%2520efficacy%2520data%2520in%2520youth%26jtitle%3DBrain%2520Res.%26date%3D2014%26volume%3D1580%26spage%3D188%26epage%3D198%26doi%3D10.1016%2Fj.brainres.2014.01.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagitani-Shimono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanefuji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniike, M.</span></span> <span> </span><span class="NLM_article-title">Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders</span>. <i>J. Child Adolesc. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1089/cap.2012.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1089%2Fcap.2012.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23480321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=123-127&author=M.+Tachibanaauthor=K.+Kagitani-Shimonoauthor=I.+Mohriauthor=T.+Yamamotoauthor=W.+Sanefujiauthor=A.+Nakamuraauthor=M.+Oishiauthor=T.+Kimuraauthor=T.+Onakaauthor=K.+Ozonoauthor=M.+Taniike&title=Long-term+administration+of+intranasal+oxytocin+is+a+safe+and+promising+therapy+for+early+adolescent+boys+with+autism+spectrum+disorders&doi=10.1089%2Fcap.2012.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Administration of Intranasal Oxytocin Is a Safe and Promising Therapy for Early Adolescent Boys with Autism Spectrum Disorders</span></div><div class="casAuthors">Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Nakamura, Ayumi; Oishi, Masako; Kimura, Tadashi; Onaka, Tatsushi; Ozono, Keiichi; Taniike, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Child and Adolescent Psychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-127</span>CODEN:
                <span class="NLM_cas:coden">JADPET</span>;
        ISSN:<span class="NLM_cas:issn">1044-5463</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated.  However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified.  Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10-14 years of age; intelligence quotient [IQ] 20-101).  The OT administration was performed in a stepwise increased dosage manner every 2 mo (8, 16, 24 IU/dose).  A placebo period (1-2 wk) was inserted before each step.  The outcome measures were Autism Diagnostic Observation Schedule - Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC).  In addn., side effects were monitored by measuring blood pressure and examg. urine and blood samples.  Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G.  However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement.  Caregivers of five of the eight participants reported certain pos. effects of the OT therapy, esp. on the quality of reciprocal communication.  All participants showed excellent compliance and no side effects.  Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD.  Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1W2Z4_SZIxbVg90H21EOLACvtfcHk0lhZRy6dohVpnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D&md5=8b84a3857e1b54023f3b4d181b1e2f37</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1089%2Fcap.2012.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcap.2012.0048%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DKagitani-Shimono%26aufirst%3DK.%26aulast%3DMohri%26aufirst%3DI.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSanefuji%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DOishi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOnaka%26aufirst%3DT.%26aulast%3DOzono%26aufirst%3DK.%26aulast%3DTaniike%26aufirst%3DM.%26atitle%3DLong-term%2520administration%2520of%2520intranasal%2520oxytocin%2520is%2520a%2520safe%2520and%2520promising%2520therapy%2520for%2520early%2520adolescent%2520boys%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DJ.%2520Child%2520Adolesc.%2520Psychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D123%26epage%3D127%26doi%3D10.1089%2Fcap.2012.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dadds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, J.</span></span> <span> </span><span class="NLM_article-title">Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial</span>. <i>J. Autism Dev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s10803-013-1899-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2Fs10803-013-1899-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23888359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktFyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=521-531&author=M.+R.+Daddsauthor=E.+Macdonaldauthor=A.+Cauchiauthor=K.+Williamsauthor=F.+Levyauthor=J.+Brennan&title=Nasal+oxytocin+for+social+deficits+in+childhood+autism%3A+a+randomized+controlled+trial&doi=10.1007%2Fs10803-013-1899-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial</span></div><div class="casAuthors">Dadds Mark R; MacDonald Elayne; Cauchi Avril; Williams Katrina; Levy Florence; Brennan John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autism and developmental disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The last two decades have witnessed a surge in research investigating the application of oxytocin as a method of enhancing social behaviour in humans.  Preliminary evidence suggests oxytocin may have potential as an intervention for autism.  We evaluated a 5-day 'live-in' intervention using a double-blind randomized control trial. 38 male youths (7-16 years old) with autism spectrum disorders were administered 24 or 12 international units (depending on weight) intranasal placebo or oxytocin once daily over four consecutive days.  The oxytocin or placebo was administered during parent-child interaction training sessions.  Parent and child behaviours were assessed using parent reports, clinician ratings, and independent observations, at multiple time points to measure side-effects; social interaction skills; repetitive behaviours; emotion recognition and diagnostic status.  Compared to placebo, intranasal oxytocin did not significantly improve emotion recognition, social interaction skills, or general behavioral adjustment in male youths with autism spectrum disorders.  The results show that the benefits of nasal oxytocin for young individuals with autism spectrum disorders may be more circumscribed than suggested by previous studies, and suggest caution in recommending it as an intervention that is broadly effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCr6Wb1tqsnNy3lHz94U-GfW6udTcc2eZUJ7Bb2Kg98bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktFyntQ%253D%253D&md5=dd8a1a7c59e80f2dd8d04f52e522d6ab</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10803-013-1899-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10803-013-1899-3%26sid%3Dliteratum%253Aachs%26aulast%3DDadds%26aufirst%3DM.%2BR.%26aulast%3DMacdonald%26aufirst%3DE.%26aulast%3DCauchi%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DF.%26aulast%3DBrennan%26aufirst%3DJ.%26atitle%3DNasal%2520oxytocin%2520for%2520social%2520deficits%2520in%2520childhood%2520autism%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Autism%2520Dev.%2520Disord.%26date%3D2014%26volume%3D44%26spage%3D521%26epage%3D531%26doi%3D10.1007%2Fs10803-013-1899-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchi, A. J.</span></span> <span> </span><span class="NLM_article-title">A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1016/j.psyneuen.2011.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.psyneuen.2011.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=1114-1126&author=E.+MacDonaldauthor=M.+R.+Daddsauthor=J.+L.+Brennanauthor=K.+Williamsauthor=F.+Levyauthor=A.+J.+Cauchi&title=A+review+of+safety%2C+side-effects+and+subjective+reactions+to+intranasal+oxytocin+in+human+research&doi=10.1016%2Fj.psyneuen.2011.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2011.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2011.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DE.%26aulast%3DDadds%26aufirst%3DM.%2BR.%26aulast%3DBrennan%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DF.%26aulast%3DCauchi%26aufirst%3DA.%2BJ.%26atitle%3DA%2520review%2520of%2520safety%252C%2520side-effects%2520and%2520subjective%2520reactions%2520to%2520intranasal%2520oxytocin%2520in%2520human%2520research%26jtitle%3DPsychoneuroendocrinology%26date%3D2011%26volume%3D36%26spage%3D1114%26epage%3D1126%26doi%3D10.1016%2Fj.psyneuen.2011.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijers, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noltes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucha, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, P. J.</span></span> <span> </span><span class="NLM_article-title">Oxytocin enhances orienting to social information in a selective group of high-functioning male adults with autism spectrum disorder</span>. <i>Neuropsychologia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.neuropsychologia.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neuropsychologia.2015.10.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=53-69&author=M.+Althausauthor=Y.+Groenauthor=A.+A.+Wijersauthor=H.+Noltesauthor=O.+Tuchaauthor=P.+J.+Hoekstra&title=Oxytocin+enhances+orienting+to+social+information+in+a+selective+group+of+high-functioning+male+adults+with+autism+spectrum+disorder&doi=10.1016%2Fj.neuropsychologia.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropsychologia.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropsychologia.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DAlthaus%26aufirst%3DM.%26aulast%3DGroen%26aufirst%3DY.%26aulast%3DWijers%26aufirst%3DA.%2BA.%26aulast%3DNoltes%26aufirst%3DH.%26aulast%3DTucha%26aufirst%3DO.%26aulast%3DHoekstra%26aufirst%3DP.%2BJ.%26atitle%3DOxytocin%2520enhances%2520orienting%2520to%2520social%2520information%2520in%2520a%2520selective%2520group%2520of%2520high-functioning%2520male%2520adults%2520with%2520autism%2520spectrum%2520disorder%26jtitle%3DNeuropsychologia%26date%3D2015%26volume%3D79%26spage%3D53%26epage%3D69%26doi%3D10.1016%2Fj.neuropsychologia.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirigu, A.</span></span> <span> </span><span class="NLM_article-title">Adaptive coding of the value of social cues with oxytocin, an fMRI study in autism spectrum disorder</span>. <i>Cortex</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.cortex.2015.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.cortex.2015.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=79-88&author=E.+Andariauthor=N.+Richardauthor=M.+Leboyerauthor=A.+Sirigu&title=Adaptive+coding+of+the+value+of+social+cues+with+oxytocin%2C+an+fMRI+study+in+autism+spectrum+disorder&doi=10.1016%2Fj.cortex.2015.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cortex.2015.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cortex.2015.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DAndari%26aufirst%3DE.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DSirigu%26aufirst%3DA.%26atitle%3DAdaptive%2520coding%2520of%2520the%2520value%2520of%2520social%2520cues%2520with%2520oxytocin%252C%2520an%2520fMRI%2520study%2520in%2520autism%2520spectrum%2520disorder%26jtitle%3DCortex%26date%3D2016%26volume%3D76%26spage%3D79%26epage%3D88%26doi%3D10.1016%2Fj.cortex.2015.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsubori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonoi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunimatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">3073</span>– <span class="NLM_lpage">3086</span>, <span class="refDoi"> DOI: 10.1093/brain/awu231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1093%2Fbrain%2Fawu231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=3073-3086&author=Y.+Aokiauthor=N.+Yahataauthor=T.+Watanabeauthor=Y.+Takanoauthor=Y.+Kawakuboauthor=H.+Kuwabaraauthor=N.+Iwashiroauthor=T.+Natsuboriauthor=H.+Inoueauthor=M.+Sugaauthor=H.+Takaoauthor=H.+Sasakiauthor=W.+Gonoiauthor=A.+Kunimatsuauthor=K.+Kasaiauthor=H.+Yamasue&title=Oxytocin+improves+behavioural+and+neural+deficits+in+inferring+others%E2%80%99+social+emotions+in+autism&doi=10.1093%2Fbrain%2Fawu231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu231%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DYahata%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DNatsubori%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DGonoi%26aufirst%3DW.%26aulast%3DKunimatsu%26aufirst%3DA.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DOxytocin%2520improves%2520behavioural%2520and%2520neural%2520deficits%2520in%2520inferring%2520others%25E2%2580%2599%2520social%2520emotions%2520in%2520autism%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D3073%26epage%3D3086%26doi%3D10.1093%2Fbrain%2Fawu231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsubori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1038/mp.2014.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fmp.2014.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25070538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GhsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=447-453&author=Y.+Aokiauthor=T.+Watanabeauthor=O.+Abeauthor=H.+Kuwabaraauthor=N.+Yahataauthor=Y.+Takanoauthor=N.+Iwashiroauthor=T.+Natsuboriauthor=H.+Takaoauthor=Y.+Kawakuboauthor=K.+Kasaiauthor=H.+Yamasue&title=Oxytocin%E2%80%99s+neurochemical+effects+in+the+medial+prefrontal+cortex+underlie+recovery+of+task-specific+brain+activity+in+autism%3A+a+randomized+controlled+trial&doi=10.1038%2Fmp.2014.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial</span></div><div class="casAuthors">Aoki, Y.; Watanabe, T.; Abe, O.; Kuwabara, H.; Yahata, N.; Takano, Y.; Iwashiro, N.; Natsubori, T.; Takao, H.; Kawakubo, Y.; Kasai, K.; Yamasue, H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">447-453</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deficits assocd. with autism.  Our recent paper reported that oxytocin mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex (vmPFC), as demonstrated with functional magnetic resonance imaging (fMRI) during a socio-communication task.  However, it is unknown whether oxytocin exhibited effects at the neuronal level, which was outside of the specific task examd.  In the same randomized, double-blind, placebo-controlled, within-subject cross-over clin. trial in which a single dose of intranasal oxytocin (24 IU) was administered to 40 men with high-functioning autism spectrum disorder (UMIN000002241/000004393), we measured N-acetylaspartate (NAA) levels, a marker for neuronal energy demand, in the vmPFC using 1H-magnetic resonance spectroscopy (1H-MRS).  The differences in the NAA levels between the oxytocin and placebo sessions were assocd. with oxytocin-induced fMRI signal changes in the vmPFC.  The oxytocin-induced increases in the fMRI signal could be predicted by the NAA differences between the oxytocin and placebo sessions (P=0.002), an effect that remained after controlling for variability in the time between the fMRI and 1H-MRS scans (P=0.006) and the order of administration of oxytocin and placebo (P=0.001).  Furthermore, path anal. showed that the NAA differences in the vmPFC triggered increases in the task-dependent fMRI signals in the vmPFC, which consequently led to improvements in the socio-communication difficulties assocd. with autism.  The present study suggests that the beneficial effects of oxytocin are not limited to the autistic behavior elicited by our psychol. task, but may generalize to other autistic behavioral problems assocd. with the vmPFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5tYMOOqHfULVg90H21EOLACvtfcHk0lhuV1aXcirltQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GhsrzJ&md5=48a17e446e9bda3edda9174014cf162f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fmp.2014.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2014.74%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DO.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DYahata%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DNatsubori%26aufirst%3DT.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DOxytocin%25E2%2580%2599s%2520neurochemical%2520effects%2520in%2520the%2520medial%2520prefrontal%2520cortex%2520underlie%2520recovery%2520of%2520task-specific%2520brain%2520activity%2520in%2520autism%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DMol.%2520Psychiatry%26date%3D2015%26volume%3D20%26spage%3D447%26epage%3D453%26doi%3D10.1038%2Fmp.2014.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auyeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethlehem, R. A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipple, J. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron-Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e507</span>, <span class="refDoi"> DOI: 10.1038/tp.2014.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2014.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25668435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e507&author=B.+Auyeungauthor=M.+V.+Lombardoauthor=M.+Heinrichsauthor=B.+Chakrabartiauthor=A.+Suleauthor=J.+B.+Deakinauthor=R.+A.+I.+Bethlehemauthor=L.+Dickensauthor=N.+Mooneyauthor=J.+A.+N.+Sippleauthor=P.+Thiemannauthor=S.+Baron-Cohen&title=Oxytocin+increases+eye+contact+during+a+real-time%2C+naturalistic+social+interaction+in+males+with+and+without+autism&doi=10.1038%2Ftp.2014.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism</span></div><div class="casAuthors">Auyeung, B.; Lombardo, M. V.; Heinrichs, M.; Chakrabarti, B.; Sule, A.; Deakin, J. B.; Bethlehem, R. A. I.; Dickens, L.; Mooney, N.; Sipple, J. A. N.; Thiemann, P.; Baron-Cohen, S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e507</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autism spectrum conditions (autism) affect ∼1% of the population and are characterized by deficits in social communication.  Oxytocin has been widely reported to affect social-communicative function and its neural underpinnings.  Here we report the first evidence that intranasal oxytocin administration improves a core problem that individuals with autism have in using eye contact appropriately in real-world social settings.  A randomized double-blind, placebo-controlled, within-subjects design is used to examine how intranasal administration of 24 IU of oxytocin affects gaze behavior for 32 adult males with autism and 34 controls in a real-time interaction with a researcher.  This interactive paradigm bypasses many of the limitations encountered with conventional static or computer-based stimuli.  Eye movements are recorded using eye tracking, providing an objective measurement of looking patterns.  The measure is shown to be sensitive to the reduced eye contact commonly reported in autism, with the autism group spending less time looking to the eye region of the face than controls.  Oxytocin administration selectively enhanced gaze to the eyes in both the autism and control groups (transformed mean eye-fixation difference per s=0.082; 95% CI:0.025-0.14, P=0.006).  Within the autism group, oxytocin has the most effect on fixation duration in individuals with impaired levels of eye contact at baseline (Cohen's d=0.86).  These findings demonstrate that the potential benefits of oxytocin in autism extend to a real-time interaction, providing evidence of a therapeutic effect in a key aspect of social communication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplKgtAe3rzhbVg90H21EOLACvtfcHk0lhuV1aXcirltQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCgt7c%253D&md5=6bd13bfd402ab6df8b4ee8682cced347</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Ftp.2014.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2014.146%26sid%3Dliteratum%253Aachs%26aulast%3DAuyeung%26aufirst%3DB.%26aulast%3DLombardo%26aufirst%3DM.%2BV.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DChakrabarti%26aufirst%3DB.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DDeakin%26aufirst%3DJ.%2BB.%26aulast%3DBethlehem%26aufirst%3DR.%2BA.%2BI.%26aulast%3DDickens%26aufirst%3DL.%26aulast%3DMooney%26aufirst%3DN.%26aulast%3DSipple%26aufirst%3DJ.%2BA.%2BN.%26aulast%3DThiemann%26aufirst%3DP.%26aulast%3DBaron-Cohen%26aufirst%3DS.%26atitle%3DOxytocin%2520increases%2520eye%2520contact%2520during%2520a%2520real-time%252C%2520naturalistic%2520social%2520interaction%2520in%2520males%2520with%2520and%2520without%2520autism%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De507%26doi%3D10.1038%2Ftp.2014.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpertz, S. C.</span></span> <span> </span><span class="NLM_article-title">Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23510581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2013&pages=164-171&author=G.+Domesauthor=M.+Heinrichsauthor=E.+Kumbierauthor=A.+Grossmannauthor=K.+Hauensteinauthor=S.+C.+Herpertz&title=Effects+of+intranasal+oxytocin+on+the+neural+basis+of+face+processing+in+autism+spectrum+disorder&doi=10.1016%2Fj.biopsych.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Intranasal Oxytocin on the Neural Basis of Face Processing in Autism Spectrum Disorder</span></div><div class="casAuthors">Domes, Gregor; Heinrichs, Markus; Kumbier, Ekkehardt; Grossmann, Annette; Hauenstein, Karlheinz; Herpertz, Sabine C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Autism spectrum disorder (ASD) is assocd. with altered face processing and decreased activity in brain regions involved in face processing.  The neuropeptide oxytocin has been shown to promote face processing and modulate brain activity in healthy adults.  The present study examd. the effects of oxytocin on the neural basis of face processing in adults with Asperger syndrome (AS).  Methods: A group of 14 individuals with AS and a group of 14 neurotypical control participants performed a face-matching and a house-matching task during functional magnetic resonance imaging.  The effects of a single dose of 24 IU intranasally administered oxytocin were tested in a randomized, placebo-controlled, within-subject, cross-over design.  Results: Under placebo, the AS group showed decreased activity in the right amygdala, fusiform gyrus, and inferior occipital gyrus compared with the control group during face processing.  After oxytocin treatment, right amygdala activity to facial stimuli increased in the AS group.  Conclusions: These findings indicate that oxytocin increases the saliency of social stimuli and in ASD and suggest that oxytocin might promote face processing and eye contact in individuals with ASD as prerequisites for neurotypical social interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrThR5xUWpbIrVg90H21EOLACvtfcHk0ljFX7gFFFTSaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jtbk%253D&md5=cd0d31448b6374b0f42d208bea69749e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DDomes%26aufirst%3DG.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DKumbier%26aufirst%3DE.%26aulast%3DGrossmann%26aufirst%3DA.%26aulast%3DHauenstein%26aufirst%3DK.%26aulast%3DHerpertz%26aufirst%3DS.%2BC.%26atitle%3DEffects%2520of%2520intranasal%2520oxytocin%2520on%2520the%2520neural%2520basis%2520of%2520face%2520processing%2520in%2520autism%2520spectrum%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2013%26volume%3D74%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.biopsych.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpertz, S. C.</span></span> <span> </span><span class="NLM_article-title">Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with Asperger syndrome</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2013.254" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=698-706&author=G.+Domesauthor=E.+Kumbierauthor=M.+Heinrichsauthor=S.+C.+Herpertz&title=Oxytocin+promotes+facial+emotion+recognition+and+amygdala+reactivity+in+adults+with+Asperger+syndrome&doi=10.1038%2Fnpp.2013.254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.254%26sid%3Dliteratum%253Aachs%26aulast%3DDomes%26aufirst%3DG.%26aulast%3DKumbier%26aufirst%3DE.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DHerpertz%26aufirst%3DS.%2BC.%26atitle%3DOxytocin%2520promotes%2520facial%2520emotion%2520recognition%2520and%2520amygdala%2520reactivity%2520in%2520adults%2520with%2520Asperger%2520syndrome%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D698%26epage%3D706%26doi%3D10.1038%2Fnpp.2013.254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Wyk, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeaux, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilbott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagoory-Sharon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leckman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelphrey, K. A.</span></span> <span> </span><span class="NLM_article-title">Oxytocin enhances brain function in children with autism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">20953</span>– <span class="NLM_lpage">20958</span>, <span class="refDoi"> DOI: 10.1073/pnas.1312857110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1073%2Fpnas.1312857110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=20953-20958&author=I.+Gordonauthor=B.+C.+Vander+Wykauthor=R.+H.+Bennettauthor=C.+O.+Cordeauxauthor=M.+V.+Lucasauthor=J.+A.+Eilbottauthor=O.+Zagoory-Sharonauthor=J.+F.+Leckmanauthor=R.+Feldmanauthor=K.+A.+Pelphrey&title=Oxytocin+enhances+brain+function+in+children+with+autism&doi=10.1073%2Fpnas.1312857110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1312857110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1312857110%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DI.%26aulast%3DVander%2BWyk%26aufirst%3DB.%2BC.%26aulast%3DBennett%26aufirst%3DR.%2BH.%26aulast%3DCordeaux%26aufirst%3DC.%2BO.%26aulast%3DLucas%26aufirst%3DM.%2BV.%26aulast%3DEilbott%26aufirst%3DJ.%2BA.%26aulast%3DZagoory-Sharon%26aufirst%3DO.%26aulast%3DLeckman%26aufirst%3DJ.%2BF.%26aulast%3DFeldman%26aufirst%3DR.%26aulast%3DPelphrey%26aufirst%3DK.%2BA.%26atitle%3DOxytocin%2520enhances%2520brain%2520function%2520in%2520children%2520with%2520autism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D20953%26epage%3D20958%26doi%3D10.1073%2Fpnas.1312857110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spenthof, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Elst, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span> <span> </span><span class="NLM_article-title">Restoring effects of oxytocin on the attentional preference for faces in autism</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1097</span>, <span class="refDoi"> DOI: 10.1038/tp.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28418399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e1097&author=M.+Kanatauthor=I.+Spenthofauthor=A.+Riedelauthor=L.+T.+van+Elstauthor=M.+Heinrichsauthor=G.+Domes&title=Restoring+effects+of+oxytocin+on+the+attentional+preference+for+faces+in+autism&doi=10.1038%2Ftp.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Restoring effects of oxytocin on the attentional preference for faces in autism</span></div><div class="casAuthors">Kanat, M.; Spenthof, I.; Riedel, A.; van Elst, L. T.; Heinrichs, M.; Domes, G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1097</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reduced attentional preference for faces and symptoms of social anxiety are common in autism spectrum disorders (ASDs).  The neuropeptide oxytocin triggers anxiolytic functions and enhances eye gaze, facial emotion recognition and neural correlates of face processing in ASD.  Here we investigated whether a single dose of oxytocin increases attention to faces in ASD.  As a secondary question, we explored the influence of social anxiety on these effects.  We tested for oxytocin's effects on attention to neutral faces as compared to houses in a sample of 29 autistic individuals and 30 control participants using a dot-probe paradigm with two different presentation times (100 or 500 ms).  A single dose of 24 IU oxytocin was administered in a randomized, double-blind placebo-controlled, cross-over design.  Under placebo, ASD individuals paid less attention to faces presented for 500 ms than did controls.  Oxytocin administration increased the allocation of attention toward faces in ASD to a level obsd. in controls.  Secondary analyses revealed that these oxytocin effects primarily occurred in ASD individuals with high levels of social anxiety who were characterized by attentional avoidance of faces under placebo.  Our results confirm a pos. influence of intranasal oxytocin on social attention processes in ASD.  Further, they suggest that oxytocin may in particular restore the attentional preference for facial information in ASD individuals with high social anxiety.  We conclude that oxytocin's anxiolytic properties may partially account for its pos. effects on socio-cognitive functioning in ASD, such as enhanced eye gaze and facial emotion recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UJ6xcYpBMbVg90H21EOLACvtfcHk0ljdAesB9AjEpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhtr8%253D&md5=6f00325307ee2dddb4b1631d30fb7c6f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Ftp.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DKanat%26aufirst%3DM.%26aulast%3DSpenthof%26aufirst%3DI.%26aulast%3DRiedel%26aufirst%3DA.%26aulast%3Dvan%2BElst%26aufirst%3DL.%2BT.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DDomes%26aufirst%3DG.%26atitle%3DRestoring%2520effects%2520of%2520oxytocin%2520on%2520the%2520attentional%2520preference%2520for%2520faces%2520in%2520autism%26jtitle%3DTransl.%2520Psychiatry%26date%3D2017%26volume%3D7%26spage%3De1097%26doi%3D10.1038%2Ftp.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsunobu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nippashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunimatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">3400</span>– <span class="NLM_lpage">3412</span>, <span class="refDoi"> DOI: 10.1093/brain/awv249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1093%2Fbrain%2Fawv249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=3400-3412&author=T.+Watanabeauthor=M.+Kurodaauthor=H.+Kuwabaraauthor=Y.+Aokiauthor=N.+Iwashiroauthor=N.+Tatsunobuauthor=H.+Takaoauthor=Y.+Nippashiauthor=Y.+Kawakuboauthor=A.+Kunimatsuauthor=K.+Kasaiauthor=H.+Yamasue&title=Clinical+and+neural+effects+of+six-week+administration+of+oxytocin+on+core+symptoms+of+autism&doi=10.1093%2Fbrain%2Fawv249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawv249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawv249%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DTatsunobu%26aufirst%3DN.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DNippashi%26aufirst%3DY.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKunimatsu%26aufirst%3DA.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DClinical%2520and%2520neural%2520effects%2520of%2520six-week%2520administration%2520of%2520oxytocin%2520on%2520core%2520symptoms%2520of%2520autism%26jtitle%3DBrain%26date%3D2015%26volume%3D138%26spage%3D3400%26epage%3D3412%26doi%3D10.1093%2Fbrain%2Fawv249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yatawara, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einfeld, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span> <span> </span><span class="NLM_article-title">The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1038/mp.2015.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fmp.2015.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26503762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsleks7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1225-1231&author=C.+J.+Yatawaraauthor=S.+L.+Einfeldauthor=I.+B.+Hickieauthor=T.+A.+Davenportauthor=A.+J.+Guastella&title=The+effect+of+oxytocin+nasal+spray+on+social+interaction+deficits+observed+in+young+children+with+autism%3A+a+randomized+clinical+crossover+trial&doi=10.1038%2Fmp.2015.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial</span></div><div class="casAuthors">Yatawara, C. J.; Einfeld, S. L.; Hickie, I. B.; Davenport, T. A.; Guastella, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1225-1231</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interventions for autism are limited.  The synthetic hormone oxytocin may provide a potential treatment to improve core social and behavioral difficulties in autism, but its efficacy has yet to be evaluated in young children who potentially may benefit to a greater extent.  We investigated the efficacy, tolerability and safety of oxytocin treatment in young children with autism using a double-blind, randomized, placebo-controlled, crossover, clin. trial.  Thirty-one children with autism received 12 IU (IU) of oxytocin and placebo nasal spray morning and night (24 IU per day) for 5 wk, with a 4-wk washout period between each treatment.  Compared with placebo, oxytocin led to significant improvements on the primary outcome of caregiver-rated social responsiveness.  Overall, nasal spray was well tolerated, and the most common reported adverse events were thirst, urination and constipation.  This study is the first clin. trial to support the potential of oxytocin as an early intervention for young children with autism to help improve social interaction deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYvRBN9eJKqLVg90H21EOLACvtfcHk0lgYC5hWJhgGyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsleks7zI&md5=37397699a7098e3572851c47c2ff2948</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fmp.2015.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2015.162%26sid%3Dliteratum%253Aachs%26aulast%3DYatawara%26aufirst%3DC.%2BJ.%26aulast%3DEinfeld%26aufirst%3DS.%2BL.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DDavenport%26aufirst%3DT.%2BA.%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520effect%2520of%2520oxytocin%2520nasal%2520spray%2520on%2520social%2520interaction%2520deficits%2520observed%2520in%2520young%2520children%2520with%2520autism%253A%2520a%2520randomized%2520clinical%2520crossover%2520trial%26jtitle%3DMol.%2520Psychiatry%26date%3D2016%26volume%3D21%26spage%3D1225%26epage%3D1231%26doi%3D10.1038%2Fmp.2015.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preckel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanske, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krach, S.</span></span> <span> </span><span class="NLM_article-title">Clinical trial of modulatory effects of oxytocin treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-controlled, double-blind and crossover trial</span>. <i>BMC Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">329</span>, <span class="refDoi"> DOI: 10.1186/s12888-016-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1186%2Fs12888-016-1036-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=329&author=K.+Preckelauthor=P.+Kanskeauthor=T.+Singerauthor=F.+M.+Paulusauthor=S.+Krach&title=Clinical+trial+of+modulatory+effects+of+oxytocin+treatment+on+higher-order+social+cognition+in+autism+spectrum+disorder%3A+a+randomized%2C+placebo-controlled%2C+double-blind+and+crossover+trial&doi=10.1186%2Fs12888-016-1036-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs12888-016-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12888-016-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DPreckel%26aufirst%3DK.%26aulast%3DKanske%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DPaulus%26aufirst%3DF.%2BM.%26aulast%3DKrach%26aufirst%3DS.%26atitle%3DClinical%2520trial%2520of%2520modulatory%2520effects%2520of%2520oxytocin%2520treatment%2520on%2520higher-order%2520social%2520cognition%2520in%2520autism%2520spectrum%2520disorder%253A%2520a%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%2520and%2520crossover%2520trial%26jtitle%3DBMC%2520Psychiatry%26date%3D2016%26volume%3D16%26spage%3D329%26doi%3D10.1186%2Fs12888-016-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvares, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span> <span> </span><span class="NLM_article-title">Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model</span>. <i>Neurosci. Biobehav. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.neubiorev.2014.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neubiorev.2014.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=182-192&author=D.+S.+Quintanaauthor=G.+A.+Alvaresauthor=I.+B.+Hickieauthor=A.+J.+Guastella&title=Do+delivery+routes+of+intranasally+administered+oxytocin+account+for+observed+effects+on+social+cognition+and+behavior%3F+A+two-level+model&doi=10.1016%2Fj.neubiorev.2014.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neubiorev.2014.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neubiorev.2014.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DD.%2BS.%26aulast%3DAlvares%26aufirst%3DG.%2BA.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26atitle%3DDo%2520delivery%2520routes%2520of%2520intranasally%2520administered%2520oxytocin%2520account%2520for%2520observed%2520effects%2520on%2520social%2520cognition%2520and%2520behavior%253F%2520A%2520two-level%2520model%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D2015%26volume%3D49%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.neubiorev.2014.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munesue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashida, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study</span>. <i>Front. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.3389/fpsyt.2016.00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffpsyt.2016.00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26834651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC28nmslOmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2&author=T.+Munesueauthor=H.+Nakamuraauthor=M.+Kikuchiauthor=Y.+Miuraauthor=N.+Takeuchiauthor=T.+Anmeauthor=E.+Nanbaauthor=K.+Adachiauthor=K.+Tsubouchiauthor=Y.+Saiauthor=K.+Miyamotoauthor=S.+Horikeauthor=S.+Yokoyamaauthor=H.+Nakataniauthor=Y.+Niidaauthor=H.+Kosakaauthor=Y.+Minabeauthor=H.+Higashida&title=Oxytocin+for+male+subjects+with+autism+spectrum+disorder+and+comorbid+intellectual+disabilities%3A+a+randomized+pilot+study&doi=10.3389%2Ffpsyt.2016.00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study</span></div><div class="casAuthors">Munesue Toshio; Kikuchi Mitsuru; Miura Yui; Takeuchi Noriyuki; Yokoyama Shigeru; Higashida Haruhiro; Nakamura Hiroyuki; Anme Tokie; Nanba Eiji; Adachi Kaori; Tsubouchi Kiyotaka; Sai Yoshimichi; Miyamoto Ken-Ichi; Horike Shin-Ichi; Nakatani Hideo; Minabe Yoshio; Niida Yo; Kosaka Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">1664-0640</span>.
    </div><div class="casAbstract">UNLABELLED:  Approximately half of autism spectrum disorder (ASD) individuals suffer from comorbid intellectual disabilities (IDs).  Oxytocin (OXT) receptors are highly expressed in temporal lobe structures and are likely to play a modulatory role in excitatory/inhibitory balance, at least based on animal model findings.  Thus, it is feasible that in the highly representative group of Kanner-type ASD subjects, OXT could have a beneficial effect on social communication and social interaction.  The aim of this pilot study is to investigate the feasibility and adverse events, such as epilepsy, of the long-term administration of intranasal OXT for adolescent and adult ASD subjects with ID because such patients frequently have seizures.  We also addressed the question on how to scale the OXT effects to the core symptoms of social deficits because of the relative difficulty in obtaining objective measurements.  Twenty-nine males (aged 15-40 years old) participated in a randomized, double-blind, and placebo-controlled crossover study (each for 8 weeks) with OXT (16 IU/day).  Except for seizures experienced by one participant, other serious adverse events did not occur.  The primary and secondary outcomes measured using the Childhood Autism Rating Scale and several standard scales, respectively, revealed no difference between the OXT and placebo groups.  Instead, in an exploratory analysis, the social interactions observed in the play sessions or in daily life were significantly more frequent in the initial half period in the OXT-first arm of the crossover trial.  There were also significant correlations between the plasma OXT concentration and subscale scores for irritability on the Aberrant Behavior Checklist.  In conclusion, this pilot study demonstrates that long-term administration of intranasal OXT is tolerable in a representative cohort of ASD individuals with ID and suggests that future multicenter trials of OXT are warranted and should include measurements of reciprocal social interactions based on daily life under closer surveillance for epilepsy.  TRIAL REGISTRATION:  UMIN000007250.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGkT-vVqjel4qdXsLcGTEUfW6udTcc2eYZdV_KuETaGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nmslOmug%253D%253D&md5=e322f9798adde3575b34cf0e83bbf0d5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3389%2Ffpsyt.2016.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpsyt.2016.00002%26sid%3Dliteratum%253Aachs%26aulast%3DMunesue%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DN.%26aulast%3DAnme%26aufirst%3DT.%26aulast%3DNanba%26aufirst%3DE.%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DTsubouchi%26aufirst%3DK.%26aulast%3DSai%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DK.%26aulast%3DHorike%26aufirst%3DS.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DNiida%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DH.%26aulast%3DMinabe%26aufirst%3DY.%26aulast%3DHigashida%26aufirst%3DH.%26atitle%3DOxytocin%2520for%2520male%2520subjects%2520with%2520autism%2520spectrum%2520disorder%2520and%2520comorbid%2520intellectual%2520disabilities%253A%2520a%2520randomized%2520pilot%2520study%26jtitle%3DFront.%2520Psychiatry%26date%3D2016%26volume%3D7%26spage%3D2%26doi%3D10.3389%2Ffpsyt.2016.00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Targets for drug therapy for autism spectrum disorder: challenges and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9114</span>– <span class="NLM_lpage">9141</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9114-9141&author=E.+Lacivitaauthor=R.+Perroneauthor=L.+Margariauthor=M.+Leopoldo&title=Targets+for+drug+therapy+for+autism+spectrum+disorder%3A+challenges+and+future+directions&doi=10.1021%2Facs.jmedchem.7b00965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions</span></div><div class="casAuthors">Lacivita, Enza; Perrone, Roberto; Margari, Lucia; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9114-9141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, and activities.  Various factors are involved in the etiopathogenesis of ASD, including genetic factors, environmental toxins and stressors, impaired immune responses, mitochondrial dysfunction, and neuroinflammation.  The heterogeneity in the phenotype among ASD patients and the complex etiol. of the condition have long impeded the advancement of the development of pharmacol. therapies.  In the recent years, the integration of findings from mouse models to human genetics resulted in considerable progress toward the understanding of ASD pathophysiol.  Currently, strategies to treat core symptoms of ASD are directed to correct synaptic dysfunctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation.  Here, we present a survey of the studies that have suggested mol. targets for drug development for ASD and the state-of-the-art of medicinal chem. efforts in related areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBnoRlTN2U9rVg90H21EOLACvtfcHk0lijITthrXd25g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsLnL&md5=32311ccf6d8bc345129c00fe6dc0a23a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00965%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DMargari%26aufirst%3DL.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DTargets%2520for%2520drug%2520therapy%2520for%2520autism%2520spectrum%2520disorder%253A%2520challenges%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9114%26epage%3D9141%26doi%3D10.1021%2Facs.jmedchem.7b00965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollitor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukic-Stefanovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vraka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donat, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitterhauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span> <span> </span><span class="NLM_article-title">Development of a novel nonpeptidic (18)F-labeled radiotracer for in vivo imaging of oxytocin receptors with positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1800</span>– <span class="NLM_lpage">1817</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1800-1817&author=B.+Wenzelauthor=J.+Mollitorauthor=W.+Deuther-Conradauthor=S.+Dukic-Stefanovicauthor=M.+Kranzauthor=C.+Vrakaauthor=R.+Teodoroauthor=R.+G%C3%BCntherauthor=C.+K.+Donatauthor=F.+Ludwigauthor=S.+Fischerauthor=R.+Smitsauthor=W.+Wadsakauthor=M.+Mitterhauserauthor=J.+Steinbachauthor=A.+Hoeppingauthor=P.+Brust&title=Development+of+a+novel+nonpeptidic+%2818%29F-labeled+radiotracer+for+in+vivo+imaging+of+oxytocin+receptors+with+positron+emission+tomography&doi=10.1021%2Facs.jmedchem.5b01080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01080%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DB.%26aulast%3DMollitor%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DDukic-Stefanovic%26aufirst%3DS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DVraka%26aufirst%3DC.%26aulast%3DTeodoro%26aufirst%3DR.%26aulast%3DG%25C3%25BCnther%26aufirst%3DR.%26aulast%3DDonat%26aufirst%3DC.%2BK.%26aulast%3DLudwig%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DWadsak%26aufirst%3DW.%26aulast%3DMitterhauser%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DHoepping%26aufirst%3DA.%26aulast%3DBrust%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520nonpeptidic%2520%252818%2529F-labeled%2520radiotracer%2520for%2520in%2520vivo%2520imaging%2520of%2520oxytocin%2520receptors%2520with%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1800%26epage%3D1817%26doi%3D10.1021%2Facs.jmedchem.5b01080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C. J.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of 1-substituted 3-(2,3-dihydro-1H-inden-2-yl)-6-(1-ethylpropyl)- (3R,6R)-2,5-piperazinedione derivatives as PET tracers for imaging the central oxytocinergic system</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1002%2Fjlcr.3535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28670707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFClu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=556-565&author=C.+Marzanoauthor=S.+Jakobsenauthor=C.+Salinasauthor=S.+P.+Tangauthor=D.+Benderauthor=J.+Passchierauthor=C.+J.+Plisson&title=Radiosynthesis+and+evaluation+of+1-substituted+3-%282%2C3-dihydro-1H-inden-2-yl%29-6-%281-ethylpropyl%29-+%283R%2C6R%29-2%2C5-piperazinedione+derivatives+as+PET+tracers+for+imaging+the+central+oxytocinergic+system&doi=10.1002%2Fjlcr.3535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of 1-substituted 3-(2,3-dihydro-1H-inden-2-yl)-6-(1-ethylpropyl)-(3R,6R)-2,5-piperazinedione derivatives as PET tracers for imaging the central oxytocinergic system</span></div><div class="casAuthors">Marzano, Carmine; Jakobsen, Steen; Salinas, Cristian; Tang, Sac Pham; Bender, Dirk; Passchier, Jan; Plisson, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Oxytocin is known to be implicated in a variety of functions, such as learning, stress, anxiety, feeding, and pain perception.  Oxytocin is also important for social memory and attachment, human bonding, sexual and maternal behavior, and aggression.  Human disorders characterized by aberrant social interactions, such as autism and schizophrenia, may also involve abnormal oxytocin levels.  GSK712043 (I,R = H), GSK711320 (II, R = H), and GSK664004 (III, R = H), three antagonists exhibiting subnanomolar affinity for the human oxytocin receptor (hOTR) and high selectivity over vasopressin receptors were successfully labeled with carbon-11 with suitable yields (0.5-1GBq @EOS), high molar activity (275-700 GBq/μmol), and radiochem. purities.  The in vivo regional uptake of these radiotracers was detd. in porcine brain. [11C]GSK711320 (II, R = 11CH3) baseline scan showed no significant brain uptake, and limited initial uptake was obsd. following administration of [11C]GSK712043 (I, R = 11CH3) or [11C]GSK664004 (III, R = 11CH3).  The [11C]GSK712043 (I, R = 11CH3) and [11C]GSK664004 (III, R = 11CH3) kinetics were slow and peaked at around 2%ID/L at 90 min post-injection.  For both tracers, the distribution of activity was homogeneous throughout the brain.  All the tracers showed high uptake in the pituitary gland, esp. [11C]GSK711320 (II, R = 11CH3) ; however, its uptake could not be blocked by pretreatment with the known OTR antagonist, L368,899.  In vivo evaluation of these candidates demonstrated that they are not suitable as central OTR PET imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTvribcWPYmLVg90H21EOLACvtfcHk0lhkHI_kQ9c9eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFClu7fF&md5=b245e7a359963266d53dd3a22a213cc7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3535%26sid%3Dliteratum%253Aachs%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DJakobsen%26aufirst%3DS.%26aulast%3DSalinas%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DS.%2BP.%26aulast%3DBender%26aufirst%3DD.%26aulast%3DPasschier%26aufirst%3DJ.%26aulast%3DPlisson%26aufirst%3DC.%2BJ.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%25201-substituted%25203-%25282%252C3-dihydro-1H-inden-2-yl%2529-6-%25281-ethylpropyl%2529-%2520%25283R%252C6R%2529-2%252C5-piperazinedione%2520derivatives%2520as%2520PET%2520tracers%2520for%2520imaging%2520the%2520central%2520oxytocinergic%2520system%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2017%26volume%3D60%26spage%3D556%26epage%3D565%26doi%3D10.1002%2Fjlcr.3535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimpl, G.</span></span> <span> </span><span class="NLM_article-title">Oxytocin receptor ligands: a survey of the patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1517/13543776.18.11.1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1517%2F13543776.18.11.1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlShu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1239-1251&author=G.+Gimpl&title=Oxytocin+receptor+ligands%3A+a+survey+of+the+patent+literature&doi=10.1517%2F13543776.18.11.1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin receptor ligands: a survey of the patent literature</span></div><div class="casAuthors">Gimpl, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1239-1251</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Background: Oxytocin is produced primarily in hypothalamic neurons and is secreted from the posterior pituitary gland into the circulation in response to stimuli such as suckling, parturition, or stress.  Oxytocin functions as an essential component in milk ejection and is among the most potent uterotonic substances known.  The oxytocin receptor system supports physiol. processes assocd. with reprodn. at several levels.  Objective: To characterize and evaluate oxytocin receptor ligands for therapeutic applications.  Methods: Anal. of oxytocin analogs and nonpeptide oxytocin receptor ligands, and major applications of these substances.  Results/conclusion: Oxytocin receptor ligands, peptides, and nonpeptide mols., with high specificity over the related vasopressin receptors, are currently available.  These ligands are expected to show therapeutic utility for a vast range of applications, e.g., increasing lactation, improving in vitro inseminations, and inducing cardiomyogenesis; and also acting against preterm labor, breast cancer, an over-reactive immune system, osteoporosis, and autism-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXEAZdk8Cy8bVg90H21EOLACvtfcHk0lhkHI_kQ9c9eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlShu7jK&md5=02503dd059ccf4cdee3e6ca8f2b37bf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.11.1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.11.1239%26sid%3Dliteratum%253Aachs%26aulast%3DGimpl%26aufirst%3DG.%26atitle%3DOxytocin%2520receptor%2520ligands%253A%2520a%2520survey%2520of%2520the%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D1239%26epage%3D1251%26doi%3D10.1517%2F13543776.18.11.1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff Rizzo, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logue, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span> <span> </span><span class="NLM_article-title">Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2009.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neuropharm.2009.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=19615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjjs1GqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=69-77&author=R.+H.+Ringauthor=L.+E.+Schechterauthor=S.+K.+Leonardauthor=J.+M.+Dwyerauthor=B.+J.+Plattauthor=R.+Grafauthor=S.+Grauerauthor=C.+Pulicicchioauthor=L.+Resnickauthor=Z.+Rahmanauthor=S.+J.+Sukoff+Rizzoauthor=B.+Luoauthor=C.+E.+Beyerauthor=S.+F.+Logueauthor=K.+L.+Marquisauthor=Z.+A.+Hughesauthor=S.+Rosenzweig-Lipson&title=Receptor+and+behavioral+pharmacology+of+WAY-267464%2C+a+non-peptide+oxytocin+receptor+agonist&doi=10.1016%2Fj.neuropharm.2009.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist</span></div><div class="casAuthors">Ring Robert H; Schechter Lee E; Leonard Sarah K; Dwyer Jason M; Platt Brian J; Graf Radka; Grauer Steven; Pulicicchio Claudine; Resnick Lynn; Rahman Zia; Sukoff Rizzo Stacey J; Luo Bin; Beyer Chad E; Logue Sheree F; Marquis Karen L; Hughes Zoe A; Rosenzweig-Lipson Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression.  The utility of synthetic OT, as both a research tool and neurotherapeutic, is limited by the physiochemical properties inherent in most neuropeptides, notably its short half-life and poor blood brain barrier penetration.  Subsequently, the discovery and development of non-peptide molecules that act as selective agonists of the oxytocin receptor (OTR) has been an important goal of the field.  In this study, we report the receptor and behavioral pharmacology of WAY-267464, a first generation small-molecule OTR agonist.  WAY-267464 is a high-affinity, potent, and selective (vs.  V1a, V2, V1b) agonist of the OTR.  In assays measuring both behavioral (four-plate test, elevated zero maze) and autonomic (stress-induced hyperthermia) parameters of the anxiety response, WAY-267464 exhibits an anxiolytic-like profile similar to OT.  We have demonstrated that the anxiolytic-like profile of WAY-267464 is mediated through central sites of action.  WAY-267464 also significantly reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine, similar to the antipsychotic-like effects previously reported for OT.  Interestingly, in the mouse tail suspension test, WAY-267464 failed to produce changes in immobility that are seen with OT, raising the question of whether the antidepressant-like activity of OT may be working independently of the OTR.  A selective OTR antagonist also failed to block the effects of OT on immobility in the TST.  The significance of these findings for shaping the clinical development of OTR agonists is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8S-KlSxighgMthz5_Rx5rfW6udTcc2eYFVHUdcjIoRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjjs1GqsQ%253D%253D&md5=699434bd2c444cd29345d24db54fbbb5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2009.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2009.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DR.%2BH.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DLeonard%26aufirst%3DS.%2BK.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DPlatt%26aufirst%3DB.%2BJ.%26aulast%3DGraf%26aufirst%3DR.%26aulast%3DGrauer%26aufirst%3DS.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DRahman%26aufirst%3DZ.%26aulast%3DSukoff%2BRizzo%26aufirst%3DS.%2BJ.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DBeyer%26aufirst%3DC.%2BE.%26aulast%3DLogue%26aufirst%3DS.%2BF.%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26aulast%3DHughes%26aufirst%3DZ.%2BA.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DReceptor%2520and%2520behavioral%2520pharmacology%2520of%2520WAY-267464%252C%2520a%2520non-peptide%2520oxytocin%2520receptor%2520agonist%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D58%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.neuropharm.2009.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gossen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gründer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreckelmeyer, K. N.</span></span> <span> </span><span class="NLM_article-title">Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men</span>. <i>Neuropeptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/j.npep.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.npep.2012.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=211-215&author=A.+Gossenauthor=A.+Hahnauthor=L.+Westphalauthor=S.+Prinzauthor=R.+T.+Schultzauthor=G.+Gr%C3%BCnderauthor=K.+N.+Spreckelmeyer&title=Oxytocin+plasma+concentrations+after+single+intranasal+oxytocin+administration+-+a+study+in+healthy+men&doi=10.1016%2Fj.npep.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.npep.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.npep.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGossen%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DA.%26aulast%3DWestphal%26aufirst%3DL.%26aulast%3DPrinz%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DR.%2BT.%26aulast%3DGr%25C3%25BCnder%26aufirst%3DG.%26aulast%3DSpreckelmeyer%26aufirst%3DK.%2BN.%26atitle%3DOxytocin%2520plasma%2520concentrations%2520after%2520single%2520intranasal%2520oxytocin%2520administration%2520-%2520a%2520study%2520in%2520healthy%2520men%26jtitle%3DNeuropeptides%26date%3D2012%26volume%3D46%26spage%3D211%26epage%3D215%26doi%3D10.1016%2Fj.npep.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinness, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disinger, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banati, R. B.</span></span> <span> </span><span class="NLM_article-title">Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1016/j.psyneuen.2012.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.psyneuen.2012.11.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=612-625&author=A.+J.+Guastellaauthor=I.+B.+Hickieauthor=M.+M.+McGuinnessauthor=M.+Otisauthor=E.+A.+Woodsauthor=H.+M.+Disingerauthor=H.+K.+Chanauthor=T.+F.+Chenauthor=R.+B.+Banati&title=Recommendations+for+the+standardisation+of+oxytocin+nasal+administration+and+guidelines+for+its+reporting+in+human+research&doi=10.1016%2Fj.psyneuen.2012.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2012.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2012.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DMcGuinness%26aufirst%3DM.%2BM.%26aulast%3DOtis%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DE.%2BA.%26aulast%3DDisinger%26aufirst%3DH.%2BM.%26aulast%3DChan%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DT.%2BF.%26aulast%3DBanati%26aufirst%3DR.%2BB.%26atitle%3DRecommendations%2520for%2520the%2520standardisation%2520of%2520oxytocin%2520nasal%2520administration%2520and%2520guidelines%2520for%2520its%2520reporting%2520in%2520human%2520research%26jtitle%3DPsychoneuroendocrinology%26date%3D2013%26volume%3D38%26spage%3D612%26epage%3D625%26doi%3D10.1016%2Fj.psyneuen.2012.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of oxytocin receptor signaling in the brain: what we know and what we need to know</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/7854_2017_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2F7854_2017_6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3-29&author=M.+Busnelliauthor=B.+Chini&title=Molecular+basis+of+oxytocin+receptor+signaling+in+the+brain%3A+what+we+know+and+what+we+need+to+know&doi=10.1007%2F7854_2017_6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2F7854_2017_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2017_6%26sid%3Dliteratum%253Aachs%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DMolecular%2520basis%2520of%2520oxytocin%2520receptor%2520signaling%2520in%2520the%2520brain%253A%2520what%2520we%2520know%2520and%2520what%2520we%2520need%2520to%2520know%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2017%26volume%3D35%26spage%3D3%26epage%3D29%26doi%3D10.1007%2F7854_2017_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grinevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobloch-Bollmann, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Assembling the puzzle: pathways of oxytocin signaling in the brain</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26001309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXos1Oku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=155-164&author=V.+Grinevichauthor=H.+S.+Knobloch-Bollmannauthor=M.+Eliavaauthor=M.+Busnelliauthor=B.+Chini&title=Assembling+the+puzzle%3A+pathways+of+oxytocin+signaling+in+the+brain&doi=10.1016%2Fj.biopsych.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain</span></div><div class="casAuthors">Grinevich, Valery; Knobloch-Bollmann, H. Sophie; Eliava, Marina; Busnelli, Marta; Chini, Bice</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Oxytocin (OT) is a neuropeptide, which can be seen to be one of the mols. of the decade due to its profound prosocial effects in nonvertebrate and vertebrate species, including humans.  Although OT can be detected in various physiol. fluids (blood, saliva, urine, cerebrospinal fluid) and brain tissue, it is unclear whether peripheral and central OT releases match and synergize.  Moreover, the pathways of OT delivery to brain regions involved in specific behaviors are far from clear.  Here, we discuss the evolutionarily and ontogenetically detd. pathways of OT delivery and OT signaling, which orchestrate activity of the mesolimbic social decision-making network.  Furthermore, we speculate that both the alteration in OT delivery and OT receptor expression may cause behavioral abnormalities in patients afflicted with psychosocial diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6gjPAwBbAP7Vg90H21EOLACvtfcHk0li7zi3F1ZGx7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXos1Oku7g%253D&md5=4b8181c48d1a7dacc13144a675893e1d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DGrinevich%26aufirst%3DV.%26aulast%3DKnobloch-Bollmann%26aufirst%3DH.%2BS.%26aulast%3DEliava%26aufirst%3DM.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DAssembling%2520the%2520puzzle%253A%2520pathways%2520of%2520oxytocin%2520signaling%2520in%2520the%2520brain%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D79%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.biopsych.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulgheroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capurro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donzelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2010.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2010.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=21306704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=875-882&author=M.+Salaauthor=D.+Braidaauthor=D.+Lentiniauthor=M.+Busnelliauthor=E.+Bulgheroniauthor=V.+Capurroauthor=A.+Finardiauthor=A.+Donzelliauthor=L.+Pattiniauthor=T.+Rubinoauthor=D.+Parolaroauthor=K.+Nishimoriauthor=M.+Parentiauthor=B.+Chini&title=Pharmacologic+rescue+of+impaired+cognitive+flexibility%2C+social+deficits%2C+increased+aggression%2C+and+seizure+susceptibility+in+oxytocin+receptor+null+mice%3A+a+neurobehavioral+model+of+autism&doi=10.1016%2Fj.biopsych.2010.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic Rescue of Impaired Cognitive Flexibility, Social Deficits, Increased Aggression, and Seizure Susceptibility in Oxytocin Receptor Null Mice: A Neurobehavioral Model of Autism</span></div><div class="casAuthors">Sala, Mariaelvina; Braida, Daniela; Lentini, Daniela; Busnelli, Marta; Bulgheroni, Elisabetta; Capurro, Valeria; Finardi, Annamaria; Donzelli, Andrea; Pattini, Linda; Rubino, Tiziana; Parolaro, Daniela; Nishimori, Katsuhiko; Parenti, Marco; Chini, Bice</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">875-882</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Oxytocin (OT) has been suggested as a treatment to improve social behavior in autistic patients.  Accordingly, the OT (Oxt -/-) and the OT receptor null mice (Oxtr -/-) display autistic-like deficits in social behavior, increased aggression, and reduced ultrasonic vocalization.  Oxtr -/- mice were characterized for general health, sociability, social novelty, cognitive flexibility, aggression, and seizure susceptibility.  Because vasopressin (AVP) and OT cooperate in controlling social behavior, learning, and aggression, they were tested for possible rescue of the impaired behaviors.  Primary hippocampal cultures from Oxtr +/+ and Oxtr -/- mouse embryos were established to investigate the balance between gamma-aminobutyric acid (GABA) and glutamate synapses and the expression levels of OT and AVP (V1a) receptors were detd. by autoradiog.  Oxtr -/- mice display two addnl., highly relevant, phenotypic characteristics: (1) a resistance to change in a learned pattern of behavior, comparable to restricted interests and repetitive behavior in autism, and (2) an increased susceptibility to seizures, a frequent and clin. relevant symptom of autism.  We also show that intracerebral administration of both OT and AVP lowers aggression and fully reverts social and learning defects by acting on V1a receptors and that seizure susceptibility is antagonized by peripherally administered OT.  Finally, we detect a decreased ratio of GABA-ergic vs. total presynapses in hippocampal neurons of Oxtr -/- mice.  Autistic-like symptoms are rescued on administration of AVP and OT to young Oxtr -/- adult animals.  The Oxtr -/- mouse is thus instrumental to investigate the neurochem. and synaptic abnormalities underlying autistic-like disturbances and to test new strategies of pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6DumVxrrcLVg90H21EOLACvtfcHk0liyJgnkQ0Dd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVWhtrY%253D&md5=dac04a34fe240ba735f788881f98e772</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2010.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2010.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%26aulast%3DBraida%26aufirst%3DD.%26aulast%3DLentini%26aufirst%3DD.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DBulgheroni%26aufirst%3DE.%26aulast%3DCapurro%26aufirst%3DV.%26aulast%3DFinardi%26aufirst%3DA.%26aulast%3DDonzelli%26aufirst%3DA.%26aulast%3DPattini%26aufirst%3DL.%26aulast%3DRubino%26aufirst%3DT.%26aulast%3DParolaro%26aufirst%3DD.%26aulast%3DNishimori%26aufirst%3DK.%26aulast%3DParenti%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DPharmacologic%2520rescue%2520of%2520impaired%2520cognitive%2520flexibility%252C%2520social%2520deficits%252C%2520increased%2520aggression%252C%2520and%2520seizure%2520susceptibility%2520in%2520oxytocin%2520receptor%2520null%2520mice%253A%2520a%2520neurobehavioral%2520model%2520of%2520autism%26jtitle%3DBiol.%2520Psychiatry%26date%3D2011%26volume%3D69%26spage%3D875%26epage%3D882%26doi%3D10.1016%2Fj.biopsych.2010.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivière, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, potent, and selective peptidic oxytocin receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5306</span>– <span class="NLM_lpage">5317</span>, <span class="refDoi"> DOI: 10.1021/jm500365s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500365s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5306-5317&author=K.+Wi%C5%9Bniewskiauthor=S.+Alagarsamyauthor=R.+Galyeanauthor=H.+Tarigaauthor=D.+Thompsonauthor=B.+Lyauthor=H.+Wi%C5%9Bniewskaauthor=S.+Qiauthor=G.+Crostonauthor=R.+Laporteauthor=P.+J.+Rivi%C3%A8reauthor=C.+D.+Schteingart&title=New%2C+potent%2C+and+selective+peptidic+oxytocin+receptor+agonists&doi=10.1021%2Fjm500365s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span></div><div class="casAuthors">Wisniewski, Kazimierz; Alagarsamy, Sudarkodi; Galyean, Robert; Tariga, Hiroe; Thompson, Dorain; Ly, Brian; Wisniewska, Halina; Qi, Steve; Croston, Glenn; Laporte, Regent; Riviere, Pierre J.-M.; Schteingart, Claudio D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5306-5317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex.  Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation.  The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis.  We have designed a series of potent oxytocin analogs contg. N-alkylglycines in position 7 with excellent selectivity vs. the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios vs. related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min-1 kg-1.  Compd. 57 (FE 202767) is currently in clin. development for the treatment of preterm mothers requiring lactation support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ykZz5KXVXbVg90H21EOLACvtfcHk0liyJgnkQ0Dd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D&md5=8076f2bbeb06371908b462d1c8f25321</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm500365s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500365s%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniewski%26aufirst%3DK.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DWi%25C5%259Bniewska%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DP.%2BJ.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520potent%252C%2520and%2520selective%2520peptidic%2520oxytocin%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5306%26epage%3D5317%26doi%3D10.1021%2Fjm500365s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span> <span> </span><span class="NLM_article-title">Potent and selective oxytocin receptor agonists without disulfide bridges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2335</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2017.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2331-2335&author=Y.+Adachiauthor=K.+Sakimuraauthor=Y.+Shimizuauthor=M.+Nakayamaauthor=Y.+Teraoauthor=T.+Yanoauthor=T.+Asami&title=Potent+and+selective+oxytocin+receptor+agonists+without+disulfide+bridges&doi=10.1016%2Fj.bmcl.2017.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DM.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DT.%26atitle%3DPotent%2520and%2520selective%2520oxytocin%2520receptor%2520agonists%2520without%2520disulfide%2520bridges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2331%26epage%3D2335%26doi%3D10.1016%2Fj.bmcl.2017.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yea, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. B.</span></span> <span> </span><span class="NLM_article-title">Non-peptide oxytocin agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4585</span>– <span class="NLM_lpage">4589</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.04.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2004.04.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4585-4589&author=G.+R.+Pittauthor=A.+R.+Battauthor=R.+M.+Haighauthor=A.+M.+Pensonauthor=P.+A.+Robsonauthor=D.+P.+Rookerauthor=A.+L.+Tartarauthor=J.+E.+Trimauthor=C.+M.+Yeaauthor=M.+B.+Roe&title=Non-peptide+oxytocin+agonists&doi=10.1016%2Fj.bmcl.2004.04.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.04.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.04.107%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DG.%2BR.%26aulast%3DBatt%26aufirst%3DA.%2BR.%26aulast%3DHaigh%26aufirst%3DR.%2BM.%26aulast%3DPenson%26aufirst%3DA.%2BM.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRooker%26aufirst%3DD.%2BP.%26aulast%3DTartar%26aufirst%3DA.%2BL.%26aulast%3DTrim%26aufirst%3DJ.%2BE.%26aulast%3DYea%26aufirst%3DC.%2BM.%26aulast%3DRoe%26aufirst%3DM.%2BB.%26atitle%3DNon-peptide%2520oxytocin%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4585%26epage%3D4589%26doi%3D10.1016%2Fj.bmcl.2004.04.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span> <span> </span><span class="NLM_article-title">Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1562</span>, <span class="refDoi"> DOI: 10.1021/jm901084f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901084f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1546-1562&author=M.+C.+Frantzauthor=J.+Rodrigoauthor=L.+Boudierauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Hibert&title=Subtlety+of+the+structure-affinity+and+structure-efficacy+relationships+around+a+nonpeptide+oxytocin+receptor+agonist&doi=10.1021%2Fjm901084f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm901084f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901084f%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DM.%2BC.%26aulast%3DRodrigo%26aufirst%3DJ.%26aulast%3DBoudier%26aufirst%3DL.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DHibert%26aufirst%3DM.%26atitle%3DSubtlety%2520of%2520the%2520structure-affinity%2520and%2520structure-efficacy%2520relationships%2520around%2520a%2520nonpeptide%2520oxytocin%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1546%26epage%3D1562%26doi%3D10.1021%2Fjm901084f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. S.</span></span> <span> </span><span class="NLM_article-title">A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: insights into changes in c-Fos immunoreactivity</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.pbb.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25038444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ymsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=367-372&author=P.+K.+Olszewskiauthor=C.+Ulrichauthor=N.+Lingauthor=K.+Allenauthor=A.+S.+Levine&title=A+non-peptide+oxytocin+receptor+agonist%2C+WAY-267%2C464%2C+alleviates+novelty-induced+hypophagia+in+mice%3A+insights+into+changes+in+c-Fos+immunoreactivity&doi=10.1016%2Fj.pbb.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: Insights into changes in c-Fos immunoreactivity</span></div><div class="casAuthors">Olszewski, Pawel K.; Ulrich, Christine; Ling, Nicholas; Allen, Kerry; Levine, Allen S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anxiety caused by the novelty of food or of the environment where the food is presented leads to suppression of consumption (hyponeophagia) reflected by an increased latency to begin feeding and decreased food intake.  Studies suggest that some anxiolytics, mainly benzodiazepines and SSRIs, resolve hyponeophagia.  Though the neurohormone oxytocin (OT) affects both anxiety responsiveness and feeding-related homeostasis, the link between OT and hyponeophagia has not been established.  The current expts. examd. the effect of OT receptor stimulation on hyponeophagia in mice and assocd. changes in brain activity.  We found that the OT receptor agonist, WAY-267,464, at 10 and 30 mg/kg,i.p., reduced the latency to approach food and increased the amt. of food eaten in hyponeophagia tests differing in animals' motivation to eat (hunger, reward) and the anxiogenic context of environmental novelty (illumination and type of the cage).  This effect was abolished by the pretreatment with the OT receptor antagonist, L-368,899, at 10 mg/kg.  The antagonist also suppressed social transmission of preference for novel food.  Mice subjected to novelty conditions causing hypophagia showed significant changes in c-Fos immunoreactivity in the hippocampus, lateral septum, cingulate and piriform cortex and in the bed nucleus of the stria terminalis, lateral division, posterolateral part (STLP).  The pretreatment with WAY-267,464 restored c-Fos levels in the STLP to values detected in control animals subjected to non-anxiogenic conditions.  We conclude that OT plays a role in shaping the magnitude of the novelty stress-provoked hypophagia and the activity of the relevant neural networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdycCb2qN4UrVg90H21EOLACvtfcHk0lhHDPZ18S35YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ymsLfM&md5=a707a62d7989a3a42f14921b653ff323</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOlszewski%26aufirst%3DP.%2BK.%26aulast%3DUlrich%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DN.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DLevine%26aufirst%3DA.%2BS.%26atitle%3DA%2520non-peptide%2520oxytocin%2520receptor%2520agonist%252C%2520WAY-267%252C464%252C%2520alleviates%2520novelty-induced%2520hypophagia%2520in%2520mice%253A%2520insights%2520into%2520changes%2520in%2520c-Fos%2520immunoreactivity%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2014%26volume%3D124%26spage%3D367%26epage%3D372%26doi%3D10.1016%2Fj.pbb.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span> <span> </span><span class="NLM_article-title">The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2012.02311.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fj.1365-2826.2012.02311.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=22420322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2it7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=1012-1029&author=C.+Hicksauthor=W.+Jorgensenauthor=C.+Brownauthor=J.+Fardellauthor=J.+Koehbachauthor=C.+W.+Gruberauthor=M.+Kassiouauthor=G.+E.+Huntauthor=I.+S.+McGregor&title=The+nonpeptide+oxytocin+receptor+agonist+WAY+267%2C464%3A+receptor-binding+profile%2C+prosocial+effects+and+distribution+of+c-Fos+expression+in+adolescent+rats&doi=10.1111%2Fj.1365-2826.2012.02311.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats</span></div><div class="casAuthors">Hicks, C.; Jorgensen, W.; Brown, C.; Fardell, J.; Koehbach, J.; Gruber, C. W.; Kassiou, M.; Hunt, G. E.; McGregor, I. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1029</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Previous research suggests that the nonpeptide oxytocin receptor (OTR) agonist WAY 267,464 may only partly mimic the effects of oxytocin in rodents.  The present study further explored these differences and related them to OTR and vasopressin 1a receptor (V1aR) pharmacol. and regional patterns of c-Fos expression.  Binding data for WAY 267,464 and oxytocin were obtained by displacement binding assays on cellular membranes, while functional receptor data were generated by luciferase reporter assays.  For behavioral testing, adolescent rats were tested in a social preference paradigm, the elevated plus-maze (EPM) and for locomotor activity changes following WAY 267,464 (10 and 100 mg/kg, i.p.) or oxytocin (0.1 and 1 mg/kg, i.p.).  The higher doses were also examd. for their effects on regional c-Fos expression.  Results showed that WAY 267,464 had higher affinity (Ki) at the V1aR than the OTR (113 vs. 978 nM).  However, it had no functional response at the V1aR and only a weak functional effect (EC50) at the OTR (881 nM).  This suggests WAY 267,464 is an OTR agonist with weak affinity and a possible V1aR antagonist.  Oxytocin showed high binding at the OTR (1.0 nM) and V1aR (503 nM), with a functional EC50 of 9.0 and 59.7 nM, resp., indicating it is a potent OTR agonist and full V1aR agonist.  WAY 267,464 (100 mg/kg), but not oxytocin, significantly increased the proportion of time spent with a live rat, over a dummy rat, in the social preference test.  Neither compd. affected EPM behavior, whereas the higher doses of WAY 267,464 and oxytocin suppressed locomotor activity.  WAY 267,464 and oxytocin produced similar c-Fos expression in the paraventricular hypothalamic nucleus, central amygdala, lateral parabrachial nucleus and nucleus of the solitary tract, suggesting a commonality of action at the OTR with the differential doses employed.  However, WAY 267,464 caused greater c-Fos expression in the medial amygdala and the supraoptic nucleus than oxytocin, and lesser effects in the locus coeruleus.  Overall, our results confirm the differential effects of WAY 267,464 and oxytocin and suggest that this may reflect contrasting actions of WAY 267,464 and oxytocin at the V1aR.  Antagonism of the V1aR by WAY 267,464 could underlie some of the prosocial effects of this drug either through a direct action or through disinhibition of oxytocin circuitry that is subject to vasopressin inhibitory influences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpfQk61DzJ_7Vg90H21EOLACvtfcHk0lhHDPZ18S35YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2it7bF&md5=0c04b65cdb69bc2729c28efebf9a9b27</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02311.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02311.x%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DC.%26aulast%3DJorgensen%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DFardell%26aufirst%3DJ.%26aulast%3DKoehbach%26aufirst%3DJ.%26aulast%3DGruber%26aufirst%3DC.%2BW.%26aulast%3DKassiou%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DG.%2BE.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26atitle%3DThe%2520nonpeptide%2520oxytocin%2520receptor%2520agonist%2520WAY%2520267%252C464%253A%2520receptor-binding%2520profile%252C%2520prosocial%2520effects%2520and%2520distribution%2520of%2520c-Fos%2520expression%2520in%2520adolescent%2520rats%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D1012%26epage%3D1029%26doi%3D10.1111%2Fj.1365-2826.2012.02311.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weill, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Identification of non peptide Oxytocin receptor ligands by receptor-ligand fingerprint similarity research</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/minf.201100026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1002%2Fminf.201100026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27467153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=521-526&author=N.+Weillauthor=C.+Valenciaauthor=S.+Gioriaauthor=P.+Villaauthor=M.+Hibertauthor=D.+Rognan&title=Identification+of+non+peptide+Oxytocin+receptor+ligands+by+receptor-ligand+fingerprint+similarity+research&doi=10.1002%2Fminf.201100026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Nonpeptide Oxytocin Receptor Ligands by Receptor-Ligand Fingerprint Similarity Search</span></div><div class="casAuthors">Weill, Nathanael; Valencia, Christel; Gioria, Sophie; Villa, Pascal; Hibert, Marcel; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">521-526</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The in silico screening of an inhouse collection of com.-available drug-like compds. (Bioinfo-DB) is presented as part of the global initiative for identifying novel non-peptide oxytocin receptor (OTR) agonists.  Four different virtual screening methods have been used to identify, among a library of com.-available drug-like compds., non-peptide agonists for the oxytocin receptor.  Due to the peculiar ligand space occupied by the single OTR agonist known to date, no hits with the desired functional effect could be found.  However, 10 out of the 128 tested compds. could be characterized as OTR antagonists.  Interestingly, a majority of validated hits were identified by a chemogenomic approach in which target and ligand descriptors are embedded on a single fingerprint.  The good performance of this novel virtual screening method could be explained by the extension of the ref. space to ligands of neighboring receptors.  Chemogenomic approaches to hit identification are particularly promising for receptors for which ligand information is sparse, at the condition that closely related liganded targets are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrieSEshir8GbVg90H21EOLACvtfcHk0lgaHAStdm03MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyrtb0%253D&md5=873fee63631419847293b920ca84dea1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100026%26sid%3Dliteratum%253Aachs%26aulast%3DWeill%26aufirst%3DN.%26aulast%3DValencia%26aufirst%3DC.%26aulast%3DGioria%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520non%2520peptide%2520Oxytocin%2520receptor%2520ligands%2520by%2520receptor-ligand%2520fingerprint%2520similarity%2520research%26jtitle%3DMol.%2520Inf.%26date%3D2011%26volume%3D30%26spage%3D521%26epage%3D526%26doi%3D10.1002%2Fminf.201100026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1021/ci034181a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034181a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVOqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=1162-1176&author=C.+Bissantzauthor=A.+Logeanauthor=D.+Rognan&title=High-throughput+modeling+of+human+G-protein+coupled+receptors%3A+amino+acid+sequence+alignment%2C+three-dimensional+model+building%2C+and+receptor+library+screening&doi=10.1021%2Fci034181a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput modeling of human g-protein coupled receptors: Amino acid sequence alignment, three-dimensional model building, and receptor library screening</span></div><div class="casAuthors">Bissantz, Caterina; Logean, Antoine; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1162-1176</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current study describes the development of a computer package (GPCRmod) aimed at the high-throughput modeling of the therapeutically important family of human G-protein coupled receptors (GPCRs).  GPCRmod first proposes a reliable alignment of the seven transmembrane domains (7 TMs) of most druggable human GPCRs based on pattern/motif recognition for each of the 7 TMs that are considered independently.  It then converts the alignment into knowledge-based three-dimensional (3-D) models starting from a set of 3-D backbone templates and two sep. rotamer libraries for side chain positioning.  The 7 TMs of 277 human GPCRs have been accurately aligned, unambiguously clustered in three different classes (rhodopsin-like, secretin-like, metabotropic glutamate-like), and converted into high-quality 3-D models at a remarkable throughput (∼3s/model).  A 3-D GPCR target library of 277 receptors has consequently been setup.  Its utility for "in silico" inverse screening purpose has been demonstrated by recovering among top scorers the receptor of a selective GPCR antagonist as well as the receptors of a promiscuous antagonist.  The current GPCR target library thus constitutes a 3-D database of choice to address as soon as possible the "virtual selectivity" profile of any GPCR antagonist or inverse agonist in an early hit optimization process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC6Zv_92nPmrVg90H21EOLACvtfcHk0lgaHAStdm03MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVOqt74%253D&md5=6037a68d2d7ba136a5ab51c822d681f1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fci034181a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034181a%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DLogean%26aufirst%3DA.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DHigh-throughput%2520modeling%2520of%2520human%2520G-protein%2520coupled%2520receptors%253A%2520amino%2520acid%2520sequence%2520alignment%252C%2520three-dimensional%2520model%2520building%252C%2520and%2520receptor%2520library%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2004%26volume%3D44%26spage%3D1162%26epage%3D1176%26doi%3D10.1021%2Fci034181a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=9223568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaK2sXksFyhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=301-308&author=A.+Taharaauthor=Y.+Tomuraauthor=K.+Wadaauthor=T.+Kusayamaauthor=J.+Tsukadaauthor=M.+Takanashiauthor=T.+Yatsuauthor=W.+Uchidaauthor=A.+Tanaka&title=Pharmacological+profile+of+YM087%2C+a+novel+potent+nonpeptide+vasopressin+V1a+and+V2+receptor+antagonist%2C+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A an V2 receptor antagonist, in vitro and in vivo</span></div><div class="casAuthors">Tahara, Atsuo; Tomura, Yuichi; Wada, Koh-Ichi; Kusayama, Toshiyuki; Tsukada, Junko; Takanashi, Masahiro; Yatsu, Takeyuki; Uchida, Wataru; Tanaka, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The biochem. and pharmacol. profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies.  YM087 showed high affinity for V1A receptors from rat liver and V2 receptors from rat kidney with Ki values of 0.48 and 3.04 mM, resp.  YM087 also inhibited [3H]oxytocin (OT) binding to rat uterus (OT receptors) plasma membranes with a Ki value of 44.4 nM, and at 100 μM did not affect the binding of [3H]AVP to anterior pituitary (V1B receptors) plasma membranes, which indicated that it had less affinity for these OT and V1B receptors.  YM087 had no effect on cytosolic free calcium concn. ([Ca++]i) itself, but suppressed AVP-induced increase in [Ca++]i of cultured vascular smooth muscle cells at the same concns. as the binding affinities.  Furthermore, YM087 potently blocked AVP-induced cAMP prodn. of cultured renal epithelium cells concn. dependently and had no agonistic activities.  In in vivo studies, i.v. administration of YM087 inhibited the pressor response to exogenous AVP in pithed rats and produced an aquaretic effect in dehydrated conscious rats in a dose-dependent manner.  These results demonstrate that YM087 is a potent and nonpeptide dual AVP V1A and V2 receptors antagonist and can be used in future studies of help clarify the physiol. and pathophysiol. roles of AVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT7lS9DQiIOLVg90H21EOLACvtfcHk0lgaHAStdm03MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFyhsr4%253D&md5=d6e3fabcafeabccef789a6af06a143cc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DTomura%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DKusayama%26aufirst%3DT.%26aulast%3DTsukada%26aufirst%3DJ.%26aulast%3DTakanashi%26aufirst%3DM.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DW.%26aulast%3DTanaka%26aufirst%3DA.%26atitle%3DPharmacological%2520profile%2520of%2520YM087%252C%2520a%2520novel%2520potent%2520nonpeptide%2520vasopressin%2520V1a%2520and%2520V2%2520receptor%2520antagonist%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D301%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2004.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.phrs.2004.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=15661579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Grtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2005&pages=275-281&author=A.+Taharaauthor=J.+Tsukadaauthor=Y.+Tomuraauthor=T.+Kusayamaauthor=K.+Wadaauthor=N.+Ishiiauthor=N.+Taniguchiauthor=T.+Suzukiauthor=T.+Yatsuauthor=W.+Uchidaauthor=M.+Shibasaki&title=Effects+of+YM218%2C+a+nonpeptide+vasopressin+V1A+receptor-selective+antagonist%2C+on+human+vasopressin+and+oxytocin+receptors&doi=10.1016%2Fj.phrs.2004.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors</span></div><div class="casAuthors">Tahara, Atsuo; Tsukada, Junko; Tomura, Yuichi; Kusayama, Toshiyuki; Wada, Koh-ichi; Ishii, Noe; Taniguchi, Nobuaki; Suzuki, Takeshi; Yatsu, Takeyuki; Uchida, Wataru; Shibasaki, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-281</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The binding and signal transduction characteristics of YM218 ((Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene]-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl}-2-methyl-3-furanilide hemifumarate), a newly synthesized, potent arginine vasopressin (AVP) V1A receptor-selective antagonist, were examd. using cloned human AVP receptors (V1A, V1B and V2) stably expressed in Chinese hamster ovary (CHO) cells and human uterine smooth muscle cells (USMCs) expressing oxytocin receptors.  YM218 potently inhibited specific binding of [3H] AVP to V1A receptors, exhibiting a Ki value of 0.30 nM.  In contrast, YM218 exhibited much lower affinity for V1B, V2 and oxytocin receptors, exhibiting Ki values of 25,500 nM, 381 nM and 71.0 nM, resp.  In CHO cells expressing V1A receptors, YM218 potently inhibited the AVP-induced increase in intracellular Ca2+ concn. ([Ca2+]i), exhibiting an IC50 value of 0.25 nM.  However, in human USMCs expressing oxytocin receptors, YM218 exhibited a much lower potency in inhibiting the oxytocin-induced [Ca2+]i increase, showing an IC50 value of 607 nM, and had no effect on the AVP-induced [Ca2+]i increase in CHO cells expressing V1B receptors.  Furthermore, in CHO cells expressing V2 receptors, YM218 did not potently inhibit the prodn. of cAMP stimulated by AVP, showing an IC50 value of 62.2 nM.  In all assays used, YM218 did not exhibit any agonistic activity.  These results demonstrate that YM218 is a potent, nonpeptide human V1A receptor-selective antagonist, and that YM218 will be a valuable new tool to gain further insight into the physiol. and pharmacol. actions of AVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokm-gZ2HMQ37Vg90H21EOLACvtfcHk0lheHfXx1LPBqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Grtg%253D%253D&md5=3efcb5c96b5071304e1bab201913c86c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2004.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2004.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DTsukada%26aufirst%3DJ.%26aulast%3DTomura%26aufirst%3DY.%26aulast%3DKusayama%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DTaniguchi%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DW.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DEffects%2520of%2520YM218%252C%2520a%2520nonpeptide%2520vasopressin%2520V1A%2520receptor-selective%2520antagonist%252C%2520on%2520human%2520vasopressin%2520and%2520oxytocin%2520receptors%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D51%26spage%3D275%26epage%3D281%26doi%3D10.1016%2Fj.phrs.2004.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybczynski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunnet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villani, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6623</span>– <span class="NLM_lpage">6628</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2007.09.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6623-6628&author=M.+A.+Xiangauthor=P.+J.+Rybczynskiauthor=M.+Patelauthor=R.+H.+Chenauthor=D.+F.+McComseyauthor=H.+C.+Zhangauthor=J.+W.+Gunnetauthor=R.+Lookauthor=Y.+Wangauthor=L.+K.+Minorauthor=H.+M.+Zhongauthor=F.+J.+Villaniauthor=K.+T.+Demarestauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Next-generation+spirobenzazepines%3A+identification+of+RWJ-676070+as+a+balanced+vasopressin+V1a%2FV2+receptor+antagonist+for+human+clinical+studies&doi=10.1016%2Fj.bmcl.2007.09.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.059%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%2BA.%26aulast%3DRybczynski%26aufirst%3DP.%2BJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DR.%2BH.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BC.%26aulast%3DGunnet%26aufirst%3DJ.%2BW.%26aulast%3DLook%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMinor%26aufirst%3DL.%2BK.%26aulast%3DZhong%26aufirst%3DH.%2BM.%26aulast%3DVillani%26aufirst%3DF.%2BJ.%26aulast%3DDemarest%26aufirst%3DK.%2BT.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DNext-generation%2520spirobenzazepines%253A%2520identification%2520of%2520RWJ-676070%2520as%2520a%2520balanced%2520vasopressin%2520V1a%252FV2%2520receptor%2520antagonist%2520for%2520human%2520clinical%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6623%26epage%3D6628%26doi%3D10.1016%2Fj.bmcl.2007.09.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.bjp.0703221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10780976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2000&pages=1700-1706&author=S.+Nakamuraauthor=Y.+Yamamuraauthor=S.+Itohauthor=T.+Hiranoauthor=K.+Tsujimaeauthor=M.+Aoyamaauthor=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=K.+Kanauthor=Y.+Tanadaauthor=S.+Teramotoauthor=T.+Sumidaauthor=S.+Nakayamaauthor=K.+Sekiguchiauthor=T.+Kambeauthor=G.+Tsujimotoauthor=T.+Moriauthor=M.+Tominaga&title=Characterization+of+a+novel+nonpeptide+vasopressin+V2-agonist%2C+OPC-51803%2C+in+cells+transfected+human+vasopressin+receptor+subtypes&doi=10.1038%2Fsj.bjp.0703221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span></div><div class="casAuthors">Nakamura, Shigeki; Yamamura, Yoshitaka; Itoh, Shuji; Hirano, Takahiro; Tsujimae, Kenji; Aoyama, Masashi; Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kan, Keizo; Tanada, Yoshihisa; Teramoto, Shuji; Sumida, Takumi; Nakayama, Sunao; Sekiguchi, Kazuo; Kambe, Toshimi; Tsujimoto, Gozoh; Mori, Toyoki; Tominaga, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1700-1706</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We discovered the first nonpeptide arginine-vasopressin (AVP) V2-receptor agonist, OPC-51803.  Pharmacol. properties of OPC-51803 were elucidated using HeLa cells expressing human AVP receptor subtypes (V2, V1a and V1b) and compared with those of 1-desamino-8-D-arginine vasopressin (dDAVP), a peptide V2-receptor agonist.  OPC-51803 and dDAVP displaced [3H]-AVP binding to human V2- and V1a-receptors with Ki values of 91.9±10.8 nM (n=6) and 3.12±0.38 nM (n=6) for V2-receptors, and 819±39 nM (n=6) and 41.5±9.9 nM (n=6) for V1a-receptors, indicating that OPC-51803 was about nine times more selective for V2-receptors, similar to the selectivity of dDAVP.  OPC-51803 scarcely displaced [3H]-AVP binding to human V1b-receptors even at 10-4 M, while dDAVP showed potent affinity to human V1b-receptors with the Ki value of 13.7±3.2 nM (n=4).  OPC-51803 concn.-dependently increased cyclic adenosine 3', 5'-monophosphate (cAMP) prodn. in HeLa cells expressing human V2-receptors with an EC50 value of 189±14 nM (n=6).  The concn.-response curve for cAMP prodn. induced by OPC-51803 was shifted to the right in the presence of a V2-antagonist, OPC-31260.  At 10-5 M, OPC-51803 did not increase the intracellular Ca2+ concn. ([Ca2+]i) in HeLa cells expressing human V1a-receptors.  On the other hand, dDAVP increased [Ca2+]i in HeLa cells expressing human V1a- and V1b-receptors in a concn.-dependent fashion.  From these results, OPC-51803 has been confirmed to be the first nonpeptide agonist for human AVP V2-receptors without agonistic activities for V1a- and V1b-receptors.  OPC-51803 may be useful for the treatment of AVP-deficient pathophysiol. states and as a tool for AVP researches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP6Ey2VlQ77Vg90H21EOLACvtfcHk0lheHfXx1LPBqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D&md5=435c824ff32701169445cb4a1c35a94c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703221%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DTsujimae%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DSumida%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DKambe%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520nonpeptide%2520vasopressin%2520V2-agonist%252C%2520OPC-51803%252C%2520in%2520cells%2520transfected%2520human%2520vasopressin%2520receptor%2520subtypes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D129%26spage%3D1700%26epage%3D1706%26doi%3D10.1038%2Fsj.bjp.0703221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuhisa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, I.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide arginine vasopressin antagonists for both V1a and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4′-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide derivatives</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1248/cpb.45.1870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1248%2Fcpb.45.1870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1997&pages=1870-1874&author=A.+Matsuhisaauthor=A.+Tanakaauthor=K.+Kikuchiauthor=Y.+Shimadaauthor=T.+Yatsuauthor=I.+Yanagisawa&title=Nonpeptide+arginine+vasopressin+antagonists+for+both+V1a+and+V2+receptors%3A+synthesis+and+pharmacological+properties+of+2-phenyl-4%E2%80%B2-%5B%282%2C3%2C4%2C5-tetrahydro-1H-1-benzazepin-1-yl%29carbonyl%5Dbenzanilide+derivatives&doi=10.1248%2Fcpb.45.1870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1248%2Fcpb.45.1870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.45.1870%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuhisa%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DYanagisawa%26aufirst%3DI.%26atitle%3DNonpeptide%2520arginine%2520vasopressin%2520antagonists%2520for%2520both%2520V1a%2520and%2520V2%2520receptors%253A%2520synthesis%2520and%2520pharmacological%2520properties%2520of%25202-phenyl-4%25E2%2580%25B2-%255B%25282%252C3%252C4%252C5-tetrahydro-1H-1-benzazepin-1-yl%2529carbonyl%255Dbenzanilide%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1997%26volume%3D45%26spage%3D1870%26epage%3D1874%26doi%3D10.1248%2Fcpb.45.1870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itai, A.</span></span> <span> </span><span class="NLM_article-title">Novel design of nonpeptide AVP V2 receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.1021/jm000108p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000108p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4388-4397&author=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=M.+Kurimuraauthor=Y.+Tanadaauthor=K.+Kanauthor=H.+Yamashitaauthor=S.+Nakamuraauthor=T.+Hiranoauthor=Y.+Yamamuraauthor=T.+Moriauthor=M.+Tominagaauthor=A.+Itai&title=Novel+design+of+nonpeptide+AVP+V2+receptor+agonists%3A+structural+requirements+for+an+agonist+having+1-%284-aminobenzoyl%29-2%2C3%2C4%2C5-tetrahydro-1H-1-benzazepine+as+a+template&doi=10.1021%2Fjm000108p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Design of Nonpeptide AVP V2 Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template</span></div><div class="casAuthors">Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kurimura, Muneaki; Tanada, Yoshihisa; Kan, Keizo; Yamashita, Hiroshi; Nakamura, Shigeki; Hirano, Takahiro; Yamamura, Yoshitaka; Mori, Toyoki; Tominaga, Michiaki; Itai, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4388-4397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a series of nonpeptide arginine vasopressin V2 receptor agonists is described.  After identifying the aniline deriv. (I) as our lead compd. from the metabolites of a previously studied compd. that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken.  These studies led to a series of compds. e.g. (II) that show potent agonist activity for the V2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr32gXY0qnlHLVg90H21EOLACvtfcHk0linRxhmssm5Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKgtbY%253D&md5=4d92852bb3625fa50e5ebe2cb504e04e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm000108p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000108p%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKurimura%26aufirst%3DM.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26aulast%3DItai%26aufirst%3DA.%26atitle%3DNovel%2520design%2520of%2520nonpeptide%2520AVP%2520V2%2520receptor%2520agonists%253A%2520structural%2520requirements%2520for%2520an%2520agonist%2520having%25201-%25284-aminobenzoyl%2529-2%252C3%252C4%252C5-tetrahydro-1H-1-benzazepine%2520as%2520a%2520template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4388%26epage%3D4397%26doi%3D10.1021%2Fjm000108p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932. Treatment of central diabetes insipidus, treatment of nocturnal enuresis, treatment of nocturia, vasopressin V2 agonist</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932.+Treatment+of+central+diabetes+insipidus%2C+treatment+of+nocturnal+enuresis%2C+treatment+of+nocturia%2C+vasopressin+V2+agonist&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0linRxhmssm5Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932.%2520Treatment%2520of%2520central%2520diabetes%2520insipidus%252C%2520treatment%2520of%2520nocturnal%2520enuresis%252C%2520treatment%2520of%2520nocturia%252C%2520vasopressin%2520V2%2520agonist%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Failli, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shumsky, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trybulski, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanikella, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span> <span> </span><span class="NLM_article-title">Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.10.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2005.10.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16297621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Khsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=954-959&author=A.+A.+Failliauthor=J.+S.+Shumskyauthor=R.+J.+Steffanauthor=T.+J.+Caggianoauthor=D.+K.+Williamsauthor=E.+J.+Trybulskiauthor=X.+Ningauthor=Y.+Lockauthor=T.+Tanikellaauthor=D.+Hartmannauthor=P.+S.+Chanauthor=C.+H.+Park&title=Pyridobenzodiazepines%3A+a+novel+class+of+orally+active%2C+vasopressin+V2+receptor+selective+agonists&doi=10.1016%2Fj.bmcl.2005.10.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridobenzodiazepines: A novel class of orally active, vasopressin V2 receptor selective agonists</span></div><div class="casAuthors">Failli, Amedeo A.; Shumsky, Jay S.; Steffan, Robert J.; Caggiano, Thomas J.; Williams, David K.; Trybulski, Eugene J.; Ning, Xiaoping; Lock, Yeungwai; Tanikella, Tarak; Hartmann, David; Chan, Peter S.; Park, C. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">954-959</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our efforts in seeking low mol. wt. agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clin. candidate WAY-151932 (VNA-932).  Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEEecZqI4Di7Vg90H21EOLACvtfcHk0lhBU2BhkhAU8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Khsw%253D%253D&md5=b334797a5b857d47f0aff692664250a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.10.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.10.107%26sid%3Dliteratum%253Aachs%26aulast%3DFailli%26aufirst%3DA.%2BA.%26aulast%3DShumsky%26aufirst%3DJ.%2BS.%26aulast%3DSteffan%26aufirst%3DR.%2BJ.%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DTrybulski%26aufirst%3DE.%2BJ.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLock%26aufirst%3DY.%26aulast%3DTanikella%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DP.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26atitle%3DPyridobenzodiazepines%253A%2520a%2520novel%2520class%2520of%2520orally%2520active%252C%2520vasopressin%2520V2%2520receptor%2520selective%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D954%26epage%3D959%26doi%3D10.1016%2Fj.bmcl.2005.10.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of heteroaryl benzoic acids via Suzuki reaction</span>. <i>Synlett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=829-831&author=Y.+Gongauthor=H.+W.+Pauls&title=A+convenient+synthesis+of+heteroaryl+benzoic+acids+via+Suzuki+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520heteroaryl%2520benzoic%2520acids%2520via%2520Suzuki%2520reaction%26jtitle%3DSynlett.%26date%3D2000%26volume%3D6%26spage%3D829%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span> <span> </span><span class="NLM_article-title">Diisobutylaluminium hydride: a novel reagent for the reduction of oximes</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4711</span>– <span class="NLM_lpage">4712</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)86234-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2FS0040-4039%2800%2986234-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=4711-4712&author=S.+Sasataniauthor=T.+Miyazakiauthor=K.+Maruokaauthor=H.+Yamamoto&title=Diisobutylaluminium+hydride%3A+a+novel+reagent+for+the+reduction+of+oximes&doi=10.1016%2FS0040-4039%2800%2986234-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2986234-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252986234-6%26sid%3Dliteratum%253Aachs%26aulast%3DSasatani%26aufirst%3DS.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26atitle%3DDiisobutylaluminium%2520hydride%253A%2520a%2520novel%2520reagent%2520for%2520the%2520reduction%2520of%2520oximes%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D4711%26epage%3D4712%26doi%3D10.1016%2FS0040-4039%2800%2986234-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1743</span>– <span class="NLM_lpage">1754</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(99)00101-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2FS0968-0896%2899%2900101-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=1743-1754&author=K.+Kondoauthor=H.+Ogawaauthor=H.+Yamashitaauthor=H.+Miyamotoauthor=M.+Tanakaauthor=K.+Nakayaauthor=K.+Kitanoauthor=Y.+Yamamuraauthor=S.+Nakamuraauthor=T.+Onogawaauthor=T.+Moriauthor=M.+Tominaga&title=7-chloro-5-hydroxy-1-%5B2-methyl-4-%282-methylbenzoyl-amino%29benzoyl%5D-2%2C3%2C4%2C5-tetrahydro-1H-1-benzazepine+%28OPC-41061%29%3A+a+potent%2C+orally+active+nonpeptide+arginine+vasopressin+V2+receptor+antagonist&doi=10.1016%2FS0968-0896%2899%2900101-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900101-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900101-7%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DMiyamoto%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DNakaya%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DOnogawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3D7-chloro-5-hydroxy-1-%255B2-methyl-4-%25282-methylbenzoyl-amino%2529benzoyl%255D-2%252C3%252C4%252C5-tetrahydro-1H-1-benzazepine%2520%2528OPC-41061%2529%253A%2520a%2520potent%252C%2520orally%2520active%2520nonpeptide%2520arginine%2520vasopressin%2520V2%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D1743%26epage%3D1754%26doi%3D10.1016%2FS0968-0896%2899%2900101-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, Y.</span></span> <span> </span><span class="NLM_article-title">Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3547</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1021/jm960133o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960133o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3547-3555&author=H.+Ogawaauthor=H.+Yamashitaauthor=K.+Kondoauthor=Y.+Yamamuraauthor=H.+Miyamotoauthor=K.+Kanauthor=K.+Kitanoauthor=M.+Tanakaauthor=K.+Nakayaauthor=S.+Nakamuraauthor=T.+Moriauthor=M.+Tominagaauthor=Y.+Yabuuchi&title=Orally+active%2C+nonpeptide+vasopressin+V2+receptor+antagonists%3A+a+novel+series+of+1-%5B4-%28benzoylamino%29benzoyl%5D-2%2C3%2C4%2C5-tetrahydro-1H-benzazepines+and+related+compounds&doi=10.1021%2Fjm960133o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm960133o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960133o%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DH.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DNakaya%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26aulast%3DYabuuchi%26aufirst%3DY.%26atitle%3DOrally%2520active%252C%2520nonpeptide%2520vasopressin%2520V2%2520receptor%2520antagonists%253A%2520a%2520novel%2520series%2520of%25201-%255B4-%2528benzoylamino%2529benzoyl%255D-2%252C3%252C4%252C5-tetrahydro-1H-benzazepines%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3547%26epage%3D3555%26doi%3D10.1021%2Fjm960133o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliopulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, J. K.</span></span> <span> </span><span class="NLM_article-title">Alkyltransferase model reactions: synthesis of sulfonium and ammonium compounds containing neighboring nucleophiles. Kinetic studies of the intramolecular reaction of amino, hydroxy, phenoxy, and mercapto onium salts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1021/jo00275a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00275a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=3436-3448&author=R.+J.+Millerauthor=A.+Kuliopulosauthor=J.+K.+Coward&title=Alkyltransferase+model+reactions%3A+synthesis+of+sulfonium+and+ammonium+compounds+containing+neighboring+nucleophiles.+Kinetic+studies+of+the+intramolecular+reaction+of+amino%2C+hydroxy%2C+phenoxy%2C+and+mercapto+onium+salts&doi=10.1021%2Fjo00275a034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjo00275a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00275a034%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BJ.%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCoward%26aufirst%3DJ.%2BK.%26atitle%3DAlkyltransferase%2520model%2520reactions%253A%2520synthesis%2520of%2520sulfonium%2520and%2520ammonium%2520compounds%2520containing%2520neighboring%2520nucleophiles.%2520Kinetic%2520studies%2520of%2520the%2520intramolecular%2520reaction%2520of%2520amino%252C%2520hydroxy%252C%2520phenoxy%252C%2520and%2520mercapto%2520onium%2520salts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D3436%26epage%3D3448%26doi%3D10.1021%2Fjo00275a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, G. R.</span></span> <span> </span><span class="NLM_article-title">Azabenzocycloheptenones. Part III. 2,3,4,5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz[b]azepine</span>. <i>J. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_fpage">3989</span>– <span class="NLM_lpage">3994</span>, <span class="refDoi"> DOI: 10.1039/jr9610003989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1039%2Fjr9610003989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaF38XisFSgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1961&pages=3989-3994&author=G.+R.+Proctor&title=Azabenzocycloheptenones.+Part+III.+2%2C3%2C4%2C5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz%5Bb%5Dazepine&doi=10.1039%2Fjr9610003989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Azabenzocycloheptenones. III. 2,3,4,5-Tetrahydro-5- oxo-1-toluene-p-sulfonylbenz[b]azepine</span></div><div class="casAuthors">Proctor, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3989-94</span>CODEN:
                <span class="NLM_cas:coden">JCSOA9</span>;
        ISSN:<span class="NLM_cas:issn">0368-1769</span>.
    </div><div class="casAbstract">cf. CA 51, 14754g.-2,3,4,5-Tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (I), now available in good yield, could not be dehydrogenated by bromination dehydrobromination procedures, but it could be oxidized to an α-dione which gave an enol acetate.  Although this represented a partial dehydrogenation, the p-tosyl group could not be extruded nor could the amino dione be obtained by std. methods.  The basic ketone, 2,3,4,5-tetrahydro-5-oxobenz[b]azepine (II), could be obtained by hydrolysis of the p-tosylate (III).  Me N-(p-tolylsulfonyl)anthranilate (302 g.), 300 g. anhyd. Na2CO3, and 1.5l.  Decalin refluxed with addn. during 1.5 h. of 234 g. Et γ-bromobutyrate, after 4 h. the mixt. cooled, dild., filtered, and the residue washed, the solvents evapd., and the product crystd. gave 197 g. Et γ-[N-(o-methoxycarbonylphenyl)-p-toluenesulfonamido]butyrate (IV), m. 98-100° (alc.).  K (10 g.) in excess Me3COH evapd., and 1l. PhMe added, this refluxing mixt. treated with 50 g. IV in 500 mL.  PhMe during 2 h., and worked up gave 2,3,4,5-tetrahydro-5-oxo-4-carbethoxy-1- (p-tolylsulfonyl)benz[b]azepine (V), m. 120° (ligroine); 2,4-dinitrophenylhydrazone m. 208° (MeOH-AcOH).  V (42.5 g.) refluxed with 100 mL. alc., 300 mL. AcOH, 50 mL. concd. HCl, and 50 mL. H2O 8 h. and the product chromatographed gave 71% 2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (III), m. 126° (MeOH).  III (9.7 g.), 10 mL. HCO2Et, and 160 mL. PhMe at 0° treated with NaOEt (from 6 g. Na) in 80 mL.  PhMe at 0°, left 24 h. at 20°, washed, and the product crystd. gave 8.7 g. 2,3,4,5-tetrahydro-4-hydroxymethylene-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VI), m. 126° (ligroine); 2,4-dinitrophenylhydrazone, crimson needles, m. 207°; Me ether m. 197°.  III (6.6 g.) in 100 mL. CHCl3 treated 1 h. at 20° with 1 mL. Br gave 7 g. 4-bromo-2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine x2(VIa), m. 132° (MeOH); 2,4-dinitrophenylhydrazone m. 236°. III (4.8 g.) in 100 mL. CHCl3 treated with 1.47 mL. Br gave 5.6 g. 4,4-dibromo-2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VIb), m. 173° (alc.), failed to form a 2,4-dinitrophenylhydrazone.  III (4.92 g.), 200 mL. concd. HCl, and 200 mL. AcOH refluxed 8 h., extd. with CHCl3, and the product isolated gave 600 mg. II, b0.1 135-40°; 2,4-dinitrophenylhydrazone, violet solid, m. 248°; picrate m. 228°.  The ketone (0.64 g.) heated 3 h. with 10 g. polyphosphoric acid and extd. with CHCl3 gave 148 mg. crude II.  III (1.17 g.) in 15 mL. THF stirred 10 min. with 2 g. Ca in 100 mL. liq. NH3 gave 100 mg. crude II.  VI (5.6 g.) in 150 mL. EtOAc treated at -70° with 72.5% of the calcd. amt. of O3, hydrogenated over Pd(OH)2-BaCO3, and the product isolated gave 2.43 g. 2,3,4,5-tetrahydro-4,5-dioxo-1-(p-tolylsulfonyl)benz[b]azepine (VII), m. 148° (ligroine); 2,4-dinitrophenylhydrazone, orange, m. 252°; quinoxaline deriv., yellow solid, m. 198°.  When VII was chromatographed on active Al2O3, elution with CHCl3 gave a poor yield of product, m. 142°, judged to be the Et ether of the enol ketone; the oxime m. 136°.  VIa (5.4 g.) in 100 mL. AcOH refluxed 2 h. with 1.95 g. SeO2 in 10 mL. H2O, filtered, stirred with Hg, dild. with H2O, and extd. with CHCl3 gave 4.7 g. VII.  VIb (1.38 g.), 3.5 g. KHCO3, and 50 mL. H2O refluxed 4 h., extd. with CHCl3, and the product isolated gave 0.93 g. crude VII. VII (380 mg.) in 25 mL. MeOH left 1 h. with 1 mL. 10% NaOH and the ext. sepd. gave 350 mg. unchanged VII.  VII (1.8 g.) in 60 mL. PhMe treated with 4 g. Ca in 150 liq. NH3, after 3 min. 8 g. dry PhBr in 50 mL. PhMe added, the mixt. stirred 2 h., acidified, extd., and distd. gave 80 mg. oil, whose IR spectrum, although similar to that of II, lacked the detail.  VII (1.39 g.), 90 mL. isopropenyl acetate, and 4 drops concd. H2SO4 refluxed 2 h. and the crude product either crystd. or chromatographed on Al2O3 failed to give pure product.  When this enol acetate was treated with KOCMe3 in PhMe at room temp. it was recovered in 65% yield, the remainder, 20%, being a S-contg. acid which could not be purified.  VII (2 g.) treated 80 min. at 165-70° with polyphosphoric acid gave a black insol. residue contg. S which could not be purified.  At low temps. similar insol. materials were obtained accompanied by traces of starting material.  VII (0.21 g.), 25 mL. AcOH, and 0.22 g. Br left 4 days at 20°, poured into 100 mL. H2O and 30 mL. CHCl3, evapd., and the product crystd. gave VIb.  Treatment of VIa with an alc. soln. of 2,4-dinitrophenylhydrazine contg. concd. HCl gave the 2,4-dinitrophenylhydrazone, m. 236°.  VIa (3.34 g.), 115 mL. CCl4, and 25 mL. NEt3 refluxed 7 h., evapd., and the product chromatographed on Al2O3 gave 1.6 g. starting material and 1.1 g. of very crude VIa.  VIa (3 g.) refluxed 24 h. with 40 mL. collidine, cooled, treated with dil. HCl and CHCl3, washed, and the residual oil chromatographed on Al2O3 gave 0.8 g. III.  Similar treatment 28 h. at 100° with collidine gave 75% unchanged VIa.  VIb (2.84 g.) refluxed 7 h. with 15 mL. NEt3 and the product crystd. gave 510 mg. VIa.  VIa (1.78 g.) refluxed 1 h. with 60 mL. alc. and 20 mL. 10% Na2CO1, extd. with CHCl3, and the 1.45 g. of tarry residue chromatographed on silica gel gave impure 2,3,4,5-tetrahydro-4-hydroxy-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VIII), m. 196°; 2,4-dinitrophenylhydrazone, m. 231°.  VIII (120 mg.), 1 g. P2O5, and 40 mL. PhMe refluxed 6 h., cooled, dild. with H2O, washed, and the product chromatographed on Al2O3 gave 10 mg. cryst. product, m. 152°.  Basification of the acid washings gave 10 mg. of a basic ketone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogyg-Ye4oQN7Vg90H21EOLACvtfcHk0liFgpWxZjYY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XisFSgtw%253D%253D&md5=bb83bc20780bf400e47e2885c4f67c8f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1039%2Fjr9610003989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fjr9610003989%26sid%3Dliteratum%253Aachs%26aulast%3DProctor%26aufirst%3DG.%2BR.%26atitle%3DAzabenzocycloheptenones.%2520Part%2520III.%25202%252C3%252C4%252C5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz%255Bb%255Dazepine%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1961%26spage%3D3989%26epage%3D3994%26doi%3D10.1039%2Fjr9610003989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boeglin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span> <span> </span><span class="NLM_article-title">Solid-phase preparation of a pilot library derived from the 2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine scaffold</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1021/cc060164x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc060164x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=487-500&author=D.+Boeglinauthor=D.+Bonnetauthor=M.+Hibert&title=Solid-phase+preparation+of+a+pilot+library+derived+from+the+2%2C3%2C4%2C5-tetrahydro-1H-benzo%5Bb%5Dazepin-5-amine+scaffold&doi=10.1021%2Fcc060164x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-Phase Preparation of a Pilot Library Derived from the 2,3,4,5-Tetrahydro-1H-benzo[b]azepin-5-amine Scaffold</span></div><div class="casAuthors">Boeglin, Damien; Bonnet, Dominique; Hibert, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-500</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convenient and reliable solid-phase strategy for the synthesis of di- and trisubstituted benzazepine derivs. was developed.  5-Amino-1-tert-butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine and 5-amino-1-tert-butoxycarbonyl-7-bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine G-protein coupled receptor-targeted (GPCR-targeted) scaffolds were efficiently synthesized in a six-step soln.-phase process, immobilized on the acid-labile FMPB-AM resin, and further functionalized through acylation, sulfonation, reductive amination, alkylation, and Suzuki or Buchwald-Hartwig cross-coupling reactions.  The efficacy of this strategy was exemplified by the prepn. of an original pilot library of di- and trisubstituted benzazepines I (R1 = Me2CHCH2CH2, cyclohexyl, Ph, n-PrCO, PhCO, 4-MeOC6H4SO2, PhNHCO, etc.; R2 = H2NCH2CO, n-PrCO, PhCO, 4-MeOC6H4SO2, etc.; R3 = H, Me2CHCH2, Ph, 4-NCC6H4, 2-thienyl, 1-pyrrolidinyl, etc.) obtained in high purity as assessed by both 1H NMR and liq. chromatog./mass spectrometry (LC/MS) anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozJa1TkOwR_bVg90H21EOLACvtfcHk0liFgpWxZjYY-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislKktb4%253D&md5=96a2d16179d8878e596445f455c35fca</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fcc060164x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc060164x%26sid%3Dliteratum%253Aachs%26aulast%3DBoeglin%26aufirst%3DD.%26aulast%3DBonnet%26aufirst%3DD.%26aulast%3DHibert%26aufirst%3DM.%26atitle%3DSolid-phase%2520preparation%2520of%2520a%2520pilot%2520library%2520derived%2520from%2520the%25202%252C3%252C4%252C5-tetrahydro-1H-benzo%255Bb%255Dazepin-5-amine%2520scaffold%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2007%26volume%3D9%26spage%3D487%26epage%3D500%26doi%3D10.1021%2Fcc060164x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Martino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filacchioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, R.</span></span> <span> </span><span class="NLM_article-title">Ricerche su sostanze ad attivita’ antiblastica</span>. <i>Il Farmaco – Ed. Sc.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">284</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=5822122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaF1MXps1Oktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1969&pages=276-284&author=M.+Articoauthor=G.+De+Martinoauthor=G.+Filacchioniauthor=R.+Giuliano&title=Ricerche+su+sostanze+ad+attivita%E2%80%99+antiblastica"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Antiblastic agents.  XXXVI.  Anthramycin and analogous compounds.  1.  Synthesis of 10,11-dihydro-5H-pyrrolo-[2,1-s][1,4]-benzodiazepine</span></div><div class="casAuthors">Artico, Marino; De Martino, Giovanni; Filacchioni, G.; Giuliano, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco, Edizione Scientifica</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-84</span>CODEN:
                <span class="NLM_cas:coden">FRPSAX</span>;
        ISSN:<span class="NLM_cas:issn">0430-0920</span>.
    </div><div class="casAbstract">10-(R-Substituted)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepines (I) are prepd.  Thus, N is passed through a soln. of 4.75 g. 2-pyrrolecarboxaldehyde in 100 ml. tetrahydrofuran (THF), 1.56 g. K is added, the mixt. is refluxed to give a soln., a soln. of 8.64 g. o-O2NC6H4COBr in 100 ml. THF is added, and the mixt. is agitated 8 hrs. at 65° to give 1-(o-nitrobenzoyl)-2-pyrrolecarboxaldehyde (II), m. 136-8°; oxime m. 130-2°.  II (2.3 g.) is dissolved in 250 ml. mixt. of EtOAc and EtOH and hydrogenated over 200 mg. 10% Pd/C 3 hrs. at 4 atm. to give 1.2 g. 10,11-dihydro-5H-pyrrolo-[2,1-c][1,4]benzodiazepine (III), m. 152-4° (decompn.).  III is converted to the following I (R and m.p. given): Ac, 154-5°; ClCH2CO, 122-3°; Cl2CHCO, 118-19°.  Ir data are given; also given is the ir spectrum of III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3kywPi1TwNrVg90H21EOLACvtfcHk0lg6jtMQ54hCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXps1Oktw%253D%253D&md5=b66a573f9e4491d69d10c3488c0d7aa3</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DDe%2BMartino%26aufirst%3DG.%26aulast%3DFilacchioni%26aufirst%3DG.%26aulast%3DGiuliano%26aufirst%3DR.%26atitle%3DRicerche%2520su%2520sostanze%2520ad%2520attivita%25E2%2580%2599%2520antiblastica%26jtitle%3DIl%2520Farmaco%2520%25E2%2580%2593%2520Ed.%2520Sc.%26date%3D1969%26volume%3D24%26spage%3D276%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0liIJMdJKd5raw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karpenko, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margathe, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflimlin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span> <span> </span><span class="NLM_article-title">Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2552</span>, <span class="refDoi"> DOI: 10.1021/jm501395b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501395b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2547-2552&author=I.+A.+Karpenkoauthor=J.+F.+Margatheauthor=T.+Rodriguezauthor=E.+Pflimlinauthor=E.+Dupuisauthor=M.+Hibertauthor=T.+Durrouxauthor=D.+Bonnet&title=Selective+nonpeptidic+fluorescent+ligands+for+oxytocin+receptor%3A+design%2C+synthesis%2C+and+application+to+time-resolved+FRET+binding+assay&doi=10.1021%2Fjm501395b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Nonpeptidic Fluorescent Ligands for Oxytocin Receptor: Design, Synthesis, and Application to Time-Resolved FRET Binding Assay</span></div><div class="casAuthors">Karpenko, Iuliia A.; Margathe, Jean-Francois; Rodriguez, Thieric; Pflimlin, Elsa; Dupuis, Elodie; Hibert, Marcel; Durroux, Thierry; Bonnet, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2547-2552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and the synthesis of the first high-affinity fluorescent ligands for oxytocin receptor (OTR) are described.  These compds. enabled the development of a TR-FRET based assay for OTR, readily amenable to high throughput screening.  The validation of the assay was achieved by competition expts. with both peptide and nonpeptide OTR ligands as competitors.  These probes represent the first selective fluorescent ligands for the oxytocin G protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYix67Nh90z7Vg90H21EOLACvtfcHk0liIJMdJKd5raw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2ju74%253D&md5=7ba9dddc66ed6bafb60b83cbc2efc9ff</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm501395b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501395b%26sid%3Dliteratum%253Aachs%26aulast%3DKarpenko%26aufirst%3DI.%2BA.%26aulast%3DMargathe%26aufirst%3DJ.%2BF.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DPflimlin%26aufirst%3DE.%26aulast%3DDupuis%26aufirst%3DE.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DSelective%2520nonpeptidic%2520fluorescent%2520ligands%2520for%2520oxytocin%2520receptor%253A%2520design%252C%2520synthesis%252C%2520and%2520application%2520to%2520time-resolved%2520FRET%2520binding%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2547%26epage%3D2552%26doi%3D10.1021%2Fjm501395b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, A. D.</span></span> <span> </span><span class="NLM_article-title">Oral oxytocin antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6525</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1021/jm901812z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901812z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6525-6538&author=A.+D.+Borthwick&title=Oral+oxytocin+antagonists&doi=10.1021%2Fjm901812z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Oxytocin Antagonists</span></div><div class="casAuthors">Borthwick, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6525-6538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics and oral bioavailability of oxytocin antagonists is discussed.  Templates investigated in the previous decade contravene the Lipinski "role of five", which accounts for their poor oral bioavailability, but this is not the case with the more recent compds.  Mol. structure and properties of different compds. are studied in view if their efficiency, bioavailability, bioaccumulation, and applicability, penetration of the blood brain barrier, accumulation in the brain, and blocking central effects of oxytocin both in the fetus and in the mother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRMlf_5Dp9rVg90H21EOLACvtfcHk0liIJMdJKd5raw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D&md5=4fd042ed2404adeae482a27ca77d07a9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm901812z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901812z%26sid%3Dliteratum%253Aachs%26aulast%3DBorthwick%26aufirst%3DA.%2BD.%26atitle%3DOral%2520oxytocin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6525%26epage%3D6538%26doi%3D10.1021%2Fjm901812z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelhalter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Merrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span> <span> </span><span class="NLM_article-title">Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1038/npp.2014.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2014.59" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=2049-2060&author=J.+A.+Beckerauthor=D.+Clesseauthor=C.+Spiegelhalterauthor=Y.+Schwabauthor=J.+Le+Merrerauthor=B.+L.+Kieffer&title=Autistic-like+syndrome+in+mu+opioid+receptor+null+mice+is+relieved+by+facilitated+mGluR4+activity&doi=10.1038%2Fnpp.2014.59"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2014.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2014.59%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DJ.%2BA.%26aulast%3DClesse%26aufirst%3DD.%26aulast%3DSpiegelhalter%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DY.%26aulast%3DLe%2BMerrer%26aufirst%3DJ.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26atitle%3DAutistic-like%2520syndrome%2520in%2520mu%2520opioid%2520receptor%2520null%2520mice%2520is%2520relieved%2520by%2520facilitated%2520mGluR4%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D2049%26epage%3D2060%26doi%3D10.1038%2Fnpp.2014.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, F. R.</span></span> <span> </span><span class="NLM_article-title">Deficit in attachment behavior in mice lacking the mu-opioid receptor gene</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1983</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1126/science.1095943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1095943" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1983-1986&author=A.+Molesauthor=B.+L.+Kiefferauthor=F.+R.+D%E2%80%99Amato&title=Deficit+in+attachment+behavior+in+mice+lacking+the+mu-opioid+receptor+gene&doi=10.1126%2Fscience.1095943"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1126%2Fscience.1095943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1095943%26sid%3Dliteratum%253Aachs%26aulast%3DMoles%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DF.%2BR.%26atitle%3DDeficit%2520in%2520attachment%2520behavior%2520in%2520mice%2520lacking%2520the%2520mu-opioid%2520receptor%2520gene%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1983%26epage%3D1986%26doi%3D10.1126%2Fscience.1095943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellissier, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandía, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laboute, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Merrer, J.</span></span> <span> </span><span class="NLM_article-title">μ opioid receptor, social behaviour and autism spectrum disorder: reward matters</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2769</span>, <span class="refDoi"> DOI: 10.1111/bph.13808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fbph.13808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28369738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2750-2769&author=L.+P.+Pellissierauthor=J.+Gand%C3%ADaauthor=T.+Labouteauthor=J.+A.+Beckerauthor=J.+Le+Merrer&title=%CE%BC+opioid+receptor%2C+social+behaviour+and+autism+spectrum+disorder%3A+reward+matters&doi=10.1111%2Fbph.13808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">μ opioid receptor, social behavior and autism spectrum disorder: reward matters</span></div><div class="casAuthors">Pellissier, Lucie P.; Gandia, Jorge; Laboute, Thibaut; Becker, Jerome A. J.; Le Merrer, Julie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2750-2769</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The endogenous opioid system is well known to relieve pain and underpin the rewarding properties of most drugs of abuse.  Among opioid receptors, the μ receptor mediates most of the analgesic and rewarding properties of opioids.  Based on striking similarities between social distress, phys. pain and opiate withdrawal, μ receptors have been proposed to play a crit. role in modulating social behavior in humans and animals.  This review summarizes exptl. data demonstrating such role and proposes a novel model, the μ opioid receptor balance model, to account for the contribution of μ receptors to the subtle regulation of social behavior.  Interestingly, μ receptor null mice show behavioral deficits similar to those obsd. in patients with autism spectrum disorder (ASD), including severe impairment in social interactions.  Therefore, after a brief summary of recent evidence for blunted (social) reward processes in subjects with ASD, we review here arguments for altered μ receptor function in this pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2xMRtV0S8rVg90H21EOLACvtfcHk0lid0XrqP79vfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyjsbw%253D&md5=f14f43165e45b7c9a22d59c0f6cd09c8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fbph.13808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13808%26sid%3Dliteratum%253Aachs%26aulast%3DPellissier%26aufirst%3DL.%2BP.%26aulast%3DGand%25C3%25ADa%26aufirst%3DJ.%26aulast%3DLaboute%26aufirst%3DT.%26aulast%3DBecker%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BMerrer%26aufirst%3DJ.%26atitle%3D%25CE%25BC%2520opioid%2520receptor%252C%2520social%2520behaviour%2520and%2520autism%2520spectrum%2520disorder%253A%2520reward%2520matters%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2750%26epage%3D2769%26doi%3D10.1111%2Fbph.13808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dölen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darvishzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1038/nature12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnature12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=24025838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntlyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=179-184&author=G.+D%C3%B6lenauthor=A.+Darvishzadehauthor=K.+W.+Huangauthor=R.+C.+Malenka&title=Social+reward+requires+coordinated+activity+of+nucleus+accumbens+oxytocin+and+serotonin&doi=10.1038%2Fnature12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin</span></div><div class="casAuthors">Dolen Gul; Darvishzadeh Ayeh; Huang Kee Wui; Malenka Robert C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">179-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Social behaviours in species as diverse as honey bees and humans promote group survival but often come at some cost to the individual.  Although reinforcement of adaptive social interactions is ostensibly required for the evolutionary persistence of these behaviours, the neural mechanisms by which social reward is encoded by the brain are largely unknown.  Here we demonstrate that in mice oxytocin acts as a social reinforcement signal within the nucleus accumbens core, where it elicits a presynaptically expressed long-term depression of excitatory synaptic transmission in medium spiny neurons.  Although the nucleus accumbens receives oxytocin-receptor-containing inputs from several brain regions, genetic deletion of these receptors specifically from dorsal raphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus accumbens, abolishes the reinforcing properties of social interaction.  Furthermore, oxytocin-induced synaptic plasticity requires activation of nucleus accumbens 5-HT1B receptors, the blockade of which prevents social reward.  These results demonstrate that the rewarding properties of social interaction in mice require the coordinated activity of oxytocin and 5-HT in the nucleus accumbens, a mechanistic insight with implications for understanding the pathogenesis of social dysfunction in neuropsychiatric disorders such as autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtavUaLESyEAaK-_ZudimnfW6udTcc2eYeQt9C11kAXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntlyruw%253D%253D&md5=4253ec1c708c193707c9ae25d1464e92</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12518%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6len%26aufirst%3DG.%26aulast%3DDarvishzadeh%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DK.%2BW.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DSocial%2520reward%2520requires%2520coordinated%2520activity%2520of%2520nucleus%2520accumbens%2520oxytocin%2520and%2520serotonin%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D179%26epage%3D184%26doi%3D10.1038%2Fnature12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gigliucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonzino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Region specific up-regulation of oxytocin receptors in the opioid oprm1 (−/−) mouse model of autism</span>. <i>Front Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.3389/fped.2014.00091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffped.2014.00091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25225634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC2M7hvVCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=91&author=V.+Gigliucciauthor=M.+Leonzinoauthor=M.+Busnelliauthor=A.+Luchettiauthor=V.+S.+Palladinoauthor=F.+R.+D%E2%80%99Amatoauthor=B.+Chini&title=Region+specific+up-regulation+of+oxytocin+receptors+in+the+opioid+oprm1+%28%E2%88%92%2F%E2%88%92%29+mouse+model+of+autism&doi=10.3389%2Ffped.2014.00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Region specific up-regulation of oxytocin receptors in the opioid oprm1 (-/-) mouse model of autism</span></div><div class="casAuthors">Gigliucci Valentina; Leonzino Marianna; Busnelli Marta; Chini Bice; Luchetti Alessandra; Palladino Viola Stella; D'Amato Francesca R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">Autism spectrum disorders (ASDs) are characterized by impaired communication, social impairments, and restricted and repetitive behaviors and interests.  Recently, altered motivation and reward processes have been suggested to participate in the physiopathology of ASDs, and μ-opioid receptors (MORs) have been investigated in relation to social reward due to their involvement in the neural circuitry of reward.  Mice lacking a functional MOR gene (Oprm1 (-/-) mice) display abnormal social behavior and major autistic-like core symptoms, making them an animal model of autism.  The oxytocin (OXT) system is a key regulator of social behavior and co-operates with the opioidergic system in the modulation of social behavior.  To better understand the opioid-OXT interplay in the central nervous system, we first determined the expression of the oxytocin receptor (OXTR) in the brain of WT C57BL6/J mice by quantitative autoradiography; we then evaluated OXTR regional alterations in Oprm1 (-/-) mice.  Moreover, we tested these mice in a paradigm of social behavior, the male-female social interaction test, and analyzed the effects of acute intranasal OXT treatment on their performance.  In autoradiography, Oprm1 (-/-) mice selectively displayed increased OXTR expression in the Medial Anterior Olfactory Nucleus, the Central and Medial Amygdaloid nuclei, and the Nucleus Accumbens.  Our behavioral results confirmed that Oprm1 (-/-) male mice displayed social impairments, as indicated by reduced ultrasonic calls, and that these were rescued by a single intranasal administration of OXT.  Taken together, our results provide evidence of an interaction between OXT and opioids in socially relevant brain areas and in the modulation of social behavior.  Moreover, they suggest that the oxytocinergic system may act as a compensative mechanism to bypass and/or restore alterations in circuits linked to impaired social behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQFICkwsHpyhpyrDyM_m9cfW6udTcc2eYmnnMr5cuId7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7hvVCltg%253D%253D&md5=206d770aa6aaa486b64e1eb040940135</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffped.2014.00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2014.00091%26sid%3Dliteratum%253Aachs%26aulast%3DGigliucci%26aufirst%3DV.%26aulast%3DLeonzino%26aufirst%3DM.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DLuchetti%26aufirst%3DA.%26aulast%3DPalladino%26aufirst%3DV.%2BS.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DF.%2BR.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DRegion%2520specific%2520up-regulation%2520of%2520oxytocin%2520receptors%2520in%2520the%2520opioid%2520oprm1%2520%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2520mouse%2520model%2520of%2520autism%26jtitle%3DFront%2520Pediatr.%26date%3D2014%26volume%3D2%26spage%3D91%26doi%3D10.3389%2Ffped.2014.00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulliver, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werry, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.ejmech.2015.11.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=730-740&author=W.+T.+Jorgensenauthor=D.+Gulliverauthor=E.+L.+Werryauthor=T.+Reekieauthor=M.+Connorauthor=M.+Kassiou&title=Flexible+analogues+of+WAY-267%2C464%3A+Synthesis+and+pharmacology+at+the+human+oxytocin+and+vasopressin+1a+receptors&doi=10.1016%2Fj.ejmech.2015.11.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BT.%26aulast%3DGulliver%26aufirst%3DD.%26aulast%3DWerry%26aufirst%3DE.%2BL.%26aulast%3DReekie%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DFlexible%2520analogues%2520of%2520WAY-267%252C464%253A%2520Synthesis%2520and%2520pharmacology%2520at%2520the%2520human%2520oxytocin%2520and%2520vasopressin%25201a%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D730%26epage%3D740%26doi%3D10.1016%2Fj.ejmech.2015.11.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span> <span> </span><span class="NLM_article-title">ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2152</span>, <span class="refDoi"> DOI: 10.1021/ci034134i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034134i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=2137-2152&author=T.+J.+Houauthor=X.+J.+Xu&title=ADME+evaluation+in+drug+discovery.+3.+Modeling+blood-brain+barrier+partitioning+using+simple+molecular+descriptors&doi=10.1021%2Fci034134i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">ADME Evaluation in Drug Discovery. 3. Modeling Blood-Brain Barrier Partitioning Using Simple Molecular Descriptors</span></div><div class="casAuthors">Hou, T. J.; Xu, X. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2137-2152</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, QSPR models were developed for in vivo blood-brain partitioning data (logBB) of a large data set consisting of 115 diverse org. compds.  The best model is based on three descriptors: n-octanol/water partition coeff. calcd. using the SLOGP approach, logP; high-charged polar surface areas based on the Gasteiger partial charges, HCPSA, and the excessive mol. wt. larger than 360, MW360.  The model bears good statistical significance, n = 78, r = 0.88, q = 0.86, s = 0.36, F = 81.5.  The actual prediction potential of the model was validated through two external validation sets of 37 diverse compds.  The predicted results demonstrate that the model bears better prediction potential than many other models and can be used for logBB estns. for drug and drug-like mols.  Comparison of several logP calcn. approaches suggests that logP calcd. by SLOGP can be used as a significant descriptor for the prediction of mol. transport properties because SLOGP gives the most similar results with CLOGP.  The QSPR model indicates that larger polar surface areas have a more neg. contribution to logBB, but the abs. partial charges on the atoms surrounded by the polar surfaces should be larger than 0.10|e|. Meanwhile, tight junction membranes limit the size of hydrophilic mols. that can cross the membrane with a mol. wt. of approx. 360, because when a mol.'s wt. is larger than 360 it shows a neg. contribution to logBB.  The computations of mol. surface, partial charges, logP, and logBB have been accomplished using a program called Drug-BB. Moreover, to improve the efficiency of the computations of logP, we made an extensive reparametrization of SLOGP, and the newly developed SLOGP model is only based on simple at. addn.  Further, we developed a set of parameters to calc. the topol. polar surface area (TPSA), thus the high-charged topol. polar surface area (HCTPSA) could be estd. from the 2D connection information of a mol.  Adopting the new strategies, the estns. of logP, HCTPSA, and logBB are only based on the topol. structure of a mol. and therefore, can be used for fast screening of virtual libraries having millions of mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC2FViiKM9xbVg90H21EOLACvtfcHk0liZzOP8ng-kpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFSjs7w%253D&md5=f7562b8bcba229cb19189075d769e07c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fci034134i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034134i%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DT.%2BJ.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26atitle%3DADME%2520evaluation%2520in%2520drug%2520discovery.%25203.%2520Modeling%2520blood-brain%2520barrier%2520partitioning%2520using%2520simple%2520molecular%2520descriptors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D2137%26epage%3D2152%26doi%3D10.1021%2Fci034134i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span> <i>MarvinSketch 6.0.0</i>; <span class="NLM_publisher-name">ChemAxon Software</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MarvinSketch+6.0.0%3B+ChemAxon+Software%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMarvinSketch%25206.0.0%26pub%3DChemAxon%2520Software%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">GTEx
Consortium</span> <span> </span><span class="NLM_article-title">The genotype-tissue
expression (GTEx) pilot analysis: multitissue gene regulation in humans</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1126/science.1262110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1262110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=648-660&author=GTEx%0AConsortium&title=The+genotype-tissue%0Aexpression+%28GTEx%29+pilot+analysis%3A+multitissue+gene+regulation+in+humans&doi=10.1126%2Fscience.1262110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.1262110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1262110%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520genotype-tissue%250Aexpression%2520%2528GTEx%2529%2520pilot%2520analysis%253A%2520multitissue%2520gene%2520regulation%2520in%2520humans%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D648%26epage%3D660%26doi%3D10.1126%2Fscience.1262110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisgo, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerrelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clowry, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxhead, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santibanez-Koref, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnery, P. F.</span></span> <span> </span><span class="NLM_article-title">HDBR expression: a unique resource for global and individual gene expression studies during early human brain development</span>. <i>Front. Neuroanat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.3389/fnana.2016.00086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffnana.2016.00086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27833533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSkt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=86&author=S.+J.+Lindsayauthor=Y.+Xuauthor=S.+N.+Lisgoauthor=L.+F.+Harkinauthor=A.+J.+Coppauthor=D.+Gerrelliauthor=G.+J.+Clowryauthor=A.+Talbotauthor=M.+J.+Keoghauthor=J.+Coxheadauthor=M.+Santibanez-Korefauthor=P.+F.+Chinnery&title=HDBR+expression%3A+a+unique+resource+for+global+and+individual+gene+expression+studies+during+early+human+brain+development&doi=10.3389%2Ffnana.2016.00086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">HDBR expression: a unique resource for global and individual gene expression studies during early human brain development</span></div><div class="casAuthors">Lindsay, Susan J.; Xu, Yaobo; Lisgo, Steven N.; Harkin, Lauren F.; Copp, Andrew J.; Gerrelli, Dianne; Clowry, Gavin J.; Talbot, Aysha; Keogh, Michael J.; Coxhead, Jonathan; Santibanez-Koref, Mauro; Chinnery, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Neuroanatomy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86/1-86/6</span>CODEN:
                <span class="NLM_cas:coden">FNREB8</span>;
        ISSN:<span class="NLM_cas:issn">1662-5129</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX8kPQZqNCb7Vg90H21EOLACvtfcHk0ljdQ8MBwm031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSkt7jI&md5=93e969cd21d81473902d3926a6979aec</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffnana.2016.00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnana.2016.00086%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DS.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLisgo%26aufirst%3DS.%2BN.%26aulast%3DHarkin%26aufirst%3DL.%2BF.%26aulast%3DCopp%26aufirst%3DA.%2BJ.%26aulast%3DGerrelli%26aufirst%3DD.%26aulast%3DClowry%26aufirst%3DG.%2BJ.%26aulast%3DTalbot%26aufirst%3DA.%26aulast%3DKeogh%26aufirst%3DM.%2BJ.%26aulast%3DCoxhead%26aufirst%3DJ.%26aulast%3DSantibanez-Koref%26aufirst%3DM.%26aulast%3DChinnery%26aufirst%3DP.%2BF.%26atitle%3DHDBR%2520expression%253A%2520a%2520unique%2520resource%2520for%2520global%2520and%2520individual%2520gene%2520expression%2520studies%2520during%2520early%2520human%2520brain%2520development%26jtitle%3DFront.%2520Neuroanat.%26date%3D2016%26volume%3D10%26spage%3D86%26doi%3D10.3389%2Ffnana.2016.00086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udelson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghiade, M.</span></span> <span> </span><span class="NLM_article-title">Dual vasopressin V1a/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure?</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2017.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.cardfail.2017.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=29329950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislOru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=112-114&author=S.+R.+Goldsmithauthor=J.+E.+Udelsonauthor=M.+Gheorghiade&title=Dual+vasopressin+V1a%2FV2+antagonism%3A+the+next+step+in+neurohormonal+modulation+in+patients+with+heart+failure%3F&doi=10.1016%2Fj.cardfail.2017.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?</span></div><div class="casAuthors">Goldsmith, Steven R.; Udelson, James E.; Gheorghiade, Mihai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-114</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stimulation of the V1a receptor for arginine vasopressin produces myocardial and vascular effects similar to those of angiotensin II while stimulation of the V2 receptor causes fluid retention.  There are no data with sustained blockade of the V1a receptor while single-dose expts. suggest benefit.  Acute and chronic administration of selective V2 receptor antagonists reliably relieves dyspnea and produces diuresis without adverse effects on renal function or neurohormonal stimulation, either as adjunctive or alternative therapy to loop diuretics, but has not been shown to improve outcomes as adjunctive therapy.  Combined antagonism has been tried only in single-dose studies in stable patients or over the short-term in acute heart failure, with encouraging results.  Based on the both the pathophysiol. rationale for addnl. neurohormonal blockade and these results, chronically blocking both receptors, particularly in more congested patients, may offer significant benefit either as adjunctive or alternative therapy to std. diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpPlZ5rW25pLVg90H21EOLACvtfcHk0ljdQ8MBwm031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislOru7g%253D&md5=61bba1d09f25ba888698dcb9dab8f53a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2017.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2017.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26aulast%3DUdelson%26aufirst%3DJ.%2BE.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DDual%2520vasopressin%2520V1a%252FV2%2520antagonism%253A%2520the%2520next%2520step%2520in%2520neurohormonal%2520modulation%2520in%2520patients%2520with%2520heart%2520failure%253F%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2018%26volume%3D24%26spage%3D112%26epage%3D114%26doi%3D10.1016%2Fj.cardfail.2017.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagitani-Shimono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanefuji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniike, M.</span></span> <span> </span><span class="NLM_article-title">Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders</span>. <i>J. Child Adolesc. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1089/cap.2012.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1089%2Fcap.2012.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23480321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=123-127&author=M.+Tachibanaauthor=K.+Kagitani-Shimonoauthor=I.+Mohriauthor=T.+Yamamotoauthor=W.+Sanefujiauthor=A.+Nakamuraauthor=M.+Oishiauthor=T.+Kimuraauthor=T.+Onakaauthor=K.+Ozonoauthor=M.+Taniike&title=Long-term+administration+of+intranasal+oxytocin+is+a+safe+and+promising+therapy+for+early+adolescent+boys+with+autism+spectrum+disorders&doi=10.1089%2Fcap.2012.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Administration of Intranasal Oxytocin Is a Safe and Promising Therapy for Early Adolescent Boys with Autism Spectrum Disorders</span></div><div class="casAuthors">Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Nakamura, Ayumi; Oishi, Masako; Kimura, Tadashi; Onaka, Tatsushi; Ozono, Keiichi; Taniike, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Child and Adolescent Psychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-127</span>CODEN:
                <span class="NLM_cas:coden">JADPET</span>;
        ISSN:<span class="NLM_cas:issn">1044-5463</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated.  However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified.  Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10-14 years of age; intelligence quotient [IQ] 20-101).  The OT administration was performed in a stepwise increased dosage manner every 2 mo (8, 16, 24 IU/dose).  A placebo period (1-2 wk) was inserted before each step.  The outcome measures were Autism Diagnostic Observation Schedule - Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC).  In addn., side effects were monitored by measuring blood pressure and examg. urine and blood samples.  Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G.  However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement.  Caregivers of five of the eight participants reported certain pos. effects of the OT therapy, esp. on the quality of reciprocal communication.  All participants showed excellent compliance and no side effects.  Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD.  Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1W2Z4_SZIxbVg90H21EOLACvtfcHk0ljdQ8MBwm031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D&md5=8b84a3857e1b54023f3b4d181b1e2f37</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1089%2Fcap.2012.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcap.2012.0048%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DKagitani-Shimono%26aufirst%3DK.%26aulast%3DMohri%26aufirst%3DI.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSanefuji%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DOishi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOnaka%26aufirst%3DT.%26aulast%3DOzono%26aufirst%3DK.%26aulast%3DTaniike%26aufirst%3DM.%26atitle%3DLong-term%2520administration%2520of%2520intranasal%2520oxytocin%2520is%2520a%2520safe%2520and%2520promising%2520therapy%2520for%2520early%2520adolescent%2520boys%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DJ.%2520Child%2520Adolesc.%2520Psychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D123%26epage%3D127%26doi%3D10.1089%2Fcap.2012.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umbricht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle Rubido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scahill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noeldeke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khwaja, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squassante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundschober, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kletzl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontoura, P.</span></span> <span> </span><span class="NLM_article-title">A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2016.232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27711048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2gtLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1914-1923&author=D.+Umbrichtauthor=M.+Del+Valle+Rubidoauthor=E.+Hollanderauthor=J.+T.+McCrackenauthor=F.+Shicauthor=L.+Scahillauthor=J.+Noeldekeauthor=L.+Boakauthor=O.+Khwajaauthor=L.+Squassanteauthor=C.+Grundschoberauthor=H.+Kletzlauthor=P.+Fontoura&title=A+single+dose%2C+randomized%2C+controlled+proof-of-mechanism+study+of+a+novel+vasopressin+1a+receptor+antagonist+%28RG7713%29+in+high-functioning+adults+with+autism+spectrum+disorder&doi=10.1038%2Fnpp.2016.232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder</span></div><div class="casAuthors">Umbricht, Daniel; del Valle Rubido, Marta; Hollander, Eric; McCracken, James T.; Shic, Frederick; Scahill, Lawrence; Noeldeke, Jana; Boak, Lauren; Khwaja, Omar; Squassante, Lisa; Grundschober, Christophe; Kletzl, Heidemarie; Fontoura, Paulo</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1914-1923</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The core symptoms of autism spectrum disorder (ASD) include impaired social communication, repetitive behaviors, and restricted interests.  No effective pharmacotherapy for these core deficits exists.  Within the domain of social communication, the vasopressin system is implicated in social cognition and social signaling deficits of ASD, and represents a potential therapeutic target.  We assessed the effects of a single 20 mg i.v. dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exploratory biomarkers (eye tracking), behavioral and clin. measures of social cognition and communication (affective speech recognition (ASR), reading the mind in the eyes, olfactory identification, scripted interaction), and safety and tolerability in a multicenter, randomized, double-blind, placebo-controlled, cross-over study of 19 high-functioning adult male subjects with DSM-IV Autistic Disorder (age 18-45 years; full scale IQ >70; ABC-Irritability subscale ≤13).  Eye-tracking showed an increase in biol. motion orienting preference with RG7713 (ES=0.8, p=0.047) and a non-significant improvement in the composite score (ES=0.2, p=0.29).  RG7713 reduced ability to detect lust (ES=-0.8, p=0.03) and fear (ES=-0.7, p=0.07) in ASR.  However, when all eight individual emotion subscales were combined into an overall ASR performance score, the redn. was non-significant (ES=-0.1, p=0.59).  Thirteen adverse events were reported in 10 subjects; all were of mild (11/13) or moderate (2/13) severity.  Although interpretation should be cautious due to multiple comparisons and small sample size, these results provide preliminary evidence from exptl. and behavioral biomarkers, that blockade of the V1a receptor may improve social communication in adults with high-functioning ASD.  ClinicalTrials.gov identifier: NCT01474278 A Study of RO5028442 in Adult Male High-Functioning Autistic Patients.  Available at: https://clinicaltrials.gov/ct2/show/NCT01474278.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAsg9CGg4pmLVg90H21EOLACvtfcHk0ljlFAF2dmP2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2gtLvE&md5=c0cfa97b338f184d08a073f21ab0fe7c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.232%26sid%3Dliteratum%253Aachs%26aulast%3DUmbricht%26aufirst%3DD.%26aulast%3DDel%2BValle%2BRubido%26aufirst%3DM.%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DMcCracken%26aufirst%3DJ.%2BT.%26aulast%3DShic%26aufirst%3DF.%26aulast%3DScahill%26aufirst%3DL.%26aulast%3DNoeldeke%26aufirst%3DJ.%26aulast%3DBoak%26aufirst%3DL.%26aulast%3DKhwaja%26aufirst%3DO.%26aulast%3DSquassante%26aufirst%3DL.%26aulast%3DGrundschober%26aufirst%3DC.%26aulast%3DKletzl%26aufirst%3DH.%26aulast%3DFontoura%26aufirst%3DP.%26atitle%3DA%2520single%2520dose%252C%2520randomized%252C%2520controlled%2520proof-of-mechanism%2520study%2520of%2520a%2520novel%2520vasopressin%25201a%2520receptor%2520antagonist%2520%2528RG7713%2529%2520in%2520high-functioning%2520adults%2520with%2520autism%2520spectrum%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1914%26epage%3D1923%26doi%3D10.1038%2Fnpp.2016.232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passoni, I.</span>; <span class="NLM_string-name">Leonzino, M.</span>; <span class="NLM_string-name">Gigliucci, V.</span>; <span class="NLM_string-name">Chini, B.</span>; <span class="NLM_string-name">Busnelli, M.</span></span> <span> </span><span class="NLM_article-title">Carbetocin is a functional selective Gq agonist that does not promote oxytocin receptor recycling after inducing β-arrestin-independent internalisation</span>.  <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">28</span>(<span class="NLM_issue">4</span>), doi: <span class="refDoi"> DOI: 10.1111/jne.12363</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fjne.12363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26751410" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&issue=4&author=I.+Passoni&author=M.+Leonzino&author=V.+Gigliucci&author=B.+Chini&author=M.+Busnelli&title=Carbetocin+is+a+functional+selective+Gq+agonist+that+does+not+promote+oxytocin+receptor+recycling+after+inducing+%CE%B2-arrestin-independent+internalisation&doi=10.1111%2Fjne.12363"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1111%2Fjne.12363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjne.12363%26sid%3Dliteratum%253Aachs%26aulast%3DPassoni%26aufirst%3DI.%26atitle%3DCarbetocin%2520is%2520a%2520functional%2520selective%2520Gq%2520agonist%2520that%2520does%2520not%2520promote%2520oxytocin%2520receptor%2520recycling%2520after%2520inducing%2520%25CE%25B2-arrestin-independent%2520internalisation%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2016%26volume%3D28%26issue%3D4%26doi%3D10.1111%2Fjne.12363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curcuruto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslam, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span> <span> </span><span class="NLM_article-title">Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.bjp.0706383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16158071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKht7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=744-751&author=C.+Griffanteauthor=A.+Greenauthor=O.+Curcurutoauthor=C.+P.+Haslamauthor=B.+A.+Dickinsonauthor=R.+Arban&title=Selectivity+of+d%5BCha4%5DAVP+and+SSR149415+at+human+vasopressin+and+oxytocin+receptors%3A+evidence+that+SSR149415+is+a+mixed+vasopressin+V1b%2Foxytocin+receptor+antagonist&doi=10.1038%2Fsj.bjp.0706383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist</span></div><div class="casAuthors">Griffante, Cristiana; Green, Andrew; Curcuruto, Ornella; Haslam, Carl P.; Dickinson, Bryony A.; Arban, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">744-751</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A possible role of arginine vasopressin (AVP) V1b receptor subtype in stress-related disorders has been recently highlighted by the discovery of the agonist [1-deamino-4-cyclohexylalanine] AVP (d[Cha4]AVP) and the antagonist SSR149415.  Both compds. have been proposed to target specifically V1b receptors, since the reported affinities for the related V1a, V2 and oxytocin receptors are in the micromolar or submicromolar range.  In the present study, we further investigated the binding affinities of d[Cha4]AVP and SSR149415 at recombinant human vasopressin V1b (hV1b) and oxytocin (hOT) receptors expressed in Chinese hamster ovary (CHO) cells and functional properties of both compds. at hV1b, hV1a, hV2 and hOT receptors.  D[Cha4]AVP bound to hV1b receptors and hOT receptors with pKi values of 9.68 ± 0.06 and 7.68 ± 0.09, resp.  SSR149415 showed pKi values of 9.34 ± 0.06 at hV1b and 8.82 ± 0.16 at hOT receptors; d[Cha4]AVP stimulated [Ca2-]i increase in hVib-CHO cells with a pEC50 value of 10.05 ± 0.15.  It showed pEC50 values of 6.53 ± 0.17 and 5.92 ± 0.02 at hV1a and hV2 receptors, resp., and behaved as a weak antagonist at hOT receptors (pKB = 6.31 ± 0.12).  SSR149415 inhibited the agonist-induced [Ca2+]i increase with pKB values of 9.19 ± 0.07 in hV1b-CHO and 8.72 ± 0.15 in hOT-CHO cells.  A functional pKi value of 7.23 ± 0.10 was found for SSR149415 at hV1a receptors, whereas it did not inhibit 20 nM AVP response at hV2 receptors up to 3 μM.  Data obtained confirmed the high potency and selectivity of d[Cha4]AVP at hV1b receptors, but revealed that SSR149415, in addn. to the high potency at hV1b receptors, displays a significant antagonism at hOT receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolzZMU_xq36bVg90H21EOLACvtfcHk0ljlFAF2dmP2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKht7nO&md5=c0700acd4dc1348a56ae1e5e9f8f319e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706383%26sid%3Dliteratum%253Aachs%26aulast%3DGriffante%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DCurcuruto%26aufirst%3DO.%26aulast%3DHaslam%26aufirst%3DC.%2BP.%26aulast%3DDickinson%26aufirst%3DB.%2BA.%26aulast%3DArban%26aufirst%3DR.%26atitle%3DSelectivity%2520of%2520d%255BCha4%255DAVP%2520and%2520SSR149415%2520at%2520human%2520vasopressin%2520and%2520oxytocin%2520receptors%253A%2520evidence%2520that%2520SSR149415%2520is%2520a%2520mixed%2520vasopressin%2520V1b%252Foxytocin%2520receptor%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D146%26spage%3D744%26epage%3D751%26doi%3D10.1038%2Fsj.bjp.0706383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karpenko, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymchenko, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mély, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span> <span> </span><span class="NLM_article-title">Squaraine as a bright, stable and environment-sensitive far-red label for receptor-specific cellular imaging</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2963</span>, <span class="refDoi"> DOI: 10.1039/C4CC09113B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1039%2FC4CC09113B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25594279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkslCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=2960-2963&author=I.+A.+Karpenkoauthor=A.+S.+Klymchenkoauthor=S.+Gioriaauthor=R.+Krederauthor=I.+Shulovauthor=P.+Villaauthor=Y.+M%C3%A9lyauthor=M.+Hibertauthor=D.+Bonnet&title=Squaraine+as+a+bright%2C+stable+and+environment-sensitive+far-red+label+for+receptor-specific+cellular+imaging&doi=10.1039%2FC4CC09113B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Squaraine as a bright, stable and environment-sensitive far-red label for receptor-specific cellular imaging</span></div><div class="casAuthors">Karpenko, I. A.; Klymchenko, A. S.; Gioria, S.; Kreder, R.; Shulov, I.; Villa, P.; Mely, Y.; Hibert, M.; Bonnet, D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2960-2963</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein, we show that a far-red arylidene-squaraine dye is stable against nucleophiles, in contrast to arene-squaraines.  Owing to the fluorescence enhancement in apolar media together with high brightness and photostability, this dye was successfully applied to detect the oxytocin G protein-coupled receptor and monitor its internalization in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8aP5Evtjn7Vg90H21EOLACvtfcHk0lg_uWNwHEtSSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkslCqsg%253D%253D&md5=d9d41cb4fc6f56657de35e793c450dc2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1039%2FC4CC09113B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC09113B%26sid%3Dliteratum%253Aachs%26aulast%3DKarpenko%26aufirst%3DI.%2BA.%26aulast%3DKlymchenko%26aufirst%3DA.%2BS.%26aulast%3DGioria%26aufirst%3DS.%26aulast%3DKreder%26aufirst%3DR.%26aulast%3DShulov%26aufirst%3DI.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DM%25C3%25A9ly%26aufirst%3DY.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DSquaraine%2520as%2520a%2520bright%252C%2520stable%2520and%2520environment-sensitive%2520far-red%2520label%2520for%2520receptor-specific%2520cellular%2520imaging%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D2960%26epage%3D2963%26doi%3D10.1039%2FC4CC09113B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahtaoui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galzi, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilien, B.</span></span> <span> </span><span class="NLM_article-title">On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7847</span>– <span class="NLM_lpage">7859</span>, <span class="refDoi"> DOI: 10.1021/jm050459+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050459%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7847-7859&author=C.+Tahtaouiauthor=F.+Guillierauthor=P.+Klotzauthor=J.-L.+Galziauthor=M.+Hibertauthor=B.+Ilien&title=On+the+use+of+nonfluorescent+dye+labeled+ligands+in+FRET-based+receptor+binding+studies&doi=10.1021%2Fjm050459%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm050459%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050459%252B%26sid%3Dliteratum%253Aachs%26aulast%3DTahtaoui%26aufirst%3DC.%26aulast%3DGuillier%26aufirst%3DF.%26aulast%3DKlotz%26aufirst%3DP.%26aulast%3DGalzi%26aufirst%3DJ.-L.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DIlien%26aufirst%3DB.%26atitle%3DOn%2520the%2520use%2520of%2520nonfluorescent%2520dye%2520labeled%2520ligands%2520in%2520FRET-based%2520receptor%2520binding%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7847%26epage%3D7859%26doi%3D10.1021%2Fjm050459%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douzon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bdioui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oueslati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yverneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier-Savournin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span> <span> </span><span class="NLM_article-title">A fluorescent ligand-binding alternative using Tag-lite® technology</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1177/1087057110384611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1177%2F1087057110384611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=20974902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1248-1259&author=J.+M.+Zwierauthor=T.+Rouxauthor=M.+Cottetauthor=T.+Durrouxauthor=S.+Douzonauthor=S.+Bdiouiauthor=N.+Gregorauthor=E.+Bourrierauthor=N.+Oueslatiauthor=L.+Nicolasauthor=N.+Tinelauthor=C.+Boisseauauthor=P.+Yverneauauthor=F.+Charrier-Savourninauthor=M.+Finkauthor=E.+Trinquet&title=A+fluorescent+ligand-binding+alternative+using+Tag-lite%C2%AE+technology&doi=10.1177%2F1087057110384611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescent ligand-binding alternative using Tag-lite technology</span></div><div class="casAuthors">Zwier, Jurriaan M.; Roux, Thomas; Cottet, Martin; Durroux, Thierry; Douzon, Stephanie; Bdioui, Sara; Gregor, Nathalie; Bourrier, Emmanuel; Oueslati, Nadia; Nicolas, Ludovic; Tinel, Norbert; Boisseau, Chloe; Yverneau, Paul; Charrier-Savournin, Fabienne; Fink, Michel; Trinquet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are crucial cell surface receptors that transmit signals from a wide range of extracellular ligands.  Indeed, 40% to 50% of all marketed drugs are thought to modulate GPCR activity, making them the major class of targets in the drug discovery process.  Binding assays are widely used to identify high-affinity, selective, and potent GPCR drugs.  In this field, the use of radiolabeled ligands has remained so far the gold-std. method.  Here the authors report a less hazardous alternative for high-throughput screening (HTS) applications by the setup of a nonradioactive fluorescence-based technol. named Tag-lite.  Selective binding of various fluorescent ligands, either peptidic or not, covering a large panel of GPCRs from different classes is illustrated, particularly for chemokine (CXCR4), opioid (δ, μ, and κ), and cholecystokinin (CCK1 and CCK2) receptors.  Affinity consts. of well-known pharmacol. agents of numerous GPCRs are in line with values published in the literature.  The authors clearly demonstrate that the Tag-lite binding assay format can be successfully and reproducibly applied by using different cellular materials such as transient or stable recombinant cells lines expressing SNAP-tagged GPCR.  Such fluorescent-based binding assays can be performed with adherent cells or cells in suspension, in 96- or 384-well plates.  Altogether, this new technol. offers great advantages in terms of flexibility, rapidity, and user-friendliness; allows easy miniaturization; and makes it completely suitable for HTS applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ4y-qYZVkzbVg90H21EOLACvtfcHk0lg_uWNwHEtSSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWgtLY%253D&md5=ebb276667f42394eb16e8f0b64b365da</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1177%2F1087057110384611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110384611%26sid%3Dliteratum%253Aachs%26aulast%3DZwier%26aufirst%3DJ.%2BM.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DCottet%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DDouzon%26aufirst%3DS.%26aulast%3DBdioui%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DN.%26aulast%3DBourrier%26aufirst%3DE.%26aulast%3DOueslati%26aufirst%3DN.%26aulast%3DNicolas%26aufirst%3DL.%26aulast%3DTinel%26aufirst%3DN.%26aulast%3DBoisseau%26aufirst%3DC.%26aulast%3DYverneau%26aufirst%3DP.%26aulast%3DCharrier-Savournin%26aufirst%3DF.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DTrinquet%26aufirst%3DE.%26atitle%3DA%2520fluorescent%2520ligand-binding%2520alternative%2520using%2520Tag-lite%25C2%25AE%2520technology%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26spage%3D1248%26epage%3D1259%26doi%3D10.1177%2F1087057110384611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, A. D.</span></span> <span> </span><span class="NLM_article-title">Oral oxytocin antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6525</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1021/jm901812z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901812z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6525-6538&author=A.+D.+Borthwick&title=Oral+oxytocin+antagonists&doi=10.1021%2Fjm901812z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Oxytocin Antagonists</span></div><div class="casAuthors">Borthwick, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6525-6538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics and oral bioavailability of oxytocin antagonists is discussed.  Templates investigated in the previous decade contravene the Lipinski "role of five", which accounts for their poor oral bioavailability, but this is not the case with the more recent compds.  Mol. structure and properties of different compds. are studied in view if their efficiency, bioavailability, bioaccumulation, and applicability, penetration of the blood brain barrier, accumulation in the brain, and blocking central effects of oxytocin both in the fetus and in the mother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRMlf_5Dp9rVg90H21EOLACvtfcHk0ljV3un5tGTPIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D&md5=4fd042ed2404adeae482a27ca77d07a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm901812z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901812z%26sid%3Dliteratum%253Aachs%26aulast%3DBorthwick%26aufirst%3DA.%2BD.%26atitle%3DOral%2520oxytocin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6525%26epage%3D6538%26doi%3D10.1021%2Fjm901812z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthes, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slowe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Befort, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Meur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dollé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzavara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanoune, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span> <span> </span><span class="NLM_article-title">Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1038/383819a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2F383819a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=8893006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaK28Xms1Sjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=1996&pages=819-823&author=H.+W.+Matthesauthor=R.+Maldonadoauthor=F.+Simoninauthor=O.+Valverdeauthor=S.+Sloweauthor=I.+Kitchenauthor=K.+Befortauthor=A.+Dierichauthor=M.+Le+Meurauthor=P.+Doll%C3%A9author=E.+Tzavaraauthor=J.+Hanouneauthor=B.+P.+Roquesauthor=B.+L.+Kieffer&title=Loss+of+morphine-induced+analgesia%2C+reward+effect+and+withdrawal+symptoms+in+mice+lacking+the+mu-opioid-receptor+gene&doi=10.1038%2F383819a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene</span></div><div class="casAuthors">Matthes, Hans W. D.; Maldonado, Rafael; Simonin, Frederic; Valverde, Olga; Slowe, Susan; Kitchen, Ian; Befort, Katia; Dierich, Andree; Le Meur, Marianne; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">6603</span>),
    <span class="NLM_cas:pages">819-823</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable pain killer in contemporary medicine.  Opioids exert their pharmacol. actions through three opioid-receptor classes, μ, δ and κ, whose genes have been cloned.  Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo.  Here we disrupt the μ-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioral abnormalities or major compensatory changes within the opioid system in these animals.  Investigation of the behavioral effects of morphine reveals that a lack of μ receptors abolishes the analgesic effect of morphine, as well as place-preference activity and phys. dependence.  We obsd. no behavioral responses related to δ- or κ-receptor activation with morphine, although these receptors are present and bind opioid ligands.  We conclude that the μ-opioid-receptor gene product is the mol. target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkOHxWXClmHbVg90H21EOLACvtfcHk0ljV3un5tGTPIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xms1Sjtbw%253D&md5=f0db56cf496bf6ffbc291986e004993d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2F383819a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F383819a0%26sid%3Dliteratum%253Aachs%26aulast%3DMatthes%26aufirst%3DH.%2BW.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DSimonin%26aufirst%3DF.%26aulast%3DValverde%26aufirst%3DO.%26aulast%3DSlowe%26aufirst%3DS.%26aulast%3DKitchen%26aufirst%3DI.%26aulast%3DBefort%26aufirst%3DK.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLe%2BMeur%26aufirst%3DM.%26aulast%3DDoll%25C3%25A9%26aufirst%3DP.%26aulast%3DTzavara%26aufirst%3DE.%26aulast%3DHanoune%26aufirst%3DJ.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26atitle%3DLoss%2520of%2520morphine-induced%2520analgesia%252C%2520reward%2520effect%2520and%2520withdrawal%2520symptoms%2520in%2520mice%2520lacking%2520the%2520mu-opioid-receptor%2520gene%26jtitle%3DNature%26date%3D1996%26volume%3D383%26spage%3D819%26epage%3D823%26doi%3D10.1038%2F383819a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Maria Dichiara, Benedetto Amata, Rita Turnaturi, Agostino Marrazzo, <span class="NLM_string-name hlFld-ContribAuthor">Emanuele Amata</span>. </span><span class="cited-content_cbyCitation_article-title">Tuning Properties for Blood–Brain Barrier Permeation: A Statistics-Based Analysis. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 34-44. <a href="https://doi.org/10.1021/acschemneuro.9b00541" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00541%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DTuning%252BProperties%252Bfor%252BBlood%2525E2%252580%252593Brain%252BBarrier%252BPermeation%25253A%252BA%252BStatistics-Based%252BAnalysis%26aulast%3DDichiara%26aufirst%3DMaria%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07102019%26date%3D03122019%26date%3D18122019%26date%3D03122019%26volume%3D11%26issue%3D1%26spage%3D34%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abimael  González-Hernández</span>, <span class="hlFld-ContribAuthor ">Miguel  Condés-Lara</span>, <span class="hlFld-ContribAuthor ">Enrique  García-Boll</span>, <span class="hlFld-ContribAuthor ">Carlos M.  Villalón</span>. </span><span class="cited-content_cbyCitation_article-title">An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (2)
                                     , 179-199. <a href="https://doi.org/10.1080/17425255.2021.1856366" title="DOI URL">https://doi.org/10.1080/17425255.2021.1856366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1856366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1856366%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DAn%252Boutlook%252Bon%252Bthe%252Btrigeminovascular%252Bmechanisms%252Bof%252Baction%252Band%252Bside%252Beffects%252Bconcerns%252Bof%252Bsome%252Bpotential%252Bneuropeptidergic%252Bantimigraine%252Btherapies%26aulast%3DGonz%25C3%25A1lez-Hern%25C3%25A1ndez%26aufirst%3DAbimael%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D2%26spage%3D179%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louis  Hilfiger</span>, <span class="hlFld-ContribAuthor ">Qian  Zhao</span>, <span class="hlFld-ContribAuthor ">Damien  Kerspern</span>, <span class="hlFld-ContribAuthor ">Perrine  Inquimbert</span>, <span class="hlFld-ContribAuthor ">Virginie  Andry</span>, <span class="hlFld-ContribAuthor ">Yannick  Goumon</span>, <span class="hlFld-ContribAuthor ">Pascal  Darbon</span>, <span class="hlFld-ContribAuthor ">Marcel  Hibert</span>, <span class="hlFld-ContribAuthor ">Alexandre  Charlet</span>. </span><span class="cited-content_cbyCitation_article-title">A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-59929-w" title="DOI URL">https://doi.org/10.1038/s41598-020-59929-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-59929-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-59929-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252BNonpeptide%252BOxytocin%252BReceptor%252BAgonist%252Bfor%252Ba%252BDurable%252BRelief%252Bof%252BInflammatory%252BPain%26aulast%3DHilfiger%26aufirst%3DLouis%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linghua  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanshuang  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinying  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesen  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of pyrazolone fused benzodiazepines
              via
              Rh(
              iii
              )-catalyzed [4 + 3] annulation of 1-phenylpyrazolidinones with propargyl alcohols. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (16)
                                     , 2284-2290. <a href="https://doi.org/10.1039/D0QO00657B" title="DOI URL">https://doi.org/10.1039/D0QO00657B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO00657B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO00657B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DSynthesis%252Bof%252Bpyrazolone%252Bfused%252Bbenzodiazepines%252Bvia%252BRh%252528%252Biii%252B%252529-catalyzed%252B%25255B4%252B%25252B%252B3%25255D%252Bannulation%252Bof%252B1-phenylpyrazolidinones%252Bwith%252Bpropargyl%252Balcohols%26aulast%3DZhang%26aufirst%3DLinghua%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D16%26spage%3D2284%26epage%3D2290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryotaro  Hayashi</span>, <span class="hlFld-ContribAuthor ">Yoshiyuki  Kasahara</span>, <span class="hlFld-ContribAuthor ">Shizu  Hidema</span>, <span class="hlFld-ContribAuthor ">Satoshi  Fukumitsu</span>, <span class="hlFld-ContribAuthor ">Kiyotaka  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Katsuhiko  Nishimori</span>. </span><span class="cited-content_cbyCitation_article-title">Oxytocin Ameliorates Impaired Behaviors of High Fat Diet-Induced Obese Mice. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fendo.2020.00379" title="DOI URL">https://doi.org/10.3389/fendo.2020.00379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2020.00379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2020.00379%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DOxytocin%252BAmeliorates%252BImpaired%252BBehaviors%252Bof%252BHigh%252BFat%252BDiet-Induced%252BObese%252BMice%26aulast%3DHayashi%26aufirst%3DRyotaro%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Courtney E.  King</span>, <span class="hlFld-ContribAuthor ">Anny  Gano</span>, <span class="hlFld-ContribAuthor ">Howard C.  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">The role of oxytocin in alcohol and drug abuse. </span><span class="cited-content_cbyCitation_journal-name">Brain Research</span><span> <strong>2020,</strong> <em>1736 </em>, 146761. <a href="https://doi.org/10.1016/j.brainres.2020.146761" title="DOI URL">https://doi.org/10.1016/j.brainres.2020.146761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.brainres.2020.146761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.brainres.2020.146761%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%2520Research%26atitle%3DThe%252Brole%252Bof%252Boxytocin%252Bin%252Balcohol%252Band%252Bdrug%252Babuse%26aulast%3DKing%26aufirst%3DCourtney%2BE.%26date%3D2020%26volume%3D1736%26spage%3D146761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam G.  Meyer</span>, <span class="hlFld-ContribAuthor ">Alex C.  Bissember</span>, <span class="hlFld-ContribAuthor ">Christopher J.T.  Hyland</span>, <span class="hlFld-ContribAuthor ">Charlotte C.  Williams</span>, <span class="hlFld-ContribAuthor ">Monika  Szabo</span>, <span class="hlFld-ContribAuthor ">Melanie A.  Pearsall</span>, <span class="hlFld-ContribAuthor ">Isabel K.  Hyland</span>, <span class="hlFld-ContribAuthor ">Wesley J.  Olivier</span>. </span><span class="cited-content_cbyCitation_article-title">Seven-Membered Rings. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 597-647. <a href="https://doi.org/10.1016/B978-0-12-819962-6.00016-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-819962-6.00016-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819962-6.00016-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819962-6.00016-6%26sid%3Dliteratum%253Aachs%26atitle%3DSeven-Membered%252BRings%26aulast%3DMeyer%26aufirst%3DAdam%2BG.%26date%3D2020%26spage%3D597%26epage%3D647%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan J.  Danon</span>, <span class="hlFld-ContribAuthor ">Tristan A.  Reekie</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Central Nervous System Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Trends in Chemistry</span><span> <strong>2019,</strong> <em>1 </em>
                                    (6)
                                     , 612-624. <a href="https://doi.org/10.1016/j.trechm.2019.04.009" title="DOI URL">https://doi.org/10.1016/j.trechm.2019.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trechm.2019.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trechm.2019.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Chemistry%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCentral%252BNervous%252BSystem%252BDrug%252BDiscovery%26aulast%3DDanon%26aufirst%3DJonathan%2BJ.%26date%3D2019%26volume%3D1%26issue%3D6%26spage%3D612%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Damien  Gulliver</span>, <span class="hlFld-ContribAuthor ">Eryn  Werry</span>, <span class="hlFld-ContribAuthor ">Tristan A.  Reekie</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Katte</span>, <span class="hlFld-ContribAuthor ">William  Jorgensen</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Oxytocin System: New Pharmacotherapeutic Approaches. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2019,</strong> <em>40 </em>
                                    (1)
                                     , 22-37. <a href="https://doi.org/10.1016/j.tips.2018.11.001" title="DOI URL">https://doi.org/10.1016/j.tips.2018.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2018.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DTargeting%252Bthe%252BOxytocin%252BSystem%25253A%252BNew%252BPharmacotherapeutic%252BApproaches%26aulast%3DGulliver%26aufirst%3DDamien%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of the Acid Precursors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-methylpyrazole, K<sub>2</sub>CO<sub>3</sub>, NMP, 120 °C, 6 h, 21–41%; (ii) HCl/H<sub>2</sub>O, AcOH, reflux, 7 h, 96–98%; (iii) aryl bromide, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, MeCN, MW 140–150 °C, 15–20 min.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Unsubstituted Benzazepine <b>8</b> and Acid Coupling<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NH<sub>2</sub>OH·HCl, KOH, H<sub>2</sub>O, EtOH, 100 °C, 30 min, 92%, (ii) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 4 h, 73%, (iii) acyl chloride, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 4–20 h, (iv) <b>18</b>, H<sub>2</sub>, Pd/C, EtOH, AcOEt, 5 h, (v) <b>19</b>, MeI, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 6 h, (vi) <b>20</b>, MeI, AgClO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 2 h, (vii) <b>19</b>, Ac<sub>2</sub>O, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 4 h, (viii) (a) 2-phenylbenzoic acid, (COCl)<sub>2</sub>, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, 2 h; (b) <b>19</b>, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0–10 °C, 2 h.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Cyclic Amines Used<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, pyridine, 0 °C, 1 h, 98%; (ii) (a) NaH, Br(CH<sub>2</sub>)<sub>3</sub>COOEt, DMF, 14 h, rt, then 90 °C, 6 h, (b) NaH, MeOH/toluene 17 h, (c) AcOH, HCl, EtOH, H<sub>2</sub>O, 100 °C, 8 h, 62%; (iii) PPA, 110 °C, 2 h, quant; (iv) (a) MeNH<sub>2</sub>, MeOH, MW 130 °C, 8 min, (b) NaBH<sub>4</sub>, 1 h, 98%; (v) HCHO, NaBH<sub>3</sub>CN, AcOH, MeOH, 2 h, 90%; (vi) PPA, 120 °C, 2 h, quant; (vii) pyrrole-2-carboxaldehyde, NaH, DMF, 4 h, quant; (viii) H<sub>2</sub>, Pd/C, EtOH, 60 psi, 3 h, 70%; (ix) MeNHNH<sub>2</sub>, EtOH, reflux, 17 h, 92%; (x) NaH, 2-fluoronitrobenzene, THF, 48 h, 78%; (xi) H<sub>2</sub>, Pd/C, EtOH, AcOEt, 1 h, 99%; (xii) AcOH/<i>i</i>PrOH 1:9, 160 °C, 48 h, 89%; (xiii) LiAlH<sub>4</sub>, THF, reflux, 44 h, 86%.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Coupling of the Different Amines with Acids <b>3a</b> and <b>3b</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Proline Derivatives <b>45</b>–<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDCI, HOBt, Et<sub>3</sub>N, NMe<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, overnight; (ii) Lawesson reagent, toluene, overnight, 70 °C; (iii) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, v/v), 30 min.</p></p></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Fragments <b>52</b>–<b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDCI, HOBt, Et<sub>3</sub>N, NMe<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, overnight, 46%; (ii) Lawesson reagent, toluene, overnight, 70 °C, 63%; (iii) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1/1, 30 min), quant.</p></p></figure><figure data-id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>57</b>–<b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(i) (a) (COCl)<sub>2</sub>, DMF cat., CH<sub>2</sub>Cl<sub>2</sub>, 2 h, (b) Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, overnight; (ii) NaBH<sub>4</sub>, CoCl<sub>2</sub>.6H<sub>2</sub>O, MeOH, 1 h; (iii) (a) compounds <b>48</b>, <b>49</b>, or <b>52</b>–<b>54</b>, CDI, DIEA, DMF, overnight, 41–67%.</p></p></figure><figure data-id="fig1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0001.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Pharmacological profile of OTR agonists, oxytocin, compound <b>57</b>, carbetocin, and WAY-267464, on oxytocin and vasopressin receptors. Representative dose–responses from three to four experiments of oxytocin (red), compound <b>57</b> (orange), carbetocin (purple), and WAY-267464 (black) on OT (A,B), V<sub>1a</sub> (C,D), V<sub>1b</sub> (E,F), and V<sub>2</sub> (G,H) receptors are presented on the two major signaling pathways of these receptors, calcium release (A,C,E,G), and β-arrestin2 recruitment (B,D,F,H). Oxytocin appears as the most potent agonist on OTR to activate calcium release; carbetocin, WAY-267464, and compound <b>57</b> have similar affinities, with compound <b>57</b> showing the best maximal effect. Regarding β-arrestin recruitment, carbetocin acts as a partial agonist and WAY-267464 shows lower affinity compared to that measured for calcium release, suggesting a bias in its signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/medium/jm-2018-006978_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0002.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>57</b> restores social interaction in <i>Oprm1</i><sup><i>–/–</i></sup> mice. In the direct social interaction test, an acute administration of compound <b>57</b> (ip; 10 or 20 mg/kg) increases the number of nose contacts (NCs), the time spent in NC, duration of NC, and number of following episodes in <i>Oprm1</i><sup><i>–/–</i></sup> mice while it decreases the number of grooming episodes occurring after a social contact. Compound <b>57</b> at a moderate dose (10 mg/kg) fully restores these social parameters to <i>Oprm1</i><sup><i>+/+</i></sup> levels, whereas at a higher dose (20 mg/kg) this beneficial outcome is less significant and detrimental effects start to be observed in wild-type controls. Data are presented as mean ± SEM (<i>n</i> = 8 per genotype and treatment). Solid stars: comparison to vehicle-treated <i>Oprm1</i><sup><i>+/+</i></sup> mice. Asterisks: comparison to vehicle-treated animals of the same genotype (two-way ANOVA followed by Newman–Keules posthoc test). One symbo,: <i>p</i> < 0.05; two symbols, <i>p</i> < 0.01; three symbols, <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b00697/20181004/images/large/jm-2018-006978_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00697&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 92 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doernberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span> <span> </span><span class="NLM_article-title">Neurodevelopmental disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11</span>. <i>CNS Spectrums</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1017/S1092852916000262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1017%2FS1092852916000262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=295-299&author=E.+Doernbergauthor=E.+Hollander&title=Neurodevelopmental+disorders+%28ASD+and+ADHD%29%3A+DSM-5%2C+ICD-10%2C+and+ICD-11&doi=10.1017%2FS1092852916000262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1017%2FS1092852916000262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1092852916000262%26sid%3Dliteratum%253Aachs%26aulast%3DDoernberg%26aufirst%3DE.%26aulast%3DHollander%26aufirst%3DE.%26atitle%3DNeurodevelopmental%2520disorders%2520%2528ASD%2520and%2520ADHD%2529%253A%2520DSM-5%252C%2520ICD-10%252C%2520and%2520ICD-11%26jtitle%3DCNS%2520Spectrums%26date%3D2016%26volume%3D21%26spage%3D295%26epage%3D299%26doi%3D10.1017%2FS1092852916000262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Centers
for Disease Control and Prevention</span> <span> </span><span class="NLM_article-title">Prevalence of autism spectrum disorders—Autism
and developmental disabilities monitoring network, 14 sites, United
States, 2008</span>. <i>MMWR Surveill. Summ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1-19&author=Centers%0Afor+Disease+Control+and+Prevention&title=Prevalence+of+autism+spectrum+disorders%E2%80%94Autism%0Aand+developmental+disabilities+monitoring+network%2C+14+sites%2C+United%0AStates%2C+2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DPrevalence%2520of%2520autism%2520spectrum%2520disorders%25E2%2580%2594Autism%250Aand%2520developmental%2520disabilities%2520monitoring%2520network%252C%252014%2520sites%252C%2520United%250AStates%252C%25202008%26jtitle%3DMMWR%2520Surveill.%2520Summ.%26date%3D2012%26volume%3D61%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vorstman, J. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-De-Luca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anney, R. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurnberger, J. I.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallmayer, J. F.</span></span> <span> </span><span class="NLM_article-title">Autism genetics: opportunities and challenges for clinical translation</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1038/nrg.2017.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnrg.2017.4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28260791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=362-376&author=J.+A.+S.+Vorstmanauthor=J.+R.+Parrauthor=D.+Moreno-De-Lucaauthor=R.+J.+L.+Anneyauthor=J.+I.+Nurnbergerauthor=J.+F.+Hallmayer&title=Autism+genetics%3A+opportunities+and+challenges+for+clinical+translation&doi=10.1038%2Fnrg.2017.4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Autism genetics: opportunities and challenges for clinical translation</span></div><div class="casAuthors">Vorstman, Jacob A. S.; Parr, Jeremy R.; Moreno-De-Luca, Daniel; Anney, Richard J. L.; Nurnberger, John I., Jr.; Hallmayer, Joachim F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">362-376</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genetic studies have revealed the involvement of hundreds of gene variants in autism.  Their risk effects are highly variable, and they are frequently related to other conditions besides autism.  However, many different variants converge on common biol. pathways.  These findings indicate that etiol. heterogeneity, variable penetrance and genetic pleiotropy are pervasive characteristics of autism genetics.  Although this advancing insight should improve clin. care, at present there is a substantial discrepancy between research knowledge and its clin. application.  In this Review, we discuss the current challenges and opportunities for the translation of autism genetics knowledge into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEPKQYBSCnWbVg90H21EOLACvtfcHk0lhdPObw1Gk7QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlKns7o%253D&md5=f0ad0bb3fb96e5e9254115023806fe75</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrg.2017.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg.2017.4%26sid%3Dliteratum%253Aachs%26aulast%3DVorstman%26aufirst%3DJ.%2BA.%2BS.%26aulast%3DParr%26aufirst%3DJ.%2BR.%26aulast%3DMoreno-De-Luca%26aufirst%3DD.%26aulast%3DAnney%26aufirst%3DR.%2BJ.%2BL.%26aulast%3DNurnberger%26aufirst%3DJ.%2BI.%26aulast%3DHallmayer%26aufirst%3DJ.%2BF.%26atitle%3DAutism%2520genetics%253A%2520opportunities%2520and%2520challenges%2520for%2520clinical%2520translation%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2017%26volume%3D18%26spage%3D362%26epage%3D376%26doi%3D10.1038%2Fnrg.2017.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Torre-Ubieta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geschwind, D. H.</span></span> <span> </span><span class="NLM_article-title">Advancing the understanding of autism disease mechanisms through genetics</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nm.4071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnm.4071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27050589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1GjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=345-361&author=L.+de%0Ala+Torre-Ubietaauthor=H.+Wonauthor=J.+L.+Steinauthor=D.+H.+Geschwind&title=Advancing+the+understanding+of+autism+disease+mechanisms+through+genetics&doi=10.1038%2Fnm.4071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing the understanding of autism disease mechanisms through genetics</span></div><div class="casAuthors">de la Torre-Ubieta, Luis; Won, Hyejung; Stein, Jason L.; Geschwind, Daniel H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-361</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Progress in understanding the genetic etiol. of autism spectrum disorders (ASD) has fueled remarkable advances in our understanding of its potential neurobiol. mechanisms.  Yet, at the same time, these findings highlight extraordinary causal diversity and complexity at many levels ranging from mols. to circuits and emphasize the gaps in our current knowledge.  Here we review current understanding of the genetic architecture of ASD and integrate genetic evidence, neuropathol. and studies in model systems with how they inform mechanistic models of ASD pathophysiol.  Despite the challenges, these advances provide a solid foundation for the development of rational, targeted mol. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5JQSQA5DjbVg90H21EOLACvtfcHk0liRhzPg3TDekA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1GjsLY%253D&md5=6067f01b5e065abb392cf0538d489390</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.4071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4071%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BTorre-Ubieta%26aufirst%3DL.%26aulast%3DWon%26aufirst%3DH.%26aulast%3DStein%26aufirst%3DJ.%2BL.%26aulast%3DGeschwind%26aufirst%3DD.%2BH.%26atitle%3DAdvancing%2520the%2520understanding%2520of%2520autism%2520disease%2520mechanisms%2520through%2520genetics%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D345%26epage%3D361%26doi%3D10.1038%2Fnm.4071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theesfeld, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadych, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volfovsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lash, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyanskaya, O. G.</span></span> <span> </span><span class="NLM_article-title">Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1462</span>, <span class="refDoi"> DOI: 10.1038/nn.4353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnn.4353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27479844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=1454-1462&author=A.+Krishnanauthor=R.+Zhangauthor=V.+Yaoauthor=C.+L.+Theesfeldauthor=A.+K.+Wongauthor=A.+Tadychauthor=N.+Volfovskyauthor=A.+Packerauthor=A.+Lashauthor=O.+G.+Troyanskaya&title=Genome-wide+prediction+and+functional+characterization+of+the+genetic+basis+of+autism+spectrum+disorder&doi=10.1038%2Fnn.4353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder</span></div><div class="casAuthors">Krishnan, Arjun; Zhang, Ran; Yao, Victoria; Theesfeld, Chandra L.; Wong, Aaron K.; Tadych, Alicja; Volfovsky, Natalia; Packer, Alan; Lash, Alex; Troyanskaya, Olga G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1462</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic basis.  Yet, only a small fraction of potentially causal genes-about 65 genes out of an estd. several hundred-are known with strong genetic evidence from sequencing studies.  We developed a complementary machine-learning approach based on a human brain-specific gene network to present a genome-wide prediction of autism risk genes, including hundreds of candidates for which there is minimal or no prior genetic evidence.  Our approach was validated in a large independent case-control sequencing study.  Leveraging these genome-wide predictions and the brain-specific network, we demonstrated that the large set of ASD genes converges on a smaller no. of key pathways and developmental stages of the brain.  Finally, we identified likely pathogenic genes within frequent autism-assocd. copy-no. variants and proposed genes and pathways that are likely mediators of ASD across multiple copy-no. variants.  All predictions and functional insights are available at http://asd.princeton.edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Vs0FEdOWrrVg90H21EOLACvtfcHk0liRhzPg3TDekA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu73N&md5=3eb90af28009147f808ec3a14b270579</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnn.4353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4353%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DV.%26aulast%3DTheesfeld%26aufirst%3DC.%2BL.%26aulast%3DWong%26aufirst%3DA.%2BK.%26aulast%3DTadych%26aufirst%3DA.%26aulast%3DVolfovsky%26aufirst%3DN.%26aulast%3DPacker%26aufirst%3DA.%26aulast%3DLash%26aufirst%3DA.%26aulast%3DTroyanskaya%26aufirst%3DO.%2BG.%26atitle%3DGenome-wide%2520prediction%2520and%2520functional%2520characterization%2520of%2520the%2520genetic%2520basis%2520of%2520autism%2520spectrum%2520disorder%26jtitle%3DNat.%2520Neurosci.%26date%3D2016%26volume%3D19%26spage%3D1454%26epage%3D1462%26doi%3D10.1038%2Fnn.4353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazdoba, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawley, J. N.</span></span> <span> </span><span class="NLM_article-title">Translational mouse models of autism: advancing toward pharmacological therapeutics</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/7854_2015_5003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2F7854_2015_5003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=1-52&author=T.+M.+Kazdobaauthor=P.+T.+Leachauthor=M.+Yangauthor=J.+L.+Silvermanauthor=M.+Solomonauthor=J.+N.+Crawley&title=Translational+mouse+models+of+autism%3A+advancing+toward+pharmacological+therapeutics&doi=10.1007%2F7854_2015_5003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2F7854_2015_5003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2015_5003%26sid%3Dliteratum%253Aachs%26aulast%3DKazdoba%26aufirst%3DT.%2BM.%26aulast%3DLeach%26aufirst%3DP.%2BT.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSilverman%26aufirst%3DJ.%2BL.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DCrawley%26aufirst%3DJ.%2BN.%26atitle%3DTranslational%2520mouse%2520models%2520of%2520autism%253A%2520advancing%2520toward%2520pharmacological%2520therapeutics%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2015%26volume%3D28%26spage%3D1%26epage%3D52%26doi%3D10.1007%2F7854_2015_5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilby, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill-Yardin, E. L.</span></span> <span> </span><span class="NLM_article-title">Studying autism in rodent models: reconciling endophenotypes with comorbidities</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2013.00417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffnhum.2013.00417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23898259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sfltFegtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=417&author=A.+Argyropoulosauthor=K.+L.+Gilbyauthor=E.+L.+Hill-Yardin&title=Studying+autism+in+rodent+models%3A+reconciling+endophenotypes+with+comorbidities&doi=10.3389%2Ffnhum.2013.00417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Studying autism in rodent models: reconciling endophenotypes with comorbidities</span></div><div class="casAuthors">Argyropoulos Andrew; Gilby Krista L; Hill-Yardin Elisa L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in human neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417</span>
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    </div><div class="casAbstract">Autism spectrum disorder (ASD) patients commonly exhibit a variety of comorbid traits including seizures, anxiety, aggressive behavior, gastrointestinal problems, motor deficits, abnormal sensory processing, and sleep disturbances for which the cause is unknown.  These features impact negatively on daily life and can exaggerate the effects of the core diagnostic traits (social communication deficits and repetitive behaviors).  Studying endophenotypes relevant to both core and comorbid features of ASD in rodent models can provide insight into biological mechanisms underlying these disorders.  Here we review the characterization of endophenotypes in a selection of environmental, genetic, and behavioral rodent models of ASD.  In addition to exhibiting core ASD-like behaviors, each of these animal models display one or more endophenotypes relevant to comorbid features including altered sensory processing, seizure susceptibility, anxiety-like behavior, and disturbed motor functions, suggesting that these traits are indicators of altered biological pathways in ASD.  However, the study of behaviors paralleling comorbid traits in animal models of ASD is an emerging field and further research is needed to assess altered gastrointestinal function, aggression, and disorders of sleep onset across models.  Future studies should include investigation of these endophenotypes in order to advance our understanding of the etiology of this complex disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpzURl5Nx3ae3MPKNEWB5RfW6udTcc2eaY-s-RSE4lCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfltFegtQ%253D%253D&md5=1d799c78d39ad524b9064584a79af0da</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2013.00417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2013.00417%26sid%3Dliteratum%253Aachs%26aulast%3DArgyropoulos%26aufirst%3DA.%26aulast%3DGilby%26aufirst%3DK.%2BL.%26aulast%3DHill-Yardin%26aufirst%3DE.%2BL.%26atitle%3DStudying%2520autism%2520in%2520rodent%2520models%253A%2520reconciling%2520endophenotypes%2520with%2520comorbidities%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D417%26doi%3D10.3389%2Ffnhum.2013.00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leigh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States</span>. <i>J. Autism Dev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4139</span>, <span class="refDoi"> DOI: 10.1007/s10803-015-2521-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2Fs10803-015-2521-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26183723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjvVartQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=4135-4139&author=J.+P.+Leighauthor=J.+Du&title=Brief+report%3A+forecasting+the+economic+burden+of+autism+in+2015+and+2025+in+the+United+States&doi=10.1007%2Fs10803-015-2521-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Brief Report: Forecasting the Economic Burden of Autism in 2015 and 2025 in the United States</span></div><div class="casAuthors">Leigh J Paul; Du Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autism and developmental disorders</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4135-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Few US estimates of the economic burden of autism spectrum disorders (ASD) are available and none provide estimates for 2015 and 2025.  We forecast annual direct medical, direct non-medical, and productivity costs combined will be $268 billion (range $162-$367 billion; 0.884-2.009 % of GDP) for 2015 and $461 billion (range $276-$1011 billion; 0.982-3.600 % of GDP) for 2025.  These 2015 figures are on a par with recent estimates for diabetes and attention deficit and hyperactivity disorder (ADHD) and exceed the costs of stroke and hypertension.  If the prevalence of ASD continues to grow as it has in recent years, ASD costs will likely far exceed those of diabetes and ADHD by 2025.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGTB-qgTKfBfEeosoOnpOLfW6udTcc2eamaNWB_b9ir7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjvVartQ%253D%253D&md5=947e6ac2f8d4203b58031f258216cf4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs10803-015-2521-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10803-015-2521-7%26sid%3Dliteratum%253Aachs%26aulast%3DLeigh%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%26atitle%3DBrief%2520report%253A%2520forecasting%2520the%2520economic%2520burden%2520of%2520autism%2520in%25202015%2520and%25202025%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Autism%2520Dev.%2520Disord.%26date%3D2015%26volume%3D45%26spage%3D4135%26epage%3D4139%26doi%3D10.1007%2Fs10803-015-2521-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacquemont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">des Portes, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrioli, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry-Kravis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornish, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadjikhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delange, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilse, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floesser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Mancilla, B.</span></span> <span> </span><span class="NLM_article-title">Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">64ra1</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3001708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscitranslmed.3001708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=21209411" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=64ra1&author=S.+Jacquemontauthor=A.+Curieauthor=V.+des+Portesauthor=M.+G.+Torrioliauthor=E.+Berry-Kravisauthor=R.+J.+Hagermanauthor=F.+J.+Ramosauthor=K.+Cornishauthor=Y.+Heauthor=C.+Pauldingauthor=G.+Neriauthor=F.+Chenauthor=N.+Hadjikhaniauthor=D.+Martinetauthor=J.+Meyerauthor=J.+S.+Beckmannauthor=K.+Delangeauthor=A.+Brunauthor=G.+Bussyauthor=F.+Gaspariniauthor=T.+Hilseauthor=A.+Floesserauthor=J.+Bransonauthor=G.+Bilbeauthor=D.+Johnsauthor=B.+Gomez-Mancilla&title=Epigenetic+modification+of+the+FMR1+gene+in+fragile+X+syndrome+is+associated+with+differential+response+to+the+mGluR5+antagonist+AFQ056&doi=10.1126%2Fscitranslmed.3001708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001708%26sid%3Dliteratum%253Aachs%26aulast%3DJacquemont%26aufirst%3DS.%26aulast%3DCurie%26aufirst%3DA.%26aulast%3Ddes%2BPortes%26aufirst%3DV.%26aulast%3DTorrioli%26aufirst%3DM.%2BG.%26aulast%3DBerry-Kravis%26aufirst%3DE.%26aulast%3DHagerman%26aufirst%3DR.%2BJ.%26aulast%3DRamos%26aufirst%3DF.%2BJ.%26aulast%3DCornish%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DPaulding%26aufirst%3DC.%26aulast%3DNeri%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHadjikhani%26aufirst%3DN.%26aulast%3DMartinet%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DBeckmann%26aufirst%3DJ.%2BS.%26aulast%3DDelange%26aufirst%3DK.%26aulast%3DBrun%26aufirst%3DA.%26aulast%3DBussy%26aufirst%3DG.%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DHilse%26aufirst%3DT.%26aulast%3DFloesser%26aufirst%3DA.%26aulast%3DBranson%26aufirst%3DJ.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DJohns%26aufirst%3DD.%26aulast%3DGomez-Mancilla%26aufirst%3DB.%26atitle%3DEpigenetic%2520modification%2520of%2520the%2520FMR1%2520gene%2520in%2520fragile%2520X%2520syndrome%2520is%2520associated%2520with%2520differential%2520response%2520to%2520the%2520mGluR5%2520antagonist%2520AFQ056%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D64ra1%26doi%3D10.1126%2Fscitranslmed.3001708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. E.</span></span> <span> </span><span class="NLM_article-title">Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder</span>. <i>Drug, Healthcare Patient Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.2147/DHPS.S39595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.2147%2FDHPS.S39595" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=69-76&author=R.+E.+Frye&title=Clinical+potential%2C+safety%2C+and+tolerability+of+arbaclofen+in+the+treatment+of+autism+spectrum+disorder&doi=10.2147%2FDHPS.S39595"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FDHPS.S39595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDHPS.S39595%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DR.%2BE.%26atitle%3DClinical%2520potential%252C%2520safety%252C%2520and%2520tolerability%2520of%2520arbaclofen%2520in%2520the%2520treatment%2520of%2520autism%2520spectrum%2520disorder%26jtitle%3DDrug%252C%2520Healthcare%2520Patient%2520Saf.%26date%3D2014%26volume%3D10%26spage%3D69%26epage%3D76%26doi%3D10.2147%2FDHPS.S39595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemonnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeneuve, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosset, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viellard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thummler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Y.</span></span> <span> </span><span class="NLM_article-title">Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1056</span>, <span class="refDoi"> DOI: 10.1038/tp.2017.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2017.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28291262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e1056&author=E.+Lemonnierauthor=N.+Villeneuveauthor=S.+Sonieauthor=S.+Serretauthor=A.+Rosierauthor=M.+Roueauthor=P.+Brossetauthor=M.+Viellardauthor=D.+Bernouxauthor=S.+Rondeauauthor=S.+Thummlerauthor=D.+Ravelauthor=Y.+Ben-Ari&title=Effects+of+bumetanide+on+neurobehavioral+function+in+children+and+adolescents+with+autism+spectrum+disorders&doi=10.1038%2Ftp.2017.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders</span></div><div class="casAuthors">Lemonnier, E.; Villeneuve, N.; Sonie, S.; Serret, S.; Rosier, A.; Roue, M.; Brosset, P.; Viellard, M.; Bernoux, D.; Rondeau, S.; Thummler, S.; Ravel, D.; Ben-Ari, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1056</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In animal models of autism spectrum disorder (ASD), the NKCC1 chloride-importer inhibitor bumetanide restores physiol. (Cl-)i levels, enhances GABAergic inhibition and attenuates elec. and behavioral symptoms of ASD.  In an earlier phase 2 trial; bumetanide reduced the severity of ASD in children and adolescents (3-11 years old).  Here we report the results of a multicenter phase 2B study primarily to assess dose/response and safety effects of bumetanide.  Efficacy outcome measures included the Childhood Autism Rating Scale (CARS), the Social Responsive Scale (SRS) and the Clin. Global Impressions (CGI) Improvement scale (CGI-I).  Eighty-eight patients with ASD spanning across the entire pediatric population (2-18 years old) were subdivided in four age groups and randomized to receive bumetanide (0.5, 1.0 or 2.0 mg twice daily) or placebo for 3 mo.  The mean CARS value was significantly improved in the completers group (P: 0.015).  Also, 23 treated children had more than a six-point improvement in the CARS compared with only one placebo-treated individual.  Bumetanide significantly improved CGI (P: 0.0043) and the SRS score by more than 10 points (P: 0.02).  The most frequent adverse events were hypokalemia, increased urine elimination, loss of appetite, dehydration and asthenia.  Hypokalemia occurred mainly at the beginning of the treatment at 1.0 and 2.0 mg twice-daily doses and improved gradually with oral potassium supplements.  The frequency and incidence of adverse event were directly correlated with the dose of bumetanide.  Therefore, bumetanide improves the core symptoms of ASD and presents a favorable benefit/risk ratio particularly at 1.0 mg twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2IjlM6ANm4bVg90H21EOLACvtfcHk0lj3qqhRAacZCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSnsL0%253D&md5=4745991a7af97307e2562b916afa90bf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Ftp.2017.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2017.10%26sid%3Dliteratum%253Aachs%26aulast%3DLemonnier%26aufirst%3DE.%26aulast%3DVilleneuve%26aufirst%3DN.%26aulast%3DSonie%26aufirst%3DS.%26aulast%3DSerret%26aufirst%3DS.%26aulast%3DRosier%26aufirst%3DA.%26aulast%3DRoue%26aufirst%3DM.%26aulast%3DBrosset%26aufirst%3DP.%26aulast%3DViellard%26aufirst%3DM.%26aulast%3DBernoux%26aufirst%3DD.%26aulast%3DRondeau%26aufirst%3DS.%26aulast%3DThummler%26aufirst%3DS.%26aulast%3DRavel%26aufirst%3DD.%26aulast%3DBen-Ari%26aufirst%3DY.%26atitle%3DEffects%2520of%2520bumetanide%2520on%2520neurobehavioral%2520function%2520in%2520children%2520and%2520adolescents%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DTransl.%2520Psychiatry%26date%3D2017%26volume%3D7%26spage%3De1056%26doi%3D10.1038%2Ftp.2017.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyzio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsintsadze, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahrokhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalilov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsintsadze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouchoud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemonnier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozovaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Ari, Y.</span></span> <span> </span><span class="NLM_article-title">Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">675</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1126/science.1247190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1247190" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=675-679&author=R.+Tyzioauthor=R.+Nardouauthor=D.+C.+Ferrariauthor=T.+Tsintsadzeauthor=A.+Shahrokhiauthor=S.+Eftekhariauthor=I.+Khalilovauthor=V.+Tsintsadzeauthor=C.+Brouchoudauthor=G.+Chazalauthor=E.+Lemonnierauthor=N.+Lozovayaauthor=N.+Burnashevauthor=Y.+Ben-Ari&title=Oxytocin-mediated+GABA+inhibition+during+delivery+attenuates+autism+pathogenesis+in+rodent+offspring&doi=10.1126%2Fscience.1247190"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.1247190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1247190%26sid%3Dliteratum%253Aachs%26aulast%3DTyzio%26aufirst%3DR.%26aulast%3DNardou%26aufirst%3DR.%26aulast%3DFerrari%26aufirst%3DD.%2BC.%26aulast%3DTsintsadze%26aufirst%3DT.%26aulast%3DShahrokhi%26aufirst%3DA.%26aulast%3DEftekhari%26aufirst%3DS.%26aulast%3DKhalilov%26aufirst%3DI.%26aulast%3DTsintsadze%26aufirst%3DV.%26aulast%3DBrouchoud%26aufirst%3DC.%26aulast%3DChazal%26aufirst%3DG.%26aulast%3DLemonnier%26aufirst%3DE.%26aulast%3DLozovaya%26aufirst%3DN.%26aulast%3DBurnashev%26aufirst%3DN.%26aulast%3DBen-Ari%26aufirst%3DY.%26atitle%3DOxytocin-mediated%2520GABA%2520inhibition%2520during%2520delivery%2520attenuates%2520autism%2520pathogenesis%2520in%2520rodent%2520offspring%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D675%26epage%3D679%26doi%3D10.1126%2Fscience.1247190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanratty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCaria, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronowitz, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosovich, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1300021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.npp.1300021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=193-198&author=E.+Hollanderauthor=S.+Novotnyauthor=M.+Hanrattyauthor=R.+Yaffeauthor=C.+M.+DeCariaauthor=B.+R.+Aronowitzauthor=S.+Mosovich&title=Oxytocin+infusion+reduces+repetitive+behaviors+in+adults+with+autistic+and+Asperger%E2%80%99s+disorders&doi=10.1038%2Fsj.npp.1300021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300021%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DNovotny%26aufirst%3DS.%26aulast%3DHanratty%26aufirst%3DM.%26aulast%3DYaffe%26aufirst%3DR.%26aulast%3DDeCaria%26aufirst%3DC.%2BM.%26aulast%3DAronowitz%26aufirst%3DB.%2BR.%26aulast%3DMosovich%26aufirst%3DS.%26atitle%3DOxytocin%2520infusion%2520reduces%2520repetitive%2520behaviors%2520in%2520adults%2520with%2520autistic%2520and%2520Asperger%25E2%2580%2599s%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D193%26epage%3D198%26doi%3D10.1038%2Fsj.npp.1300021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soorya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin increases retention of social cognition in autism</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2006.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16904652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2007&pages=498-550&author=E.+Hollanderauthor=J.+Bartzauthor=W.+Chaplinauthor=A.+Phillipsauthor=J.+Sumnerauthor=L.+Sooryaauthor=E.+Anagnostouauthor=S.+Wasserman&title=Oxytocin+increases+retention+of+social+cognition+in+autism&doi=10.1016%2Fj.biopsych.2006.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin Increases Retention of Social Cognition in Autism</span></div><div class="casAuthors">Hollander, Eric; Bartz, Jennifer; Chaplin, William; Phillips, Ann; Sumner, Jennifer; Soorya, Latha; Anagnostou, Evdokia; Wasserman, Stacey</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-503</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Oxytocin dysfunction might contribute to the development of social deficits in autism, a core symptom domain and potential target for intervention.  This study explored the effect of i.v. oxytocin administration on the retention of social information in autism.  Methods: Oxytocin and placebo challenges were administered to 15 adult subjects diagnosed with autism or Asperger's disorder, and comprehension of affective speech (happy, indifferent, angry, and sad) in neutral content sentences was tested.  Results: All subjects showed improvements in affective speech comprehension from pre- to post-infusion; however, whereas those who received placebo first tended to revert to baseline after a delay, those who received oxytocin first retained the ability to accurately assign emotional significance to speech intonation on the speech comprehension task.  Conclusions: These results are consistent with studies linking oxytocin to social recognition in rodents as well as studies linking oxytocin to prosocial behavior in humans and suggest that oxytocin might facilitate social information processing in those with autism.  These findings also provide preliminary support for the use of oxytocin in the treatment of autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreES3yFX-HhbVg90H21EOLACvtfcHk0lgS-_NT6qAi4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjurk%253D&md5=e6276eeae44187f43175e253393f141a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DBartz%26aufirst%3DJ.%26aulast%3DChaplin%26aufirst%3DW.%26aulast%3DPhillips%26aufirst%3DA.%26aulast%3DSumner%26aufirst%3DJ.%26aulast%3DSoorya%26aufirst%3DL.%26aulast%3DAnagnostou%26aufirst%3DE.%26aulast%3DWasserman%26aufirst%3DS.%26atitle%3DOxytocin%2520increases%2520retention%2520of%2520social%2520cognition%2520in%2520autism%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D61%26spage%3D498%26epage%3D550%26doi%3D10.1016%2Fj.biopsych.2006.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhamel, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbrecht, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirigu, A.</span></span> <span> </span><span class="NLM_article-title">Promoting social behavior with oxytocin in high-functioning autism spectrum disorders</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4389</span>– <span class="NLM_lpage">4394</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910249107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1073%2Fpnas.0910249107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4389-4394&author=E.+Andariauthor=J.+R.+Duhamelauthor=T.+Zallaauthor=E.+Herbrechtauthor=M.+Leboyerauthor=A.+Sirigu&title=Promoting+social+behavior+with+oxytocin+in+high-functioning+autism+spectrum+disorders&doi=10.1073%2Fpnas.0910249107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910249107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910249107%26sid%3Dliteratum%253Aachs%26aulast%3DAndari%26aufirst%3DE.%26aulast%3DDuhamel%26aufirst%3DJ.%2BR.%26aulast%3DZalla%26aufirst%3DT.%26aulast%3DHerbrecht%26aufirst%3DE.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DSirigu%26aufirst%3DA.%26atitle%3DPromoting%2520social%2520behavior%2520with%2520oxytocin%2520in%2520high-functioning%2520autism%2520spectrum%2520disorders%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0910249107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einfeld, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span> <span> </span><span class="NLM_article-title">Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.09.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2009.09.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=19897177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1akur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=692-694&author=A.+J.+Guastellaauthor=S.+L.+Einfeldauthor=K.+M.+Grayauthor=N.+J.+Rinehartauthor=B.+J.+Tongeauthor=T.+J.+Lambertauthor=I.+B.+Hickie&title=Intranasal+oxytocin+improves+emotion+recognition+for+youth+with+autism+spectrum+disorders&doi=10.1016%2Fj.biopsych.2009.09.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders</span></div><div class="casAuthors">Guastella, Adam J.; Einfeld, Stewart L.; Gray, Kylie M.; Rinehart, Nicole J.; Tonge, Bruce J.; Lambert, Timothy J.; Hickie, Ian B.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">692-694</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: A diagnostic hallmark of autism spectrum disorders is a qual. impairment in social communication and interaction.  Deficits in the ability to recognize the emotions of others are believed to contribute to this.  There is currently no effective treatment for these problems.  Methods: In a double-blind, randomized, placebo-controlled, crossover design, we administered oxytocin nasal spray (18 or 24 IU) or a placebo to 16 male youth aged 12 to 19 who were diagnosed with Autistic or Asperger's Disorder.  Participants then completed the Reading the Mind in the Eyes Task, a widely used and reliable test of emotion recognition.  Results: In comparison with placebo, oxytocin administration improved performance on the Reading the Mind in the Eyes Task.  This effect was also shown when anal. was restricted to the younger participants aged 12 to 15 who received the lower dose.  Conclusions: This study provides the first evidence that oxytocin nasal spray improves emotion recognition in young people diagnosed with autism spectrum disorders.  Findings suggest the potential of earlier intervention and further evaluation of oxytocin nasal spray as a treatment to improve social communication and interaction in young people with autism spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoMPTv7Z_o7Vg90H21EOLACvtfcHk0lhyqqxKzQmRng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1akur0%253D&md5=450f9d9fb6fffb0b4716e777828bc306</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.09.020%26sid%3Dliteratum%253Aachs%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26aulast%3DEinfeld%26aufirst%3DS.%2BL.%26aulast%3DGray%26aufirst%3DK.%2BM.%26aulast%3DRinehart%26aufirst%3DN.%2BJ.%26aulast%3DTonge%26aufirst%3DB.%2BJ.%26aulast%3DLambert%26aufirst%3DT.%2BJ.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26atitle%3DIntranasal%2520oxytocin%2520improves%2520emotion%2520recognition%2520for%2520youth%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2010%26volume%3D67%26spage%3D692%26epage%3D694%26doi%3D10.1016%2Fj.biopsych.2009.09.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munesue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishitobi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span> <span> </span><span class="NLM_article-title">Long-term oxytocin administration improves social behaviors in a girl with autistic disorder</span>. <i>BMC Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">110</span>, <span class="refDoi"> DOI: 10.1186/1471-244X-12-110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1186%2F1471-244X-12-110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=110&author=H.+Kosakaauthor=T.+Munesueauthor=M.+Ishitobiauthor=M.+Asanoauthor=M.+Omoriauthor=M.+Satoauthor=A.+Tomodaauthor=Y.+Wada&title=Long-term+oxytocin+administration+improves+social+behaviors+in+a+girl+with+autistic+disorder&doi=10.1186%2F1471-244X-12-110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2F1471-244X-12-110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-244X-12-110%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DH.%26aulast%3DMunesue%26aufirst%3DT.%26aulast%3DIshitobi%26aufirst%3DM.%26aulast%3DAsano%26aufirst%3DM.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DTomoda%26aufirst%3DA.%26aulast%3DWada%26aufirst%3DY.%26atitle%3DLong-term%2520oxytocin%2520administration%2520improves%2520social%2520behaviors%2520in%2520a%2520girl%2520with%2520autistic%2520disorder%26jtitle%3DBMC%2520Psychiatry%26date%3D2012%26volume%3D12%26spage%3D110%26doi%3D10.1186%2F1471-244X-12-110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soorya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span> <span> </span><span class="NLM_article-title">Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1580</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2014.01.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.brainres.2014.01.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=24508578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFCkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1580&publication_year=2014&pages=188-198&author=E.+Anagnostouauthor=L.+Sooryaauthor=J.+Brianauthor=A.+Dupuisauthor=D.+Mankadauthor=S.+Smileauthor=S.+Jacob&title=Intranasal+oxytocin+in+the+treatment+of+autism+spectrum+disorders%3A+a+review+of+literature+and+early+safety+and+efficacy+data+in+youth&doi=10.1016%2Fj.brainres.2014.01.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal oxytocin in the treatment of autism spectrum disorders: A review of literature and early safety and efficacy data in youth</span></div><div class="casAuthors">Anagnostou, Evdokia; Soorya, Latha; Brian, Jessica; Dupuis, Annie; Mankad, Deepali; Smile, Sharon; Jacob, Suma</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1580</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">188-198</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  There is a paucity of treatments targeting core symptom domains in Autism Spectrum Disorder (ASD).  Several animal models and research in typically developing volunteers suggests that manipulation of the oxytocin system may have therapeutic potential for the treatment of social deficits.  We review the literature for oxytocin and ASD and report on early dosing, safety and efficacy data of multi-dose oxytocin on aspects of social cognition/function, as well as repetitive behaviors and co-occurring anxiety within ASD.  Methods: Fifteen children and adolescents with verbal IQs≥70 were diagnosed with ASD using the ADOS and the ADI-R.  They participated in a modified max. tolerated dose study of intranasal oxytocin (Syntocinon).  Data were modeled using repeated measures regression anal. controlling for week, dose, age, and sex.  Results: Among 4 doses tested, the highest dose evaluated, 0.4 IU/kg/dose, was found to be well tolerated.  No serious or severe adverse events were reported and adverse events reported/obsd. were mild to moderate.  Over 12 wk of treatment, several measures of social cognition/function, repetitive behaviors and anxiety showed sensitivity to change with some measures suggesting maintenance of effect 3 mo past discontinuation of intranasal oxytocin.  Conclusions: This pilot study suggests that daily administration of intranasal oxytocin at 0.4 IU/kg/dose in children and adolescents with ASD is safe and has therapeutic potential.  Larger studies are warranted.This article is part of a Special Issue entitled Oxytocin and Social Behav.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpknvrr6ILrZbVg90H21EOLACvtfcHk0lhyqqxKzQmRng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFCkur4%253D&md5=cc7fbed811b4f4b58bae6fca09475ad9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2014.01.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2014.01.049%26sid%3Dliteratum%253Aachs%26aulast%3DAnagnostou%26aufirst%3DE.%26aulast%3DSoorya%26aufirst%3DL.%26aulast%3DBrian%26aufirst%3DJ.%26aulast%3DDupuis%26aufirst%3DA.%26aulast%3DMankad%26aufirst%3DD.%26aulast%3DSmile%26aufirst%3DS.%26aulast%3DJacob%26aufirst%3DS.%26atitle%3DIntranasal%2520oxytocin%2520in%2520the%2520treatment%2520of%2520autism%2520spectrum%2520disorders%253A%2520a%2520review%2520of%2520literature%2520and%2520early%2520safety%2520and%2520efficacy%2520data%2520in%2520youth%26jtitle%3DBrain%2520Res.%26date%3D2014%26volume%3D1580%26spage%3D188%26epage%3D198%26doi%3D10.1016%2Fj.brainres.2014.01.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagitani-Shimono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanefuji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniike, M.</span></span> <span> </span><span class="NLM_article-title">Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders</span>. <i>J. Child Adolesc. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1089/cap.2012.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1089%2Fcap.2012.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23480321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=123-127&author=M.+Tachibanaauthor=K.+Kagitani-Shimonoauthor=I.+Mohriauthor=T.+Yamamotoauthor=W.+Sanefujiauthor=A.+Nakamuraauthor=M.+Oishiauthor=T.+Kimuraauthor=T.+Onakaauthor=K.+Ozonoauthor=M.+Taniike&title=Long-term+administration+of+intranasal+oxytocin+is+a+safe+and+promising+therapy+for+early+adolescent+boys+with+autism+spectrum+disorders&doi=10.1089%2Fcap.2012.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Administration of Intranasal Oxytocin Is a Safe and Promising Therapy for Early Adolescent Boys with Autism Spectrum Disorders</span></div><div class="casAuthors">Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Nakamura, Ayumi; Oishi, Masako; Kimura, Tadashi; Onaka, Tatsushi; Ozono, Keiichi; Taniike, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Child and Adolescent Psychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-127</span>CODEN:
                <span class="NLM_cas:coden">JADPET</span>;
        ISSN:<span class="NLM_cas:issn">1044-5463</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated.  However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified.  Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10-14 years of age; intelligence quotient [IQ] 20-101).  The OT administration was performed in a stepwise increased dosage manner every 2 mo (8, 16, 24 IU/dose).  A placebo period (1-2 wk) was inserted before each step.  The outcome measures were Autism Diagnostic Observation Schedule - Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC).  In addn., side effects were monitored by measuring blood pressure and examg. urine and blood samples.  Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G.  However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement.  Caregivers of five of the eight participants reported certain pos. effects of the OT therapy, esp. on the quality of reciprocal communication.  All participants showed excellent compliance and no side effects.  Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD.  Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1W2Z4_SZIxbVg90H21EOLACvtfcHk0lh21inRxhFXUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D&md5=8b84a3857e1b54023f3b4d181b1e2f37</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1089%2Fcap.2012.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcap.2012.0048%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DKagitani-Shimono%26aufirst%3DK.%26aulast%3DMohri%26aufirst%3DI.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSanefuji%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DOishi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOnaka%26aufirst%3DT.%26aulast%3DOzono%26aufirst%3DK.%26aulast%3DTaniike%26aufirst%3DM.%26atitle%3DLong-term%2520administration%2520of%2520intranasal%2520oxytocin%2520is%2520a%2520safe%2520and%2520promising%2520therapy%2520for%2520early%2520adolescent%2520boys%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DJ.%2520Child%2520Adolesc.%2520Psychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D123%26epage%3D127%26doi%3D10.1089%2Fcap.2012.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dadds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, J.</span></span> <span> </span><span class="NLM_article-title">Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial</span>. <i>J. Autism Dev. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1007/s10803-013-1899-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2Fs10803-013-1899-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23888359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sfktFyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2014&pages=521-531&author=M.+R.+Daddsauthor=E.+Macdonaldauthor=A.+Cauchiauthor=K.+Williamsauthor=F.+Levyauthor=J.+Brennan&title=Nasal+oxytocin+for+social+deficits+in+childhood+autism%3A+a+randomized+controlled+trial&doi=10.1007%2Fs10803-013-1899-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial</span></div><div class="casAuthors">Dadds Mark R; MacDonald Elayne; Cauchi Avril; Williams Katrina; Levy Florence; Brennan John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of autism and developmental disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The last two decades have witnessed a surge in research investigating the application of oxytocin as a method of enhancing social behaviour in humans.  Preliminary evidence suggests oxytocin may have potential as an intervention for autism.  We evaluated a 5-day 'live-in' intervention using a double-blind randomized control trial. 38 male youths (7-16 years old) with autism spectrum disorders were administered 24 or 12 international units (depending on weight) intranasal placebo or oxytocin once daily over four consecutive days.  The oxytocin or placebo was administered during parent-child interaction training sessions.  Parent and child behaviours were assessed using parent reports, clinician ratings, and independent observations, at multiple time points to measure side-effects; social interaction skills; repetitive behaviours; emotion recognition and diagnostic status.  Compared to placebo, intranasal oxytocin did not significantly improve emotion recognition, social interaction skills, or general behavioral adjustment in male youths with autism spectrum disorders.  The results show that the benefits of nasal oxytocin for young individuals with autism spectrum disorders may be more circumscribed than suggested by previous studies, and suggest caution in recommending it as an intervention that is broadly effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCr6Wb1tqsnNy3lHz94U-GfW6udTcc2eZgcVn47kSpN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfktFyntQ%253D%253D&md5=dd8a1a7c59e80f2dd8d04f52e522d6ab</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs10803-013-1899-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10803-013-1899-3%26sid%3Dliteratum%253Aachs%26aulast%3DDadds%26aufirst%3DM.%2BR.%26aulast%3DMacdonald%26aufirst%3DE.%26aulast%3DCauchi%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DF.%26aulast%3DBrennan%26aufirst%3DJ.%26atitle%3DNasal%2520oxytocin%2520for%2520social%2520deficits%2520in%2520childhood%2520autism%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Autism%2520Dev.%2520Disord.%26date%3D2014%26volume%3D44%26spage%3D521%26epage%3D531%26doi%3D10.1007%2Fs10803-013-1899-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadds, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchi, A. J.</span></span> <span> </span><span class="NLM_article-title">A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1114</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1016/j.psyneuen.2011.02.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.psyneuen.2011.02.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=1114-1126&author=E.+MacDonaldauthor=M.+R.+Daddsauthor=J.+L.+Brennanauthor=K.+Williamsauthor=F.+Levyauthor=A.+J.+Cauchi&title=A+review+of+safety%2C+side-effects+and+subjective+reactions+to+intranasal+oxytocin+in+human+research&doi=10.1016%2Fj.psyneuen.2011.02.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2011.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2011.02.015%26sid%3Dliteratum%253Aachs%26aulast%3DMacDonald%26aufirst%3DE.%26aulast%3DDadds%26aufirst%3DM.%2BR.%26aulast%3DBrennan%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DF.%26aulast%3DCauchi%26aufirst%3DA.%2BJ.%26atitle%3DA%2520review%2520of%2520safety%252C%2520side-effects%2520and%2520subjective%2520reactions%2520to%2520intranasal%2520oxytocin%2520in%2520human%2520research%26jtitle%3DPsychoneuroendocrinology%26date%3D2011%26volume%3D36%26spage%3D1114%26epage%3D1126%26doi%3D10.1016%2Fj.psyneuen.2011.02.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijers, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noltes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucha, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekstra, P. J.</span></span> <span> </span><span class="NLM_article-title">Oxytocin enhances orienting to social information in a selective group of high-functioning male adults with autism spectrum disorder</span>. <i>Neuropsychologia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.neuropsychologia.2015.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neuropsychologia.2015.10.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=53-69&author=M.+Althausauthor=Y.+Groenauthor=A.+A.+Wijersauthor=H.+Noltesauthor=O.+Tuchaauthor=P.+J.+Hoekstra&title=Oxytocin+enhances+orienting+to+social+information+in+a+selective+group+of+high-functioning+male+adults+with+autism+spectrum+disorder&doi=10.1016%2Fj.neuropsychologia.2015.10.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropsychologia.2015.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropsychologia.2015.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DAlthaus%26aufirst%3DM.%26aulast%3DGroen%26aufirst%3DY.%26aulast%3DWijers%26aufirst%3DA.%2BA.%26aulast%3DNoltes%26aufirst%3DH.%26aulast%3DTucha%26aufirst%3DO.%26aulast%3DHoekstra%26aufirst%3DP.%2BJ.%26atitle%3DOxytocin%2520enhances%2520orienting%2520to%2520social%2520information%2520in%2520a%2520selective%2520group%2520of%2520high-functioning%2520male%2520adults%2520with%2520autism%2520spectrum%2520disorder%26jtitle%3DNeuropsychologia%26date%3D2015%26volume%3D79%26spage%3D53%26epage%3D69%26doi%3D10.1016%2Fj.neuropsychologia.2015.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leboyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirigu, A.</span></span> <span> </span><span class="NLM_article-title">Adaptive coding of the value of social cues with oxytocin, an fMRI study in autism spectrum disorder</span>. <i>Cortex</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.cortex.2015.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.cortex.2015.12.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=79-88&author=E.+Andariauthor=N.+Richardauthor=M.+Leboyerauthor=A.+Sirigu&title=Adaptive+coding+of+the+value+of+social+cues+with+oxytocin%2C+an+fMRI+study+in+autism+spectrum+disorder&doi=10.1016%2Fj.cortex.2015.12.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cortex.2015.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cortex.2015.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DAndari%26aufirst%3DE.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DLeboyer%26aufirst%3DM.%26aulast%3DSirigu%26aufirst%3DA.%26atitle%3DAdaptive%2520coding%2520of%2520the%2520value%2520of%2520social%2520cues%2520with%2520oxytocin%252C%2520an%2520fMRI%2520study%2520in%2520autism%2520spectrum%2520disorder%26jtitle%3DCortex%26date%3D2016%26volume%3D76%26spage%3D79%26epage%3D88%26doi%3D10.1016%2Fj.cortex.2015.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsubori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonoi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunimatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">3073</span>– <span class="NLM_lpage">3086</span>, <span class="refDoi"> DOI: 10.1093/brain/awu231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1093%2Fbrain%2Fawu231" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2014&pages=3073-3086&author=Y.+Aokiauthor=N.+Yahataauthor=T.+Watanabeauthor=Y.+Takanoauthor=Y.+Kawakuboauthor=H.+Kuwabaraauthor=N.+Iwashiroauthor=T.+Natsuboriauthor=H.+Inoueauthor=M.+Sugaauthor=H.+Takaoauthor=H.+Sasakiauthor=W.+Gonoiauthor=A.+Kunimatsuauthor=K.+Kasaiauthor=H.+Yamasue&title=Oxytocin+improves+behavioural+and+neural+deficits+in+inferring+others%E2%80%99+social+emotions+in+autism&doi=10.1093%2Fbrain%2Fawu231"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawu231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawu231%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DYahata%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DNatsubori%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DGonoi%26aufirst%3DW.%26aulast%3DKunimatsu%26aufirst%3DA.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DOxytocin%2520improves%2520behavioural%2520and%2520neural%2520deficits%2520in%2520inferring%2520others%25E2%2580%2599%2520social%2520emotions%2520in%2520autism%26jtitle%3DBrain%26date%3D2014%26volume%3D137%26spage%3D3073%26epage%3D3086%26doi%3D10.1093%2Fbrain%2Fawu231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yahata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsubori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1038/mp.2014.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fmp.2014.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25070538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GhsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=447-453&author=Y.+Aokiauthor=T.+Watanabeauthor=O.+Abeauthor=H.+Kuwabaraauthor=N.+Yahataauthor=Y.+Takanoauthor=N.+Iwashiroauthor=T.+Natsuboriauthor=H.+Takaoauthor=Y.+Kawakuboauthor=K.+Kasaiauthor=H.+Yamasue&title=Oxytocin%E2%80%99s+neurochemical+effects+in+the+medial+prefrontal+cortex+underlie+recovery+of+task-specific+brain+activity+in+autism%3A+a+randomized+controlled+trial&doi=10.1038%2Fmp.2014.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial</span></div><div class="casAuthors">Aoki, Y.; Watanabe, T.; Abe, O.; Kuwabara, H.; Yahata, N.; Takano, Y.; Iwashiro, N.; Natsubori, T.; Takao, H.; Kawakubo, Y.; Kasai, K.; Yamasue, H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">447-453</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deficits assocd. with autism.  Our recent paper reported that oxytocin mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex (vmPFC), as demonstrated with functional magnetic resonance imaging (fMRI) during a socio-communication task.  However, it is unknown whether oxytocin exhibited effects at the neuronal level, which was outside of the specific task examd.  In the same randomized, double-blind, placebo-controlled, within-subject cross-over clin. trial in which a single dose of intranasal oxytocin (24 IU) was administered to 40 men with high-functioning autism spectrum disorder (UMIN000002241/000004393), we measured N-acetylaspartate (NAA) levels, a marker for neuronal energy demand, in the vmPFC using 1H-magnetic resonance spectroscopy (1H-MRS).  The differences in the NAA levels between the oxytocin and placebo sessions were assocd. with oxytocin-induced fMRI signal changes in the vmPFC.  The oxytocin-induced increases in the fMRI signal could be predicted by the NAA differences between the oxytocin and placebo sessions (P=0.002), an effect that remained after controlling for variability in the time between the fMRI and 1H-MRS scans (P=0.006) and the order of administration of oxytocin and placebo (P=0.001).  Furthermore, path anal. showed that the NAA differences in the vmPFC triggered increases in the task-dependent fMRI signals in the vmPFC, which consequently led to improvements in the socio-communication difficulties assocd. with autism.  The present study suggests that the beneficial effects of oxytocin are not limited to the autistic behavior elicited by our psychol. task, but may generalize to other autistic behavioral problems assocd. with the vmPFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5tYMOOqHfULVg90H21EOLACvtfcHk0lhAMaaYmW4lWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GhsrzJ&md5=48a17e446e9bda3edda9174014cf162f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fmp.2014.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2014.74%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DO.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DYahata%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DY.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DNatsubori%26aufirst%3DT.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DOxytocin%25E2%2580%2599s%2520neurochemical%2520effects%2520in%2520the%2520medial%2520prefrontal%2520cortex%2520underlie%2520recovery%2520of%2520task-specific%2520brain%2520activity%2520in%2520autism%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DMol.%2520Psychiatry%26date%3D2015%26volume%3D20%26spage%3D447%26epage%3D453%26doi%3D10.1038%2Fmp.2014.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auyeung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sule, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethlehem, R. A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipple, J. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron-Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e507</span>, <span class="refDoi"> DOI: 10.1038/tp.2014.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2014.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25668435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFCgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e507&author=B.+Auyeungauthor=M.+V.+Lombardoauthor=M.+Heinrichsauthor=B.+Chakrabartiauthor=A.+Suleauthor=J.+B.+Deakinauthor=R.+A.+I.+Bethlehemauthor=L.+Dickensauthor=N.+Mooneyauthor=J.+A.+N.+Sippleauthor=P.+Thiemannauthor=S.+Baron-Cohen&title=Oxytocin+increases+eye+contact+during+a+real-time%2C+naturalistic+social+interaction+in+males+with+and+without+autism&doi=10.1038%2Ftp.2014.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism</span></div><div class="casAuthors">Auyeung, B.; Lombardo, M. V.; Heinrichs, M.; Chakrabarti, B.; Sule, A.; Deakin, J. B.; Bethlehem, R. A. I.; Dickens, L.; Mooney, N.; Sipple, J. A. N.; Thiemann, P.; Baron-Cohen, S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e507</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Autism spectrum conditions (autism) affect ∼1% of the population and are characterized by deficits in social communication.  Oxytocin has been widely reported to affect social-communicative function and its neural underpinnings.  Here we report the first evidence that intranasal oxytocin administration improves a core problem that individuals with autism have in using eye contact appropriately in real-world social settings.  A randomized double-blind, placebo-controlled, within-subjects design is used to examine how intranasal administration of 24 IU of oxytocin affects gaze behavior for 32 adult males with autism and 34 controls in a real-time interaction with a researcher.  This interactive paradigm bypasses many of the limitations encountered with conventional static or computer-based stimuli.  Eye movements are recorded using eye tracking, providing an objective measurement of looking patterns.  The measure is shown to be sensitive to the reduced eye contact commonly reported in autism, with the autism group spending less time looking to the eye region of the face than controls.  Oxytocin administration selectively enhanced gaze to the eyes in both the autism and control groups (transformed mean eye-fixation difference per s=0.082; 95% CI:0.025-0.14, P=0.006).  Within the autism group, oxytocin has the most effect on fixation duration in individuals with impaired levels of eye contact at baseline (Cohen's d=0.86).  These findings demonstrate that the potential benefits of oxytocin in autism extend to a real-time interaction, providing evidence of a therapeutic effect in a key aspect of social communication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplKgtAe3rzhbVg90H21EOLACvtfcHk0lhAMaaYmW4lWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFCgt7c%253D&md5=6bd13bfd402ab6df8b4ee8682cced347</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Ftp.2014.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2014.146%26sid%3Dliteratum%253Aachs%26aulast%3DAuyeung%26aufirst%3DB.%26aulast%3DLombardo%26aufirst%3DM.%2BV.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DChakrabarti%26aufirst%3DB.%26aulast%3DSule%26aufirst%3DA.%26aulast%3DDeakin%26aufirst%3DJ.%2BB.%26aulast%3DBethlehem%26aufirst%3DR.%2BA.%2BI.%26aulast%3DDickens%26aufirst%3DL.%26aulast%3DMooney%26aufirst%3DN.%26aulast%3DSipple%26aufirst%3DJ.%2BA.%2BN.%26aulast%3DThiemann%26aufirst%3DP.%26aulast%3DBaron-Cohen%26aufirst%3DS.%26atitle%3DOxytocin%2520increases%2520eye%2520contact%2520during%2520a%2520real-time%252C%2520naturalistic%2520social%2520interaction%2520in%2520males%2520with%2520and%2520without%2520autism%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De507%26doi%3D10.1038%2Ftp.2014.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpertz, S. C.</span></span> <span> </span><span class="NLM_article-title">Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23510581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2013&pages=164-171&author=G.+Domesauthor=M.+Heinrichsauthor=E.+Kumbierauthor=A.+Grossmannauthor=K.+Hauensteinauthor=S.+C.+Herpertz&title=Effects+of+intranasal+oxytocin+on+the+neural+basis+of+face+processing+in+autism+spectrum+disorder&doi=10.1016%2Fj.biopsych.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Intranasal Oxytocin on the Neural Basis of Face Processing in Autism Spectrum Disorder</span></div><div class="casAuthors">Domes, Gregor; Heinrichs, Markus; Kumbier, Ekkehardt; Grossmann, Annette; Hauenstein, Karlheinz; Herpertz, Sabine C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Autism spectrum disorder (ASD) is assocd. with altered face processing and decreased activity in brain regions involved in face processing.  The neuropeptide oxytocin has been shown to promote face processing and modulate brain activity in healthy adults.  The present study examd. the effects of oxytocin on the neural basis of face processing in adults with Asperger syndrome (AS).  Methods: A group of 14 individuals with AS and a group of 14 neurotypical control participants performed a face-matching and a house-matching task during functional magnetic resonance imaging.  The effects of a single dose of 24 IU intranasally administered oxytocin were tested in a randomized, placebo-controlled, within-subject, cross-over design.  Results: Under placebo, the AS group showed decreased activity in the right amygdala, fusiform gyrus, and inferior occipital gyrus compared with the control group during face processing.  After oxytocin treatment, right amygdala activity to facial stimuli increased in the AS group.  Conclusions: These findings indicate that oxytocin increases the saliency of social stimuli and in ASD and suggest that oxytocin might promote face processing and eye contact in individuals with ASD as prerequisites for neurotypical social interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrThR5xUWpbIrVg90H21EOLACvtfcHk0liduxDNrgtKzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jtbk%253D&md5=cd0d31448b6374b0f42d208bea69749e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DDomes%26aufirst%3DG.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DKumbier%26aufirst%3DE.%26aulast%3DGrossmann%26aufirst%3DA.%26aulast%3DHauenstein%26aufirst%3DK.%26aulast%3DHerpertz%26aufirst%3DS.%2BC.%26atitle%3DEffects%2520of%2520intranasal%2520oxytocin%2520on%2520the%2520neural%2520basis%2520of%2520face%2520processing%2520in%2520autism%2520spectrum%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2013%26volume%3D74%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.biopsych.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumbier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpertz, S. C.</span></span> <span> </span><span class="NLM_article-title">Oxytocin promotes facial emotion recognition and amygdala reactivity in adults with Asperger syndrome</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2013.254" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=698-706&author=G.+Domesauthor=E.+Kumbierauthor=M.+Heinrichsauthor=S.+C.+Herpertz&title=Oxytocin+promotes+facial+emotion+recognition+and+amygdala+reactivity+in+adults+with+Asperger+syndrome&doi=10.1038%2Fnpp.2013.254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.254%26sid%3Dliteratum%253Aachs%26aulast%3DDomes%26aufirst%3DG.%26aulast%3DKumbier%26aufirst%3DE.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DHerpertz%26aufirst%3DS.%2BC.%26atitle%3DOxytocin%2520promotes%2520facial%2520emotion%2520recognition%2520and%2520amygdala%2520reactivity%2520in%2520adults%2520with%2520Asperger%2520syndrome%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D698%26epage%3D706%26doi%3D10.1038%2Fnpp.2013.254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Wyk, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeaux, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilbott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagoory-Sharon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leckman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelphrey, K. A.</span></span> <span> </span><span class="NLM_article-title">Oxytocin enhances brain function in children with autism</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">20953</span>– <span class="NLM_lpage">20958</span>, <span class="refDoi"> DOI: 10.1073/pnas.1312857110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1073%2Fpnas.1312857110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=20953-20958&author=I.+Gordonauthor=B.+C.+Vander+Wykauthor=R.+H.+Bennettauthor=C.+O.+Cordeauxauthor=M.+V.+Lucasauthor=J.+A.+Eilbottauthor=O.+Zagoory-Sharonauthor=J.+F.+Leckmanauthor=R.+Feldmanauthor=K.+A.+Pelphrey&title=Oxytocin+enhances+brain+function+in+children+with+autism&doi=10.1073%2Fpnas.1312857110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1312857110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1312857110%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DI.%26aulast%3DVander%2BWyk%26aufirst%3DB.%2BC.%26aulast%3DBennett%26aufirst%3DR.%2BH.%26aulast%3DCordeaux%26aufirst%3DC.%2BO.%26aulast%3DLucas%26aufirst%3DM.%2BV.%26aulast%3DEilbott%26aufirst%3DJ.%2BA.%26aulast%3DZagoory-Sharon%26aufirst%3DO.%26aulast%3DLeckman%26aufirst%3DJ.%2BF.%26aulast%3DFeldman%26aufirst%3DR.%26aulast%3DPelphrey%26aufirst%3DK.%2BA.%26atitle%3DOxytocin%2520enhances%2520brain%2520function%2520in%2520children%2520with%2520autism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D20953%26epage%3D20958%26doi%3D10.1073%2Fpnas.1312857110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spenthof, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Elst, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrichs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domes, G.</span></span> <span> </span><span class="NLM_article-title">Restoring effects of oxytocin on the attentional preference for faces in autism</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1097</span>, <span class="refDoi"> DOI: 10.1038/tp.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Ftp.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28418399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=e1097&author=M.+Kanatauthor=I.+Spenthofauthor=A.+Riedelauthor=L.+T.+van+Elstauthor=M.+Heinrichsauthor=G.+Domes&title=Restoring+effects+of+oxytocin+on+the+attentional+preference+for+faces+in+autism&doi=10.1038%2Ftp.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Restoring effects of oxytocin on the attentional preference for faces in autism</span></div><div class="casAuthors">Kanat, M.; Spenthof, I.; Riedel, A.; van Elst, L. T.; Heinrichs, M.; Domes, G.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e1097</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reduced attentional preference for faces and symptoms of social anxiety are common in autism spectrum disorders (ASDs).  The neuropeptide oxytocin triggers anxiolytic functions and enhances eye gaze, facial emotion recognition and neural correlates of face processing in ASD.  Here we investigated whether a single dose of oxytocin increases attention to faces in ASD.  As a secondary question, we explored the influence of social anxiety on these effects.  We tested for oxytocin's effects on attention to neutral faces as compared to houses in a sample of 29 autistic individuals and 30 control participants using a dot-probe paradigm with two different presentation times (100 or 500 ms).  A single dose of 24 IU oxytocin was administered in a randomized, double-blind placebo-controlled, cross-over design.  Under placebo, ASD individuals paid less attention to faces presented for 500 ms than did controls.  Oxytocin administration increased the allocation of attention toward faces in ASD to a level obsd. in controls.  Secondary analyses revealed that these oxytocin effects primarily occurred in ASD individuals with high levels of social anxiety who were characterized by attentional avoidance of faces under placebo.  Our results confirm a pos. influence of intranasal oxytocin on social attention processes in ASD.  Further, they suggest that oxytocin may in particular restore the attentional preference for facial information in ASD individuals with high social anxiety.  We conclude that oxytocin's anxiolytic properties may partially account for its pos. effects on socio-cognitive functioning in ASD, such as enhanced eye gaze and facial emotion recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UJ6xcYpBMbVg90H21EOLACvtfcHk0liduxDNrgtKzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKhtr8%253D&md5=6f00325307ee2dddb4b1631d30fb7c6f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Ftp.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DKanat%26aufirst%3DM.%26aulast%3DSpenthof%26aufirst%3DI.%26aulast%3DRiedel%26aufirst%3DA.%26aulast%3Dvan%2BElst%26aufirst%3DL.%2BT.%26aulast%3DHeinrichs%26aufirst%3DM.%26aulast%3DDomes%26aufirst%3DG.%26atitle%3DRestoring%2520effects%2520of%2520oxytocin%2520on%2520the%2520attentional%2520preference%2520for%2520faces%2520in%2520autism%26jtitle%3DTransl.%2520Psychiatry%26date%3D2017%26volume%3D7%26spage%3De1097%26doi%3D10.1038%2Ftp.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwashiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsunobu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nippashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakubo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunimatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasue, H.</span></span> <span> </span><span class="NLM_article-title">Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">3400</span>– <span class="NLM_lpage">3412</span>, <span class="refDoi"> DOI: 10.1093/brain/awv249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1093%2Fbrain%2Fawv249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2015&pages=3400-3412&author=T.+Watanabeauthor=M.+Kurodaauthor=H.+Kuwabaraauthor=Y.+Aokiauthor=N.+Iwashiroauthor=N.+Tatsunobuauthor=H.+Takaoauthor=Y.+Nippashiauthor=Y.+Kawakuboauthor=A.+Kunimatsuauthor=K.+Kasaiauthor=H.+Yamasue&title=Clinical+and+neural+effects+of+six-week+administration+of+oxytocin+on+core+symptoms+of+autism&doi=10.1093%2Fbrain%2Fawv249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawv249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawv249%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DKuwabara%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DY.%26aulast%3DIwashiro%26aufirst%3DN.%26aulast%3DTatsunobu%26aufirst%3DN.%26aulast%3DTakao%26aufirst%3DH.%26aulast%3DNippashi%26aufirst%3DY.%26aulast%3DKawakubo%26aufirst%3DY.%26aulast%3DKunimatsu%26aufirst%3DA.%26aulast%3DKasai%26aufirst%3DK.%26aulast%3DYamasue%26aufirst%3DH.%26atitle%3DClinical%2520and%2520neural%2520effects%2520of%2520six-week%2520administration%2520of%2520oxytocin%2520on%2520core%2520symptoms%2520of%2520autism%26jtitle%3DBrain%26date%3D2015%26volume%3D138%26spage%3D3400%26epage%3D3412%26doi%3D10.1093%2Fbrain%2Fawv249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yatawara, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einfeld, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span> <span> </span><span class="NLM_article-title">The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1038/mp.2015.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fmp.2015.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26503762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsleks7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1225-1231&author=C.+J.+Yatawaraauthor=S.+L.+Einfeldauthor=I.+B.+Hickieauthor=T.+A.+Davenportauthor=A.+J.+Guastella&title=The+effect+of+oxytocin+nasal+spray+on+social+interaction+deficits+observed+in+young+children+with+autism%3A+a+randomized+clinical+crossover+trial&doi=10.1038%2Fmp.2015.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial</span></div><div class="casAuthors">Yatawara, C. J.; Einfeld, S. L.; Hickie, I. B.; Davenport, T. A.; Guastella, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1225-1231</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Interventions for autism are limited.  The synthetic hormone oxytocin may provide a potential treatment to improve core social and behavioral difficulties in autism, but its efficacy has yet to be evaluated in young children who potentially may benefit to a greater extent.  We investigated the efficacy, tolerability and safety of oxytocin treatment in young children with autism using a double-blind, randomized, placebo-controlled, crossover, clin. trial.  Thirty-one children with autism received 12 IU (IU) of oxytocin and placebo nasal spray morning and night (24 IU per day) for 5 wk, with a 4-wk washout period between each treatment.  Compared with placebo, oxytocin led to significant improvements on the primary outcome of caregiver-rated social responsiveness.  Overall, nasal spray was well tolerated, and the most common reported adverse events were thirst, urination and constipation.  This study is the first clin. trial to support the potential of oxytocin as an early intervention for young children with autism to help improve social interaction deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYvRBN9eJKqLVg90H21EOLACvtfcHk0ljJ15T0B0tp7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsleks7zI&md5=37397699a7098e3572851c47c2ff2948</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fmp.2015.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2015.162%26sid%3Dliteratum%253Aachs%26aulast%3DYatawara%26aufirst%3DC.%2BJ.%26aulast%3DEinfeld%26aufirst%3DS.%2BL.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DDavenport%26aufirst%3DT.%2BA.%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520effect%2520of%2520oxytocin%2520nasal%2520spray%2520on%2520social%2520interaction%2520deficits%2520observed%2520in%2520young%2520children%2520with%2520autism%253A%2520a%2520randomized%2520clinical%2520crossover%2520trial%26jtitle%3DMol.%2520Psychiatry%26date%3D2016%26volume%3D21%26spage%3D1225%26epage%3D1231%26doi%3D10.1038%2Fmp.2015.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Preckel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanske, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krach, S.</span></span> <span> </span><span class="NLM_article-title">Clinical trial of modulatory effects of oxytocin treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-controlled, double-blind and crossover trial</span>. <i>BMC Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">329</span>, <span class="refDoi"> DOI: 10.1186/s12888-016-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1186%2Fs12888-016-1036-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=329&author=K.+Preckelauthor=P.+Kanskeauthor=T.+Singerauthor=F.+M.+Paulusauthor=S.+Krach&title=Clinical+trial+of+modulatory+effects+of+oxytocin+treatment+on+higher-order+social+cognition+in+autism+spectrum+disorder%3A+a+randomized%2C+placebo-controlled%2C+double-blind+and+crossover+trial&doi=10.1186%2Fs12888-016-1036-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs12888-016-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12888-016-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DPreckel%26aufirst%3DK.%26aulast%3DKanske%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DT.%26aulast%3DPaulus%26aufirst%3DF.%2BM.%26aulast%3DKrach%26aufirst%3DS.%26atitle%3DClinical%2520trial%2520of%2520modulatory%2520effects%2520of%2520oxytocin%2520treatment%2520on%2520higher-order%2520social%2520cognition%2520in%2520autism%2520spectrum%2520disorder%253A%2520a%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%2520and%2520crossover%2520trial%26jtitle%3DBMC%2520Psychiatry%26date%3D2016%26volume%3D16%26spage%3D329%26doi%3D10.1186%2Fs12888-016-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvares, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span> <span> </span><span class="NLM_article-title">Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model</span>. <i>Neurosci. Biobehav. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.neubiorev.2014.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neubiorev.2014.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=182-192&author=D.+S.+Quintanaauthor=G.+A.+Alvaresauthor=I.+B.+Hickieauthor=A.+J.+Guastella&title=Do+delivery+routes+of+intranasally+administered+oxytocin+account+for+observed+effects+on+social+cognition+and+behavior%3F+A+two-level+model&doi=10.1016%2Fj.neubiorev.2014.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.neubiorev.2014.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neubiorev.2014.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DQuintana%26aufirst%3DD.%2BS.%26aulast%3DAlvares%26aufirst%3DG.%2BA.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26atitle%3DDo%2520delivery%2520routes%2520of%2520intranasally%2520administered%2520oxytocin%2520account%2520for%2520observed%2520effects%2520on%2520social%2520cognition%2520and%2520behavior%253F%2520A%2520two-level%2520model%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D2015%26volume%3D49%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.neubiorev.2014.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munesue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanba, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashida, H.</span></span> <span> </span><span class="NLM_article-title">Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study</span>. <i>Front. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.3389/fpsyt.2016.00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffpsyt.2016.00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26834651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC28nmslOmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2&author=T.+Munesueauthor=H.+Nakamuraauthor=M.+Kikuchiauthor=Y.+Miuraauthor=N.+Takeuchiauthor=T.+Anmeauthor=E.+Nanbaauthor=K.+Adachiauthor=K.+Tsubouchiauthor=Y.+Saiauthor=K.+Miyamotoauthor=S.+Horikeauthor=S.+Yokoyamaauthor=H.+Nakataniauthor=Y.+Niidaauthor=H.+Kosakaauthor=Y.+Minabeauthor=H.+Higashida&title=Oxytocin+for+male+subjects+with+autism+spectrum+disorder+and+comorbid+intellectual+disabilities%3A+a+randomized+pilot+study&doi=10.3389%2Ffpsyt.2016.00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study</span></div><div class="casAuthors">Munesue Toshio; Kikuchi Mitsuru; Miura Yui; Takeuchi Noriyuki; Yokoyama Shigeru; Higashida Haruhiro; Nakamura Hiroyuki; Anme Tokie; Nanba Eiji; Adachi Kaori; Tsubouchi Kiyotaka; Sai Yoshimichi; Miyamoto Ken-Ichi; Horike Shin-Ichi; Nakatani Hideo; Minabe Yoshio; Niida Yo; Kosaka Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">1664-0640</span>.
    </div><div class="casAbstract">UNLABELLED:  Approximately half of autism spectrum disorder (ASD) individuals suffer from comorbid intellectual disabilities (IDs).  Oxytocin (OXT) receptors are highly expressed in temporal lobe structures and are likely to play a modulatory role in excitatory/inhibitory balance, at least based on animal model findings.  Thus, it is feasible that in the highly representative group of Kanner-type ASD subjects, OXT could have a beneficial effect on social communication and social interaction.  The aim of this pilot study is to investigate the feasibility and adverse events, such as epilepsy, of the long-term administration of intranasal OXT for adolescent and adult ASD subjects with ID because such patients frequently have seizures.  We also addressed the question on how to scale the OXT effects to the core symptoms of social deficits because of the relative difficulty in obtaining objective measurements.  Twenty-nine males (aged 15-40 years old) participated in a randomized, double-blind, and placebo-controlled crossover study (each for 8 weeks) with OXT (16 IU/day).  Except for seizures experienced by one participant, other serious adverse events did not occur.  The primary and secondary outcomes measured using the Childhood Autism Rating Scale and several standard scales, respectively, revealed no difference between the OXT and placebo groups.  Instead, in an exploratory analysis, the social interactions observed in the play sessions or in daily life were significantly more frequent in the initial half period in the OXT-first arm of the crossover trial.  There were also significant correlations between the plasma OXT concentration and subscale scores for irritability on the Aberrant Behavior Checklist.  In conclusion, this pilot study demonstrates that long-term administration of intranasal OXT is tolerable in a representative cohort of ASD individuals with ID and suggests that future multicenter trials of OXT are warranted and should include measurements of reciprocal social interactions based on daily life under closer surveillance for epilepsy.  TRIAL REGISTRATION:  UMIN000007250.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGkT-vVqjel4qdXsLcGTEUfW6udTcc2eZkXQ2rw5rJe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nmslOmug%253D%253D&md5=e322f9798adde3575b34cf0e83bbf0d5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3389%2Ffpsyt.2016.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpsyt.2016.00002%26sid%3Dliteratum%253Aachs%26aulast%3DMunesue%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DN.%26aulast%3DAnme%26aufirst%3DT.%26aulast%3DNanba%26aufirst%3DE.%26aulast%3DAdachi%26aufirst%3DK.%26aulast%3DTsubouchi%26aufirst%3DK.%26aulast%3DSai%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DK.%26aulast%3DHorike%26aufirst%3DS.%26aulast%3DYokoyama%26aufirst%3DS.%26aulast%3DNakatani%26aufirst%3DH.%26aulast%3DNiida%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DH.%26aulast%3DMinabe%26aufirst%3DY.%26aulast%3DHigashida%26aufirst%3DH.%26atitle%3DOxytocin%2520for%2520male%2520subjects%2520with%2520autism%2520spectrum%2520disorder%2520and%2520comorbid%2520intellectual%2520disabilities%253A%2520a%2520randomized%2520pilot%2520study%26jtitle%3DFront.%2520Psychiatry%26date%3D2016%26volume%3D7%26spage%3D2%26doi%3D10.3389%2Ffpsyt.2016.00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacivita, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span> <span> </span><span class="NLM_article-title">Targets for drug therapy for autism spectrum disorder: challenges and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9114</span>– <span class="NLM_lpage">9141</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9114-9141&author=E.+Lacivitaauthor=R.+Perroneauthor=L.+Margariauthor=M.+Leopoldo&title=Targets+for+drug+therapy+for+autism+spectrum+disorder%3A+challenges+and+future+directions&doi=10.1021%2Facs.jmedchem.7b00965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions</span></div><div class="casAuthors">Lacivita, Enza; Perrone, Roberto; Margari, Lucia; Leopoldo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9114-9141</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, and activities.  Various factors are involved in the etiopathogenesis of ASD, including genetic factors, environmental toxins and stressors, impaired immune responses, mitochondrial dysfunction, and neuroinflammation.  The heterogeneity in the phenotype among ASD patients and the complex etiol. of the condition have long impeded the advancement of the development of pharmacol. therapies.  In the recent years, the integration of findings from mouse models to human genetics resulted in considerable progress toward the understanding of ASD pathophysiol.  Currently, strategies to treat core symptoms of ASD are directed to correct synaptic dysfunctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation.  Here, we present a survey of the studies that have suggested mol. targets for drug development for ASD and the state-of-the-art of medicinal chem. efforts in related areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBnoRlTN2U9rVg90H21EOLACvtfcHk0ljOpsH1GxYBQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsLnL&md5=32311ccf6d8bc345129c00fe6dc0a23a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00965%26sid%3Dliteratum%253Aachs%26aulast%3DLacivita%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DMargari%26aufirst%3DL.%26aulast%3DLeopoldo%26aufirst%3DM.%26atitle%3DTargets%2520for%2520drug%2520therapy%2520for%2520autism%2520spectrum%2520disorder%253A%2520challenges%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9114%26epage%3D9141%26doi%3D10.1021%2Facs.jmedchem.7b00965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollitor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukic-Stefanovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kranz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vraka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teodoro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donat, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitterhauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span> <span> </span><span class="NLM_article-title">Development of a novel nonpeptidic (18)F-labeled radiotracer for in vivo imaging of oxytocin receptors with positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1800</span>– <span class="NLM_lpage">1817</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1800-1817&author=B.+Wenzelauthor=J.+Mollitorauthor=W.+Deuther-Conradauthor=S.+Dukic-Stefanovicauthor=M.+Kranzauthor=C.+Vrakaauthor=R.+Teodoroauthor=R.+G%C3%BCntherauthor=C.+K.+Donatauthor=F.+Ludwigauthor=S.+Fischerauthor=R.+Smitsauthor=W.+Wadsakauthor=M.+Mitterhauserauthor=J.+Steinbachauthor=A.+Hoeppingauthor=P.+Brust&title=Development+of+a+novel+nonpeptidic+%2818%29F-labeled+radiotracer+for+in+vivo+imaging+of+oxytocin+receptors+with+positron+emission+tomography&doi=10.1021%2Facs.jmedchem.5b01080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01080%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DB.%26aulast%3DMollitor%26aufirst%3DJ.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DDukic-Stefanovic%26aufirst%3DS.%26aulast%3DKranz%26aufirst%3DM.%26aulast%3DVraka%26aufirst%3DC.%26aulast%3DTeodoro%26aufirst%3DR.%26aulast%3DG%25C3%25BCnther%26aufirst%3DR.%26aulast%3DDonat%26aufirst%3DC.%2BK.%26aulast%3DLudwig%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DWadsak%26aufirst%3DW.%26aulast%3DMitterhauser%26aufirst%3DM.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DHoepping%26aufirst%3DA.%26aulast%3DBrust%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520nonpeptidic%2520%252818%2529F-labeled%2520radiotracer%2520for%2520in%2520vivo%2520imaging%2520of%2520oxytocin%2520receptors%2520with%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1800%26epage%3D1817%26doi%3D10.1021%2Facs.jmedchem.5b01080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plisson, C. J.</span></span> <span> </span><span class="NLM_article-title">Radiosynthesis and evaluation of 1-substituted 3-(2,3-dihydro-1H-inden-2-yl)-6-(1-ethylpropyl)- (3R,6R)-2,5-piperazinedione derivatives as PET tracers for imaging the central oxytocinergic system</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1002/jlcr.3535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1002%2Fjlcr.3535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28670707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFClu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=556-565&author=C.+Marzanoauthor=S.+Jakobsenauthor=C.+Salinasauthor=S.+P.+Tangauthor=D.+Benderauthor=J.+Passchierauthor=C.+J.+Plisson&title=Radiosynthesis+and+evaluation+of+1-substituted+3-%282%2C3-dihydro-1H-inden-2-yl%29-6-%281-ethylpropyl%29-+%283R%2C6R%29-2%2C5-piperazinedione+derivatives+as+PET+tracers+for+imaging+the+central+oxytocinergic+system&doi=10.1002%2Fjlcr.3535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosynthesis and evaluation of 1-substituted 3-(2,3-dihydro-1H-inden-2-yl)-6-(1-ethylpropyl)-(3R,6R)-2,5-piperazinedione derivatives as PET tracers for imaging the central oxytocinergic system</span></div><div class="casAuthors">Marzano, Carmine; Jakobsen, Steen; Salinas, Cristian; Tang, Sac Pham; Bender, Dirk; Passchier, Jan; Plisson, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Oxytocin is known to be implicated in a variety of functions, such as learning, stress, anxiety, feeding, and pain perception.  Oxytocin is also important for social memory and attachment, human bonding, sexual and maternal behavior, and aggression.  Human disorders characterized by aberrant social interactions, such as autism and schizophrenia, may also involve abnormal oxytocin levels.  GSK712043 (I,R = H), GSK711320 (II, R = H), and GSK664004 (III, R = H), three antagonists exhibiting subnanomolar affinity for the human oxytocin receptor (hOTR) and high selectivity over vasopressin receptors were successfully labeled with carbon-11 with suitable yields (0.5-1GBq @EOS), high molar activity (275-700 GBq/μmol), and radiochem. purities.  The in vivo regional uptake of these radiotracers was detd. in porcine brain. [11C]GSK711320 (II, R = 11CH3) baseline scan showed no significant brain uptake, and limited initial uptake was obsd. following administration of [11C]GSK712043 (I, R = 11CH3) or [11C]GSK664004 (III, R = 11CH3).  The [11C]GSK712043 (I, R = 11CH3) and [11C]GSK664004 (III, R = 11CH3) kinetics were slow and peaked at around 2%ID/L at 90 min post-injection.  For both tracers, the distribution of activity was homogeneous throughout the brain.  All the tracers showed high uptake in the pituitary gland, esp. [11C]GSK711320 (II, R = 11CH3) ; however, its uptake could not be blocked by pretreatment with the known OTR antagonist, L368,899.  In vivo evaluation of these candidates demonstrated that they are not suitable as central OTR PET imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTvribcWPYmLVg90H21EOLACvtfcHk0ljOpsH1GxYBQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFClu7fF&md5=b245e7a359963266d53dd3a22a213cc7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3535%26sid%3Dliteratum%253Aachs%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DJakobsen%26aufirst%3DS.%26aulast%3DSalinas%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DS.%2BP.%26aulast%3DBender%26aufirst%3DD.%26aulast%3DPasschier%26aufirst%3DJ.%26aulast%3DPlisson%26aufirst%3DC.%2BJ.%26atitle%3DRadiosynthesis%2520and%2520evaluation%2520of%25201-substituted%25203-%25282%252C3-dihydro-1H-inden-2-yl%2529-6-%25281-ethylpropyl%2529-%2520%25283R%252C6R%2529-2%252C5-piperazinedione%2520derivatives%2520as%2520PET%2520tracers%2520for%2520imaging%2520the%2520central%2520oxytocinergic%2520system%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2017%26volume%3D60%26spage%3D556%26epage%3D565%26doi%3D10.1002%2Fjlcr.3535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimpl, G.</span></span> <span> </span><span class="NLM_article-title">Oxytocin receptor ligands: a survey of the patent literature</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1517/13543776.18.11.1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1517%2F13543776.18.11.1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlShu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1239-1251&author=G.+Gimpl&title=Oxytocin+receptor+ligands%3A+a+survey+of+the+patent+literature&doi=10.1517%2F13543776.18.11.1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin receptor ligands: a survey of the patent literature</span></div><div class="casAuthors">Gimpl, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1239-1251</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Background: Oxytocin is produced primarily in hypothalamic neurons and is secreted from the posterior pituitary gland into the circulation in response to stimuli such as suckling, parturition, or stress.  Oxytocin functions as an essential component in milk ejection and is among the most potent uterotonic substances known.  The oxytocin receptor system supports physiol. processes assocd. with reprodn. at several levels.  Objective: To characterize and evaluate oxytocin receptor ligands for therapeutic applications.  Methods: Anal. of oxytocin analogs and nonpeptide oxytocin receptor ligands, and major applications of these substances.  Results/conclusion: Oxytocin receptor ligands, peptides, and nonpeptide mols., with high specificity over the related vasopressin receptors, are currently available.  These ligands are expected to show therapeutic utility for a vast range of applications, e.g., increasing lactation, improving in vitro inseminations, and inducing cardiomyogenesis; and also acting against preterm labor, breast cancer, an over-reactive immune system, osteoporosis, and autism-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXEAZdk8Cy8bVg90H21EOLACvtfcHk0ljRlXH2ItmPYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlShu7jK&md5=02503dd059ccf4cdee3e6ca8f2b37bf5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.11.1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.11.1239%26sid%3Dliteratum%253Aachs%26aulast%3DGimpl%26aufirst%3DG.%26atitle%3DOxytocin%2520receptor%2520ligands%253A%2520a%2520survey%2520of%2520the%2520patent%2520literature%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26spage%3D1239%26epage%3D1251%26doi%3D10.1517%2F13543776.18.11.1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukoff Rizzo, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logue, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig-Lipson, S.</span></span> <span> </span><span class="NLM_article-title">Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2009.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.neuropharm.2009.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=19615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjjs1GqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2010&pages=69-77&author=R.+H.+Ringauthor=L.+E.+Schechterauthor=S.+K.+Leonardauthor=J.+M.+Dwyerauthor=B.+J.+Plattauthor=R.+Grafauthor=S.+Grauerauthor=C.+Pulicicchioauthor=L.+Resnickauthor=Z.+Rahmanauthor=S.+J.+Sukoff+Rizzoauthor=B.+Luoauthor=C.+E.+Beyerauthor=S.+F.+Logueauthor=K.+L.+Marquisauthor=Z.+A.+Hughesauthor=S.+Rosenzweig-Lipson&title=Receptor+and+behavioral+pharmacology+of+WAY-267464%2C+a+non-peptide+oxytocin+receptor+agonist&doi=10.1016%2Fj.neuropharm.2009.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist</span></div><div class="casAuthors">Ring Robert H; Schechter Lee E; Leonard Sarah K; Dwyer Jason M; Platt Brian J; Graf Radka; Grauer Steven; Pulicicchio Claudine; Resnick Lynn; Rahman Zia; Sukoff Rizzo Stacey J; Luo Bin; Beyer Chad E; Logue Sheree F; Marquis Karen L; Hughes Zoe A; Rosenzweig-Lipson Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression.  The utility of synthetic OT, as both a research tool and neurotherapeutic, is limited by the physiochemical properties inherent in most neuropeptides, notably its short half-life and poor blood brain barrier penetration.  Subsequently, the discovery and development of non-peptide molecules that act as selective agonists of the oxytocin receptor (OTR) has been an important goal of the field.  In this study, we report the receptor and behavioral pharmacology of WAY-267464, a first generation small-molecule OTR agonist.  WAY-267464 is a high-affinity, potent, and selective (vs.  V1a, V2, V1b) agonist of the OTR.  In assays measuring both behavioral (four-plate test, elevated zero maze) and autonomic (stress-induced hyperthermia) parameters of the anxiety response, WAY-267464 exhibits an anxiolytic-like profile similar to OT.  We have demonstrated that the anxiolytic-like profile of WAY-267464 is mediated through central sites of action.  WAY-267464 also significantly reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine, similar to the antipsychotic-like effects previously reported for OT.  Interestingly, in the mouse tail suspension test, WAY-267464 failed to produce changes in immobility that are seen with OT, raising the question of whether the antidepressant-like activity of OT may be working independently of the OTR.  A selective OTR antagonist also failed to block the effects of OT on immobility in the TST.  The significance of these findings for shaping the clinical development of OTR agonists is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8S-KlSxighgMthz5_Rx5rfW6udTcc2eYnLl7a8rszJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjjs1GqsQ%253D%253D&md5=699434bd2c444cd29345d24db54fbbb5</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2009.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2009.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DR.%2BH.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DLeonard%26aufirst%3DS.%2BK.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DPlatt%26aufirst%3DB.%2BJ.%26aulast%3DGraf%26aufirst%3DR.%26aulast%3DGrauer%26aufirst%3DS.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DRahman%26aufirst%3DZ.%26aulast%3DSukoff%2BRizzo%26aufirst%3DS.%2BJ.%26aulast%3DLuo%26aufirst%3DB.%26aulast%3DBeyer%26aufirst%3DC.%2BE.%26aulast%3DLogue%26aufirst%3DS.%2BF.%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26aulast%3DHughes%26aufirst%3DZ.%2BA.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DReceptor%2520and%2520behavioral%2520pharmacology%2520of%2520WAY-267464%252C%2520a%2520non-peptide%2520oxytocin%2520receptor%2520agonist%26jtitle%3DNeuropharmacology%26date%3D2010%26volume%3D58%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.neuropharm.2009.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gossen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gründer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreckelmeyer, K. N.</span></span> <span> </span><span class="NLM_article-title">Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men</span>. <i>Neuropeptides</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1016/j.npep.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.npep.2012.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=211-215&author=A.+Gossenauthor=A.+Hahnauthor=L.+Westphalauthor=S.+Prinzauthor=R.+T.+Schultzauthor=G.+Gr%C3%BCnderauthor=K.+N.+Spreckelmeyer&title=Oxytocin+plasma+concentrations+after+single+intranasal+oxytocin+administration+-+a+study+in+healthy+men&doi=10.1016%2Fj.npep.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.npep.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.npep.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGossen%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DA.%26aulast%3DWestphal%26aufirst%3DL.%26aulast%3DPrinz%26aufirst%3DS.%26aulast%3DSchultz%26aufirst%3DR.%2BT.%26aulast%3DGr%25C3%25BCnder%26aufirst%3DG.%26aulast%3DSpreckelmeyer%26aufirst%3DK.%2BN.%26atitle%3DOxytocin%2520plasma%2520concentrations%2520after%2520single%2520intranasal%2520oxytocin%2520administration%2520-%2520a%2520study%2520in%2520healthy%2520men%26jtitle%3DNeuropeptides%26date%3D2012%26volume%3D46%26spage%3D211%26epage%3D215%26doi%3D10.1016%2Fj.npep.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guastella, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickie, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinness, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disinger, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banati, R. B.</span></span> <span> </span><span class="NLM_article-title">Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1016/j.psyneuen.2012.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.psyneuen.2012.11.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=612-625&author=A.+J.+Guastellaauthor=I.+B.+Hickieauthor=M.+M.+McGuinnessauthor=M.+Otisauthor=E.+A.+Woodsauthor=H.+M.+Disingerauthor=H.+K.+Chanauthor=T.+F.+Chenauthor=R.+B.+Banati&title=Recommendations+for+the+standardisation+of+oxytocin+nasal+administration+and+guidelines+for+its+reporting+in+human+research&doi=10.1016%2Fj.psyneuen.2012.11.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.psyneuen.2012.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psyneuen.2012.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DGuastella%26aufirst%3DA.%2BJ.%26aulast%3DHickie%26aufirst%3DI.%2BB.%26aulast%3DMcGuinness%26aufirst%3DM.%2BM.%26aulast%3DOtis%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DE.%2BA.%26aulast%3DDisinger%26aufirst%3DH.%2BM.%26aulast%3DChan%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DT.%2BF.%26aulast%3DBanati%26aufirst%3DR.%2BB.%26atitle%3DRecommendations%2520for%2520the%2520standardisation%2520of%2520oxytocin%2520nasal%2520administration%2520and%2520guidelines%2520for%2520its%2520reporting%2520in%2520human%2520research%26jtitle%3DPsychoneuroendocrinology%26date%3D2013%26volume%3D38%26spage%3D612%26epage%3D625%26doi%3D10.1016%2Fj.psyneuen.2012.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of oxytocin receptor signaling in the brain: what we know and what we need to know</span>. <i>Curr. Top. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1007/7854_2017_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1007%2F7854_2017_6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=3-29&author=M.+Busnelliauthor=B.+Chini&title=Molecular+basis+of+oxytocin+receptor+signaling+in+the+brain%3A+what+we+know+and+what+we+need+to+know&doi=10.1007%2F7854_2017_6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2F7854_2017_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7854_2017_6%26sid%3Dliteratum%253Aachs%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DMolecular%2520basis%2520of%2520oxytocin%2520receptor%2520signaling%2520in%2520the%2520brain%253A%2520what%2520we%2520know%2520and%2520what%2520we%2520need%2520to%2520know%26jtitle%3DCurr.%2520Top.%2520Behav.%2520Neurosci.%26date%3D2017%26volume%3D35%26spage%3D3%26epage%3D29%26doi%3D10.1007%2F7854_2017_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grinevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobloch-Bollmann, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Assembling the puzzle: pathways of oxytocin signaling in the brain</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26001309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXos1Oku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=155-164&author=V.+Grinevichauthor=H.+S.+Knobloch-Bollmannauthor=M.+Eliavaauthor=M.+Busnelliauthor=B.+Chini&title=Assembling+the+puzzle%3A+pathways+of+oxytocin+signaling+in+the+brain&doi=10.1016%2Fj.biopsych.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain</span></div><div class="casAuthors">Grinevich, Valery; Knobloch-Bollmann, H. Sophie; Eliava, Marina; Busnelli, Marta; Chini, Bice</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-164</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Oxytocin (OT) is a neuropeptide, which can be seen to be one of the mols. of the decade due to its profound prosocial effects in nonvertebrate and vertebrate species, including humans.  Although OT can be detected in various physiol. fluids (blood, saliva, urine, cerebrospinal fluid) and brain tissue, it is unclear whether peripheral and central OT releases match and synergize.  Moreover, the pathways of OT delivery to brain regions involved in specific behaviors are far from clear.  Here, we discuss the evolutionarily and ontogenetically detd. pathways of OT delivery and OT signaling, which orchestrate activity of the mesolimbic social decision-making network.  Furthermore, we speculate that both the alteration in OT delivery and OT receptor expression may cause behavioral abnormalities in patients afflicted with psychosocial diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6gjPAwBbAP7Vg90H21EOLACvtfcHk0lgoa8byfyWfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXos1Oku7g%253D&md5=4b8181c48d1a7dacc13144a675893e1d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DGrinevich%26aufirst%3DV.%26aulast%3DKnobloch-Bollmann%26aufirst%3DH.%2BS.%26aulast%3DEliava%26aufirst%3DM.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DAssembling%2520the%2520puzzle%253A%2520pathways%2520of%2520oxytocin%2520signaling%2520in%2520the%2520brain%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D79%26spage%3D155%26epage%3D164%26doi%3D10.1016%2Fj.biopsych.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulgheroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capurro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finardi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donzelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2010.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.biopsych.2010.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=21306704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVWhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2011&pages=875-882&author=M.+Salaauthor=D.+Braidaauthor=D.+Lentiniauthor=M.+Busnelliauthor=E.+Bulgheroniauthor=V.+Capurroauthor=A.+Finardiauthor=A.+Donzelliauthor=L.+Pattiniauthor=T.+Rubinoauthor=D.+Parolaroauthor=K.+Nishimoriauthor=M.+Parentiauthor=B.+Chini&title=Pharmacologic+rescue+of+impaired+cognitive+flexibility%2C+social+deficits%2C+increased+aggression%2C+and+seizure+susceptibility+in+oxytocin+receptor+null+mice%3A+a+neurobehavioral+model+of+autism&doi=10.1016%2Fj.biopsych.2010.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic Rescue of Impaired Cognitive Flexibility, Social Deficits, Increased Aggression, and Seizure Susceptibility in Oxytocin Receptor Null Mice: A Neurobehavioral Model of Autism</span></div><div class="casAuthors">Sala, Mariaelvina; Braida, Daniela; Lentini, Daniela; Busnelli, Marta; Bulgheroni, Elisabetta; Capurro, Valeria; Finardi, Annamaria; Donzelli, Andrea; Pattini, Linda; Rubino, Tiziana; Parolaro, Daniela; Nishimori, Katsuhiko; Parenti, Marco; Chini, Bice</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">875-882</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Oxytocin (OT) has been suggested as a treatment to improve social behavior in autistic patients.  Accordingly, the OT (Oxt -/-) and the OT receptor null mice (Oxtr -/-) display autistic-like deficits in social behavior, increased aggression, and reduced ultrasonic vocalization.  Oxtr -/- mice were characterized for general health, sociability, social novelty, cognitive flexibility, aggression, and seizure susceptibility.  Because vasopressin (AVP) and OT cooperate in controlling social behavior, learning, and aggression, they were tested for possible rescue of the impaired behaviors.  Primary hippocampal cultures from Oxtr +/+ and Oxtr -/- mouse embryos were established to investigate the balance between gamma-aminobutyric acid (GABA) and glutamate synapses and the expression levels of OT and AVP (V1a) receptors were detd. by autoradiog.  Oxtr -/- mice display two addnl., highly relevant, phenotypic characteristics: (1) a resistance to change in a learned pattern of behavior, comparable to restricted interests and repetitive behavior in autism, and (2) an increased susceptibility to seizures, a frequent and clin. relevant symptom of autism.  We also show that intracerebral administration of both OT and AVP lowers aggression and fully reverts social and learning defects by acting on V1a receptors and that seizure susceptibility is antagonized by peripherally administered OT.  Finally, we detect a decreased ratio of GABA-ergic vs. total presynapses in hippocampal neurons of Oxtr -/- mice.  Autistic-like symptoms are rescued on administration of AVP and OT to young Oxtr -/- adult animals.  The Oxtr -/- mouse is thus instrumental to investigate the neurochem. and synaptic abnormalities underlying autistic-like disturbances and to test new strategies of pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6DumVxrrcLVg90H21EOLACvtfcHk0lgoa8byfyWfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVWhtrY%253D&md5=dac04a34fe240ba735f788881f98e772</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2010.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2010.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%26aulast%3DBraida%26aufirst%3DD.%26aulast%3DLentini%26aufirst%3DD.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DBulgheroni%26aufirst%3DE.%26aulast%3DCapurro%26aufirst%3DV.%26aulast%3DFinardi%26aufirst%3DA.%26aulast%3DDonzelli%26aufirst%3DA.%26aulast%3DPattini%26aufirst%3DL.%26aulast%3DRubino%26aufirst%3DT.%26aulast%3DParolaro%26aufirst%3DD.%26aulast%3DNishimori%26aufirst%3DK.%26aulast%3DParenti%26aufirst%3DM.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DPharmacologic%2520rescue%2520of%2520impaired%2520cognitive%2520flexibility%252C%2520social%2520deficits%252C%2520increased%2520aggression%252C%2520and%2520seizure%2520susceptibility%2520in%2520oxytocin%2520receptor%2520null%2520mice%253A%2520a%2520neurobehavioral%2520model%2520of%2520autism%26jtitle%3DBiol.%2520Psychiatry%26date%3D2011%26volume%3D69%26spage%3D875%26epage%3D882%26doi%3D10.1016%2Fj.biopsych.2010.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagarsamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galyean, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiśniewska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croston, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivière, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schteingart, C. D.</span></span> <span> </span><span class="NLM_article-title">New, potent, and selective peptidic oxytocin receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5306</span>– <span class="NLM_lpage">5317</span>, <span class="refDoi"> DOI: 10.1021/jm500365s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500365s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5306-5317&author=K.+Wi%C5%9Bniewskiauthor=S.+Alagarsamyauthor=R.+Galyeanauthor=H.+Tarigaauthor=D.+Thompsonauthor=B.+Lyauthor=H.+Wi%C5%9Bniewskaauthor=S.+Qiauthor=G.+Crostonauthor=R.+Laporteauthor=P.+J.+Rivi%C3%A8reauthor=C.+D.+Schteingart&title=New%2C+potent%2C+and+selective+peptidic+oxytocin+receptor+agonists&doi=10.1021%2Fjm500365s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">New, Potent, and Selective Peptidic Oxytocin Receptor Agonists</span></div><div class="casAuthors">Wisniewski, Kazimierz; Alagarsamy, Sudarkodi; Galyean, Robert; Tariga, Hiroe; Thompson, Dorain; Ly, Brian; Wisniewska, Halina; Qi, Steve; Croston, Glenn; Laporte, Regent; Riviere, Pierre J.-M.; Schteingart, Claudio D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5306-5317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex.  Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation.  The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V2 receptor mediated antidiuresis.  We have designed a series of potent oxytocin analogs contg. N-alkylglycines in position 7 with excellent selectivity vs. the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31([2-ThiMeGly7]dOT), 47 (carba-6-[Phe2,BuGly7]dOT), 55 (carba-6-[3-MeBzlGly7]dOT), and 57 (carba-1-[4-FBzlGly7]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios vs. related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min-1 kg-1.  Compd. 57 (FE 202767) is currently in clin. development for the treatment of preterm mothers requiring lactation support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ykZz5KXVXbVg90H21EOLACvtfcHk0lhXKwHK050Znw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVWhs78%253D&md5=8076f2bbeb06371908b462d1c8f25321</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm500365s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500365s%26sid%3Dliteratum%253Aachs%26aulast%3DWi%25C5%259Bniewski%26aufirst%3DK.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DD.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DWi%25C5%259Bniewska%26aufirst%3DH.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRivi%25C3%25A8re%26aufirst%3DP.%2BJ.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520potent%252C%2520and%2520selective%2520peptidic%2520oxytocin%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5306%26epage%3D5317%26doi%3D10.1021%2Fjm500365s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span> <span> </span><span class="NLM_article-title">Potent and selective oxytocin receptor agonists without disulfide bridges</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2335</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2017.04.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2331-2335&author=Y.+Adachiauthor=K.+Sakimuraauthor=Y.+Shimizuauthor=M.+Nakayamaauthor=Y.+Teraoauthor=T.+Yanoauthor=T.+Asami&title=Potent+and+selective+oxytocin+receptor+agonists+without+disulfide+bridges&doi=10.1016%2Fj.bmcl.2017.04.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DM.%26aulast%3DTerao%26aufirst%3DY.%26aulast%3DYano%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DT.%26atitle%3DPotent%2520and%2520selective%2520oxytocin%2520receptor%2520agonists%2520without%2520disulfide%2520bridges%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2331%26epage%3D2335%26doi%3D10.1016%2Fj.bmcl.2017.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yea, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. B.</span></span> <span> </span><span class="NLM_article-title">Non-peptide oxytocin agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4585</span>– <span class="NLM_lpage">4589</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.04.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2004.04.107" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4585-4589&author=G.+R.+Pittauthor=A.+R.+Battauthor=R.+M.+Haighauthor=A.+M.+Pensonauthor=P.+A.+Robsonauthor=D.+P.+Rookerauthor=A.+L.+Tartarauthor=J.+E.+Trimauthor=C.+M.+Yeaauthor=M.+B.+Roe&title=Non-peptide+oxytocin+agonists&doi=10.1016%2Fj.bmcl.2004.04.107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.04.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.04.107%26sid%3Dliteratum%253Aachs%26aulast%3DPitt%26aufirst%3DG.%2BR.%26aulast%3DBatt%26aufirst%3DA.%2BR.%26aulast%3DHaigh%26aufirst%3DR.%2BM.%26aulast%3DPenson%26aufirst%3DA.%2BM.%26aulast%3DRobson%26aufirst%3DP.%2BA.%26aulast%3DRooker%26aufirst%3DD.%2BP.%26aulast%3DTartar%26aufirst%3DA.%2BL.%26aulast%3DTrim%26aufirst%3DJ.%2BE.%26aulast%3DYea%26aufirst%3DC.%2BM.%26aulast%3DRoe%26aufirst%3DM.%2BB.%26atitle%3DNon-peptide%2520oxytocin%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4585%26epage%3D4589%26doi%3D10.1016%2Fj.bmcl.2004.04.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span> <span> </span><span class="NLM_article-title">Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1562</span>, <span class="refDoi"> DOI: 10.1021/jm901084f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901084f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1546-1562&author=M.+C.+Frantzauthor=J.+Rodrigoauthor=L.+Boudierauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Hibert&title=Subtlety+of+the+structure-affinity+and+structure-efficacy+relationships+around+a+nonpeptide+oxytocin+receptor+agonist&doi=10.1021%2Fjm901084f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm901084f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901084f%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DM.%2BC.%26aulast%3DRodrigo%26aufirst%3DJ.%26aulast%3DBoudier%26aufirst%3DL.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DHibert%26aufirst%3DM.%26atitle%3DSubtlety%2520of%2520the%2520structure-affinity%2520and%2520structure-efficacy%2520relationships%2520around%2520a%2520nonpeptide%2520oxytocin%2520receptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1546%26epage%3D1562%26doi%3D10.1021%2Fjm901084f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. S.</span></span> <span> </span><span class="NLM_article-title">A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: insights into changes in c-Fos immunoreactivity</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.pbb.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25038444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ymsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=367-372&author=P.+K.+Olszewskiauthor=C.+Ulrichauthor=N.+Lingauthor=K.+Allenauthor=A.+S.+Levine&title=A+non-peptide+oxytocin+receptor+agonist%2C+WAY-267%2C464%2C+alleviates+novelty-induced+hypophagia+in+mice%3A+insights+into+changes+in+c-Fos+immunoreactivity&doi=10.1016%2Fj.pbb.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: Insights into changes in c-Fos immunoreactivity</span></div><div class="casAuthors">Olszewski, Pawel K.; Ulrich, Christine; Ling, Nicholas; Allen, Kerry; Levine, Allen S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">367-372</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anxiety caused by the novelty of food or of the environment where the food is presented leads to suppression of consumption (hyponeophagia) reflected by an increased latency to begin feeding and decreased food intake.  Studies suggest that some anxiolytics, mainly benzodiazepines and SSRIs, resolve hyponeophagia.  Though the neurohormone oxytocin (OT) affects both anxiety responsiveness and feeding-related homeostasis, the link between OT and hyponeophagia has not been established.  The current expts. examd. the effect of OT receptor stimulation on hyponeophagia in mice and assocd. changes in brain activity.  We found that the OT receptor agonist, WAY-267,464, at 10 and 30 mg/kg,i.p., reduced the latency to approach food and increased the amt. of food eaten in hyponeophagia tests differing in animals' motivation to eat (hunger, reward) and the anxiogenic context of environmental novelty (illumination and type of the cage).  This effect was abolished by the pretreatment with the OT receptor antagonist, L-368,899, at 10 mg/kg.  The antagonist also suppressed social transmission of preference for novel food.  Mice subjected to novelty conditions causing hypophagia showed significant changes in c-Fos immunoreactivity in the hippocampus, lateral septum, cingulate and piriform cortex and in the bed nucleus of the stria terminalis, lateral division, posterolateral part (STLP).  The pretreatment with WAY-267,464 restored c-Fos levels in the STLP to values detected in control animals subjected to non-anxiogenic conditions.  We conclude that OT plays a role in shaping the magnitude of the novelty stress-provoked hypophagia and the activity of the relevant neural networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdycCb2qN4UrVg90H21EOLACvtfcHk0lhXKwHK050Znw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ymsLfM&md5=a707a62d7989a3a42f14921b653ff323</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DOlszewski%26aufirst%3DP.%2BK.%26aulast%3DUlrich%26aufirst%3DC.%26aulast%3DLing%26aufirst%3DN.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DLevine%26aufirst%3DA.%2BS.%26atitle%3DA%2520non-peptide%2520oxytocin%2520receptor%2520agonist%252C%2520WAY-267%252C464%252C%2520alleviates%2520novelty-induced%2520hypophagia%2520in%2520mice%253A%2520insights%2520into%2520changes%2520in%2520c-Fos%2520immunoreactivity%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2014%26volume%3D124%26spage%3D367%26epage%3D372%26doi%3D10.1016%2Fj.pbb.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span> <span> </span><span class="NLM_article-title">The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats</span>. <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2826.2012.02311.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fj.1365-2826.2012.02311.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=22420322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2it7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=1012-1029&author=C.+Hicksauthor=W.+Jorgensenauthor=C.+Brownauthor=J.+Fardellauthor=J.+Koehbachauthor=C.+W.+Gruberauthor=M.+Kassiouauthor=G.+E.+Huntauthor=I.+S.+McGregor&title=The+nonpeptide+oxytocin+receptor+agonist+WAY+267%2C464%3A+receptor-binding+profile%2C+prosocial+effects+and+distribution+of+c-Fos+expression+in+adolescent+rats&doi=10.1111%2Fj.1365-2826.2012.02311.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats</span></div><div class="casAuthors">Hicks, C.; Jorgensen, W.; Brown, C.; Fardell, J.; Koehbach, J.; Gruber, C. W.; Kassiou, M.; Hunt, G. E.; McGregor, I. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1029</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Previous research suggests that the nonpeptide oxytocin receptor (OTR) agonist WAY 267,464 may only partly mimic the effects of oxytocin in rodents.  The present study further explored these differences and related them to OTR and vasopressin 1a receptor (V1aR) pharmacol. and regional patterns of c-Fos expression.  Binding data for WAY 267,464 and oxytocin were obtained by displacement binding assays on cellular membranes, while functional receptor data were generated by luciferase reporter assays.  For behavioral testing, adolescent rats were tested in a social preference paradigm, the elevated plus-maze (EPM) and for locomotor activity changes following WAY 267,464 (10 and 100 mg/kg, i.p.) or oxytocin (0.1 and 1 mg/kg, i.p.).  The higher doses were also examd. for their effects on regional c-Fos expression.  Results showed that WAY 267,464 had higher affinity (Ki) at the V1aR than the OTR (113 vs. 978 nM).  However, it had no functional response at the V1aR and only a weak functional effect (EC50) at the OTR (881 nM).  This suggests WAY 267,464 is an OTR agonist with weak affinity and a possible V1aR antagonist.  Oxytocin showed high binding at the OTR (1.0 nM) and V1aR (503 nM), with a functional EC50 of 9.0 and 59.7 nM, resp., indicating it is a potent OTR agonist and full V1aR agonist.  WAY 267,464 (100 mg/kg), but not oxytocin, significantly increased the proportion of time spent with a live rat, over a dummy rat, in the social preference test.  Neither compd. affected EPM behavior, whereas the higher doses of WAY 267,464 and oxytocin suppressed locomotor activity.  WAY 267,464 and oxytocin produced similar c-Fos expression in the paraventricular hypothalamic nucleus, central amygdala, lateral parabrachial nucleus and nucleus of the solitary tract, suggesting a commonality of action at the OTR with the differential doses employed.  However, WAY 267,464 caused greater c-Fos expression in the medial amygdala and the supraoptic nucleus than oxytocin, and lesser effects in the locus coeruleus.  Overall, our results confirm the differential effects of WAY 267,464 and oxytocin and suggest that this may reflect contrasting actions of WAY 267,464 and oxytocin at the V1aR.  Antagonism of the V1aR by WAY 267,464 could underlie some of the prosocial effects of this drug either through a direct action or through disinhibition of oxytocin circuitry that is subject to vasopressin inhibitory influences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpfQk61DzJ_7Vg90H21EOLACvtfcHk0lgVZ4vYBP1RJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2it7bF&md5=0c04b65cdb69bc2729c28efebf9a9b27</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02311.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02311.x%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DC.%26aulast%3DJorgensen%26aufirst%3DW.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DFardell%26aufirst%3DJ.%26aulast%3DKoehbach%26aufirst%3DJ.%26aulast%3DGruber%26aufirst%3DC.%2BW.%26aulast%3DKassiou%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DG.%2BE.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26atitle%3DThe%2520nonpeptide%2520oxytocin%2520receptor%2520agonist%2520WAY%2520267%252C464%253A%2520receptor-binding%2520profile%252C%2520prosocial%2520effects%2520and%2520distribution%2520of%2520c-Fos%2520expression%2520in%2520adolescent%2520rats%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D1012%26epage%3D1029%26doi%3D10.1111%2Fj.1365-2826.2012.02311.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weill, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Identification of non peptide Oxytocin receptor ligands by receptor-ligand fingerprint similarity research</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/minf.201100026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1002%2Fminf.201100026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27467153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=521-526&author=N.+Weillauthor=C.+Valenciaauthor=S.+Gioriaauthor=P.+Villaauthor=M.+Hibertauthor=D.+Rognan&title=Identification+of+non+peptide+Oxytocin+receptor+ligands+by+receptor-ligand+fingerprint+similarity+research&doi=10.1002%2Fminf.201100026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Nonpeptide Oxytocin Receptor Ligands by Receptor-Ligand Fingerprint Similarity Search</span></div><div class="casAuthors">Weill, Nathanael; Valencia, Christel; Gioria, Sophie; Villa, Pascal; Hibert, Marcel; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">521-526</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The in silico screening of an inhouse collection of com.-available drug-like compds. (Bioinfo-DB) is presented as part of the global initiative for identifying novel non-peptide oxytocin receptor (OTR) agonists.  Four different virtual screening methods have been used to identify, among a library of com.-available drug-like compds., non-peptide agonists for the oxytocin receptor.  Due to the peculiar ligand space occupied by the single OTR agonist known to date, no hits with the desired functional effect could be found.  However, 10 out of the 128 tested compds. could be characterized as OTR antagonists.  Interestingly, a majority of validated hits were identified by a chemogenomic approach in which target and ligand descriptors are embedded on a single fingerprint.  The good performance of this novel virtual screening method could be explained by the extension of the ref. space to ligands of neighboring receptors.  Chemogenomic approaches to hit identification are particularly promising for receptors for which ligand information is sparse, at the condition that closely related liganded targets are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrieSEshir8GbVg90H21EOLACvtfcHk0lgVZ4vYBP1RJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyrtb0%253D&md5=873fee63631419847293b920ca84dea1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100026%26sid%3Dliteratum%253Aachs%26aulast%3DWeill%26aufirst%3DN.%26aulast%3DValencia%26aufirst%3DC.%26aulast%3DGioria%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520non%2520peptide%2520Oxytocin%2520receptor%2520ligands%2520by%2520receptor-ligand%2520fingerprint%2520similarity%2520research%26jtitle%3DMol.%2520Inf.%26date%3D2011%26volume%3D30%26spage%3D521%26epage%3D526%26doi%3D10.1002%2Fminf.201100026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1021/ci034181a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034181a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVOqt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=1162-1176&author=C.+Bissantzauthor=A.+Logeanauthor=D.+Rognan&title=High-throughput+modeling+of+human+G-protein+coupled+receptors%3A+amino+acid+sequence+alignment%2C+three-dimensional+model+building%2C+and+receptor+library+screening&doi=10.1021%2Fci034181a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput modeling of human g-protein coupled receptors: Amino acid sequence alignment, three-dimensional model building, and receptor library screening</span></div><div class="casAuthors">Bissantz, Caterina; Logean, Antoine; Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1162-1176</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current study describes the development of a computer package (GPCRmod) aimed at the high-throughput modeling of the therapeutically important family of human G-protein coupled receptors (GPCRs).  GPCRmod first proposes a reliable alignment of the seven transmembrane domains (7 TMs) of most druggable human GPCRs based on pattern/motif recognition for each of the 7 TMs that are considered independently.  It then converts the alignment into knowledge-based three-dimensional (3-D) models starting from a set of 3-D backbone templates and two sep. rotamer libraries for side chain positioning.  The 7 TMs of 277 human GPCRs have been accurately aligned, unambiguously clustered in three different classes (rhodopsin-like, secretin-like, metabotropic glutamate-like), and converted into high-quality 3-D models at a remarkable throughput (∼3s/model).  A 3-D GPCR target library of 277 receptors has consequently been setup.  Its utility for "in silico" inverse screening purpose has been demonstrated by recovering among top scorers the receptor of a selective GPCR antagonist as well as the receptors of a promiscuous antagonist.  The current GPCR target library thus constitutes a 3-D database of choice to address as soon as possible the "virtual selectivity" profile of any GPCR antagonist or inverse agonist in an early hit optimization process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC6Zv_92nPmrVg90H21EOLACvtfcHk0ljk39A0ihG3pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVOqt74%253D&md5=6037a68d2d7ba136a5ab51c822d681f1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fci034181a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034181a%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DLogean%26aufirst%3DA.%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DHigh-throughput%2520modeling%2520of%2520human%2520G-protein%2520coupled%2520receptors%253A%2520amino%2520acid%2520sequence%2520alignment%252C%2520three-dimensional%2520model%2520building%252C%2520and%2520receptor%2520library%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2004%26volume%3D44%26spage%3D1162%26epage%3D1176%26doi%3D10.1021%2Fci034181a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=9223568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaK2sXksFyhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1997&pages=301-308&author=A.+Taharaauthor=Y.+Tomuraauthor=K.+Wadaauthor=T.+Kusayamaauthor=J.+Tsukadaauthor=M.+Takanashiauthor=T.+Yatsuauthor=W.+Uchidaauthor=A.+Tanaka&title=Pharmacological+profile+of+YM087%2C+a+novel+potent+nonpeptide+vasopressin+V1a+and+V2+receptor+antagonist%2C+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A an V2 receptor antagonist, in vitro and in vivo</span></div><div class="casAuthors">Tahara, Atsuo; Tomura, Yuichi; Wada, Koh-Ichi; Kusayama, Toshiyuki; Tsukada, Junko; Takanashi, Masahiro; Yatsu, Takeyuki; Uchida, Wataru; Tanaka, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The biochem. and pharmacol. profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies.  YM087 showed high affinity for V1A receptors from rat liver and V2 receptors from rat kidney with Ki values of 0.48 and 3.04 mM, resp.  YM087 also inhibited [3H]oxytocin (OT) binding to rat uterus (OT receptors) plasma membranes with a Ki value of 44.4 nM, and at 100 μM did not affect the binding of [3H]AVP to anterior pituitary (V1B receptors) plasma membranes, which indicated that it had less affinity for these OT and V1B receptors.  YM087 had no effect on cytosolic free calcium concn. ([Ca++]i) itself, but suppressed AVP-induced increase in [Ca++]i of cultured vascular smooth muscle cells at the same concns. as the binding affinities.  Furthermore, YM087 potently blocked AVP-induced cAMP prodn. of cultured renal epithelium cells concn. dependently and had no agonistic activities.  In in vivo studies, i.v. administration of YM087 inhibited the pressor response to exogenous AVP in pithed rats and produced an aquaretic effect in dehydrated conscious rats in a dose-dependent manner.  These results demonstrate that YM087 is a potent and nonpeptide dual AVP V1A and V2 receptors antagonist and can be used in future studies of help clarify the physiol. and pathophysiol. roles of AVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT7lS9DQiIOLVg90H21EOLACvtfcHk0ljk39A0ihG3pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksFyhsr4%253D&md5=d6e3fabcafeabccef789a6af06a143cc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DTomura%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DKusayama%26aufirst%3DT.%26aulast%3DTsukada%26aufirst%3DJ.%26aulast%3DTakanashi%26aufirst%3DM.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DW.%26aulast%3DTanaka%26aufirst%3DA.%26atitle%3DPharmacological%2520profile%2520of%2520YM087%252C%2520a%2520novel%2520potent%2520nonpeptide%2520vasopressin%2520V1a%2520and%2520V2%2520receptor%2520antagonist%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D282%26spage%3D301%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2004.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.phrs.2004.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=15661579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2MXms1Grtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2005&pages=275-281&author=A.+Taharaauthor=J.+Tsukadaauthor=Y.+Tomuraauthor=T.+Kusayamaauthor=K.+Wadaauthor=N.+Ishiiauthor=N.+Taniguchiauthor=T.+Suzukiauthor=T.+Yatsuauthor=W.+Uchidaauthor=M.+Shibasaki&title=Effects+of+YM218%2C+a+nonpeptide+vasopressin+V1A+receptor-selective+antagonist%2C+on+human+vasopressin+and+oxytocin+receptors&doi=10.1016%2Fj.phrs.2004.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors</span></div><div class="casAuthors">Tahara, Atsuo; Tsukada, Junko; Tomura, Yuichi; Kusayama, Toshiyuki; Wada, Koh-ichi; Ishii, Noe; Taniguchi, Nobuaki; Suzuki, Takeshi; Yatsu, Takeyuki; Uchida, Wataru; Shibasaki, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-281</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The binding and signal transduction characteristics of YM218 ((Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene]-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl}-2-methyl-3-furanilide hemifumarate), a newly synthesized, potent arginine vasopressin (AVP) V1A receptor-selective antagonist, were examd. using cloned human AVP receptors (V1A, V1B and V2) stably expressed in Chinese hamster ovary (CHO) cells and human uterine smooth muscle cells (USMCs) expressing oxytocin receptors.  YM218 potently inhibited specific binding of [3H] AVP to V1A receptors, exhibiting a Ki value of 0.30 nM.  In contrast, YM218 exhibited much lower affinity for V1B, V2 and oxytocin receptors, exhibiting Ki values of 25,500 nM, 381 nM and 71.0 nM, resp.  In CHO cells expressing V1A receptors, YM218 potently inhibited the AVP-induced increase in intracellular Ca2+ concn. ([Ca2+]i), exhibiting an IC50 value of 0.25 nM.  However, in human USMCs expressing oxytocin receptors, YM218 exhibited a much lower potency in inhibiting the oxytocin-induced [Ca2+]i increase, showing an IC50 value of 607 nM, and had no effect on the AVP-induced [Ca2+]i increase in CHO cells expressing V1B receptors.  Furthermore, in CHO cells expressing V2 receptors, YM218 did not potently inhibit the prodn. of cAMP stimulated by AVP, showing an IC50 value of 62.2 nM.  In all assays used, YM218 did not exhibit any agonistic activity.  These results demonstrate that YM218 is a potent, nonpeptide human V1A receptor-selective antagonist, and that YM218 will be a valuable new tool to gain further insight into the physiol. and pharmacol. actions of AVP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokm-gZ2HMQ37Vg90H21EOLACvtfcHk0ljk39A0ihG3pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXms1Grtg%253D%253D&md5=3efcb5c96b5071304e1bab201913c86c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2004.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2004.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DTahara%26aufirst%3DA.%26aulast%3DTsukada%26aufirst%3DJ.%26aulast%3DTomura%26aufirst%3DY.%26aulast%3DKusayama%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DTaniguchi%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DW.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DEffects%2520of%2520YM218%252C%2520a%2520nonpeptide%2520vasopressin%2520V1A%2520receptor-selective%2520antagonist%252C%2520on%2520human%2520vasopressin%2520and%2520oxytocin%2520receptors%26jtitle%3DPharmacol.%2520Res.%26date%3D2005%26volume%3D51%26spage%3D275%26epage%3D281%26doi%3D10.1016%2Fj.phrs.2004.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybczynski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McComsey, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunnet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villani, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damiano, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6623</span>– <span class="NLM_lpage">6628</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2007.09.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6623-6628&author=M.+A.+Xiangauthor=P.+J.+Rybczynskiauthor=M.+Patelauthor=R.+H.+Chenauthor=D.+F.+McComseyauthor=H.+C.+Zhangauthor=J.+W.+Gunnetauthor=R.+Lookauthor=Y.+Wangauthor=L.+K.+Minorauthor=H.+M.+Zhongauthor=F.+J.+Villaniauthor=K.+T.+Demarestauthor=B.+P.+Damianoauthor=B.+E.+Maryanoff&title=Next-generation+spirobenzazepines%3A+identification+of+RWJ-676070+as+a+balanced+vasopressin+V1a%2FV2+receptor+antagonist+for+human+clinical+studies&doi=10.1016%2Fj.bmcl.2007.09.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.059%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DM.%2BA.%26aulast%3DRybczynski%26aufirst%3DP.%2BJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DR.%2BH.%26aulast%3DMcComsey%26aufirst%3DD.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BC.%26aulast%3DGunnet%26aufirst%3DJ.%2BW.%26aulast%3DLook%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMinor%26aufirst%3DL.%2BK.%26aulast%3DZhong%26aufirst%3DH.%2BM.%26aulast%3DVillani%26aufirst%3DF.%2BJ.%26aulast%3DDemarest%26aufirst%3DK.%2BT.%26aulast%3DDamiano%26aufirst%3DB.%2BP.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DNext-generation%2520spirobenzazepines%253A%2520identification%2520of%2520RWJ-676070%2520as%2520a%2520balanced%2520vasopressin%2520V1a%252FV2%2520receptor%2520antagonist%2520for%2520human%2520clinical%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6623%26epage%3D6628%26doi%3D10.1016%2Fj.bmcl.2007.09.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimae, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.bjp.0703221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10780976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2000&pages=1700-1706&author=S.+Nakamuraauthor=Y.+Yamamuraauthor=S.+Itohauthor=T.+Hiranoauthor=K.+Tsujimaeauthor=M.+Aoyamaauthor=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=K.+Kanauthor=Y.+Tanadaauthor=S.+Teramotoauthor=T.+Sumidaauthor=S.+Nakayamaauthor=K.+Sekiguchiauthor=T.+Kambeauthor=G.+Tsujimotoauthor=T.+Moriauthor=M.+Tominaga&title=Characterization+of+a+novel+nonpeptide+vasopressin+V2-agonist%2C+OPC-51803%2C+in+cells+transfected+human+vasopressin+receptor+subtypes&doi=10.1038%2Fsj.bjp.0703221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes</span></div><div class="casAuthors">Nakamura, Shigeki; Yamamura, Yoshitaka; Itoh, Shuji; Hirano, Takahiro; Tsujimae, Kenji; Aoyama, Masashi; Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kan, Keizo; Tanada, Yoshihisa; Teramoto, Shuji; Sumida, Takumi; Nakayama, Sunao; Sekiguchi, Kazuo; Kambe, Toshimi; Tsujimoto, Gozoh; Mori, Toyoki; Tominaga, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1700-1706</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We discovered the first nonpeptide arginine-vasopressin (AVP) V2-receptor agonist, OPC-51803.  Pharmacol. properties of OPC-51803 were elucidated using HeLa cells expressing human AVP receptor subtypes (V2, V1a and V1b) and compared with those of 1-desamino-8-D-arginine vasopressin (dDAVP), a peptide V2-receptor agonist.  OPC-51803 and dDAVP displaced [3H]-AVP binding to human V2- and V1a-receptors with Ki values of 91.9±10.8 nM (n=6) and 3.12±0.38 nM (n=6) for V2-receptors, and 819±39 nM (n=6) and 41.5±9.9 nM (n=6) for V1a-receptors, indicating that OPC-51803 was about nine times more selective for V2-receptors, similar to the selectivity of dDAVP.  OPC-51803 scarcely displaced [3H]-AVP binding to human V1b-receptors even at 10-4 M, while dDAVP showed potent affinity to human V1b-receptors with the Ki value of 13.7±3.2 nM (n=4).  OPC-51803 concn.-dependently increased cyclic adenosine 3', 5'-monophosphate (cAMP) prodn. in HeLa cells expressing human V2-receptors with an EC50 value of 189±14 nM (n=6).  The concn.-response curve for cAMP prodn. induced by OPC-51803 was shifted to the right in the presence of a V2-antagonist, OPC-31260.  At 10-5 M, OPC-51803 did not increase the intracellular Ca2+ concn. ([Ca2+]i) in HeLa cells expressing human V1a-receptors.  On the other hand, dDAVP increased [Ca2+]i in HeLa cells expressing human V1a- and V1b-receptors in a concn.-dependent fashion.  From these results, OPC-51803 has been confirmed to be the first nonpeptide agonist for human AVP V2-receptors without agonistic activities for V1a- and V1b-receptors.  OPC-51803 may be useful for the treatment of AVP-deficient pathophysiol. states and as a tool for AVP researches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP6Ey2VlQ77Vg90H21EOLACvtfcHk0liUCQb9Lp71ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtV2ru7k%253D&md5=435c824ff32701169445cb4a1c35a94c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703221%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DTsujimae%26aufirst%3DK.%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DTeramoto%26aufirst%3DS.%26aulast%3DSumida%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DKambe%26aufirst%3DT.%26aulast%3DTsujimoto%26aufirst%3DG.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520nonpeptide%2520vasopressin%2520V2-agonist%252C%2520OPC-51803%252C%2520in%2520cells%2520transfected%2520human%2520vasopressin%2520receptor%2520subtypes%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D129%26spage%3D1700%26epage%3D1706%26doi%3D10.1038%2Fsj.bjp.0703221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuhisa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, I.</span></span> <span> </span><span class="NLM_article-title">Nonpeptide arginine vasopressin antagonists for both V1a and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4′-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide derivatives</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1870</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1248/cpb.45.1870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1248%2Fcpb.45.1870" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1997&pages=1870-1874&author=A.+Matsuhisaauthor=A.+Tanakaauthor=K.+Kikuchiauthor=Y.+Shimadaauthor=T.+Yatsuauthor=I.+Yanagisawa&title=Nonpeptide+arginine+vasopressin+antagonists+for+both+V1a+and+V2+receptors%3A+synthesis+and+pharmacological+properties+of+2-phenyl-4%E2%80%B2-%5B%282%2C3%2C4%2C5-tetrahydro-1H-1-benzazepin-1-yl%29carbonyl%5Dbenzanilide+derivatives&doi=10.1248%2Fcpb.45.1870"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1248%2Fcpb.45.1870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.45.1870%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuhisa%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DKikuchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DYatsu%26aufirst%3DT.%26aulast%3DYanagisawa%26aufirst%3DI.%26atitle%3DNonpeptide%2520arginine%2520vasopressin%2520antagonists%2520for%2520both%2520V1a%2520and%2520V2%2520receptors%253A%2520synthesis%2520and%2520pharmacological%2520properties%2520of%25202-phenyl-4%25E2%2580%25B2-%255B%25282%252C3%252C4%252C5-tetrahydro-1H-1-benzazepin-1-yl%2529carbonyl%255Dbenzanilide%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1997%26volume%3D45%26spage%3D1870%26epage%3D1874%26doi%3D10.1248%2Fcpb.45.1870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itai, A.</span></span> <span> </span><span class="NLM_article-title">Novel design of nonpeptide AVP V2 receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4388</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.1021/jm000108p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000108p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKgtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4388-4397&author=K.+Kondoauthor=H.+Ogawaauthor=T.+Shinoharaauthor=M.+Kurimuraauthor=Y.+Tanadaauthor=K.+Kanauthor=H.+Yamashitaauthor=S.+Nakamuraauthor=T.+Hiranoauthor=Y.+Yamamuraauthor=T.+Moriauthor=M.+Tominagaauthor=A.+Itai&title=Novel+design+of+nonpeptide+AVP+V2+receptor+agonists%3A+structural+requirements+for+an+agonist+having+1-%284-aminobenzoyl%29-2%2C3%2C4%2C5-tetrahydro-1H-1-benzazepine+as+a+template&doi=10.1021%2Fjm000108p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Design of Nonpeptide AVP V2 Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template</span></div><div class="casAuthors">Kondo, Kazumi; Ogawa, Hidenori; Shinohara, Tomoichi; Kurimura, Muneaki; Tanada, Yoshihisa; Kan, Keizo; Yamashita, Hiroshi; Nakamura, Shigeki; Hirano, Takahiro; Yamamura, Yoshitaka; Mori, Toyoki; Tominaga, Michiaki; Itai, Akiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4388-4397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a series of nonpeptide arginine vasopressin V2 receptor agonists is described.  After identifying the aniline deriv. (I) as our lead compd. from the metabolites of a previously studied compd. that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken.  These studies led to a series of compds. e.g. (II) that show potent agonist activity for the V2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr32gXY0qnlHLVg90H21EOLACvtfcHk0liUCQb9Lp71ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKgtbY%253D&md5=4d92852bb3625fa50e5ebe2cb504e04e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm000108p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000108p%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DKurimura%26aufirst%3DM.%26aulast%3DTanada%26aufirst%3DY.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26aulast%3DItai%26aufirst%3DA.%26atitle%3DNovel%2520design%2520of%2520nonpeptide%2520AVP%2520V2%2520receptor%2520agonists%253A%2520structural%2520requirements%2520for%2520an%2520agonist%2520having%25201-%25284-aminobenzoyl%2529-2%252C3%252C4%252C5-tetrahydro-1H-1-benzazepine%2520as%2520a%2520template%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4388%26epage%3D4397%26doi%3D10.1021%2Fjm000108p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932. Treatment of central diabetes insipidus, treatment of nocturnal enuresis, treatment of nocturia, vasopressin V2 agonist</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932.+Treatment+of+central+diabetes+insipidus%2C+treatment+of+nocturnal+enuresis%2C+treatment+of+nocturia%2C+vasopressin+V2+agonist&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0lhBQrDeuF8omw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932.%2520Treatment%2520of%2520central%2520diabetes%2520insipidus%252C%2520treatment%2520of%2520nocturnal%2520enuresis%252C%2520treatment%2520of%2520nocturia%252C%2520vasopressin%2520V2%2520agonist%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Failli, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shumsky, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trybulski, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanikella, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span> <span> </span><span class="NLM_article-title">Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.10.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.bmcl.2005.10.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16297621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Khsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=954-959&author=A.+A.+Failliauthor=J.+S.+Shumskyauthor=R.+J.+Steffanauthor=T.+J.+Caggianoauthor=D.+K.+Williamsauthor=E.+J.+Trybulskiauthor=X.+Ningauthor=Y.+Lockauthor=T.+Tanikellaauthor=D.+Hartmannauthor=P.+S.+Chanauthor=C.+H.+Park&title=Pyridobenzodiazepines%3A+a+novel+class+of+orally+active%2C+vasopressin+V2+receptor+selective+agonists&doi=10.1016%2Fj.bmcl.2005.10.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridobenzodiazepines: A novel class of orally active, vasopressin V2 receptor selective agonists</span></div><div class="casAuthors">Failli, Amedeo A.; Shumsky, Jay S.; Steffan, Robert J.; Caggiano, Thomas J.; Williams, David K.; Trybulski, Eugene J.; Ning, Xiaoping; Lock, Yeungwai; Tanikella, Tarak; Hartmann, David; Chan, Peter S.; Park, C. H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">954-959</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our efforts in seeking low mol. wt. agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clin. candidate WAY-151932 (VNA-932).  Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEEecZqI4Di7Vg90H21EOLACvtfcHk0lhBQrDeuF8omw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Khsw%253D%253D&md5=b334797a5b857d47f0aff692664250a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.10.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.10.107%26sid%3Dliteratum%253Aachs%26aulast%3DFailli%26aufirst%3DA.%2BA.%26aulast%3DShumsky%26aufirst%3DJ.%2BS.%26aulast%3DSteffan%26aufirst%3DR.%2BJ.%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DTrybulski%26aufirst%3DE.%2BJ.%26aulast%3DNing%26aufirst%3DX.%26aulast%3DLock%26aufirst%3DY.%26aulast%3DTanikella%26aufirst%3DT.%26aulast%3DHartmann%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DP.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BH.%26atitle%3DPyridobenzodiazepines%253A%2520a%2520novel%2520class%2520of%2520orally%2520active%252C%2520vasopressin%2520V2%2520receptor%2520selective%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D954%26epage%3D959%26doi%3D10.1016%2Fj.bmcl.2005.10.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of heteroaryl benzoic acids via Suzuki reaction</span>. <i>Synlett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=829-831&author=Y.+Gongauthor=H.+W.+Pauls&title=A+convenient+synthesis+of+heteroaryl+benzoic+acids+via+Suzuki+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520heteroaryl%2520benzoic%2520acids%2520via%2520Suzuki%2520reaction%26jtitle%3DSynlett.%26date%3D2000%26volume%3D6%26spage%3D829%26epage%3D831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span> <span> </span><span class="NLM_article-title">Diisobutylaluminium hydride: a novel reagent for the reduction of oximes</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4711</span>– <span class="NLM_lpage">4712</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)86234-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2FS0040-4039%2800%2986234-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=4711-4712&author=S.+Sasataniauthor=T.+Miyazakiauthor=K.+Maruokaauthor=H.+Yamamoto&title=Diisobutylaluminium+hydride%3A+a+novel+reagent+for+the+reduction+of+oximes&doi=10.1016%2FS0040-4039%2800%2986234-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2986234-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252986234-6%26sid%3Dliteratum%253Aachs%26aulast%3DSasatani%26aufirst%3DS.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DMaruoka%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DH.%26atitle%3DDiisobutylaluminium%2520hydride%253A%2520a%2520novel%2520reagent%2520for%2520the%2520reduction%2520of%2520oximes%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D4711%26epage%3D4712%26doi%3D10.1016%2FS0040-4039%2800%2986234-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span> <span> </span><span class="NLM_article-title">7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1743</span>– <span class="NLM_lpage">1754</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(99)00101-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2FS0968-0896%2899%2900101-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=1743-1754&author=K.+Kondoauthor=H.+Ogawaauthor=H.+Yamashitaauthor=H.+Miyamotoauthor=M.+Tanakaauthor=K.+Nakayaauthor=K.+Kitanoauthor=Y.+Yamamuraauthor=S.+Nakamuraauthor=T.+Onogawaauthor=T.+Moriauthor=M.+Tominaga&title=7-chloro-5-hydroxy-1-%5B2-methyl-4-%282-methylbenzoyl-amino%29benzoyl%5D-2%2C3%2C4%2C5-tetrahydro-1H-1-benzazepine+%28OPC-41061%29%3A+a+potent%2C+orally+active+nonpeptide+arginine+vasopressin+V2+receptor+antagonist&doi=10.1016%2FS0968-0896%2899%2900101-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900101-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900101-7%26sid%3Dliteratum%253Aachs%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DMiyamoto%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DNakaya%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DOnogawa%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26atitle%3D7-chloro-5-hydroxy-1-%255B2-methyl-4-%25282-methylbenzoyl-amino%2529benzoyl%255D-2%252C3%252C4%252C5-tetrahydro-1H-1-benzazepine%2520%2528OPC-41061%2529%253A%2520a%2520potent%252C%2520orally%2520active%2520nonpeptide%2520arginine%2520vasopressin%2520V2%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D1743%26epage%3D1754%26doi%3D10.1016%2FS0968-0896%2899%2900101-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakaya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominaga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, Y.</span></span> <span> </span><span class="NLM_article-title">Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3547</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1021/jm960133o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960133o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3547-3555&author=H.+Ogawaauthor=H.+Yamashitaauthor=K.+Kondoauthor=Y.+Yamamuraauthor=H.+Miyamotoauthor=K.+Kanauthor=K.+Kitanoauthor=M.+Tanakaauthor=K.+Nakayaauthor=S.+Nakamuraauthor=T.+Moriauthor=M.+Tominagaauthor=Y.+Yabuuchi&title=Orally+active%2C+nonpeptide+vasopressin+V2+receptor+antagonists%3A+a+novel+series+of+1-%5B4-%28benzoylamino%29benzoyl%5D-2%2C3%2C4%2C5-tetrahydro-1H-benzazepines+and+related+compounds&doi=10.1021%2Fjm960133o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm960133o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960133o%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DY.%26aulast%3DMiyamoto%26aufirst%3DH.%26aulast%3DKan%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DNakaya%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTominaga%26aufirst%3DM.%26aulast%3DYabuuchi%26aufirst%3DY.%26atitle%3DOrally%2520active%252C%2520nonpeptide%2520vasopressin%2520V2%2520receptor%2520antagonists%253A%2520a%2520novel%2520series%2520of%25201-%255B4-%2528benzoylamino%2529benzoyl%255D-2%252C3%252C4%252C5-tetrahydro-1H-benzazepines%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3547%26epage%3D3555%26doi%3D10.1021%2Fjm960133o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuliopulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, J. K.</span></span> <span> </span><span class="NLM_article-title">Alkyltransferase model reactions: synthesis of sulfonium and ammonium compounds containing neighboring nucleophiles. Kinetic studies of the intramolecular reaction of amino, hydroxy, phenoxy, and mercapto onium salts</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1021/jo00275a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00275a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=3436-3448&author=R.+J.+Millerauthor=A.+Kuliopulosauthor=J.+K.+Coward&title=Alkyltransferase+model+reactions%3A+synthesis+of+sulfonium+and+ammonium+compounds+containing+neighboring+nucleophiles.+Kinetic+studies+of+the+intramolecular+reaction+of+amino%2C+hydroxy%2C+phenoxy%2C+and+mercapto+onium+salts&doi=10.1021%2Fjo00275a034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjo00275a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00275a034%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BJ.%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCoward%26aufirst%3DJ.%2BK.%26atitle%3DAlkyltransferase%2520model%2520reactions%253A%2520synthesis%2520of%2520sulfonium%2520and%2520ammonium%2520compounds%2520containing%2520neighboring%2520nucleophiles.%2520Kinetic%2520studies%2520of%2520the%2520intramolecular%2520reaction%2520of%2520amino%252C%2520hydroxy%252C%2520phenoxy%252C%2520and%2520mercapto%2520onium%2520salts%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D3436%26epage%3D3448%26doi%3D10.1021%2Fjo00275a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, G. R.</span></span> <span> </span><span class="NLM_article-title">Azabenzocycloheptenones. Part III. 2,3,4,5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz[b]azepine</span>. <i>J. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_fpage">3989</span>– <span class="NLM_lpage">3994</span>, <span class="refDoi"> DOI: 10.1039/jr9610003989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1039%2Fjr9610003989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaF38XisFSgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1961&pages=3989-3994&author=G.+R.+Proctor&title=Azabenzocycloheptenones.+Part+III.+2%2C3%2C4%2C5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz%5Bb%5Dazepine&doi=10.1039%2Fjr9610003989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Azabenzocycloheptenones. III. 2,3,4,5-Tetrahydro-5- oxo-1-toluene-p-sulfonylbenz[b]azepine</span></div><div class="casAuthors">Proctor, G. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3989-94</span>CODEN:
                <span class="NLM_cas:coden">JCSOA9</span>;
        ISSN:<span class="NLM_cas:issn">0368-1769</span>.
    </div><div class="casAbstract">cf. CA 51, 14754g.-2,3,4,5-Tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (I), now available in good yield, could not be dehydrogenated by bromination dehydrobromination procedures, but it could be oxidized to an α-dione which gave an enol acetate.  Although this represented a partial dehydrogenation, the p-tosyl group could not be extruded nor could the amino dione be obtained by std. methods.  The basic ketone, 2,3,4,5-tetrahydro-5-oxobenz[b]azepine (II), could be obtained by hydrolysis of the p-tosylate (III).  Me N-(p-tolylsulfonyl)anthranilate (302 g.), 300 g. anhyd. Na2CO3, and 1.5l.  Decalin refluxed with addn. during 1.5 h. of 234 g. Et γ-bromobutyrate, after 4 h. the mixt. cooled, dild., filtered, and the residue washed, the solvents evapd., and the product crystd. gave 197 g. Et γ-[N-(o-methoxycarbonylphenyl)-p-toluenesulfonamido]butyrate (IV), m. 98-100° (alc.).  K (10 g.) in excess Me3COH evapd., and 1l. PhMe added, this refluxing mixt. treated with 50 g. IV in 500 mL.  PhMe during 2 h., and worked up gave 2,3,4,5-tetrahydro-5-oxo-4-carbethoxy-1- (p-tolylsulfonyl)benz[b]azepine (V), m. 120° (ligroine); 2,4-dinitrophenylhydrazone m. 208° (MeOH-AcOH).  V (42.5 g.) refluxed with 100 mL. alc., 300 mL. AcOH, 50 mL. concd. HCl, and 50 mL. H2O 8 h. and the product chromatographed gave 71% 2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (III), m. 126° (MeOH).  III (9.7 g.), 10 mL. HCO2Et, and 160 mL. PhMe at 0° treated with NaOEt (from 6 g. Na) in 80 mL.  PhMe at 0°, left 24 h. at 20°, washed, and the product crystd. gave 8.7 g. 2,3,4,5-tetrahydro-4-hydroxymethylene-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VI), m. 126° (ligroine); 2,4-dinitrophenylhydrazone, crimson needles, m. 207°; Me ether m. 197°.  III (6.6 g.) in 100 mL. CHCl3 treated 1 h. at 20° with 1 mL. Br gave 7 g. 4-bromo-2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine x2(VIa), m. 132° (MeOH); 2,4-dinitrophenylhydrazone m. 236°. III (4.8 g.) in 100 mL. CHCl3 treated with 1.47 mL. Br gave 5.6 g. 4,4-dibromo-2,3,4,5-tetrahydro-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VIb), m. 173° (alc.), failed to form a 2,4-dinitrophenylhydrazone.  III (4.92 g.), 200 mL. concd. HCl, and 200 mL. AcOH refluxed 8 h., extd. with CHCl3, and the product isolated gave 600 mg. II, b0.1 135-40°; 2,4-dinitrophenylhydrazone, violet solid, m. 248°; picrate m. 228°.  The ketone (0.64 g.) heated 3 h. with 10 g. polyphosphoric acid and extd. with CHCl3 gave 148 mg. crude II.  III (1.17 g.) in 15 mL. THF stirred 10 min. with 2 g. Ca in 100 mL. liq. NH3 gave 100 mg. crude II.  VI (5.6 g.) in 150 mL. EtOAc treated at -70° with 72.5% of the calcd. amt. of O3, hydrogenated over Pd(OH)2-BaCO3, and the product isolated gave 2.43 g. 2,3,4,5-tetrahydro-4,5-dioxo-1-(p-tolylsulfonyl)benz[b]azepine (VII), m. 148° (ligroine); 2,4-dinitrophenylhydrazone, orange, m. 252°; quinoxaline deriv., yellow solid, m. 198°.  When VII was chromatographed on active Al2O3, elution with CHCl3 gave a poor yield of product, m. 142°, judged to be the Et ether of the enol ketone; the oxime m. 136°.  VIa (5.4 g.) in 100 mL. AcOH refluxed 2 h. with 1.95 g. SeO2 in 10 mL. H2O, filtered, stirred with Hg, dild. with H2O, and extd. with CHCl3 gave 4.7 g. VII.  VIb (1.38 g.), 3.5 g. KHCO3, and 50 mL. H2O refluxed 4 h., extd. with CHCl3, and the product isolated gave 0.93 g. crude VII. VII (380 mg.) in 25 mL. MeOH left 1 h. with 1 mL. 10% NaOH and the ext. sepd. gave 350 mg. unchanged VII.  VII (1.8 g.) in 60 mL. PhMe treated with 4 g. Ca in 150 liq. NH3, after 3 min. 8 g. dry PhBr in 50 mL. PhMe added, the mixt. stirred 2 h., acidified, extd., and distd. gave 80 mg. oil, whose IR spectrum, although similar to that of II, lacked the detail.  VII (1.39 g.), 90 mL. isopropenyl acetate, and 4 drops concd. H2SO4 refluxed 2 h. and the crude product either crystd. or chromatographed on Al2O3 failed to give pure product.  When this enol acetate was treated with KOCMe3 in PhMe at room temp. it was recovered in 65% yield, the remainder, 20%, being a S-contg. acid which could not be purified.  VII (2 g.) treated 80 min. at 165-70° with polyphosphoric acid gave a black insol. residue contg. S which could not be purified.  At low temps. similar insol. materials were obtained accompanied by traces of starting material.  VII (0.21 g.), 25 mL. AcOH, and 0.22 g. Br left 4 days at 20°, poured into 100 mL. H2O and 30 mL. CHCl3, evapd., and the product crystd. gave VIb.  Treatment of VIa with an alc. soln. of 2,4-dinitrophenylhydrazine contg. concd. HCl gave the 2,4-dinitrophenylhydrazone, m. 236°.  VIa (3.34 g.), 115 mL. CCl4, and 25 mL. NEt3 refluxed 7 h., evapd., and the product chromatographed on Al2O3 gave 1.6 g. starting material and 1.1 g. of very crude VIa.  VIa (3 g.) refluxed 24 h. with 40 mL. collidine, cooled, treated with dil. HCl and CHCl3, washed, and the residual oil chromatographed on Al2O3 gave 0.8 g. III.  Similar treatment 28 h. at 100° with collidine gave 75% unchanged VIa.  VIb (2.84 g.) refluxed 7 h. with 15 mL. NEt3 and the product crystd. gave 510 mg. VIa.  VIa (1.78 g.) refluxed 1 h. with 60 mL. alc. and 20 mL. 10% Na2CO1, extd. with CHCl3, and the 1.45 g. of tarry residue chromatographed on silica gel gave impure 2,3,4,5-tetrahydro-4-hydroxy-5-oxo-1-(p-tolylsulfonyl)benz[b]azepine (VIII), m. 196°; 2,4-dinitrophenylhydrazone, m. 231°.  VIII (120 mg.), 1 g. P2O5, and 40 mL. PhMe refluxed 6 h., cooled, dild. with H2O, washed, and the product chromatographed on Al2O3 gave 10 mg. cryst. product, m. 152°.  Basification of the acid washings gave 10 mg. of a basic ketone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogyg-Ye4oQN7Vg90H21EOLACvtfcHk0lgaK6Dh01A9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XisFSgtw%253D%253D&md5=bb83bc20780bf400e47e2885c4f67c8f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1039%2Fjr9610003989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fjr9610003989%26sid%3Dliteratum%253Aachs%26aulast%3DProctor%26aufirst%3DG.%2BR.%26atitle%3DAzabenzocycloheptenones.%2520Part%2520III.%25202%252C3%252C4%252C5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz%255Bb%255Dazepine%26jtitle%3DJ.%2520Chem.%2520Soc.%26date%3D1961%26spage%3D3989%26epage%3D3994%26doi%3D10.1039%2Fjr9610003989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boeglin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span> <span> </span><span class="NLM_article-title">Solid-phase preparation of a pilot library derived from the 2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-amine scaffold</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1021/cc060164x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc060164x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=487-500&author=D.+Boeglinauthor=D.+Bonnetauthor=M.+Hibert&title=Solid-phase+preparation+of+a+pilot+library+derived+from+the+2%2C3%2C4%2C5-tetrahydro-1H-benzo%5Bb%5Dazepin-5-amine+scaffold&doi=10.1021%2Fcc060164x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-Phase Preparation of a Pilot Library Derived from the 2,3,4,5-Tetrahydro-1H-benzo[b]azepin-5-amine Scaffold</span></div><div class="casAuthors">Boeglin, Damien; Bonnet, Dominique; Hibert, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">487-500</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convenient and reliable solid-phase strategy for the synthesis of di- and trisubstituted benzazepine derivs. was developed.  5-Amino-1-tert-butoxycarbonyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine and 5-amino-1-tert-butoxycarbonyl-7-bromo-2,3,4,5-tetrahydro-1H-benzo[b]azepine G-protein coupled receptor-targeted (GPCR-targeted) scaffolds were efficiently synthesized in a six-step soln.-phase process, immobilized on the acid-labile FMPB-AM resin, and further functionalized through acylation, sulfonation, reductive amination, alkylation, and Suzuki or Buchwald-Hartwig cross-coupling reactions.  The efficacy of this strategy was exemplified by the prepn. of an original pilot library of di- and trisubstituted benzazepines I (R1 = Me2CHCH2CH2, cyclohexyl, Ph, n-PrCO, PhCO, 4-MeOC6H4SO2, PhNHCO, etc.; R2 = H2NCH2CO, n-PrCO, PhCO, 4-MeOC6H4SO2, etc.; R3 = H, Me2CHCH2, Ph, 4-NCC6H4, 2-thienyl, 1-pyrrolidinyl, etc.) obtained in high purity as assessed by both 1H NMR and liq. chromatog./mass spectrometry (LC/MS) anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozJa1TkOwR_bVg90H21EOLACvtfcHk0ljBSqCMjf61gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislKktb4%253D&md5=96a2d16179d8878e596445f455c35fca</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fcc060164x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc060164x%26sid%3Dliteratum%253Aachs%26aulast%3DBoeglin%26aufirst%3DD.%26aulast%3DBonnet%26aufirst%3DD.%26aulast%3DHibert%26aufirst%3DM.%26atitle%3DSolid-phase%2520preparation%2520of%2520a%2520pilot%2520library%2520derived%2520from%2520the%25202%252C3%252C4%252C5-tetrahydro-1H-benzo%255Bb%255Dazepin-5-amine%2520scaffold%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2007%26volume%3D9%26spage%3D487%26epage%3D500%26doi%3D10.1021%2Fcc060164x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Martino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filacchioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, R.</span></span> <span> </span><span class="NLM_article-title">Ricerche su sostanze ad attivita’ antiblastica</span>. <i>Il Farmaco – Ed. Sc.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">284</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=5822122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaF1MXps1Oktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1969&pages=276-284&author=M.+Articoauthor=G.+De+Martinoauthor=G.+Filacchioniauthor=R.+Giuliano&title=Ricerche+su+sostanze+ad+attivita%E2%80%99+antiblastica"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Antiblastic agents.  XXXVI.  Anthramycin and analogous compounds.  1.  Synthesis of 10,11-dihydro-5H-pyrrolo-[2,1-s][1,4]-benzodiazepine</span></div><div class="casAuthors">Artico, Marino; De Martino, Giovanni; Filacchioni, G.; Giuliano, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco, Edizione Scientifica</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-84</span>CODEN:
                <span class="NLM_cas:coden">FRPSAX</span>;
        ISSN:<span class="NLM_cas:issn">0430-0920</span>.
    </div><div class="casAbstract">10-(R-Substituted)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepines (I) are prepd.  Thus, N is passed through a soln. of 4.75 g. 2-pyrrolecarboxaldehyde in 100 ml. tetrahydrofuran (THF), 1.56 g. K is added, the mixt. is refluxed to give a soln., a soln. of 8.64 g. o-O2NC6H4COBr in 100 ml. THF is added, and the mixt. is agitated 8 hrs. at 65° to give 1-(o-nitrobenzoyl)-2-pyrrolecarboxaldehyde (II), m. 136-8°; oxime m. 130-2°.  II (2.3 g.) is dissolved in 250 ml. mixt. of EtOAc and EtOH and hydrogenated over 200 mg. 10% Pd/C 3 hrs. at 4 atm. to give 1.2 g. 10,11-dihydro-5H-pyrrolo-[2,1-c][1,4]benzodiazepine (III), m. 152-4° (decompn.).  III is converted to the following I (R and m.p. given): Ac, 154-5°; ClCH2CO, 122-3°; Cl2CHCO, 118-19°.  Ir data are given; also given is the ir spectrum of III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3kywPi1TwNrVg90H21EOLACvtfcHk0ljBSqCMjf61gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXps1Oktw%253D%253D&md5=b66a573f9e4491d69d10c3488c0d7aa3</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DDe%2BMartino%26aufirst%3DG.%26aulast%3DFilacchioni%26aufirst%3DG.%26aulast%3DGiuliano%26aufirst%3DR.%26atitle%3DRicerche%2520su%2520sostanze%2520ad%2520attivita%25E2%2580%2599%2520antiblastica%26jtitle%3DIl%2520Farmaco%2520%25E2%2580%2593%2520Ed.%2520Sc.%26date%3D1969%26volume%3D24%26spage%3D276%26epage%3D284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caggiano, T. J.</span></span> <span> </span><span class="NLM_article-title">WAY-VNA-932</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1358/dof.2002.027.03.659890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1358%2Fdof.2002.027.03.659890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2002&pages=248-253&author=T.+J.+Caggiano&title=WAY-VNA-932&doi=10.1358%2Fdof.2002.027.03.659890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-VNA-932</span></div><div class="casAuthors">Caggiano, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-253</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review. WAY-VNA-932 is a novel, orally active nonpeptide small mol. which exhibits vasopressin V2 receptor agonism.  In CHO cells transfected with human V1a, V2, V1b and oxytocin receptors, WAY-VNA-932 is a potent agonist at the V2 receptor, with an EC50 for 2nd messenger (cAMP) generation of 0.7 nM.  In water-loaded normotensive rats, Brattleboro rats, dogs and cynomolgus monkeys WAY-VNA-932 lowers urine output in a dose-dependent manner with a concomitant increase in osmolality.  It is expected that WAY-VNA-932 will offer several advantages over desmopressin, a peptide vasopressin V2 agonist, including greater and more consistent bioavailability and the lack of pressor activity.  WAY-VNA-932 is expected to be useful in conditions characterized by excessive prodn. and/or diln. of urine such as central diabetes insipidus and nocturnal enuresis as well as in conditions characterized by inappropriate prodn. of vasopressin.  WAY-VNA-932 is the 1st nonpeptide vasopressin V2 agonist to enter phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqod3Z1TipNcrVg90H21EOLACvtfcHk0ljBSqCMjf61gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslaitL4%253D&md5=4d8946fd3c506cd1b9d20658d5ca0d42</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1358%2Fdof.2002.027.03.659890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2002.027.03.659890%26sid%3Dliteratum%253Aachs%26aulast%3DCaggiano%26aufirst%3DT.%2BJ.%26atitle%3DWAY-VNA-932%26jtitle%3DDrugs%2520Future%26date%3D2002%26volume%3D27%26spage%3D248%26epage%3D253%26doi%3D10.1358%2Fdof.2002.027.03.659890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karpenko, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margathe, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflimlin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span> <span> </span><span class="NLM_article-title">Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2552</span>, <span class="refDoi"> DOI: 10.1021/jm501395b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501395b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2547-2552&author=I.+A.+Karpenkoauthor=J.+F.+Margatheauthor=T.+Rodriguezauthor=E.+Pflimlinauthor=E.+Dupuisauthor=M.+Hibertauthor=T.+Durrouxauthor=D.+Bonnet&title=Selective+nonpeptidic+fluorescent+ligands+for+oxytocin+receptor%3A+design%2C+synthesis%2C+and+application+to+time-resolved+FRET+binding+assay&doi=10.1021%2Fjm501395b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Nonpeptidic Fluorescent Ligands for Oxytocin Receptor: Design, Synthesis, and Application to Time-Resolved FRET Binding Assay</span></div><div class="casAuthors">Karpenko, Iuliia A.; Margathe, Jean-Francois; Rodriguez, Thieric; Pflimlin, Elsa; Dupuis, Elodie; Hibert, Marcel; Durroux, Thierry; Bonnet, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2547-2552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and the synthesis of the first high-affinity fluorescent ligands for oxytocin receptor (OTR) are described.  These compds. enabled the development of a TR-FRET based assay for OTR, readily amenable to high throughput screening.  The validation of the assay was achieved by competition expts. with both peptide and nonpeptide OTR ligands as competitors.  These probes represent the first selective fluorescent ligands for the oxytocin G protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYix67Nh90z7Vg90H21EOLACvtfcHk0ljJ4t0pSbpDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2ju74%253D&md5=7ba9dddc66ed6bafb60b83cbc2efc9ff</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm501395b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501395b%26sid%3Dliteratum%253Aachs%26aulast%3DKarpenko%26aufirst%3DI.%2BA.%26aulast%3DMargathe%26aufirst%3DJ.%2BF.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DPflimlin%26aufirst%3DE.%26aulast%3DDupuis%26aufirst%3DE.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DSelective%2520nonpeptidic%2520fluorescent%2520ligands%2520for%2520oxytocin%2520receptor%253A%2520design%252C%2520synthesis%252C%2520and%2520application%2520to%2520time-resolved%2520FRET%2520binding%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2547%26epage%3D2552%26doi%3D10.1021%2Fjm501395b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, A. D.</span></span> <span> </span><span class="NLM_article-title">Oral oxytocin antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6525</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1021/jm901812z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901812z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6525-6538&author=A.+D.+Borthwick&title=Oral+oxytocin+antagonists&doi=10.1021%2Fjm901812z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Oxytocin Antagonists</span></div><div class="casAuthors">Borthwick, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6525-6538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics and oral bioavailability of oxytocin antagonists is discussed.  Templates investigated in the previous decade contravene the Lipinski "role of five", which accounts for their poor oral bioavailability, but this is not the case with the more recent compds.  Mol. structure and properties of different compds. are studied in view if their efficiency, bioavailability, bioaccumulation, and applicability, penetration of the blood brain barrier, accumulation in the brain, and blocking central effects of oxytocin both in the fetus and in the mother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRMlf_5Dp9rVg90H21EOLACvtfcHk0ljJ4t0pSbpDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D&md5=4fd042ed2404adeae482a27ca77d07a9</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm901812z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901812z%26sid%3Dliteratum%253Aachs%26aulast%3DBorthwick%26aufirst%3DA.%2BD.%26atitle%3DOral%2520oxytocin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6525%26epage%3D6538%26doi%3D10.1021%2Fjm901812z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelhalter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Merrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span> <span> </span><span class="NLM_article-title">Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1038/npp.2014.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2014.59" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=2049-2060&author=J.+A.+Beckerauthor=D.+Clesseauthor=C.+Spiegelhalterauthor=Y.+Schwabauthor=J.+Le+Merrerauthor=B.+L.+Kieffer&title=Autistic-like+syndrome+in+mu+opioid+receptor+null+mice+is+relieved+by+facilitated+mGluR4+activity&doi=10.1038%2Fnpp.2014.59"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2014.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2014.59%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DJ.%2BA.%26aulast%3DClesse%26aufirst%3DD.%26aulast%3DSpiegelhalter%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DY.%26aulast%3DLe%2BMerrer%26aufirst%3DJ.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26atitle%3DAutistic-like%2520syndrome%2520in%2520mu%2520opioid%2520receptor%2520null%2520mice%2520is%2520relieved%2520by%2520facilitated%2520mGluR4%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D2049%26epage%3D2060%26doi%3D10.1038%2Fnpp.2014.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, F. R.</span></span> <span> </span><span class="NLM_article-title">Deficit in attachment behavior in mice lacking the mu-opioid receptor gene</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1983</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1126/science.1095943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1095943" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1983-1986&author=A.+Molesauthor=B.+L.+Kiefferauthor=F.+R.+D%E2%80%99Amato&title=Deficit+in+attachment+behavior+in+mice+lacking+the+mu-opioid+receptor+gene&doi=10.1126%2Fscience.1095943"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1126%2Fscience.1095943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1095943%26sid%3Dliteratum%253Aachs%26aulast%3DMoles%26aufirst%3DA.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DF.%2BR.%26atitle%3DDeficit%2520in%2520attachment%2520behavior%2520in%2520mice%2520lacking%2520the%2520mu-opioid%2520receptor%2520gene%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1983%26epage%3D1986%26doi%3D10.1126%2Fscience.1095943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellissier, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandía, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laboute, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Merrer, J.</span></span> <span> </span><span class="NLM_article-title">μ opioid receptor, social behaviour and autism spectrum disorder: reward matters</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2750</span>– <span class="NLM_lpage">2769</span>, <span class="refDoi"> DOI: 10.1111/bph.13808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fbph.13808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=28369738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2750-2769&author=L.+P.+Pellissierauthor=J.+Gand%C3%ADaauthor=T.+Labouteauthor=J.+A.+Beckerauthor=J.+Le+Merrer&title=%CE%BC+opioid+receptor%2C+social+behaviour+and+autism+spectrum+disorder%3A+reward+matters&doi=10.1111%2Fbph.13808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">μ opioid receptor, social behavior and autism spectrum disorder: reward matters</span></div><div class="casAuthors">Pellissier, Lucie P.; Gandia, Jorge; Laboute, Thibaut; Becker, Jerome A. J.; Le Merrer, Julie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2750-2769</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The endogenous opioid system is well known to relieve pain and underpin the rewarding properties of most drugs of abuse.  Among opioid receptors, the μ receptor mediates most of the analgesic and rewarding properties of opioids.  Based on striking similarities between social distress, phys. pain and opiate withdrawal, μ receptors have been proposed to play a crit. role in modulating social behavior in humans and animals.  This review summarizes exptl. data demonstrating such role and proposes a novel model, the μ opioid receptor balance model, to account for the contribution of μ receptors to the subtle regulation of social behavior.  Interestingly, μ receptor null mice show behavioral deficits similar to those obsd. in patients with autism spectrum disorder (ASD), including severe impairment in social interactions.  Therefore, after a brief summary of recent evidence for blunted (social) reward processes in subjects with ASD, we review here arguments for altered μ receptor function in this pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK2xMRtV0S8rVg90H21EOLACvtfcHk0ljJ4t0pSbpDDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyjsbw%253D&md5=f14f43165e45b7c9a22d59c0f6cd09c8</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1111%2Fbph.13808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13808%26sid%3Dliteratum%253Aachs%26aulast%3DPellissier%26aufirst%3DL.%2BP.%26aulast%3DGand%25C3%25ADa%26aufirst%3DJ.%26aulast%3DLaboute%26aufirst%3DT.%26aulast%3DBecker%26aufirst%3DJ.%2BA.%26aulast%3DLe%2BMerrer%26aufirst%3DJ.%26atitle%3D%25CE%25BC%2520opioid%2520receptor%252C%2520social%2520behaviour%2520and%2520autism%2520spectrum%2520disorder%253A%2520reward%2520matters%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2750%26epage%3D2769%26doi%3D10.1111%2Fbph.13808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dölen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darvishzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1038/nature12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnature12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=24025838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntlyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=179-184&author=G.+D%C3%B6lenauthor=A.+Darvishzadehauthor=K.+W.+Huangauthor=R.+C.+Malenka&title=Social+reward+requires+coordinated+activity+of+nucleus+accumbens+oxytocin+and+serotonin&doi=10.1038%2Fnature12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin</span></div><div class="casAuthors">Dolen Gul; Darvishzadeh Ayeh; Huang Kee Wui; Malenka Robert C</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">179-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Social behaviours in species as diverse as honey bees and humans promote group survival but often come at some cost to the individual.  Although reinforcement of adaptive social interactions is ostensibly required for the evolutionary persistence of these behaviours, the neural mechanisms by which social reward is encoded by the brain are largely unknown.  Here we demonstrate that in mice oxytocin acts as a social reinforcement signal within the nucleus accumbens core, where it elicits a presynaptically expressed long-term depression of excitatory synaptic transmission in medium spiny neurons.  Although the nucleus accumbens receives oxytocin-receptor-containing inputs from several brain regions, genetic deletion of these receptors specifically from dorsal raphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus accumbens, abolishes the reinforcing properties of social interaction.  Furthermore, oxytocin-induced synaptic plasticity requires activation of nucleus accumbens 5-HT1B receptors, the blockade of which prevents social reward.  These results demonstrate that the rewarding properties of social interaction in mice require the coordinated activity of oxytocin and 5-HT in the nucleus accumbens, a mechanistic insight with implications for understanding the pathogenesis of social dysfunction in neuropsychiatric disorders such as autism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtavUaLESyEAaK-_ZudimnfW6udTcc2eaQldxQRiNFq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntlyruw%253D%253D&md5=4253ec1c708c193707c9ae25d1464e92</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12518%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6len%26aufirst%3DG.%26aulast%3DDarvishzadeh%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DK.%2BW.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DSocial%2520reward%2520requires%2520coordinated%2520activity%2520of%2520nucleus%2520accumbens%2520oxytocin%2520and%2520serotonin%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D179%26epage%3D184%26doi%3D10.1038%2Fnature12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gigliucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonzino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palladino, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amato, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chini, B.</span></span> <span> </span><span class="NLM_article-title">Region specific up-regulation of oxytocin receptors in the opioid oprm1 (−/−) mouse model of autism</span>. <i>Front Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">91</span>, <span class="refDoi"> DOI: 10.3389/fped.2014.00091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffped.2014.00091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25225634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A280%3ADC%252BC2M7hvVCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=91&author=V.+Gigliucciauthor=M.+Leonzinoauthor=M.+Busnelliauthor=A.+Luchettiauthor=V.+S.+Palladinoauthor=F.+R.+D%E2%80%99Amatoauthor=B.+Chini&title=Region+specific+up-regulation+of+oxytocin+receptors+in+the+opioid+oprm1+%28%E2%88%92%2F%E2%88%92%29+mouse+model+of+autism&doi=10.3389%2Ffped.2014.00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Region specific up-regulation of oxytocin receptors in the opioid oprm1 (-/-) mouse model of autism</span></div><div class="casAuthors">Gigliucci Valentina; Leonzino Marianna; Busnelli Marta; Chini Bice; Luchetti Alessandra; Palladino Viola Stella; D'Amato Francesca R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pediatrics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91</span>
        ISSN:<span class="NLM_cas:issn">2296-2360</span>.
    </div><div class="casAbstract">Autism spectrum disorders (ASDs) are characterized by impaired communication, social impairments, and restricted and repetitive behaviors and interests.  Recently, altered motivation and reward processes have been suggested to participate in the physiopathology of ASDs, and μ-opioid receptors (MORs) have been investigated in relation to social reward due to their involvement in the neural circuitry of reward.  Mice lacking a functional MOR gene (Oprm1 (-/-) mice) display abnormal social behavior and major autistic-like core symptoms, making them an animal model of autism.  The oxytocin (OXT) system is a key regulator of social behavior and co-operates with the opioidergic system in the modulation of social behavior.  To better understand the opioid-OXT interplay in the central nervous system, we first determined the expression of the oxytocin receptor (OXTR) in the brain of WT C57BL6/J mice by quantitative autoradiography; we then evaluated OXTR regional alterations in Oprm1 (-/-) mice.  Moreover, we tested these mice in a paradigm of social behavior, the male-female social interaction test, and analyzed the effects of acute intranasal OXT treatment on their performance.  In autoradiography, Oprm1 (-/-) mice selectively displayed increased OXTR expression in the Medial Anterior Olfactory Nucleus, the Central and Medial Amygdaloid nuclei, and the Nucleus Accumbens.  Our behavioral results confirmed that Oprm1 (-/-) male mice displayed social impairments, as indicated by reduced ultrasonic calls, and that these were rescued by a single intranasal administration of OXT.  Taken together, our results provide evidence of an interaction between OXT and opioids in socially relevant brain areas and in the modulation of social behavior.  Moreover, they suggest that the oxytocinergic system may act as a compensative mechanism to bypass and/or restore alterations in circuits linked to impaired social behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQFICkwsHpyhpyrDyM_m9cfW6udTcc2eaQldxQRiNFq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7hvVCltg%253D%253D&md5=206d770aa6aaa486b64e1eb040940135</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffped.2014.00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffped.2014.00091%26sid%3Dliteratum%253Aachs%26aulast%3DGigliucci%26aufirst%3DV.%26aulast%3DLeonzino%26aufirst%3DM.%26aulast%3DBusnelli%26aufirst%3DM.%26aulast%3DLuchetti%26aufirst%3DA.%26aulast%3DPalladino%26aufirst%3DV.%2BS.%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DF.%2BR.%26aulast%3DChini%26aufirst%3DB.%26atitle%3DRegion%2520specific%2520up-regulation%2520of%2520oxytocin%2520receptors%2520in%2520the%2520opioid%2520oprm1%2520%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2520mouse%2520model%2520of%2520autism%26jtitle%3DFront%2520Pediatr.%26date%3D2014%26volume%3D2%26spage%3D91%26doi%3D10.3389%2Ffped.2014.00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulliver, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werry, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">740</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.ejmech.2015.11.050" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=730-740&author=W.+T.+Jorgensenauthor=D.+Gulliverauthor=E.+L.+Werryauthor=T.+Reekieauthor=M.+Connorauthor=M.+Kassiou&title=Flexible+analogues+of+WAY-267%2C464%3A+Synthesis+and+pharmacology+at+the+human+oxytocin+and+vasopressin+1a+receptors&doi=10.1016%2Fj.ejmech.2015.11.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.050%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BT.%26aulast%3DGulliver%26aufirst%3DD.%26aulast%3DWerry%26aufirst%3DE.%2BL.%26aulast%3DReekie%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DFlexible%2520analogues%2520of%2520WAY-267%252C464%253A%2520Synthesis%2520and%2520pharmacology%2520at%2520the%2520human%2520oxytocin%2520and%2520vasopressin%25201a%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D730%26epage%3D740%26doi%3D10.1016%2Fj.ejmech.2015.11.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. J.</span></span> <span> </span><span class="NLM_article-title">ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2152</span>, <span class="refDoi"> DOI: 10.1021/ci034134i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci034134i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFSjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=2137-2152&author=T.+J.+Houauthor=X.+J.+Xu&title=ADME+evaluation+in+drug+discovery.+3.+Modeling+blood-brain+barrier+partitioning+using+simple+molecular+descriptors&doi=10.1021%2Fci034134i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">ADME Evaluation in Drug Discovery. 3. Modeling Blood-Brain Barrier Partitioning Using Simple Molecular Descriptors</span></div><div class="casAuthors">Hou, T. J.; Xu, X. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2137-2152</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, QSPR models were developed for in vivo blood-brain partitioning data (logBB) of a large data set consisting of 115 diverse org. compds.  The best model is based on three descriptors: n-octanol/water partition coeff. calcd. using the SLOGP approach, logP; high-charged polar surface areas based on the Gasteiger partial charges, HCPSA, and the excessive mol. wt. larger than 360, MW360.  The model bears good statistical significance, n = 78, r = 0.88, q = 0.86, s = 0.36, F = 81.5.  The actual prediction potential of the model was validated through two external validation sets of 37 diverse compds.  The predicted results demonstrate that the model bears better prediction potential than many other models and can be used for logBB estns. for drug and drug-like mols.  Comparison of several logP calcn. approaches suggests that logP calcd. by SLOGP can be used as a significant descriptor for the prediction of mol. transport properties because SLOGP gives the most similar results with CLOGP.  The QSPR model indicates that larger polar surface areas have a more neg. contribution to logBB, but the abs. partial charges on the atoms surrounded by the polar surfaces should be larger than 0.10|e|. Meanwhile, tight junction membranes limit the size of hydrophilic mols. that can cross the membrane with a mol. wt. of approx. 360, because when a mol.'s wt. is larger than 360 it shows a neg. contribution to logBB.  The computations of mol. surface, partial charges, logP, and logBB have been accomplished using a program called Drug-BB. Moreover, to improve the efficiency of the computations of logP, we made an extensive reparametrization of SLOGP, and the newly developed SLOGP model is only based on simple at. addn.  Further, we developed a set of parameters to calc. the topol. polar surface area (TPSA), thus the high-charged topol. polar surface area (HCTPSA) could be estd. from the 2D connection information of a mol.  Adopting the new strategies, the estns. of logP, HCTPSA, and logBB are only based on the topol. structure of a mol. and therefore, can be used for fast screening of virtual libraries having millions of mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC2FViiKM9xbVg90H21EOLACvtfcHk0lgQktQroQrNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFSjs7w%253D&md5=f7562b8bcba229cb19189075d769e07c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fci034134i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci034134i%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DT.%2BJ.%26aulast%3DXu%26aufirst%3DX.%2BJ.%26atitle%3DADME%2520evaluation%2520in%2520drug%2520discovery.%25203.%2520Modeling%2520blood-brain%2520barrier%2520partitioning%2520using%2520simple%2520molecular%2520descriptors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D2137%26epage%3D2152%26doi%3D10.1021%2Fci034134i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span> <i>MarvinSketch 6.0.0</i>; <span class="NLM_publisher-name">ChemAxon Software</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MarvinSketch+6.0.0%3B+ChemAxon+Software%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMarvinSketch%25206.0.0%26pub%3DChemAxon%2520Software%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">GTEx
Consortium</span> <span> </span><span class="NLM_article-title">The genotype-tissue
expression (GTEx) pilot analysis: multitissue gene regulation in humans</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1126/science.1262110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1126%2Fscience.1262110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=648-660&author=GTEx%0AConsortium&title=The+genotype-tissue%0Aexpression+%28GTEx%29+pilot+analysis%3A+multitissue+gene+regulation+in+humans&doi=10.1126%2Fscience.1262110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.1262110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1262110%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520genotype-tissue%250Aexpression%2520%2528GTEx%2529%2520pilot%2520analysis%253A%2520multitissue%2520gene%2520regulation%2520in%2520humans%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D648%26epage%3D660%26doi%3D10.1126%2Fscience.1262110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisgo, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harkin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copp, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerrelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clowry, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxhead, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santibanez-Koref, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnery, P. F.</span></span> <span> </span><span class="NLM_article-title">HDBR expression: a unique resource for global and individual gene expression studies during early human brain development</span>. <i>Front. Neuroanat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.3389/fnana.2016.00086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.3389%2Ffnana.2016.00086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27833533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSkt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=86&author=S.+J.+Lindsayauthor=Y.+Xuauthor=S.+N.+Lisgoauthor=L.+F.+Harkinauthor=A.+J.+Coppauthor=D.+Gerrelliauthor=G.+J.+Clowryauthor=A.+Talbotauthor=M.+J.+Keoghauthor=J.+Coxheadauthor=M.+Santibanez-Korefauthor=P.+F.+Chinnery&title=HDBR+expression%3A+a+unique+resource+for+global+and+individual+gene+expression+studies+during+early+human+brain+development&doi=10.3389%2Ffnana.2016.00086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">HDBR expression: a unique resource for global and individual gene expression studies during early human brain development</span></div><div class="casAuthors">Lindsay, Susan J.; Xu, Yaobo; Lisgo, Steven N.; Harkin, Lauren F.; Copp, Andrew J.; Gerrelli, Dianne; Clowry, Gavin J.; Talbot, Aysha; Keogh, Michael J.; Coxhead, Jonathan; Santibanez-Koref, Mauro; Chinnery, Patrick F.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Neuroanatomy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86/1-86/6</span>CODEN:
                <span class="NLM_cas:coden">FNREB8</span>;
        ISSN:<span class="NLM_cas:issn">1662-5129</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX8kPQZqNCb7Vg90H21EOLACvtfcHk0lgQktQroQrNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSkt7jI&md5=93e969cd21d81473902d3926a6979aec</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffnana.2016.00086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnana.2016.00086%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DS.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLisgo%26aufirst%3DS.%2BN.%26aulast%3DHarkin%26aufirst%3DL.%2BF.%26aulast%3DCopp%26aufirst%3DA.%2BJ.%26aulast%3DGerrelli%26aufirst%3DD.%26aulast%3DClowry%26aufirst%3DG.%2BJ.%26aulast%3DTalbot%26aufirst%3DA.%26aulast%3DKeogh%26aufirst%3DM.%2BJ.%26aulast%3DCoxhead%26aufirst%3DJ.%26aulast%3DSantibanez-Koref%26aufirst%3DM.%26aulast%3DChinnery%26aufirst%3DP.%2BF.%26atitle%3DHDBR%2520expression%253A%2520a%2520unique%2520resource%2520for%2520global%2520and%2520individual%2520gene%2520expression%2520studies%2520during%2520early%2520human%2520brain%2520development%26jtitle%3DFront.%2520Neuroanat.%26date%3D2016%26volume%3D10%26spage%3D86%26doi%3D10.3389%2Ffnana.2016.00086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udelson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghiade, M.</span></span> <span> </span><span class="NLM_article-title">Dual vasopressin V1a/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure?</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2017.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1016%2Fj.cardfail.2017.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=29329950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislOru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=112-114&author=S.+R.+Goldsmithauthor=J.+E.+Udelsonauthor=M.+Gheorghiade&title=Dual+vasopressin+V1a%2FV2+antagonism%3A+the+next+step+in+neurohormonal+modulation+in+patients+with+heart+failure%3F&doi=10.1016%2Fj.cardfail.2017.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?</span></div><div class="casAuthors">Goldsmith, Steven R.; Udelson, James E.; Gheorghiade, Mihai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-114</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stimulation of the V1a receptor for arginine vasopressin produces myocardial and vascular effects similar to those of angiotensin II while stimulation of the V2 receptor causes fluid retention.  There are no data with sustained blockade of the V1a receptor while single-dose expts. suggest benefit.  Acute and chronic administration of selective V2 receptor antagonists reliably relieves dyspnea and produces diuresis without adverse effects on renal function or neurohormonal stimulation, either as adjunctive or alternative therapy to loop diuretics, but has not been shown to improve outcomes as adjunctive therapy.  Combined antagonism has been tried only in single-dose studies in stable patients or over the short-term in acute heart failure, with encouraging results.  Based on the both the pathophysiol. rationale for addnl. neurohormonal blockade and these results, chronically blocking both receptors, particularly in more congested patients, may offer significant benefit either as adjunctive or alternative therapy to std. diuretics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpPlZ5rW25pLVg90H21EOLACvtfcHk0ljq_lc_zoGaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislOru7g%253D&md5=61bba1d09f25ba888698dcb9dab8f53a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2017.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2017.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26aulast%3DUdelson%26aufirst%3DJ.%2BE.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DDual%2520vasopressin%2520V1a%252FV2%2520antagonism%253A%2520the%2520next%2520step%2520in%2520neurohormonal%2520modulation%2520in%2520patients%2520with%2520heart%2520failure%253F%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2018%26volume%3D24%26spage%3D112%26epage%3D114%26doi%3D10.1016%2Fj.cardfail.2017.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagitani-Shimono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanefuji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniike, M.</span></span> <span> </span><span class="NLM_article-title">Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders</span>. <i>J. Child Adolesc. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1089/cap.2012.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1089%2Fcap.2012.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=23480321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=123-127&author=M.+Tachibanaauthor=K.+Kagitani-Shimonoauthor=I.+Mohriauthor=T.+Yamamotoauthor=W.+Sanefujiauthor=A.+Nakamuraauthor=M.+Oishiauthor=T.+Kimuraauthor=T.+Onakaauthor=K.+Ozonoauthor=M.+Taniike&title=Long-term+administration+of+intranasal+oxytocin+is+a+safe+and+promising+therapy+for+early+adolescent+boys+with+autism+spectrum+disorders&doi=10.1089%2Fcap.2012.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Long-Term Administration of Intranasal Oxytocin Is a Safe and Promising Therapy for Early Adolescent Boys with Autism Spectrum Disorders</span></div><div class="casAuthors">Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Nakamura, Ayumi; Oishi, Masako; Kimura, Tadashi; Onaka, Tatsushi; Ozono, Keiichi; Taniike, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Child and Adolescent Psychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-127</span>CODEN:
                <span class="NLM_cas:coden">JADPET</span>;
        ISSN:<span class="NLM_cas:issn">1044-5463</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated.  However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified.  Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10-14 years of age; intelligence quotient [IQ] 20-101).  The OT administration was performed in a stepwise increased dosage manner every 2 mo (8, 16, 24 IU/dose).  A placebo period (1-2 wk) was inserted before each step.  The outcome measures were Autism Diagnostic Observation Schedule - Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC).  In addn., side effects were monitored by measuring blood pressure and examg. urine and blood samples.  Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G.  However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement.  Caregivers of five of the eight participants reported certain pos. effects of the OT therapy, esp. on the quality of reciprocal communication.  All participants showed excellent compliance and no side effects.  Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD.  Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1W2Z4_SZIxbVg90H21EOLACvtfcHk0ljq_lc_zoGaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVKlurw%253D&md5=8b84a3857e1b54023f3b4d181b1e2f37</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1089%2Fcap.2012.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcap.2012.0048%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DKagitani-Shimono%26aufirst%3DK.%26aulast%3DMohri%26aufirst%3DI.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DSanefuji%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DOishi%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DOnaka%26aufirst%3DT.%26aulast%3DOzono%26aufirst%3DK.%26aulast%3DTaniike%26aufirst%3DM.%26atitle%3DLong-term%2520administration%2520of%2520intranasal%2520oxytocin%2520is%2520a%2520safe%2520and%2520promising%2520therapy%2520for%2520early%2520adolescent%2520boys%2520with%2520autism%2520spectrum%2520disorders%26jtitle%3DJ.%2520Child%2520Adolesc.%2520Psychopharmacol.%26date%3D2013%26volume%3D23%26spage%3D123%26epage%3D127%26doi%3D10.1089%2Fcap.2012.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umbricht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Valle Rubido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shic, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scahill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noeldeke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khwaja, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squassante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundschober, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kletzl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontoura, P.</span></span> <span> </span><span class="NLM_article-title">A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1923</span>, <span class="refDoi"> DOI: 10.1038/npp.2016.232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fnpp.2016.232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=27711048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2gtLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1914-1923&author=D.+Umbrichtauthor=M.+Del+Valle+Rubidoauthor=E.+Hollanderauthor=J.+T.+McCrackenauthor=F.+Shicauthor=L.+Scahillauthor=J.+Noeldekeauthor=L.+Boakauthor=O.+Khwajaauthor=L.+Squassanteauthor=C.+Grundschoberauthor=H.+Kletzlauthor=P.+Fontoura&title=A+single+dose%2C+randomized%2C+controlled+proof-of-mechanism+study+of+a+novel+vasopressin+1a+receptor+antagonist+%28RG7713%29+in+high-functioning+adults+with+autism+spectrum+disorder&doi=10.1038%2Fnpp.2016.232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder</span></div><div class="casAuthors">Umbricht, Daniel; del Valle Rubido, Marta; Hollander, Eric; McCracken, James T.; Shic, Frederick; Scahill, Lawrence; Noeldeke, Jana; Boak, Lauren; Khwaja, Omar; Squassante, Lisa; Grundschober, Christophe; Kletzl, Heidemarie; Fontoura, Paulo</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1914-1923</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The core symptoms of autism spectrum disorder (ASD) include impaired social communication, repetitive behaviors, and restricted interests.  No effective pharmacotherapy for these core deficits exists.  Within the domain of social communication, the vasopressin system is implicated in social cognition and social signaling deficits of ASD, and represents a potential therapeutic target.  We assessed the effects of a single 20 mg i.v. dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exploratory biomarkers (eye tracking), behavioral and clin. measures of social cognition and communication (affective speech recognition (ASR), reading the mind in the eyes, olfactory identification, scripted interaction), and safety and tolerability in a multicenter, randomized, double-blind, placebo-controlled, cross-over study of 19 high-functioning adult male subjects with DSM-IV Autistic Disorder (age 18-45 years; full scale IQ >70; ABC-Irritability subscale ≤13).  Eye-tracking showed an increase in biol. motion orienting preference with RG7713 (ES=0.8, p=0.047) and a non-significant improvement in the composite score (ES=0.2, p=0.29).  RG7713 reduced ability to detect lust (ES=-0.8, p=0.03) and fear (ES=-0.7, p=0.07) in ASR.  However, when all eight individual emotion subscales were combined into an overall ASR performance score, the redn. was non-significant (ES=-0.1, p=0.59).  Thirteen adverse events were reported in 10 subjects; all were of mild (11/13) or moderate (2/13) severity.  Although interpretation should be cautious due to multiple comparisons and small sample size, these results provide preliminary evidence from exptl. and behavioral biomarkers, that blockade of the V1a receptor may improve social communication in adults with high-functioning ASD.  ClinicalTrials.gov identifier: NCT01474278 A Study of RO5028442 in Adult Male High-Functioning Autistic Patients.  Available at: https://clinicaltrials.gov/ct2/show/NCT01474278.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAsg9CGg4pmLVg90H21EOLACvtfcHk0ljq_lc_zoGaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2gtLvE&md5=c0cfa97b338f184d08a073f21ab0fe7c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.232%26sid%3Dliteratum%253Aachs%26aulast%3DUmbricht%26aufirst%3DD.%26aulast%3DDel%2BValle%2BRubido%26aufirst%3DM.%26aulast%3DHollander%26aufirst%3DE.%26aulast%3DMcCracken%26aufirst%3DJ.%2BT.%26aulast%3DShic%26aufirst%3DF.%26aulast%3DScahill%26aufirst%3DL.%26aulast%3DNoeldeke%26aufirst%3DJ.%26aulast%3DBoak%26aufirst%3DL.%26aulast%3DKhwaja%26aufirst%3DO.%26aulast%3DSquassante%26aufirst%3DL.%26aulast%3DGrundschober%26aufirst%3DC.%26aulast%3DKletzl%26aufirst%3DH.%26aulast%3DFontoura%26aufirst%3DP.%26atitle%3DA%2520single%2520dose%252C%2520randomized%252C%2520controlled%2520proof-of-mechanism%2520study%2520of%2520a%2520novel%2520vasopressin%25201a%2520receptor%2520antagonist%2520%2528RG7713%2529%2520in%2520high-functioning%2520adults%2520with%2520autism%2520spectrum%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1914%26epage%3D1923%26doi%3D10.1038%2Fnpp.2016.232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passoni, I.</span>; <span class="NLM_string-name">Leonzino, M.</span>; <span class="NLM_string-name">Gigliucci, V.</span>; <span class="NLM_string-name">Chini, B.</span>; <span class="NLM_string-name">Busnelli, M.</span></span> <span> </span><span class="NLM_article-title">Carbetocin is a functional selective Gq agonist that does not promote oxytocin receptor recycling after inducing β-arrestin-independent internalisation</span>.  <i>J. Neuroendocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">28</span>(<span class="NLM_issue">4</span>), doi: <span class="refDoi"> DOI: 10.1111/jne.12363</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1111%2Fjne.12363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=26751410" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&issue=4&author=I.+Passoni&author=M.+Leonzino&author=V.+Gigliucci&author=B.+Chini&author=M.+Busnelli&title=Carbetocin+is+a+functional+selective+Gq+agonist+that+does+not+promote+oxytocin+receptor+recycling+after+inducing+%CE%B2-arrestin-independent+internalisation&doi=10.1111%2Fjne.12363"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1111%2Fjne.12363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjne.12363%26sid%3Dliteratum%253Aachs%26aulast%3DPassoni%26aufirst%3DI.%26atitle%3DCarbetocin%2520is%2520a%2520functional%2520selective%2520Gq%2520agonist%2520that%2520does%2520not%2520promote%2520oxytocin%2520receptor%2520recycling%2520after%2520inducing%2520%25CE%25B2-arrestin-independent%2520internalisation%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2016%26volume%3D28%26issue%3D4%26doi%3D10.1111%2Fjne.12363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffante, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curcuruto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslam, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arban, R.</span></span> <span> </span><span class="NLM_article-title">Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2Fsj.bjp.0706383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=16158071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKht7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2005&pages=744-751&author=C.+Griffanteauthor=A.+Greenauthor=O.+Curcurutoauthor=C.+P.+Haslamauthor=B.+A.+Dickinsonauthor=R.+Arban&title=Selectivity+of+d%5BCha4%5DAVP+and+SSR149415+at+human+vasopressin+and+oxytocin+receptors%3A+evidence+that+SSR149415+is+a+mixed+vasopressin+V1b%2Foxytocin+receptor+antagonist&doi=10.1038%2Fsj.bjp.0706383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist</span></div><div class="casAuthors">Griffante, Cristiana; Green, Andrew; Curcuruto, Ornella; Haslam, Carl P.; Dickinson, Bryony A.; Arban, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">744-751</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A possible role of arginine vasopressin (AVP) V1b receptor subtype in stress-related disorders has been recently highlighted by the discovery of the agonist [1-deamino-4-cyclohexylalanine] AVP (d[Cha4]AVP) and the antagonist SSR149415.  Both compds. have been proposed to target specifically V1b receptors, since the reported affinities for the related V1a, V2 and oxytocin receptors are in the micromolar or submicromolar range.  In the present study, we further investigated the binding affinities of d[Cha4]AVP and SSR149415 at recombinant human vasopressin V1b (hV1b) and oxytocin (hOT) receptors expressed in Chinese hamster ovary (CHO) cells and functional properties of both compds. at hV1b, hV1a, hV2 and hOT receptors.  D[Cha4]AVP bound to hV1b receptors and hOT receptors with pKi values of 9.68 ± 0.06 and 7.68 ± 0.09, resp.  SSR149415 showed pKi values of 9.34 ± 0.06 at hV1b and 8.82 ± 0.16 at hOT receptors; d[Cha4]AVP stimulated [Ca2-]i increase in hVib-CHO cells with a pEC50 value of 10.05 ± 0.15.  It showed pEC50 values of 6.53 ± 0.17 and 5.92 ± 0.02 at hV1a and hV2 receptors, resp., and behaved as a weak antagonist at hOT receptors (pKB = 6.31 ± 0.12).  SSR149415 inhibited the agonist-induced [Ca2+]i increase with pKB values of 9.19 ± 0.07 in hV1b-CHO and 8.72 ± 0.15 in hOT-CHO cells.  A functional pKi value of 7.23 ± 0.10 was found for SSR149415 at hV1a receptors, whereas it did not inhibit 20 nM AVP response at hV2 receptors up to 3 μM.  Data obtained confirmed the high potency and selectivity of d[Cha4]AVP at hV1b receptors, but revealed that SSR149415, in addn. to the high potency at hV1b receptors, displays a significant antagonism at hOT receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolzZMU_xq36bVg90H21EOLACvtfcHk0lhg4ucR6v6Mtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKht7nO&md5=c0700acd4dc1348a56ae1e5e9f8f319e</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706383%26sid%3Dliteratum%253Aachs%26aulast%3DGriffante%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DA.%26aulast%3DCurcuruto%26aufirst%3DO.%26aulast%3DHaslam%26aufirst%3DC.%2BP.%26aulast%3DDickinson%26aufirst%3DB.%2BA.%26aulast%3DArban%26aufirst%3DR.%26atitle%3DSelectivity%2520of%2520d%255BCha4%255DAVP%2520and%2520SSR149415%2520at%2520human%2520vasopressin%2520and%2520oxytocin%2520receptors%253A%2520evidence%2520that%2520SSR149415%2520is%2520a%2520mixed%2520vasopressin%2520V1b%252Foxytocin%2520receptor%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D146%26spage%3D744%26epage%3D751%26doi%3D10.1038%2Fsj.bjp.0706383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karpenko, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klymchenko, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mély, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, D.</span></span> <span> </span><span class="NLM_article-title">Squaraine as a bright, stable and environment-sensitive far-red label for receptor-specific cellular imaging</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2963</span>, <span class="refDoi"> DOI: 10.1039/C4CC09113B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1039%2FC4CC09113B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=25594279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkslCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=2960-2963&author=I.+A.+Karpenkoauthor=A.+S.+Klymchenkoauthor=S.+Gioriaauthor=R.+Krederauthor=I.+Shulovauthor=P.+Villaauthor=Y.+M%C3%A9lyauthor=M.+Hibertauthor=D.+Bonnet&title=Squaraine+as+a+bright%2C+stable+and+environment-sensitive+far-red+label+for+receptor-specific+cellular+imaging&doi=10.1039%2FC4CC09113B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Squaraine as a bright, stable and environment-sensitive far-red label for receptor-specific cellular imaging</span></div><div class="casAuthors">Karpenko, I. A.; Klymchenko, A. S.; Gioria, S.; Kreder, R.; Shulov, I.; Villa, P.; Mely, Y.; Hibert, M.; Bonnet, D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2960-2963</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Herein, we show that a far-red arylidene-squaraine dye is stable against nucleophiles, in contrast to arene-squaraines.  Owing to the fluorescence enhancement in apolar media together with high brightness and photostability, this dye was successfully applied to detect the oxytocin G protein-coupled receptor and monitor its internalization in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8aP5Evtjn7Vg90H21EOLACvtfcHk0lgdj-RW-HEzVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkslCqsg%253D%253D&md5=d9d41cb4fc6f56657de35e793c450dc2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1039%2FC4CC09113B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC09113B%26sid%3Dliteratum%253Aachs%26aulast%3DKarpenko%26aufirst%3DI.%2BA.%26aulast%3DKlymchenko%26aufirst%3DA.%2BS.%26aulast%3DGioria%26aufirst%3DS.%26aulast%3DKreder%26aufirst%3DR.%26aulast%3DShulov%26aufirst%3DI.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DM%25C3%25A9ly%26aufirst%3DY.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DSquaraine%2520as%2520a%2520bright%252C%2520stable%2520and%2520environment-sensitive%2520far-red%2520label%2520for%2520receptor-specific%2520cellular%2520imaging%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D2960%26epage%3D2963%26doi%3D10.1039%2FC4CC09113B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tahtaoui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galzi, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilien, B.</span></span> <span> </span><span class="NLM_article-title">On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7847</span>– <span class="NLM_lpage">7859</span>, <span class="refDoi"> DOI: 10.1021/jm050459+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050459%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7847-7859&author=C.+Tahtaouiauthor=F.+Guillierauthor=P.+Klotzauthor=J.-L.+Galziauthor=M.+Hibertauthor=B.+Ilien&title=On+the+use+of+nonfluorescent+dye+labeled+ligands+in+FRET-based+receptor+binding+studies&doi=10.1021%2Fjm050459%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm050459%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050459%252B%26sid%3Dliteratum%253Aachs%26aulast%3DTahtaoui%26aufirst%3DC.%26aulast%3DGuillier%26aufirst%3DF.%26aulast%3DKlotz%26aufirst%3DP.%26aulast%3DGalzi%26aufirst%3DJ.-L.%26aulast%3DHibert%26aufirst%3DM.%26aulast%3DIlien%26aufirst%3DB.%26atitle%3DOn%2520the%2520use%2520of%2520nonfluorescent%2520dye%2520labeled%2520ligands%2520in%2520FRET-based%2520receptor%2520binding%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7847%26epage%3D7859%26doi%3D10.1021%2Fjm050459%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douzon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bdioui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oueslati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yverneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier-Savournin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span> <span> </span><span class="NLM_article-title">A fluorescent ligand-binding alternative using Tag-lite® technology</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1177/1087057110384611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1177%2F1087057110384611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=20974902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1248-1259&author=J.+M.+Zwierauthor=T.+Rouxauthor=M.+Cottetauthor=T.+Durrouxauthor=S.+Douzonauthor=S.+Bdiouiauthor=N.+Gregorauthor=E.+Bourrierauthor=N.+Oueslatiauthor=L.+Nicolasauthor=N.+Tinelauthor=C.+Boisseauauthor=P.+Yverneauauthor=F.+Charrier-Savourninauthor=M.+Finkauthor=E.+Trinquet&title=A+fluorescent+ligand-binding+alternative+using+Tag-lite%C2%AE+technology&doi=10.1177%2F1087057110384611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorescent ligand-binding alternative using Tag-lite technology</span></div><div class="casAuthors">Zwier, Jurriaan M.; Roux, Thomas; Cottet, Martin; Durroux, Thierry; Douzon, Stephanie; Bdioui, Sara; Gregor, Nathalie; Bourrier, Emmanuel; Oueslati, Nadia; Nicolas, Ludovic; Tinel, Norbert; Boisseau, Chloe; Yverneau, Paul; Charrier-Savournin, Fabienne; Fink, Michel; Trinquet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are crucial cell surface receptors that transmit signals from a wide range of extracellular ligands.  Indeed, 40% to 50% of all marketed drugs are thought to modulate GPCR activity, making them the major class of targets in the drug discovery process.  Binding assays are widely used to identify high-affinity, selective, and potent GPCR drugs.  In this field, the use of radiolabeled ligands has remained so far the gold-std. method.  Here the authors report a less hazardous alternative for high-throughput screening (HTS) applications by the setup of a nonradioactive fluorescence-based technol. named Tag-lite.  Selective binding of various fluorescent ligands, either peptidic or not, covering a large panel of GPCRs from different classes is illustrated, particularly for chemokine (CXCR4), opioid (δ, μ, and κ), and cholecystokinin (CCK1 and CCK2) receptors.  Affinity consts. of well-known pharmacol. agents of numerous GPCRs are in line with values published in the literature.  The authors clearly demonstrate that the Tag-lite binding assay format can be successfully and reproducibly applied by using different cellular materials such as transient or stable recombinant cells lines expressing SNAP-tagged GPCR.  Such fluorescent-based binding assays can be performed with adherent cells or cells in suspension, in 96- or 384-well plates.  Altogether, this new technol. offers great advantages in terms of flexibility, rapidity, and user-friendliness; allows easy miniaturization; and makes it completely suitable for HTS applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ4y-qYZVkzbVg90H21EOLACvtfcHk0lgdj-RW-HEzVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWgtLY%253D&md5=ebb276667f42394eb16e8f0b64b365da</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1177%2F1087057110384611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110384611%26sid%3Dliteratum%253Aachs%26aulast%3DZwier%26aufirst%3DJ.%2BM.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DCottet%26aufirst%3DM.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DDouzon%26aufirst%3DS.%26aulast%3DBdioui%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DN.%26aulast%3DBourrier%26aufirst%3DE.%26aulast%3DOueslati%26aufirst%3DN.%26aulast%3DNicolas%26aufirst%3DL.%26aulast%3DTinel%26aufirst%3DN.%26aulast%3DBoisseau%26aufirst%3DC.%26aulast%3DYverneau%26aufirst%3DP.%26aulast%3DCharrier-Savournin%26aufirst%3DF.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DTrinquet%26aufirst%3DE.%26atitle%3DA%2520fluorescent%2520ligand-binding%2520alternative%2520using%2520Tag-lite%25C2%25AE%2520technology%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26spage%3D1248%26epage%3D1259%26doi%3D10.1177%2F1087057110384611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borthwick, A. D.</span></span> <span> </span><span class="NLM_article-title">Oral oxytocin antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6525</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1021/jm901812z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901812z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6525-6538&author=A.+D.+Borthwick&title=Oral+oxytocin+antagonists&doi=10.1021%2Fjm901812z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Oxytocin Antagonists</span></div><div class="casAuthors">Borthwick, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6525-6538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pharmacokinetics and oral bioavailability of oxytocin antagonists is discussed.  Templates investigated in the previous decade contravene the Lipinski "role of five", which accounts for their poor oral bioavailability, but this is not the case with the more recent compds.  Mol. structure and properties of different compds. are studied in view if their efficiency, bioavailability, bioaccumulation, and applicability, penetration of the blood brain barrier, accumulation in the brain, and blocking central effects of oxytocin both in the fetus and in the mother.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVRMlf_5Dp9rVg90H21EOLACvtfcHk0ljFVMKwBzLAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFSru7g%253D&md5=4fd042ed2404adeae482a27ca77d07a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm901812z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901812z%26sid%3Dliteratum%253Aachs%26aulast%3DBorthwick%26aufirst%3DA.%2BD.%26atitle%3DOral%2520oxytocin%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6525%26epage%3D6538%26doi%3D10.1021%2Fjm901812z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthes, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slowe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Befort, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Meur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dollé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzavara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanoune, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieffer, B. L.</span></span> <span> </span><span class="NLM_article-title">Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1038/383819a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=10.1038%2F383819a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=8893006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;key=1%3ACAS%3A528%3ADyaK28Xms1Sjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=1996&pages=819-823&author=H.+W.+Matthesauthor=R.+Maldonadoauthor=F.+Simoninauthor=O.+Valverdeauthor=S.+Sloweauthor=I.+Kitchenauthor=K.+Befortauthor=A.+Dierichauthor=M.+Le+Meurauthor=P.+Doll%C3%A9author=E.+Tzavaraauthor=J.+Hanouneauthor=B.+P.+Roquesauthor=B.+L.+Kieffer&title=Loss+of+morphine-induced+analgesia%2C+reward+effect+and+withdrawal+symptoms+in+mice+lacking+the+mu-opioid-receptor+gene&doi=10.1038%2F383819a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene</span></div><div class="casAuthors">Matthes, Hans W. D.; Maldonado, Rafael; Simonin, Frederic; Valverde, Olga; Slowe, Susan; Kitchen, Ian; Befort, Katia; Dierich, Andree; Le Meur, Marianne; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">6603</span>),
    <span class="NLM_cas:pages">819-823</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable pain killer in contemporary medicine.  Opioids exert their pharmacol. actions through three opioid-receptor classes, μ, δ and κ, whose genes have been cloned.  Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo.  Here we disrupt the μ-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioral abnormalities or major compensatory changes within the opioid system in these animals.  Investigation of the behavioral effects of morphine reveals that a lack of μ receptors abolishes the analgesic effect of morphine, as well as place-preference activity and phys. dependence.  We obsd. no behavioral responses related to δ- or κ-receptor activation with morphine, although these receptors are present and bind opioid ligands.  We conclude that the μ-opioid-receptor gene product is the mol. target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkOHxWXClmHbVg90H21EOLACvtfcHk0ljFVMKwBzLAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xms1Sjtbw%253D&md5=f0db56cf496bf6ffbc291986e004993d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2F383819a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F383819a0%26sid%3Dliteratum%253Aachs%26aulast%3DMatthes%26aufirst%3DH.%2BW.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DSimonin%26aufirst%3DF.%26aulast%3DValverde%26aufirst%3DO.%26aulast%3DSlowe%26aufirst%3DS.%26aulast%3DKitchen%26aufirst%3DI.%26aulast%3DBefort%26aufirst%3DK.%26aulast%3DDierich%26aufirst%3DA.%26aulast%3DLe%2BMeur%26aufirst%3DM.%26aulast%3DDoll%25C3%25A9%26aufirst%3DP.%26aulast%3DTzavara%26aufirst%3DE.%26aulast%3DHanoune%26aufirst%3DJ.%26aulast%3DRoques%26aufirst%3DB.%2BP.%26aulast%3DKieffer%26aufirst%3DB.%2BL.%26atitle%3DLoss%2520of%2520morphine-induced%2520analgesia%252C%2520reward%2520effect%2520and%2520withdrawal%2520symptoms%2520in%2520mice%2520lacking%2520the%2520mu-opioid-receptor%2520gene%26jtitle%3DNature%26date%3D1996%26volume%3D383%26spage%3D819%26epage%3D823%26doi%3D10.1038%2F383819a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i86"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00697">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83126"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00697">10.1021/acs.jmedchem.8b00697</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of precursor compounds <b>1</b>–<b>8</b>, <b>28</b>, <b>31</b>, <b>37</b>; signaling data for compound <b>57</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_001.pdf">jm8b00697_si_001.pdf (452.8 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00697/suppl_file/jm8b00697_si_002.csv">jm8b00697_si_002.csv (2.53 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00697&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00697%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-19%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00697" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996a1d599732a9","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
